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Background: The body of knowledge regarding rhinosinusi-
tis (RS) continues to expand, with rapid growth in number
of publications, yet substantial variability in the quality of
those presentations. In an effort to both consolidate and
critically appraise this information, rhinologic experts from
around the world have produced the International Con-
sensus Statement on Allergy and Rhinology: Rhinosinusitis
(ICAR:RS).
Methods: Evidence-based reviews with recommendations
(EBRRs) were developed for scores of topics, using previ-
ously reported methodology. Where existing evidence was
insufficient for an EBRR, an evidence-based review (EBR)
was produced. The sections were then synthesized and the
entire manuscript was then reviewed by all authors for con-
sensus.
Results: The resulting ICAR:RS document addresses multi-
ple topics in RS, including acute RS (ARS), chronic RS (CRS)
with and without nasal polyps (CRSwNP and CRSsNP), re-
current acute RS (RARS), acute exacerbation of CRS (AE-
CRS), and pediatric RS.
Conclusion: As a critical review of the RS literature,
ICAR:RS provides a thorough review of pathophysiology
and evidence-based recommendations for medical and sur-
gical treatment. It also demonstrates the significant gaps
in our understanding of the pathophysiology and optimal
management of RS. Too oen the foundation upon which
these recommendations are based is comprised of lower-
level evidence. It is our hope that this summary of the evi-
dence in RS will point out where additional research efforts
may be directed. C© 2016 ARS-AAOA, LLC.
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I. Introduction
T he body of knowledge about rhinosinusitis (RS) con-tinues to expand. A search of the PubMed database us-
ing the search terms “sinusitis” or “rhinosinusitis” demon-
strates that between 2000 and 2014, 12,847 articles were
published on the subject. Further, this search shows that
the annual number of publications on RS has continued to
grow (Fig. I-1). Besides the daunting number of articles on
the topic of RS, there is considerable variation in the quality
of these publications.
The practice of evidence-based medicine (EBM) requires
a thorough knowledge of the “best external evidence”
(Fig. I-2). The sheer number and the varying quality of
publications make it increasingly difficult for the clinician
to practice EBM in caring for patients with RS.
This International Consensus statement on Allergy and
Rhinology: Rhinosinusitis (ICAR:RS) has been developed
in order to summarize that best external evidence. The
authors’ goal was to assemble and critically appraise all
available evidence on the diagnosis, pathophysiology, and
management of the various forms of RS. We employed a
structured review of the evidence by utilizing over 100 au-
thors from around the world, using a stepwise anonymous
writing and iterative review process for each of over 140
topics. This methodology has produced a robust review
of current evidence and treatment recommendations based
upon the best available evidence.
The methodology we employed seeks to rely principally
on higher-level published evidence and to diminish the im-
pact of expert opinion such as that which may be seen in
a literature review or proceedings of a consensus panel.
At the same time, ICAR:RS has limitations. It is neither a
meta-analysis nor a clinical practice guideline (CPG). Much
of the RS literature does not lend itself well to meta-analysis
because there are limited numbers of studies with vari-
able methodologies for any given topic. Although ICAR:RS
provides evidence-based care recommendations, ICAR:RS
should not itself be confused with a CPG. CPGs require
strong evidence as well as additional steps of critical review
by many stakeholders, including medical specialty societies
and patient advocates.
Importantly, although there has been a large and increas-
ing number of publications on RS, 2 important caveats
should be noted. First, as the number of RS publications
has increased, the proportion of all publications annually
has held steady at 0.10% throughout the last 15 years
(Fig. I-1). Second, review of this ICAR:RS document will
reveal that the vast majority of “best external evidence”
on RS is relatively weak. As a rhinology community, we
should reflect upon this ICAR:RS document for gaps in
high-level evidence and, where possible, dedicate ourselves
to filling those gaps.
This document as a compendium of recommendations
has limitations. This ICAR:RS document does not repre-
sent a “cookbook” for providing care for the RS patient.
The practice of EBM requires the clinician to have the best
available evidence, and then combine that with individual
expertise and the patient’s condition, values, and expec-
tations (Fig. I-2).1 RS is a set of highly variable condi-
tions, with different etiologies and a wide breadth of rec-
ommended treatments. For example, acute RS differs from
acute exacerbation of chronic RS (AECRS), which in turn
differs from chronic RS (CRS). Even within CRS, patients
with and without nasal polyps (CRSwNP and CRSsNP, re-
spectively) have significant differences in pathophysiology
and recommended treatments. Applying the diagnostic and
treatment recommendations for 1 condition to the others
would be erroneous.
In addition to recognizing variability among subsets of
RS, the clinician must also recognize the tremendous vari-
ability within a subset of RS, especially CRS. CRS patients
can be mildly symptomatic or highly symptomatic; they
may have limited findings on endoscopy or computed to-
mography (CT) or complete involvement of all sinuses; they
may be presenting for diagnosis and management for the
first time or after many failed treatments or even after multi-
ple surgeries. To assume that 1 patient is just like another—
and to apply the findings in this document under such an
assumption—is not consistent with the practice of EBM.
The recommendations offered in this document should
be interpreted in context of the robustness of the evidence
upon which they are based. Although the recommendations
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FIGURE I-1. Results of a PubMed search for the terms “sinusitis” or “rhinosinusitis” by year on the left axis. The right axis shows the sinusitis and rhinosinusitis
articles as a percentage of the total number of articles listed for that year.
in this document are based on the best available evidence,
they do not define standard of care nor do they define med-
ical necessity. Healthcare providers or any others should
not assume that a particular treatment is or is not indicated
in an individual patient solely based on what is written in
this or any other similar document.
Last, the recommendations herein should not be viewed
as static. As new and stronger evidence emerges, they
will necessarily have to undergo reevaluation and possi-
bly change. It is our hope that this summary will guide all
who care for RS patients, equipping them to provide our
patients with the best possible outcome.
II. Methods
II.A. Topic Development
This document was developed and written so as to have
the maximal reliance on published evidence. The authors
adapted the method of writing an evidence-based review
with recommendations (EBRR), as described by Rudmik
and Smith in 2011.2 The subject of RS was initially divided
into 144 topics. Each topic was then assigned to a senior
author who is a recognized expert in the field of rhinology,
and specifically in RS. Some of the topics had no significant
evidence and were assigned as literature reviews. Some
had significant evidence but did not lend themselves to
providing a recommendation, such as those addressing
diagnosis and pathogenesis, and these were assigned as
evidence-based reviews (EBRs) without recommendations.
Many had evidence to inform recommendations and were
assigned as EBRRs.
FIGURE I-2. The practice of EBM. Adapted from: Armstrong EC. Har-
nessing new technologies while preserving basic values. Fam Syst Health.
2003;21:351-355. EBM = evidence-based medicine.
To provide the content for each topic, a systematic review
of the literature for each topic using Ovid MEDLINE R©
(1947 to July 2014), EMBASE (1974 to July 2014), and
Cochrane Review databases was performed using the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) standardized guidelines.3 The search
began by identifying any previously published systematic
reviews or guidelines pertaining to the assigned topic.
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TABLE II-1. Aggregate grade of evidence
Grade Research quality
A Well-designed RCTs
B RCTs with minor limitations; overwhelming consistent evidence
from observational studies
C Observational studies (case control and cohort design)
D Expert opinion; case reports; reasoning from first principles
Because clinical recommendations are best supported by
randomized controlled trials (RCTs), the search focused on
identifying these studies to provide the strongest level of ev-
idence (LOE). Reference lists of all identified studies were
examined to ensure all relevant studies were captured. If
the authors felt as though a non-English study should be in-
cluded in the review, the paper was appropriately translated
to minimize the risk of missing important data during the
development of recommendations.3 One major exception
to the search window was made for the Clinical Practice
Guidelines of the American Academy of Otolaryngology–
Head and Neck Surgery (AAO-HNS).4 These guidelines
were updated during preparation of the manuscript and
were heavily referenced throughout the document. The up-
dated 2015 version was therefore used.
To ensure complete transparency of the evidence in EBR
and EBRR sections, all included studies were presented in
a standardized table format and the quality of each study
was evaluated to receive a level based on the Oxford levels
of evidence (from level 1a to 5).5 At the completion of the
systematic review and research quality evaluation for each
clinical topic, an aggregate grade of evidence was produced
for the topic based on the guidelines from the American
Academy of Pediatrics (AAP) Steering Committee on Qual-
ity Improvement and Management (Table II-1).6
After providing an aggregate grade of evidence for each
EBRR topic (ie, A to D), a recommendation using the AAP
guidelines was produced. It is important to note that each
evidence-based recommendation took into account the ag-
gregate grade of evidence along with the balance of benefit,
harm, and costs (Table II-2).
After the development of the initial topic EBRR, the
manuscript underwent a 2-stage online iterative review pro-
cess using 2 independent reviewers. The purpose of these
steps was to evaluate the completeness of the identified lit-
erature and ensure the recommendations were appropriate.
The topic content was reviewed by another expert on that
topic, and all changes were agreed upon by both reviewer
and initial authors. The topic content was then reviewed
by a second reviewer and changes were agreed upon by
the initial authors and the first reviewer. Figures II-1 and
II-2 show flowcharts of the topic development and EBRR
iterative review processes.
II.B. ICAR:RS Statement Development
After the completion of all topics, the principal edi-
tors (R.R.O., T.T.K., and P.H.H.) compiled them into 1
ICAR:RS statement. This draft document was then re-
viewed by all contributing authors. The final ICAR:RS
manuscript was produced once consensus was reached
among the authors regarding the literature and final rec-
ommendations.
III. Rhinosinusitis Definitions
III.A. RS Definitions: Acute Rhinosinusitis
Acute rhinosinusitis (ARS) in adults may be defined as
sinonasal inflammation lasting less than 4 weeks associated
with the sudden onset of symptoms.4,7–9 This definition is
largely based on expert opinion and consensus. Several task
forces and consensus groups have all agreed that an acute
episodemay last up to 4weeks, though this does not seem to
be based on any objective evidence.4,7–11 Adult symptoms
must include nasal blockage/obstruction/congestion or
nasal discharge (anterior/posterior) and facial pain/pressure
or reduction/loss of smell. ARS in children may be de-
fined as sinonasal inflammation associated with the sud-
den onset of 2 or more of the following symptoms:
nasal blockage/obstruction/congestion, discolored nasal
drainage, or a cough that may occur during the day or
night.7
For both adults and children, inquiry should be made
about symptoms suggestive of allergy (eg, sneezing, watery
rhinorrhea, nasal and ocular pruritus, and watery eyes) in
order to help differentiate acute viral or bacterial RS from
allergic rhinitis (AR).
The consensus groups have all agreed that in acute viral
RS nasal symptoms are generally present for fewer than
10 days. The most recent guidelines from the AAO-HNS
included data on the duration of typical viral symptoms
in support of the commonly accepted time frames used to
differentiate acute viral RS from acute bacterial RS.4
The EPOS 2012 statement describes a process referred
to as “acute postviral rhinosinusitis,” which seems to be
based on expert opinion and is defined as a worsening
of symptoms after about 5 days, or persistent symptoms
after 10 days, but with symptom duration of fewer than
12 weeks.7 This process is not recognized as a separate
entity by the 2015 AAO-HNS guidelines.4
These 2 most recent guidelines also differ slightly on how
ARS is diagnosed. Both agree that discolored discharge
(with unilateral predominance) and purulent secretions in
the nasal passage, moderate to severe local pain, and pro-
longed symptoms and/or deterioration of condition after
initial improvement are key for the diagnosis.4,7 The EPOS
statement includes an elevated erythrocyte sedimentation
rate and/or C-reactive protein (CRP) and fever as diagnostic
criteria.7 The AAO-HNS guidelines cite the low sensitivity
and specificity of fever as a rationale for not including fever
as a diagnostic criterion.4
III.B. RS Definitions: CRS
CRS in adults is defined as sinonasal inflammation per-
sisting for more than 12 weeks.7–9 This definition is
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TABLE II-2. AAP-defined strategy for recommendation development6
Preponderance of benefit Balance of benefit Preponderance of harm
Evidence quality over harm and harm over benefit
A. Well-designed RCTs Strong recommendation Option Strong recommendation against
B. RCTs with minor limitations;
overwhelmingly consistent evidence
from observational studies
Recommendation Option Strong recommendation against
C. Observational studies (case control and
cohort design)
Recommendation Option Recommendation against
D. Expert opinion, case reports, reasoning
from first principles
Option No recommendation Recommendation against
AAP = American Academy of Pediatrics.
FIGURE II-1. Topic development. PE = principal editor; 10 = primary.
based on consensus and has been relatively consistent
over the past 25 years. The most recent guidelines
agree that CRS in adults is characterized by nasal ob-
struction/congestion/blockage, nasal drainage (mucopu-
rulent) that may drain anteriorly or posteriorly, facial
pain/pressure/fullness, and decreased or loss of sense of
smell.4,7 Symptoms alone have a high sensitivity but an
unacceptably low specificity, which is why the symptoms
must be accompanied by objective findings including posi-
tive nasal endoscopy (purulence, polyps, or edema) or posi-
tive imaging findings consisting of inflammation or mucosal
changes within the sinuses.4,7
CRS in children is defined and diagnosed similarly to
CRS in adults, with the difference being cough is a much
more significant symptom than is decreased sense of smell.7
Interestingly, this definition too is essentially based on con-
sensus but does have some data supporting headache, nasal
obstruction, postnasal drainage/rhinorrhea, and cough as
the 4 most common symptoms identified in children with
sinusitis.12
For both adults and children, CRS with nasal polyps
(CRSwNP) is diagnosed when nasal polyps (NPs) can
be visualized in the nose and/or middle meati, in the
context of appropriate symptoms.4,7 Unilateral polyps
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FIGURE II-2. Topic EBRR iterative review process. 10 = primary; 20 = secondary; 30 = tertiary; EBRR = evidence-based review with recommendations; PE =
principal editor.
may require further investigation to exclude neoplastic
pathologies.
III.B.1. CRS Definition: Disease or Syndrome?
In view of the different clinical phenotypes and inflamma-
tory endotypes of CRS, it can be considered an umbrella
term covering several inflammatory disease states of the
sinonasal cavities. On the basis of clinical and/or radio-
logic examination, CRS is generally divided into CRSsNP
and CRSwNP. Apart from these 2 major clinical pheno-
types, other phenotypes relate to the variety of presenting
symptoms in CRS patients and the presence or absence of
concomitant bronchial disease.4,7 It is not surprising to find
different phenotypes of the disease, given the multitude of
underlying etiologic factors.
A wide range of inflammatory patterns may act together
with mucociliary and/or structural abnormalities to give
rise to the development of CRS. The multifactorial etiology
of CRS, involving genetic factors, environmental influences,
occupational factors, infection, allergy, immune dysfunc-
tion, and systemic diseases, has led to the recent attempt
to define endotypes of disease. CRS has been classified into
different inflammatory clusters, such as T helper 1 (Th1)-
driven or neutrophilic inflammation, and T helper 2 (Th2)-
driven or eosinophilic inflammation.13 Several specific in-
flammatory mediators have been associated with CRS, and
the beneficial effects of novel treatments with biologics like
anti–interleukin 5 (IL-5), anti–immunoglobulin E (IgE), and
others support their importance. We should, however, re-
alize that mixed inflammatory clusters are likely common
and important in these patients; this would help explain
the limited beneficial effects of targeting 1 inflammatory
mediator such as IgE or IL-5 in isolation.
Taken together, CRS represents a condition with differ-
ent phenotypes and endotypes, which we are only starting
to better understand. In a single CRS patient, pinpointing
the different etiologic factors responsible for the develop-
ment of the disease remains the challenge for the future.
III.C. RS Definitions: Recurrent
Acute Rhinosinusitis
Recurrent acute rhinosinusitis (RARS) has been defined as
4 episodes per year of ARS with distinct symptom-free in-
tervals between episodes.4,7,8,14 Each episode must meet
the criteria listed in Section III.A for ARS. The number
of episodes required for the diagnosis of RARS has var-
ied between consensus statements, but the 2007 guidelines
in Rosenfeld et al.15 addressed this number. Citing the
published literature, they reported that the average adult
gets between 1.4 and 2.3 viral upper respiratory infections
(URIs) per year. They felt that setting the number of acute
bacterial rhinosinusitis (ABRS) episodes at 4 for RARS de-
creased the chances of misdiagnosis.
Only a few cohort studies have examined the clinical
course of this group of patients. Patients with RARS tend
not to be treated surgically, and when they are, they un-
dergo less extensive surgery than CRS patients.16,17 Post-
operatively they require fewer long-term medications. This
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may possibly be due to a relatively higher number of
sinonasal anatomic variants in this patient group.18
III.D. RS Definitions: AECRS
AECRS is defined in a patient in whom a previous diagnosis
of CRS exists, and a sudden worsening of symptoms occurs,
with a return to baseline symptoms following treatment.8,11
A more stringent definition has not been proposed to this
point nor have more precise diagnostic criteria been put
forward. The concept for AECRS was based on a similar
disease pattern in otitis media (personal communication
with Donald Lanza, MD). Although the literature on this
condition is limited, potential diagnostic criteria are pro-
posed in Section IX.C.
III.E. RS Definitions: Subacute RS
Although absent from recent guidelines, subacute RS has
been a term used to describe clinical presentations that fall
between the time frames of ARS and CRS (symptoms of
4 to 12 weeks’ duration). To date, there have been very few
clinical reports on which to base the delineation of these
patients as a distinct clinical entity; reports that do make
that distinction define the process based on consensus. The
term has been used at least since 1975, and Lanza and
Kennedy11 recommended reintroducing the term although
there was no formal definition provided by the U.S. Food
and Drug Administration (FDA) for disease lasting 4 to
12 weeks.12 It is likely that patients who fall into this group
either have slow-to-resolve ARS or an early presentation of
evolving CRS. Use of this definition or classification should
be limited until a better understanding of this condition is
achieved.
III.F. RS Definitions: Sinusitis or RS?
In 1996, the Task Force on Rhinosinusitis sponsored by
the AAO-HNS reached a consensus regarding specific di-
agnostic criteria and working definitions to describe RS.19
The Task Force agreed to replace the word “sinusitis” with
the more descriptive term “rhinosinusitis” to emphasize
the close relationship between the nose and paranasal si-
nuses, the similarities in both morphology and physiology
between the mucosal lining of the 2, and the fact that the
2 conditions often exist simultaneously in the same pa-
tient, even when 1 might be the predominant feature of the
presentation.
One of the key arguments used to support the devel-
opment of this terminology is that rhinitis not only occurs
concomitantly with “sinusitis” but often heralds its onset.19
Furthermore, nasal obstruction and drainage, which are
2 of the key features of sinusitis, are closely related to
symptoms of rhinitis.20 Since the Task Force reached a
consensus regarding the use of the term “rhinosinusitis,”
several multidisciplinary position papers have supported
the notion that “sinusitis” is almost always accompanied
by rhinitis.9,19–22 However, there are very few studies that
have examined objective evidence to support the use of this
terminology.
A key study providing evidence regarding this relation-
ship was conducted by Gwaltney et al.23 The authors eval-
uated computed tomography (CT) data from 31 patients
with an acute rhinovirus infection and detected simultane-
ous involvement of both the nasal cavity and the paranasal
sinuses. Specifically, thickening of the walls of the nasal
passages, engorgement of the inferior turbinates, obstruc-
tion of the ethmoid infundibulum, and abnormalities of
the maxillary, sphenoid, and frontal sinuses were found in
77%, 87%, 39%, and 32%, respectively. The radiographic
abnormalities resolved after 2 weeks without any antibiotic
therapy in 79% of the patients.
Two studies have evaluated for the presence of in-
flammation in the nasal cavity in patients with CRS.
Bhattacharyya24 identified inflammatory cells in the nasal
septal mucosa in patients with CRS. A more recent study
conducted by Van Crombruggen et al.25 evaluated the pres-
ence of inflammatory mediators in the ethmoidal mucosa
or polyp tissue from patients with CRSsNP and those
with CRSwNP, respectively, and compared them to infe-
rior turbinate nasal mucosal tissue from the same patients
and to inferior turbinates from healthy controls. In both
CRSwNP and CRSsNP, inflammatory mediator levels were
increased in both sinus and nasal mucosa, compared to
healthy control tissues.
Although limited published experimental evidence ex-
ists supporting the term “rhinosinusitis,” it has clearly
been accepted by several multidisciplinary, international
expert groups, and it is physiologically logical and clinically
evident.
IV. The Burden of RS
IV.A. Societal Burden of RS
IV.A.1. RS Societal Burden: Direct Costs
RS (both acute and chronic forms) affects approximately
12% to 15.2% of the adult population in the United States,
annually.26,27 This annual prevalence exceeds that of other
common respiratory conditions such as hay fever (8.9%),
acute asthma (3.8%), and chronic bronchitis (4.8%).26
The direct costs of managing ARS and CRS exceed US$11
billion per year.4 These figures, however, do not distinguish
between ARS and CRS; further stratification is presented
in the next sections.
IV.A.1.a. Societal Direct Costs: ARS. Direct cost
estimates attributable to the diagnosis and treatment of
ARS are sparse in the literature. The disease burden of
ARS has been primarily assessed using utilization mea-
sures such as office visits and antibiotic prescription rates.
For example, there are approximately 5.1 million ambula-
tory office visits per year with a coded diagnosis of ARS
and approximately 86% of these visits result in an oral
antibiotic prescription.28 ARS is the fifth most common
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diagnosis associated with antibiotic therapy.4 In 1 of the
few prospective, observational studies on ARS, Scandina-
vian researchers determined the direct costs of 1 episode of
ARS at €266 (about US$300).29
IV.A.1.b. Societal Direct Costs: CRS. The direct
costs of CRS include the costs for both RARS and the tra-
ditional form of CRS. The direct costs of CRS have been
ascertained on multiple levels based on single-institutional
cohorts, analyses of claims databases, and analyses of na-
tionally representative healthcare cost data sets. For exam-
ple, individual patient cohorts, most commonly from aca-
demic medical centers, have quantified the direct medical
costs at US$921 to US$1220 per patient-year.30,31 These
data may, however, represent a bias toward more severely
diseased patient populations and also rely on some extrap-
olation of costs.
Recent claims-based studies have provided more refined
and generalized cost data for CRS. In a study of 4.4 mil-
lion patients, Bhattacharyya et al.32 identified 4460 patients
undergoing endoscopic sinus surgery (ESS). The healthcare
costs for CRS in the year leading up to ESS (therefore, the
medically refractory group) were US$2449, US$1789 of
which were attributable to facility and physicians’ charges.
Costs related to the management of CRS are not limited to
medical management only; economic studies have demon-
strated the cost of ESS to range from US$3500 per case (in
Canada) to US$7700 per case (in the United States).32,33
The presence or absence of polyps also influences direct
medical costs in CRS. Patients with recurrent polyps af-
ter prior surgery demonstrated higher direct medical costs
per year (US$866) than non-polyp patients (US$570) or
primary polyp patients (US$565).34
Finally, population-based assessments have determined
incremental costs of CRS relative to those without CRS.
Bhattacharyya35 determined significantly increased incre-
mental healthcare utilization costs of US$772 for total
healthcare expenses, US$346 for office-based expenditures,
and US$397 in prescription expenditures for CRS in a na-
tionally representative healthcare economics database (p 
0.01 vs those adults without CRS). From an international
perspective, also utilizing a national healthcare insurance
database, Chung et al.,36 found that Taiwanese patients
with CRS diagnoses incurred significantly higher outpatient
costs (US$953 vs US$665; p < 0.001) and total healthcare
costs (US$1318 vs US$946; p < 0.001) than comparison
subjects without CRS. Although less commonly studied,
recent claims-based data indicate an annual direct cost of
treatment attributable to RARS of US$1091 per patient-
year.37 The overall direct cost burden of CRS in the United
States has been estimated at US$8.6 billion per year.35
IV.A.2. RS Societal Burden: Indirect Costs
In contrast to direct healthcare costs, the indirect healthcare
costs of RS include societal costs related to absence from
work (absenteeism), decreased work productivity while at
work (presenteeism) and other forms of lost productivity
(e.g. home life). In a nationally based household study,
among the 15.2% of those reporting acute or chronic RS
annually, 5.7 workdays were missed vs 3.7 for those with-
out (p < 0.001).26 This translates into 61.2 million poten-
tial workdays missed per year among adults in the United
States and an estimated work productivity loss of US$3.79
billion per year.26,38 Data for presenteeism and other forms
of lost productivity due to RS as a whole are currently lack-
ing, but data for subtypes of RS are available.
IV.A.2.a. Societal Indirect Costs: ARS. Data for the
indirect costs of ARS are somewhat limited, with most
data coming from control arms of interventional stud-
ies for ARS. Recently, Spanish investigators found the
indirect cost of an ARS episode to range from €224 to
€439 (about US$250 to US$490) depending on treatment
intervention.39 If patients are assumed to be absent from
work during the symptomatic days of an ARS episode, the
indirect costs increase to US$747 to US$820, depending on
whether antibiotic treatment is offered.38
IV.A.2.b. Societal Indirect Costs: CRS. The overall
indirect cost burden of CRS is substantial and relates to the
underlying severity of the CRS. A recent national health-
care expenditure database investigation found that patients
with CRS experienced 1.0 ± 0.4 incremental workdays lost
per year due to CRS.40 This figure includes both nonrefrac-
tory and refractory patients and directly compares those
with and without CRS diagnoses. European investigators
found 57% of CRS patients (n= 207) reported absenteeism
from work due to CRS.41 In patients with relatively limited
CRS but planning balloon dilatation (n = 56), Stankiewicz
et al.42 found substantial proportions of patients reporting
absenteeism (6.5%), presenteeism (36.2%), and productiv-
ity loss (38.3%) via a validated work-specific survey. In a
multi-institutional study from tertiary-level rhinology clin-
ics, likely representing a cohort of the most severely dis-
eased refractory patients (n = 55), Rudmik et al.43 found
mean annual rates of absenteeism of 24.6 days per year and
presenteeism of 38.8 days per year, with an overall annual
productivity cost of US$10,077 per patient. Although cau-
tion must be exercised when extrapolating these figures to
the general CRS population, it is clear that CRS imparts
significant indirect costs.
The indirect costs of CRS are not only work-related.
Stankiewicz et al.42 identified a 40.0% rate of impairment
of activity with CRS. In a nationally representative sample,
Bhattacharyya40 determined activity limitations of 13.3%,
work limitations of 12.0%, social limitations of 9.0%, and
cognitive limitations 6.0% with CRS.
IV.A.2.c. Societal Indirect Costs: RARS. The in-
direct costs of RARS primarily relate to workdays lost
and productivity decreases due to the acute phase of each
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episode of RS. Although relatively limited data are available
for indirect costs for this RS subtype, investigators found
an average of 4.4 workdays missed per year specifically due
to RARS.44 Economic studies of RARS have identified ab-
senteeism and presenteeism rates of 1.7 and 0.66 days per
acute episode, respectively.45
IV.B. Individual Burden of RS
By definition, patients with CRS will suffer with some com-
bination of cardinal sinonasal symptoms, including nasal
congestion, nasal drainage, facial pressure/pain, and loss of
smell. Description of individual sinonasal symptoms and
overall burden of disease is often done using individual
symptoms scales or sinus-specific quality-of-life (QoL) in-
struments. However, the impact of CRS often extends be-
yond the sinonasal region and can have profound effects on
functional well-being and general health-related QoL. Sev-
eral studies have explored the burden of CRS using either
general health-related QoL or health-state utility scores and
compared these findings to scores from patients with other
chronic disease states. Health-state utility scores are partic-
ularly useful for comparing the burden of different diseases
because these instruments measure disease impacts using a
single, common metric. Using transformations of the Short
Form 6D instrument (SF-6D), health states of 230 patients
with CRSwere found to average 0.65 (0= dead, 1= perfect
health), a valuation that was worse than what has been re-
ported for congestive heart failure, chronic obstructive pul-
monary disorder, and Parkinson’s disease.46 Similar studies
have been performed showing severe impairment in general
QoL and well-being using the Short-Form 36 (SF-36) and
Euroqol 5 Dimension (EQD-5) questionnaires.47–49 When
responses of CRS patients are examined in detail, the most
common extrasinus disease manifestations include fatigue
and bodily pain, sleep dysfunction, and depression.
Severe fatigue is commonly reported by patients with
CRS. A systematic review with meta-analysis, including
data on 3427 patients from 28 studies, examined fatigue
in patients with CRS.50 The baseline median prevalence
of fatigue was 54%, ranging from 11% to 73% across
studies. Another systemic review with meta-analysis exam-
ined bodily pain in 11 studies with 1019 patients.51 Using
primarily the SF-36 instrument, pooled mean bodily pain
scores were 0.89 standard deviations below national or lo-
cal population norms (p < 0.001), exceeding bodily pain
scores reported in patient populations aged 25 years older.
Both fatigue and bodily pain were shown to significantly
improve after sinus surgery, with combined effects sizes of
0.77 (95% confidence interval [CI], 0.59 to 0.95) for fa-
tigue and 0.55 (95% CI, 0.45 to 0.64) for bodily pain.
Poor sleep quality is a frequent complaint of patients
with CRS but this dysfunction has only recently been ex-
plored in depth. Using the Pittsburgh Sleep Quality Index
(PSQI), subjective sleep quality was assessed in a multi-
institutional cohort of 268 patients with CRS.52 The PSQI
is a self-reported questionnaire (range, 0 to 21, with higher
scores indicating worse sleep) measuring sleep quality and
disturbance over the preceding 1-month period, with high
internal consistency, reliability, and construct validity. The
mean PSQI score in this group was 9.4, with 75% report-
ing “poor” sleep based on accepted cutoffs (ie, abnormal
is >5). In this group, PSQI scores significantly correlated
with sinus-specific QoL scores on both the 22-item Sino-
Nasal Outcome Test (SNOT-22) and Rhinosinusitis Dis-
ability Index (RSDI) instruments (r = 0.55 and r = 0.53,
respectively).53,54 A recent contemporary review examined
potential mechanisms of sleep dysfunction in CRS, includ-
ing alterations in nasal airflow and direct effects of anti-
somnogenic cytokines, but these hypotheses remain spec-
ulative, and further research is required to understand the
association between CRS and sleep.55
Another prominent factor that impacts overall QoL and
well-being in patients with CRS is the presence of depres-
sion. Studies have reported prevalence rates for depression
in CRS ranging from 9% to 26%.56–61 The wide range
likely reflects differences in patient populations and diag-
nostic accuracy for depression (ie, patient-report, physi-
cian diagnosis, validated questionnaire). Regardless, the
frequency of depression in patients with CRS is above pop-
ulation norms of between 5% and 10%.62 The comor-
bid presence of depression is associated with worse sinus-
specific and general QoL compared to CRS patients who
are not depressed.58,59,61 Not surprisingly, those CRS pa-
tients with depression have higher healthcare utilization,
including increased antibiotic usage and physician visits,
as well as more missed workdays than CRS patients with-
out this comorbidity.60 A number of studies have exam-
ined the impact of depression on outcomes after sinus
surgery.56,58,59,61 Universally, patients with comorbid de-
pression and CRS have worse sinus-specific QoL at both
baseline and postoperative time points compared to those
without depression even after controlling for other factors.
However, patients with depression do appear to have a
similar degree of overall improvement compared to those
without depression; they just start and endwithworseQoL.
Further studies are required to understand whether depres-
sion is simply a comorbid disease commonly found along-
side CRS or whether the presence of CRS contributes to
depression.
IV.C. Measurement of Disease Severity
Current clinical evaluation of subjects with CRS involves
evaluation of disease-specific QoL, clinical history, physi-
cal examination often including endoscopic exam, and ra-
diographic evaluation with CT. Clinicians synthesize these
data to both establish the diagnosis of CRS as well as to
decide on a potential medical or surgical intervention. A
key measure of success is outcome from the patient’s per-
spective, measured by QoL. Endoscopic and radiologic im-
provements matter little if the patient does not feel bet-
ter, especially for a QoL condition like CRS. Despite the
broad use of CT and endoscopy to confirm diagnosis and
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tailor treatment, neither endoscopic nor radiographic find-
ings have been shown to correlate strongly with preinter-
vention and postintervention QoL outcomes. However, re-
finements of current measures and potential development
of novel measures of CRS may someday improve outcome
prediction and clinical decision-making.
Endoscopic exams can be performed in both a preoper-
ative and postoperative setting, and multiple efforts have
been undertaken to standardize these exams.63–68 A vari-
ety of scoring systems exist, but fundamentally each sys-
tem comprises a weighted composite of some combination
of the available endoscopic variables: extent and location
of mucosal inflammation, presence and character of dis-
charge, presence of scar, presence of crust, and middle
turbinate (MT) position. Investigation of the test-retest re-
liability and content validity of several of these scales has
been investigated. Unfortunately, at best, endoscopic scor-
ing systems only weakly correlate with current QoL64,67
and postoperative gains in QoL.69 Although there is room
for refinement of endoscopic scoring, endoscopic exams
likely provide only a portion of the data required to accu-
rately predict symptomatology.
CT of the sinuses has been a mainstay of clinical out-
comes research,70 yet several studies have shown that this
method of scoring does not correlate well with contem-
poraneous measures of QoL.71–74 However, there is con-
flicting evidence on the ability of CT severity to predict
QoL gains postintervention, with some studies showing
correlations71,75 but more studies showing that CT stage
is not an independent predictor of outcome.71,76,77 Among
currently available radiographic scoring systems, there is
simply binary data; eg, presence or absence of inflamma-
tion. However, there is likely missing information in this
scheme. CT scans do provide important information on
anatomy, location of disease, extent of disease, and pres-
ence of osteoneogenesis. Some have tried to identify pre-
dictive data from CT scans, and have noted that presence
of osteoneogenesis on CT is associated with diminished
QoL gains after surgery,78 and also that intrasinus quan-
tity and density of opacification may correlate with QoL
measures.79
Although both endoscopic and radiographic measures
may be further refined in the future to better correlate with
QoL measures and outcomes, it seems clear that they are
not measuring exactly the same constructs, and failure to
identify a high level of correlation with symptoms does not
imply that the measure is not useful. Future research might
identify other factors that predict outcome, such as mea-
sures of immune response and regulation and the status of
the microbiome.
V. ARS
V.A. ARS: Incidence/Prevalence
The reported incidence of ARS is significantly affected by
how ARS is defined. For this consensus statement, ARS is
defined as the symptomatic inflammation of the paranasal
sinuses and nasal cavity lasting less than 4 weeks. Although
viral, bacterial, or fungal pathogens can cause ARS, the
majority of cases begin when a viral URI involves the nasal
cavity and paranasal sinuses.
It is estimated that adults will experience between 1 and 3
episodes of viral ARS per year and 12% of the adult popu-
lation will be diagnosed with RS.27,80–83 Furthermore, ARS
accounts for 2% to 10% of primary care and otolaryn-
gology visits.84,85 Data from the United States often fail to
differentiate between the various types of RS to a degree
that renders it challenging to provide an accurate estimate
of ARS prevalence.86 However, 1 prospective study esti-
mated ARS incidence at 9%.87
The current literature shows that a broad range of epi-
demiologic methods have been used to assess the preva-
lence of RS. Estimation of disease prevalence based on
review of medical records only covers patients who sought
and received medical attention, and may thus reflect a
biased selection strategy. These methods almost certainly
result in underestimation because they do not capture
episodes of disease for which patients did not seek care.
The use of household visits sought to eliminate sampling
bias by including patients who may not have had access
to medical care, thus encompassing a truly representative
population.27 These data represent the best available esti-
mates of ARS prevalence currently available.
V.B. ARS: Pathophysiology
Important in the defense of the sinonasal tract are sneezing
to remove large particles, mucus to trap smaller particles,
and ciliary transport to propel mucus to the gut for degra-
dation. Sinus health also involves identification of foreign
particles and mounting the appropriate response through
the innate and adaptive immune systems.88 It is the down-
stream effects of these defensive responses that we perceive
as the symptoms of ARS.
The immune response within the sinonasal cavity is mul-
tifaceted, complex, and interrelated. Allergic, viral, bacte-
rial, and fungal insults as well as environmental irritants
are implicated in causing ARS. Resulting mucosal swelling
causes sinus ostial obstruction, exacerbating ARS. Also,
nose blowing has been hypothesized to seed pathogen-
bearing mucus into the sinuses, and thereby serves as an-
other mechanism of sinus infection.89 As traditionally de-
fined, allergy involves a systemic IgE-mediated response
to local antigen exposure. Although data correlating al-
lergy and ARS are weak, changes at the cellular receptor
level suggest a relationship. For example, intercellular ad-
hesion molecule 1 (ICAM-1) is a receptor for rhinovirus
and is upregulated in patients with AR.90 This suggests a
possible mutually-reinforcing relationship among allergic
and infectious immune insults. Environmental exposure to
smoking91,92 and air pollution86,93,94 have also been linked
to ARS, though mechanisms remain unclear.
Several anatomic abnormalities have been suggested
to predispose to ARS. These include recirculation
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TABLE V-1. Anatomic variants as risk factors for RS*
ARS Mixed group CRS
Pathology Effect No effect Effect No effect Effect No effect Effect size
Concha bullosa S16 S17 (+ trend) S99,S100,M101 S102,M103 S104,M105,S106,S107 Mild effect if large
Intralamellar cell S99 None
Paradoxical middle turbinate S16 S102,S99,S100 S106, S107 None
Infraorbital ethmoid S17 S16 M97 S99 S106, S107 >3 mm may have effect
Septal deviation S17 (+ trend) R108,S100,M101 S102 R109,S106,S107 Small effect with increasing angle
Accessory ostium S16 Effect noted
Infundibulum stenosis S17 S16 Possible effect
Uncinate bullosa S99 S106 None
*When the classification of RS is separated into acute, chronic, or a mixed distribution, anatomical variants have greater impact on ARS than CRS. Superscripted numbers
are reference citations.
S = study with confirmed symptoms of RS in addition to CT evidence of inflammation; M = study that only identified mucosal thickening and did not confirm cases had
symptoms of RS; R = well-performed systematic review.
phenomenon, conchae bullosa, and nasal septal deviations
(NSDs).95 Periapical infections of maxillary molars can
lead to direct inoculation of the overlying sinus cavity,
although dental causes of ARS are rare and more com-
monly seen in CRS.96 The evidence addressing the relative
contribution of several factors is explored in greater detail
in the next sections.
V.B.1.a. ARS Pathophysiology Contributing Fac-
tors: Anatomic Variants. Because radiographic imaging
is not indicated for uncomplicated cases of ARS,15 there is
no direct research to determine anatomic causes of ARS.
Instead, inferences are made from studies of complex cases
including RARS, complications of ARS, and patients with
AECRS.
Anatomical anomalies that have the potential to cause
sinusitis include stenosis of the infundibulum, recirculation
phenomenon, anomalies of the uncinate and MT, infraor-
bital ethmoid cells (Haller cells), and NSDs.95 A 97-patient
case-control study by Jain et al.16 examined patients with
clinical symptoms of CRS and either CT evidence of pansi-
nusitis or isolated maxillary/ostiomeatal complex (OMC)
disease (classified as “limited sinusitis”). Both groups were
compared to normal controls. The premise of that study
was that, if anatomical anomalies truly caused obstructive
RS, patients with limited sinusitis should have a higher in-
cidence of pathologic anatomic variants relative to patients
with pansinusitis or controls. The authors searched for con-
cha bullosa, infraorbital ethmoid cells, lateralized uncinate
processes, accessory ostium, and paradoxical MTs in both
groups. They found that only the presence of a concha
bullosa and accessory ostium were significantly related to
those cases associated with obstructive pathology (“limited
disease”).
Another study, by Alkire and Bhattacharyya,17 com-
pared 36 patients meeting strict criteria for RARS to 42
contemporaneous control patients, searching for causative
anatomical anomalies. The presence of infraorbital ethmoid
cells (39.9% vs 11.9%, p = 0.006) and a narrowed in-
fundibulum (0.591 mm vs 0.823 mm, p < 0.001) were
identified as potential causative factors. Additionally, the
authors noted a trend that did not achieve statistical signif-
icance for increased presence of concha bullosa and septal
spurs in cases of RARS.
When the literature is collectively considered by sorting
studies according to ARS vs CRS, a few findings emerge
(Table V-1). CRS appears unrelated to anatomic variation
and is more likely inflammatory in nature. ARS appears
to be related to several anatomical anomalies: concha bul-
losa, infraorbital ethmoid cells greater than 3 mm in size,97
accessory ostia in the common drainage pathway,98 and
stenosis of the infundibulum.16
Non–OMC-related causes of ARS include oroantral fis-
tula and dental infections. One retrospective case series
showed that a periapical abscess of a maxillary tooth
has a 9.75 odds ratio (p < 0.001) of causing substan-
tial reactive mucosal thickening on cone beam CT.110
Additionally, another study showed that periodontal dis-
ease with tooth roots emerging into the antrum and
oroantral fistulas can cause the symptoms and signs of
ARS.96
In summary, the evidence for an association between
ARS and anatomic variants is weak and largely inferred
from studies on RARS, CRS, and mixed groups of RS
(Table V-2).
 Aggregate Grade of Evidence: C (Level 4: 16 studies).
V.B.1.b. ARS Pathophysiology Contributing Fac-
tors: Allergy. AR and ARS have been proposed to inter-
act. To reach conclusions on the relationship between these
diseases, we should consider the available epidemiologic
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TABLE V-2. Evidence for anatomic variants and ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Jain16 2013 4 Diagnostic case-control 1. Maxillary/OMC
inflammation
(limited); 2.
Pansinusitis; 3.
Normal (control)
CT evidence of sinus
disease
Limited disease showed
increased concha bullosa
and accessory ostium
Shanbhag110 2013 4 Retrospective case series CT with maxillary
sinusitis
1. Fluid filling sinus (by
thirds); 2. Mucosal
thickening
Oroantral fistula, periodontal
disease and projected root
or abscess predict
maxillary sinusitis
Azila106 2011 4 Diagnostic case-control 1. CRS symptoms; 2.
Normal
CT evidence of sinus
disease
No effect of concha bullosa,
paradoxical MT, Infraorbital
ethmoid cell, NSD, or
uncinate bullosa
Cho102 2011 4 Diagnostic case-control 1. CRS symptoms; 2.
Normal
CT evidence of sinus
disease
No effect of NSD, concha
bullosa, or paradoxical MT
Alkire17 2010 4 Diagnostic case-control 1. RARS symptoms; 2.
Normal
CT evidence of sinus
disease
RARS associated with
Infraorbital ethmoid cell and
smaller infundibular width
Bomeli96 2009 4 Retrospective case series CT with mucosal
thickening
1. Periapical tooth
lucencies; 2.
Periodontal disease
Periapical lucencies increase
presence of sinus
inflammation by 9.75 times
(odds ratio)
Caughey101 2005 4 Diagnostic case-control 1. CT evidence of
mucosal thickening;
2. Normal CT
CT evidence of sinus
disease
Concha bullosa, NSD, and
infraorbital ethmoid cell
increases risk of sinus
disease
Kieff107 2004 4 Diagnostic case-control 1. Ipsilateral maxillary
CRS; 2.
Contralateral
normal side
CT evidence of sinus
disease
No effect from concha bullosa,
Infraorbital ethmoid cell,
NSD or paradoxical middle
turbinate
Stallman103 2004 4 Diagnostic case-control 1. CT with mucosal
disease with
concha bullosa; 2.
CT with mucosal
disease without
concha bullosa
CT evidence of sinus
disease
In cases of mucosal
thickening, no increased
chance of concha bullosa
Stackpole97 1997 4 Diagnostic case-control CT evidence of
mucosal thickening
and Infraorbital
ethmoid cells
CT evidence of sinus
disease
Infraorbital ethmoid cell size
predicts mucosal
thickening on CTs
Lam104 1996 4 Diagnostic case-control CRS with concha
bullosa
CT evidence of sinus
disease
No evidence that concha
bullosa has effect on CRS
Nadas105 1995 4 Diagnostic case-control Concha bullosa:
absent, small,
medium, and large
CT evidence of sinus
disease
Concha bullosa appears
unlikely to have an effect
on CRS
Bolger99 1991 4 Diagnostic case-control 1. CRS symptoms; 2.
Normal
CT evidence of sinus
disease
Concha bullosa showed
association with CRS;
infraorbital ethmoid cell
showed no association
Calhoun100 1991 4 Diagnostic case-control 1. Any sinus
symptoms; 2. No
sinus symptoms
CT evidence of sinus
disease
Concha bullosa and NSD
increased risk of sinus
disease. Paradoxical MT
showed no effect
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TABLE V-3. Evidence for allergy and ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Baroody115 2008 1b DB crossover (n = 20) Allergic subjects who
underwent nasal
challenge; controls
Eosinophils in maxillary sinus Nasal challenge with allergen
causes increased eosinophils
in the maxillary sinus
Rantala120 2013 2a Cross-sectional
(n = 1008)
Atopic and nonatopic
adults age 21–63 years
Upper and lower respiratory
tract infections
Individuals with atopic disease
had higher risk of developing
URIs including RS
Chen114 2001 2a Questionnaire (n = 8723) Children in Taiwan Rhinosinusitis Children reporting allergic more
likely to have RS
Holzmann113 2001 2b Retrospective review
(n = 102)
Children with orbital
complications of ARS
Prevalence of AR Orbital complications more
common in allergy season
Frerichs121 2014 3a Systematic review Allergic and nonallergic
patients
Prolonged course (>4 weeks)
of RS
No significant increase in
prolonged RS
Naclerio116 1997 3a Observational (n = 10) Allergic subjects at peak
of season
Sinus CT abnormality 60% had CT abnormalities
Savolainen112 1989 3b Case control (n = 224) Acute maxillary sinusitis
with and without allergy
ARS Prevalence of AR 25% and
16.5% in non-AR patients
DB = double-blind.
evidence, plausible mechanisms that may explain their in-
teraction, relevant human and animal studies, and whether
treatment of AR changes disease expression in ARS.
The estimated prevalence of AR is about 20%, whereas
over 50% of the U.S. population has evidence of IgE sen-
sitization, demonstrating that a positive skin test does not
necessarily indicate nasal allergic disease.111 Thus, positive
skin tests in ARS patients are not proof of a relationship
between AR and ARS because they only indicate sensiti-
zation. Conversely, local nasal allergic reactions can occur
without evidence of systemic IgE sensitization. Thus, even
the absence of a positive allergy test does not rule out a role
for AR in ARS.
Many, but not all, studies support an association be-
tween AR and ARS. Savolainen112 found the incidence of
allergy to be 25% in a group of 224 patients with acute
maxillary sinusitis, which was significantly greater than the
16% incidence in a control group. Holzmann et al.113 re-
ported an increased prevalence of AR in children who had
orbital complications of ARS, and also reported that these
complications occurred more commonly during pollinating
seasons. In a study involving 8723 children, Chen et al.114
found the prevalence of RS to be significantly higher in
children with AR than in children without allergies. Impor-
tantly, having AR did not predict a prolonged course of
ARS.
Studies suggest that allergic inflammation may lead to
inflammation in the sinuses. On a pathologic basis, nasal
challenge with allergens in allergic individuals leads to an
influx of eosinophils into the maxillary sinus.115 Similarly,
the majority of subjects with ragweed-sensitive AR (60%)
had sinus mucosal abnormalities on CT imaging during the
peak of ragweed season, yet resolution of symptoms after
treatment did not correlate with radiologic imaging.116 Fur-
thermore, individuals with ragweed AR had significantly
more eosinophils in the maxillary sinus during the ragweed
season compared to outside the ragweed season.117 These
studies suggest that AR could affect the inflammation in the
sinuses.
Because of the challenges of human studies, a mouse
model was developed to address the influence of AR on
ARS.118,119 Mice with ongoing nasal allergic reaction (but
not mice with lower airway reaction or sensitization alone)
had a worsened episode of ARS, and this effect could be
transferred by Th cells. These studies suggest that local al-
lergic inflammation plays an important role in the expres-
sion of ARS.
Currently, there are no definitive data that show that
medical treatment or immunotherapy prevents the devel-
opment of ARS. There are no studies demonstrating that
treatment for seasonal or perennial rhinitis reduces the inci-
dence of ARS during allergen-exposed periods. The limited
frequency of ARS occurring during seasonal AR makes the
prospect of a definitive immunotherapy study whose out-
come is the development of ARS highly unlikely.
In summary, observational studies provide a modest LOE
supporting a relationship between AR and ARS. This is fur-
ther supported by evidence from a mouse model of ARS in-
duction in allergen-sensitized, allergen-exposedmice. There
is some evidence that AR increases the likelihood of orbital
complications of ARS but no evidence that AR prolongs
the duration of ARS (Table V-3).
 Aggregate Grade of Evidence: C (Level 1b:1 study; Level
2a:2 studies; Level 2b:1 study; Level 3a:2 studies; Level
3b:1 study).
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TABLE V-4. Evidence for viruses and ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Gwaltney134 1992 2b Prospective (n = 343) Intranasal viral inoculation Development of sinusitis
symptoms
94% of patients became infected
van den Broek132 2014 3b Systematic review
(n = 265)
Clinically diagnosed ARS Positive culture Presence of purulence is not
diagnostic for ABRS
Autio124 2014 4 Observation case
series (n = 50)
Clinically diagnosed ARS Viral and bacterial
detection early phase
(2–3 days) and late
phase (9–10 days)
Total 84% viral detection;56%
early-phase bacterial detection;
40% late-phase bacterial detection
Lu122 2013 4 Observation case
series (n = 596)
Patients presenting with
common cold
Presence/absence of virus 38.8% positive virus detection rate
Rawlings128 2013 4 Observation
case-control (n =
88 controls, n = 70
common cold)
Patients presenting with
common cold
Presence/absence of
bacterial pathogens
Positive bacterial culture 5 times more
likely in patients with the common
cold
Gutierrez131 2012 4 Observation case
series (n = 10,048
H1N1; n = 31
common cold)
Patients presenting with
H1N1 virus and
common cold
Presence/absence of
ABRS
0.55% of patients with H1N1
developed an ABRS
Han129 2011 4 Observation
case-control, (n =
8 controls; n = 70
common cold)
Patients presenting with
common cold <8 days
Presence/absence of
bacterial pathogens
Bacterial pathogens more prevalent in
patients with the common cold vs
controls (31% vs 8%)
Makela123 1998 4 Observation case
series (n = 200)
Patients presenting with
common cold
Presence/absence of virus
or bacteria
69% positive detection rate for virus.
3.5% positive for bacteria
Puhakka136 1998 4 Observation case
series (n = 197)
Patients presenting with
common cold
Presence/absence of virus
and/or bacteria days 1,
7, and 21
Virus found early in patients
presenting with the common cold
(day 7); no significant increase in
bacteria was found
Gwaltney23 1994 4 Observation case
series (n = 90 with
common cold)
Patients presenting with
common cold
Presence/absence of
rhinovirus
27% of patients found to have
rhinovirus
V.B.1.c. ARS Pathophysiology Contributing Fac-
tors: Septal Deviation. The role of NSD in ARS is not
well studied. One systematic review has examined the role
of NSD in RS in general.108 The studies included in this
review largely failed to separate ARS from CRS, so that a
definitive statement regarding NSD as a contributing factor
for ARS cannot be made. The review did, however, show
an increasing risk of RS in general with increasing angle of
NSD. Despite these findings, additional research must be
performed before NSD can be defined as a risk for devel-
opment of ARS. Clearly the role of septoplasty in reducing
the risk of ARS is unknown.
 Aggregate Grade of Evidence: not applicable.
V.B.1.d. ARS Pathophysiology Contributing Fac-
tors: Viruses. ARS is commonly associated with an an-
tecedent acute viral RS (AVRS). Although the recovery of
viral agents from the nose in the setting of ARS has ranged
from 27% to 84%, this may reflect the variability and limi-
tations of the specific techniques used.23,122–124 Inoculation
of rhinovirus in humans produced greater than a 90% infec-
tion rate with up to 74% displaying ARS symptoms.125,126
It has been hypothesized that a preceding AVRS may be
associated with subsequent ABRS by inhibition of mucocil-
iary clearance (MCC) and blockade of sinus ostia due to
local swelling. However, the LOE that supports this as-
sumption is lacking (Table V-4).
CT imaging in patients with AVRS demonstrates occlu-
sion of themaxillary sinus infundibulum 77%of the time,23
and experimentally-induced RS with rhinovirus has been
associated with symptoms of the common cold and corre-
sponding reduced MCC.127 This led to investigations that
examined bacterial pathogens in the infundibulum and si-
nuses during wellness and suspected AVRS. These studies
found that patients with the common cold had higher lev-
els of bacteria in the nasal cavity and OMC compared to
well patients.128,129 It should be noted that the authors
made the assumption that those patients who presented
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with the common cold truly had an AVRS. Therefore, it
is unclear if viral inflammation directly led to subsequent
increased bacterial loads. Interestingly, current literature
suggests that only 0.5% to 2.2% of AVRS becomes com-
plicated by bacterial RS.130 Similarly, the risk of devel-
oping a bacterial upper respiratory tract infection after a
positive H1N1 influenza virus culture was demonstrated to
be a meager 0.55% from 46.4% of patients who presented
with AVRS.131 However, time course was not specified and
study data were retrospectively collected, suggesting limited
causality.
One of the reasons we have a limited understanding of
how AVRS progresses to an ABRS is the inability to clin-
ically distinguish between the 2 entities. Current evidence
suggests that symptoms alone such as purulent nasal dis-
charge, fever, or facial pain cannot distinguish between vi-
ral or bacterial infection.132,133 For these reasons, stud-
ies that directly sample the sinuses during an infection are
needed. Autio et al.124 found that up to 84% of patients
presenting with ABRS had viral nucleic acid detected during
the early phase of the disease (days 2 to 3), and a coinfection
with bacteria (56%) during the viral infection was found
to correlate with worse disease scores.
Current clinical practice guidelines recommend that the
presence of bacterial infection is more likely with dura-
tion of symptoms greater than 10 days. This is based on
the probability of confirming a bacterial infection by sinus
aspiration (60%) following 10 days of symptoms134 in ad-
dition to the completion of the natural time course for a
spontaneous rhinovirus infection.135 It is important to un-
derstand that a bacterial infection could potentially occur
at any time during the illness.
 Aggregate Grade of Evidence: C (Level 2b: 1 study; Level
3b: 1 study; Level 4: 8 studies).
V.B.1.e. ARS Pathophysiology Contributing Fac-
tors: Odontogenic Infections. The adult maxillary si-
nus expands toward the maxillary alveolar ridge during
development. This process allows the maxillary tooth roots
to reach and even penetrate through the floor of the maxil-
lary sinus. The close anatomic proximity of the root apices
of the teeth to the maxillary sinus is most likely responsi-
ble for the development of odontogenic RS in patients with
maxillary dental pathology.137
Odontogenic RS is considered in those patients with uni-
lateral ARS or CRS, and/or with uncontrolled unilateral
disease despite medical or surgical treatment. Further, the
microbiology of odontogenic sinusitis differs in that anaer-
obic microorganisms are more commonly prevalent.138
Historically, the prevalence of RS of odontogenic origin
has been quoted to be 10% to 15%.139 A more recent study
by Bomeli et al.96 evaluated the frequency of acute maxil-
lary RS and found that oroantral fistulas to be the only
independent predictor of RS. Periodontal disease, project-
ing tooth roots, and apical abscess were not independent
predictors, but there were interaction effects: the presence
of periodontal disease along with either a projecting tooth
root or an abscess were predictive of RS using regression
analysis.
It is believed that the most common causes of odonto-
genic RS include those processes that violate the mucosal
membrane, such as dental abscesses, periodontal disease,
secondary infections caused by intraantral foreign bodies,
and sinus perforations during tooth extraction. Although
there is scarce evidence in the literature pointing to com-
plications between a dental source and ARS, several case
reports were identified suggesting an association, including
dislodged bone grafts or implants blocking the maxillary
ostium140,141; however, it should be noted that ARS was
not defined in these reports. Further, more robust data
showing an association between periapical abscesses and
RS was found in aspirates between both the periapical ab-
scess and the maxillary sinus. The authors demonstrated
a concordance in the microbiological findings between the
periapical abscess and the maxillary sinus flora, suggesting
extension from the odontogenic source.138
It has been hypothesized that endosseous implant
placement which projects into the maxillary sinus may
also be a nidus for infection resulting in acute max-
illary sinusitis,142,143 although some authors refute this
concept.144 In addition, a recent 20-year retrospective study
suggests that implants with less than 3 mm sinus penetra-
tion are not associated with clinical or radiological signs
of RS.145
The current literature demonstrates an absence of a
well-designed and published investigation into the role of
odontogenic infections in ARS. Currently, our understand-
ing of odontogenic ARS is based on low-level evidence
(Table V-5).
 Aggregate Grade of Evidence: C (Level 4: 6 studies).
V.C. ARS: Diagnosis
ARS is defined in Section III.A. The diagnosis of ARS is clin-
ical and based on multiple symptoms, including nasal con-
gestion or blockage, drainage or postnasal drip (PND), fa-
cial pressure/pain, and reduction in the sense of smell.147–151
ARS may also be associated with regional upper airway
symptoms such as sore throat, hoarseness, and cough, as
well as nonspecific systemic complaints such as malaise,
fatigue, and low-grade fever.147,152 Nasal endoscopy and
radiographic imaging are not required for diagnosis in un-
complicated cases. Anterior rhinoscopy is recommended
and may reveal evidence of inflammation, mucosal edema,
and discharge.149 Elevations in erythrocyte sedimentation
rate (ESR) and CRP may be associated with ARS, but are
not required for diagnosis.153
 Aggregate Grade of Evidence: C (Level 2a: 2 studies;
Level 2b: 2 studies; Level 3b: 1 study; Level 4b: 1 study;
Table V-6).
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TABLE V-5. Evidence for odontogenic source of ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Abi Najm145 2013 4 Observation case series (n = 70) Patients with dental
implants
Maxillary sinus
imaging
Implant penetration is not
associated with
odontogenic sinusitis
Tabrizi144 2012 4 Observation case series (n = 18) Patients with dental
implants
Maxillary sinus
imaging
No increased risk
Bomeli96 2009 4 Observation case series (n = 124) Acute maxillary sinusitis
patients
Maxillary sinus
imaging
Odontogenic infections
predictive of opacification
in 17% to 86%
Jung143 2007 4 Observation case series (n = 23) Patients with dental
implants
Maxillary sinus
imaging
Implant projection of 4 mm
associated with mucosal
thickening
Abrahams146 1996 4 Observation case series (n = 84) Patients presenting with
periodontal disease
Maxillary sinus
imaging
38% positive detection rate
for maxillary opacification
Regev142 1995 4 Observation case series (n = 8) Patients with dental
implants
Presence/absence of
maxillary sinusitis
symptoms
Maxillary sinusitis associated
with implants
TABLE V-6. Evidence for diagnosis of ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Lindbaek150 2002 2a Systematic review 1.ABRS; 2.ARS Purulence on maxillary
sinus tap correlated
with symptoms
Purulent rhinorrhea,
maxillary/dental pain, pain
when bending forward, and two
phases of illness correlated
with presence of maxillary
sinus purulence
Hansen153 1995 2a Prospective cohort study Acute maxillary
sinusitis
ESR, CRP association with
acute maxillary sinusitis
Elevations in ESR and CRP
significantly associated with
acute maxillary sinusitis
Shaikh147 2013 2b Validating cohort study 1. ARS; 2. URI Symptom prevalence Mild symptoms, absence of green
discharge or disturbed sleep
more likely viral
Berg152 1988 2b Validating cohort study 1. Maxillary empyema;
2. No maxillary
empyema
Association between sinus
symptoms and
empyema
High reliability of local pain,
purulent rhinorrhea, especially
when unilateral, with maxillary
sinus empyema
Klossek148 2011 3b Cross-sectional survey ARS Symptom prevalence Most common symptoms were
nasal obstruction, pain,
rhinorrhea, and headache
Hueston149 1998 4b Retrospective case series 1. ARS; 2. URI Association between
symptoms and ARS
diagnosis
Sinus tenderness, pressure,
postnasal drainage, and
discolored nasal discharge
were highly associated with
ARS diagnosis
V.C.1. ARS Diagnosis: Differentiating Viral from
Bacterial ARS
ABRS is frequently a complication of a viral URI, and
the symptoms associated with these conditions overlap
greatly.132,133 Duration is a key factor distinguishing ABRS
from a common cold, with persistence of symptoms beyond
10 days or worsening of symptoms after 5 days being indi-
cators of development of post–viral ABRS.4,132,154,155
The ability to determine whether bacterial infection is
present in ARS is challenging in the primary care setting,
particularly without endoscopy or imaging.133 Clinical fac-
tors associated with ABRS include purulent discharge,4
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localized unilateral pain,156 and a period of worsening af-
ter an initial milder phase of illness.147 Nasopharyngeal
cultures are not necessary for ABRS diagnosis, but can help
with antibiotic guidance in the primary care setting.
Fokkens et al.7 suggest assuming bacterial ARS if diag-
nostic criteria for ARS aremet and at least 2 of the following
criteria are additionally present: (1) the disease lasts longer
than 7 to 10 days or worsens again after initial improve-
ment (double sickening); (2) symptoms, particularly pain
over teeth and maxilla, are severe (7 to 10 cm on a visual
analog scale [VAS]); (3) purulent secretions on rhinoscopy;
(4) increased ESR or elevated CRP; and (5) fever >38°C.
In contrast, Rosenfeld et al.4 point out there are no data to
support symptom severity or purulence as differentiators of
bacterial vs viral ARS and recommended relying principally
on time course.
The evidence related to differentiating acute viral from
acute bacterial RS is variable and is summarized in
Table V-7.
 Aggregate Grade of Evidence: B (Level 1a: 1 study; Level
1b: 3 studies; Level 2a: 2 studies; Level 2b: 4 studies).
V.C.2. ARS Diagnosis: Differential Diagnosis
The differential diagnosis of ARS includes AR, den-
tal disease, chronic fatigue syndrome, and facial pain
syndromes.164,165 Accurate diagnosis is most often possi-
ble solely on clinical grounds, but additional testing may
be required for symptoms that are persistent or severe.
AR is another condition with symptoms similar to ARS,
which can mainly be differentiated from ARS on the basis
of a prior history of allergy and atopy, as well as exacerba-
tion with exposure to allergens.112 If current pollen counts
and skin-prick tests in a patient with symptoms sugges-
tive of AR yield consistent results, AR is assumed.166 The
presence of itchy and watery eyes is common in AR but
rare in ARS. Conversely, ARS symptoms of mucopurulent
discharge, pain, and anosmia are uncommon in AR.
Dental disease can present with sinus pain, sometimes in
the absence of toothache or fever.96 Diagnostic criteria for
ARS are usually not met, because nasal congestion, hyper-
secretion, and/or hyposmia are absent. The lack of other
typical ARS-associated symptoms makes the diagnosis of
ARS less likely, and dental evaluation by a specialist with
appropriate imaging will provide clarification.
Headaches and midfacial pain syndromes are frequently
in the differential diagnoses of RS.167 The most common
primary headache syndromes are tension-type headache,
atypical facial pain, migraine, paroxysmal hemicrania, clus-
ter headache, and midfacial segment pain.168,169 Usually
the chronic course and pattern of these symptoms make
differentiation from ARS easy, but some headache syn-
dromes may be episodic and, with the exception of clus-
ter headaches, nasal symptoms are frequently absent. Oc-
ular pain syndromes, particularly glaucoma, may also
mimic ARS.170 Orofacial pain syndromes including tem-
poromandibular disorders have been extensively reviewed
in recent years.171,172
In summary, the differential diagnosis of ARS includes
AR, headache or facial pain syndrome, and dental con-
ditions. Although diagnosis is most often possible solely
on clinical grounds, additional testing may be helpful to
differentiate ARS from other entities with overlapping
symptoms.
V.D. ARS: Management
V.D.1. ARS Management: Antibiotics
As noted in Section V.C.1, differentiating viral from bac-
terial ARS can be challenging, and is often based on time
course. Once the clinical suspicion of ABRS exists, the next
controversial decision point is determining whether to pre-
scribe antibiotics.
Although antibiotics have traditionally been prescribed
for ABRS, this practice has recently been questioned. There
is substantial evidence that ARS has a high spontaneous res-
olution rate and the adverse events and costs from adding
antibioticsmay outweigh any potential benefits. Four recent
systematic reviews of RCTs have compared the efficacy of
antibiotics to that of placebo for ABRS.173–176 The reviews
found that antibiotics conferred a benefit, but it was small;
cure rates at 7 to 15 days improved from 86%with placebo
to 91% with antibiotics. This effect was sufficiently small
that the number needed to treat with antibiotics to show
improvement in 1 individual ranged between 11 and 15.
Moreover, the rate of adverse events was higher in those
treated with antibiotics, with the number needed to treat
before harm was seen being 8.1 (Table V-8).
In making the decision to prescribe or withhold antibi-
otics for ABRS, clinicians must practice sound EBM, which
includes taking into account the patient’s expectations and
the clinician’s individual experience. Nonetheless, educat-
ing patients on the small benefit of antibiotics relative to
the risk of adverse events may create a more sound shared
decision-making process. As 1 option to address patients’
concerns about the inconvenience, expense, and delay in
treatment for those who fail an initial period of “watchful
waiting,” Rosenfeld et al.4 recommend the use of “wait and
see” or “safety net” prescriptions. These prescriptions can
be given at the initial visit with instructions on when to fill
them, typically if there is no improvement after 7 days or
worsening at any time.
If the decision is made to prescribe an antibiotic, next the
clinician is faced with choosing which one. Many different
antimicrobial agents are indicated for acute bacterial sinus
infections, yet none has been found to have clearly supe-
rior clinical outcomes compared to the others. Multiple sys-
tematic reviews,173,175 reviews with recommendations,7,177
and CPGs4,178 have thoroughly reviewed the scores of com-
parisons of differing antibiotics, differing dosages, and dif-
fering durations of therapy. The consensus of all of these
analyses is that amoxicillin, either alone or with clavu-
lanate, is the first antibiotic of choice in treating suspected
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TABLE V-7. Evidence for diagnosis of acute bacterial RS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Young157 2003 1a RCT 1. Augmentin; 2. Placebo Symptom improvement by
diagnostic predictors
History of purulent discharge
and visible pus in nasal
cavity were more predictive
of antibiotic improvement
than radiography or
laboratory tests
Smith158 2015 1b Systematic review 1. Radiographic evidence;
2. Purulence
Correlation of radiographic
findings or purulence with
sinus culture
Diagnosis based on
radiographs or purulent
drainage only has a 50%
correlation with positive
cultures
Lacroix156 2002 1b Validating cohort study 1. Rhinosinusitis; 2. URI Discolored discharge, facial
pain, radiograph compared
to NPx culture
Discolored drainage, facial
pain, radiological maxillary
sinusitis were associated
with positive culture
Engels159 2000 1b Meta-analysis Positive or negative
maxillary sinus cultures
Symptoms, radiographs,
ultrasound
Ultrasound was least
predictive due to variability
Hauer133 2014 2a Systematic review ABRS and ARS Fever, facial pain Cannot distinguish viral from
bacterial based on fever or
facial pain
van den Broek132 2014 2a Systematic review 1. RS; 2. URI Symptom duration, purulent
rhinorrhea
Cannot distinguish viral from
bacterial based on
symptom duration or
purulent rhinorrhea
Lee160 2013 2b Validating cohort study 1. NPx culture;
2. MM culture
Concordance between culture
locations
Good concordance for the
culture sites makes them a
viable diagnostic tool
Berger161 2011 2b Prospective cohort 1. ABRS; 2. No ABRS Correlation of fiber-optic
endoscopy, radiography
with ABRS diagnosis
Fiber-optic endoscopy is
valuable for diagnosis of
ABRS
Hansen162 2009 2b Validating cohort study Positive or negative
maxillary sinus cultures
Symptoms, blood laboratory
tests
Elevated ESR and CRP were
sensitive but not specific for
positive bacterial cultures
Savolainen163 1997 2b Validating cohort study Positive or negative
maxillary sinus cultures
ESR, CRP, WBC count None of the blood tests were
sensitive indicators of ABRS
MM = middle meatal; WBC = white blood cell.
ABRS. Second-line drugs for those who have failed
amoxicillin/amoxicillin-clavulanate or who are allergic to
amoxicillin may include trimethoprim-sulfamethoxazole,
doxycycline, or a respiratory fluoroquinolone. Duration of
therapy is typically recommended as 10 days or less, with
shorter courses favoring fewer adverse events and higher
patient compliance.4,7
High-dose (4 g/day) amoxicillin-clavulanate appears to
have greater efficacy of reducing nasopharyngeal carriage
of pneumococcus compared to lower dose (1.5 g/day). One
study reported that of 27 pneumococcal isolates, 6 (only 1
in the high-dose arm) had intermediate to high resistant
organisms, whereas none of the other isolated bacterial
species were resistant.179 Another study reported clinical
resolution using amoxicillin-clavulanate in approximately
88% of culture-proven ARS, including an 88% to 97%
response in penicillin-resistant pneumococcus-positive and
beta-lactamase–positive infections.180
Resistance of common bacteria in ARS is an in-
creasing concern. Middle meatal swabs from a mixed
adult/pediatric group showed penicillin-resistant pneumo-
coccus in 72%, and ampicillin-resistant Haemophilus in-
fluenzae and Moraxella catarrhalis in 60% and 58.3%,
respectively.181
The choice of whether to include clavulanate has dif-
fered among recent reviews and clinical practice guidelines.
Chow et al.178 recommend amoxicillin-clavulanate for all
treatments, whereas Rosenfeld et al.,4 Fokkens et al.,7 and
Desrosiers et al.177 all consider it an option, and encourage
its addition when penicillin resistance is more likely, when
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TABLE V-8. Evidence for antibiotic therapy in ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Ahovuo-Saloranta173 2014 1a Systematic review of RCTs
and meta-analysis
1. Antibiotic vs placebo for
ARS; 2. Differing classes of
antibiotics
1. Clinical symptoms; 2.
Radiologic outcome
There is moderate
evidence that
antibiotics provide a
small benefit
Lemiengre174 2012 1a Systematic review of RCTs Antibiotic vs placebo for ARS 1. Symptom resolution; 2.
Adverse events
“There is no place for
antibiotics” in
uncomplicated ARS
Falagas175 2008 1a Meta-analysis of RCTs 1. Short-term therapy (up to
7 days) for ARS;
2. Longer-term therapy
for ARS
Improvement of symptoms There is no difference
seen between
short-term and
long-term courses of
antibiotics
Young176 2008 1a Meta-analysis of RCTs Antibiotics vs placebo for ARS Symptom resolution 15 patients need to be
treated before 1 patient
benefits from antibiotics
the clinical course is more severe, or when comorbidities
are present.
Adverse events must also be taken into account. A
Cochrane review173 showed dropout rates from adverse
effects were small in both antibiotic and placebo patients
(1.5% and 1%, respectively), but highest in the amoxicillin-
clavulanate subgroup (3.4%). Also, overall adverse effects
were greater in amoxicillin-treated patients than placebo
(31% vs 22%).
Direct costs of both amoxicillin and amoxicillin-
clavulanate are similar and low given the availability of
both drugs as generics. Indirect costs are also expected to
be similar given similar side-effect profiles, and the results
of a trial demonstrating no significant difference between
amoxicillin and placebo with regard tomissed work days or
in the inability to do nonwork activities (Table V-9).173,182
 Aggregate Grade of Evidence: A for choosing whether
to prescribe antibiotics (Level 1a: 4) B for amoxicillin vs
amoxicillin-clavulanate (Level 1b: 2; Level 2b: 2; Level
4: 3).
 Benefit: Potential for shorter duration of symptoms; re-
duced pathogen carriage.
 Harm: Gastrointestinal (GI) complaints greater than ob-
served in placebo for both drugs, more pronounced for
amoxicillin-clavulanate. Potential for resistance and for
anaphylaxis.
 Cost: Low to moderate.
 Benefits-Harm Assessment: Benefit of treatment over
placebo is small.
 Value Judgments: Improvement in patient symptoms is
limited with risk of adverse events. Patient preference
may be strong and education regarding benefit-harm bal-
ance may be necessary.
 Policy Level: Antibiotic use in suspected ABRS: Op-
tion. If an antibiotic is chosen, amoxicillin-clavulanate
vs amoxicillin: Option.
 Intervention: Withholding antibiotics with close follow-
up is an option in suspected ABRS. If an antibiotic is
chosen, both amoxicillin and amoxicillin-clavulanate are
options for treatment of uncomplicated ARS. Consider
amoxicillin-clavulanate for potentially complicated in-
fection or when resistant organisms are suspected.
V.D.2. ARS Management: Corticosteroids
ARS develops as a result of structural, infectious, and
inflammatory processes. Intranasal corticosteroid sprays
(INCSs), due to their anti-inflammatory and possible decon-
gestant properties, have been investigated as possible ad-
juvant therapies to limit transcription of proinflammatory
factors, stabilize phospholipid membranes, and inhibit IgE-
induced release of histamine, all with the effect of reducing
mucosal swelling.186,187 Numerous studies have reported
varied efficacy of intranasal or systemic corticosteroids to
reduce ARS symptom severity and duration, and Cochrane
review meta-analyses have reviewed trials of both modali-
ties to provide a assessment on the role of corticosteroids
in the management of ARS.
V.D.2.a. ARS Management: INCSs. INCSs of-
fer anti-inflammatory benefits and potential deconges-
tant action with negligible systemic bioavailability vs
oral corticosteroids.186 Randomized, placebo-controlled
blinded trials have evaluated the role of various INCSs in
managing the duration and severity of ARS symptoms, as
adjuvant therapies to antibiotic-based regimens, and more
recently as monotherapies.188,189 The latest INCS trials
have used either fluticasone propionate 110 μg daily or
twice daily or mometasone furoate 200 μg daily or twice
daily to reduce daily impact of major ARS symptoms.188,189
Although an early trial using budesonide demonstrated only
minimal improvement with INCS,186 results from subse-
quent trials suggest modest but significant improvements
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TABLE V-9. Evidence for amoxicillin vs amoxicillin-clavulanate in ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Garbutt182 2001 1b RCT in pediatric
patients
1. Amoxicillin; 2. Amoxicillin-
clavulanate; 3. Placebo
Telephone interviews
at 3 to 60 days
Day 14 improvement rate was
similar between groups.
Similar relapse/recurrence
rates
Wald183 1986 1b RCT in pediatric
patients
1. Amoxicillin; 2. Amoxicillin-
clavulanate; 3. Placebo
Telephone questionnaire
at 1 to 10 days
Both antibiotics were superior
to placebo at days 3 and 10
Anon180 2006 2b Cohort study Amoxicillin-clavulanate Bacterial eradication or no
clinical evidence of
infection
Success in 87.8%
Brook179 2005 2b Cohort study Amoxicillin-clavulanate with 2
different amoxicillin doses
(4 g/day vs 1.5 g/day)
Bacteria isolated by NPx
swab pretherapy and
posttherapy
Bacteria were isolated by
pretherapy and posttherapy
Olwoch184 2010 4 Case series Patients with complicated
sinusitis treated with
antibiotics and surgery
Bacterial isolates and
resistance
Pneumococcal prevalence low
(2.6%); penicillin resistance
high (64.3%)
Brook185 2008 4 Retrospective series
without control
Culture data from 2 different
time periods
Prevalence of
Staphylococcus
aureus and MRSA
Prevalence of MRSA was
greater in the latter time
period
Huang181 2004 4 Case series Middle meatal discharge
cultured during ARS episode
Prevalence of antibiotic
resistance
First-line penicillin class
resistance in 58% to 72%
for common pathogens
MRSA = methicillin-resistant Staphylococcus aureus.
in symptom control with hastened onset of relief, when
pairing INCS with antibiotics.188–194 A Cochrane review
meta-analysis, which included 1943 participants from 4
studies, arrived at a similar conclusion: symptoms in pa-
tients receiving INCS, particularly higher-dose treatments,
were more likely to resolve or improve than in placebo-
treated patients.187 However, these effects were admittedly
modest, requiring INCS treatment of 100 patients to pro-
vide 7 patients with complete or marked symptom relief.187
With infrequent adverse events and limited systemic up-
take, INCS use in ARS is a recommendation with grade A
aggregate quality of evidence. Additional studies compar-
ing ideal INCS formulation, dose, and timing will provide
important insight into tailoring INCS treatment in ARS
(Table V-10).
V.D.2.a. ARS Management: Systemic Corticos-
teroids. Although the majority of trials have focused on
the role of INCSs in ARS, a few trials have evaluated the
implications of systemic corticosteroids as adjuvant therapy
to antibiotics. Each of the 3 studies used different corticos-
teroid formulations in varying dosing and duration regi-
mens, thus preventing direct comparison of results.195–197
Studies by Gehanno et al.197 and Ratau et al.196 offered
early support for the use of systemic corticosteroids, specif-
ically methylprednisolone and betamethasone, for man-
agement of ARS-associated symptoms, particularly facial
pain. However, Venekamp et al.195 provide the most re-
cent study, which is also the most scientifically rigorous
and the only study performed without confounding ad-
juvant antibiotics. They failed to find significant symp-
tomatic improvement in patients taking prednisolone who
had been diagnosed clinically with ARS.195 A Cochrane
review meta-analysis, which included the Venekamp et al.
study,195 failed to find significant evidence to support sys-
temic corticosteroids in ARS, despite reviewing trial results
from 1193 participants.198 Interestingly, only 3 of the 5
studies included in the Cochrane review used objective mea-
sures to diagnose ARS, the other 2 relied only on a clinical
diagnosis.
Given the lack of consensus, systemic corticosteroids in
cases of uncomplicated ARS are not recommended, with a
grade B aggregate quality of evidence (Table V-11).
 Aggregate Grade of Evidence: A (Level 1a: 7 studies;
Level 1b: 11 studies [8 for INCS, 3 for systemic corticos-
teroids]).
 Benefit: INCS improved patient symptoms as monother-
apy or adjuvant to antibiotics in severe cases, and has-
tened recovery; systemic minimal benefit.
 Harm: Minimal harm with rare mild adverse events.
 Cost: Low for both interventions.
 Benefits-Harm Assessment: Benefit of treatment over
placebo small, but tangible; minimal harm with INCS,
greater risk for prolonged systemic corticosteroids.
 Value Judgments: INCS improved patient symptoms
with low risk for adverse event.
 Policy Level: Use of INCS: Strong recommendation. Use
of systemic corticosteroid: No recommendation.
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TABLE V-10. Evidence for intranasal corticosteroids in ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
van Loon199 2013 1a Systematic review
(n = 539)
INCS review in RARS Time to clinical cure
(duration of
symptoms)
INCS not recommended as
monotherapy in RARS
Zalmanovici187 2013 1a Analysis of 4 RCTs
(n = 1943)
1. INCS; 2. Placebo Resolution of symptoms,
adverse events, rates
of relapse, etc.
INCS improved resolution of
symptoms; higher doses
may have stronger effect
on improvement
Fokkens7 2012 1a Systematic review ARS patients Recommended in moderate
ARS as monotherapy or
severe ARS as an adjunct to
antibiotics
Hayward200 2012 1a Systemic review
(n = 2495)
ARS patients Symptom improvement,
adverse events,
relapse rates, etc.
Small symptomatic benefit in
ARS; higher effect with
longer duration and higher
doses. NNT = 13
Meltzer201 2008 1a Systemic review ARS patients Effective as adjunct or as
monotherapy to reduce
symptoms
Scadding202 2008 1a Systematic review BSACI guidelines INCS with antibiotics hastens
resolution of symptoms
Keith189 2012 1b RCT (n = 737) 1. Fluticasone 110 μg BID (n =
240); 2. Fluticasone 110 μg daily
(n = 252); 3. Placebo (n = 245)
Symptom improvement Both doses of INCS reduced
symptoms. Neither dose
showed differences in time
to improvement or
SNOT-20
Meltzer188 2012 1b RCT (n = 967) 1. Mometasone 200 μg BID (n =
233); 2. Mometasone 200 μg
daily (n = 240); 3. Amoxicillin
500 mg TID (n = 248); 4.
Placebo (n = 246)
Minimal-symptom days
and minimal-
congestion days
High-dose INCS had more
minimal-symptom days
Bachert194 2007 1b RCT (n = 981) 1. Mometasone 200 μg BID (n =
243) + placebo antibiotic; 2.
Mometasone 200 μg daily (n =
235) + placebo antibiotic; 3.
Amoxicillin 500 mg TID (n = 251)
+ placebo INCS; 4. Placebo INCS
+ placebo antibiotics (n = 252)
SNOT-20 200-μg BID regimen had
clinically significant
improvement in SNOT-20
vs placebo
Williamson186 2007 1b RCT (n = 240) 1. Amoxicillin 500 mg TID +
budesonide 200 μg daily (n =
53); 2. Amoxicillin 500 mg TID +
placebo INCS daily (n = 60); 3.
Budesonide 200 μg daily +
placebo antibiotic (n = 64); 4.
Placebo antibiotic + placebo
INCS (n = 63)
Improvement in Total
Symptom Severity
Score by >4 points,
as assessed in
symptom diary
No synergistic effect between
INCS and antibiotics. Milder
cases benefited from the
INCS whereas more severe
cases did not
Meltzer191 2005 1b RCT (n = 981) 1. Mometasone 200 μg BID (n =
243) + placebo antibiotic; 2.
Mometasone 200 μg daily (n =
235) + placebo antibiotic; 3.
Amoxicillin 500 mg TID (n = 251)
+ placebo INCS; 4. Placebo INCS
+ placebo antibiotics (n = 252)
Change symptoms diary INCS BID was significantly
better than all other groups;
no difference between INCS
daily and placebo
(Continued)
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TABLE V-10. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Nayak190 2002 1b RCT (n = 967) Amoxicillin/clavulanate 875 mg BID
plus: 1. Mometasone 400 μg BID
(n = 324); 2. Mometasone 200
μg (n = 318); 3. Placebo INCS (n
= 325)
Change from baseline
symptoms and CT
normalization
High-dose and low-dose INCS
improved symptoms with
no significant change in CT
score
Dolor192 2001 1b RCT (n = 95) 1. Fluticasone propionate 200 μg
daily (n = 47); 2. Placebo INCS (n
= 48)
1. Symptoms improved
at 10–56 days); 2.
Time to success; 3.
Number of ARS
recurrences
INCS patients have higher
rates of “clinical success,”
shorter time to success
(6 vs 9 days); and trend
toward fewer recurrences
Meltzer193 2000 1b RCT (n = 407) 1. Mometasone furoate 400 μg BID
+ amoxicillin/clavulanate 875
mg BID (n = 200); 2. Placebo
INCS + amoxicillin/clavulanate
875 mg BID (n = 207)
Symptom improvement Congestion, facial pain, and
headache significantly
improved with INCS. No
difference in purulent
rhinorrhea, PND, or cough
BSACI = British Society for Allergy and Clinical Immunology; NNT = number needed to treat.
TABLE V-11. Evidence for systemic corticosteroids in ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Venekamp198 2014 1a Meta-analysis of 5
RCTs (n = 1193)
1. Systemic corticosteroid; 2.
Placebo
Symptom improvement, time
to resolution,
bacteriological
cure/relapse, adverse
events
Oral corticosteroids are
ineffective as monotherapy;
oral corticosteroids may be
beneficial as adjunct to
antibiotics
Venekamp195 2012 1b RCT (n = 185) 1. Prednisolone 30 mg daily
(n = 93); 2. Placebo
(n = 92)
Resolution of facial pain/
pressure and other
symptoms
No differences seen in any
outcomes.
Gehanno197 2000 1b RCT (n = 417) Amoxicillin/clavulanate
500 mg TID plus: 1.
Methylprednisolone 8 mg
TID (n = 208); 2. Placebo
(n = 209)
Regression of clinical
symptoms or radiologic
signs by day 14
Oral corticosteroids may help
in short-term relief,
particularly facial pain, but
effect diminishes by 14
days
Ratau196 2004 2b RCT (n = 42) 1. Betamethasone 1 mg daily
(n = 21); 2. Placebo daily
(n = 21)
Reduction in symptom
severity by day 6
Headache, facial pain, nasal
congestion, and dizziness
improved with treatment
 Intervention: INCS should be trialed as monotherapy in
moderate or as adjuvant to antibiotic therapy in severe
cases of ARS. Systemic corticosteroids may be useful in
palliation when predominant symptoms are facial pain
or headaches, otherwise no tangible benefit.
V.D.3. ARS Management: Other Treatments
Decongestants are recommended by physicians in ARSwith
the presumed benefit of reducing nasal congestion and
hence improving patient symptoms. There is minimal ev-
idence regarding the use of decongestants in adult ARS.
Inanli et al.203 performed an RCT looking at this topic.
The primary outcome measure in this study was saccharin
transit time. This was demonstrated to be slower initially
in those with ARS and faster with the use of oxymetazoline
and hypertonic saline. Ultimately, however, no significant
difference between treatment groups and controls was ob-
served at the conclusion of the study. Wilkund et al.,204
performed a double-blind RCT on patients with acute max-
illary sinusitis. They examined oxymetazoline or an oral an-
tihistamine against a placebo. The outcome measures were
patient reported symptoms and radiology. Neither treat-
ment was shown to have significant benefit over placebo at
the study conclusion.
Several systematic reviews on this topic have been
published.7,15,205 None have found sufficient evidence to
allow a recommendation to be made (Table V-12).
 Aggregate Grade of Evidence: not applicable.
Antihistamines. Antihistamines are prescribed in ARS
on the basis that they reduce nasal secretions. Systematic
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TABLE V-12. Evidence for decongestants in ARS
Study Year LOE Study Design Study groups Clinical endpoint Conclusions
Fokkens7 2012 1a Systemic review Sufficient data lacking to
recommend
Rosenfeld15 2007 1a Systematic review No evidence for efficacy in
ABRS
Inanli203 2002 1b RCT ARS patients treated with
amoxicillin/ clavulanate
and: 1. No treatment; 2.
INCS; 3. Oxymetazoline; 4.
Hypertonic saline irrigation;
5. Normal saline irrigation
Saccharin transit times Oxymetazoline was associated
with faster times than no
treatment
Wiklund204 1994 1b DBRCT Patients with acute maxillary
sinusitis treated with
phenoxymethylpenicillin
and: 1. Oxymetazoline and
an oral antihistamine; 2.
Placebo
Clinical examination through
28 days; conventional sinus
X-ray; VAS entries in patient
diary
No difference between groups
Leung212 2008 5 Expert opinion No evidence
reviews have looked at their efficacy in the treatment of
adult ARS.7,177 No evidence to support their use in this
setting was demonstrated. A review of the literature was
unable to identify any studies upon which to make recom-
mendations.
 Aggregate Grade of Evidence: not applicable.
Nasal Saline Irrigation. Saline has long been used in the
treatment of ARS. Multiple studies have shown it to im-
prove saccharin transit times in normal patients and those
with ARS.203,206–208 Limited evidence also exists to suggest
it improves symptoms andQoL for patients with ARS.15,209
A number of systematic reviews and clinical guidelines on
the subject of saline irrigation in ARS have been published
and have found an overall benefit in symptom reduction
(Table V-13).4,7,155 Although the studies individually do
not provide a compelling case for the use of saline in ARS,
taken together they can be interpreted as demonstrating a
likely benefit in terms of nasal function and patient symp-
toms with minimal likely harms.
 Aggregate Grade of Evidence: A (Level 1a: 3 studies;
Level 1b: 4 studies; Level 2b: 1 study).
 Benefit: Possible nasal symptom improvement. Improved
nasal saccharin transit times.
 Harm: Occasional patient discomfort.
 Cost: Minimal.
 Benefits-Harm Assessment: Benefit likely to outweigh
harm.
 Value Judgments: None.
 Policy Level: Option.
 Intervention: Use of saline may benefit patients in terms
of improved symptoms and is unlikely to lead to signifi-
cant harm.
Other Interventions. Although commonly prescribed
by practitioners for ARS, no identifiable evidence for or
against the use of ipratropium bromide and mucolytics in
this condition was found.
A number of herbal interventions for ARS have been
published in the literature (Table V-14). Although extract
of Pelargonium sidoides210 and cineole211 have evidence
suggesting efficacy, methodological flaws and possible
conflicts of interests in their associated studies makes it
difficult to make any useful recommendations regarding
their use other than the need for further well-designed
trials.
V.E. ARS: Complications
Complications of ARS are classified into orbital, osseous,
and intracranial,216 though some unusual complica-
tions have also been described.217–221 Sinus disease
is the underlying cause of about 10% of intracranial
suppuration,222,223and is associated with 10% to 90% of
periorbital infections.224 In large epidemiological studies,
the overall incidence of complications ranged from 3 per
million individuals per year in the Netherlands,225 to 2.7
to 4.3 per million children per year in the United States
(intracranial),226 to 2.5 per million of population per year
in France.227 In almost all studies males are significantly
more frequently affected than females225–227 and ARS was
more often the precipitating factor in children, whereas
CRS with or without nasal polyposis was more important
in adults.228,229 The most common complications were
orbital, appearing at least twice as often as intracranial,
with osseous being the least common.225,228,230 There
was a clear seasonal pattern of complications, mirroring
the incidence of URIs.226 Although orbital complications
tend to occur primarily in small children, intracranial
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TABLE V-13. Evidence for nasal saline irrigation in ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Fokkens7 2012 1a Systemic review Most studies indicate
reduction of symptoms
Rosenfeld15 2007 1a Systematic review Saline improves QoL and
reduces symptoms and
pain medication use
Slavin155 2005 1a Systematic review Hypertonic saline improves
MCC
Hauptman206 2007 1b DBRCT Patients with “RS”: 1.
Hypertonic saline; 2.
Normal saline
SNOT-20; acoustic
rhinometry; saccharin
transit time
Improved MCC with either
solution. Buffered
physiologic saline improved
acoustic rhinometry
Wabnitz213 2005 1b RCT blinded 8 healthy volunteers; 0.9% or
3% saline
Collected ciliated cells and
CBF calculated
Hypertonic saline increases
CBF at 5 minutes but not
maintained at 60 minutes
Inanli203 2002 1b RCT 1. No treatment; 2. INCS; 3.
Oxymetazoline; 4.
Hypertonic saline irrigation;
5. Normal saline irrigation
Saccharin transit times Hypertonic saline was
associated with improved
MCC
Adam214 1998 1b RCT blinded Adults with common cold or
ABRS in primary care
setting: 1. Hypertonic
saline; 2. Normal saline
Nasal symptom score on day
3 and “day of well-being”
No difference in outcomes
between treatments. No
difference between ABRS
and cold groups
Rabago209 2002 2b Lower-quality randomized
trial (not blinded or
placebo-controlled)
Patients with ARS and CRS: 1.
Hypertonic saline irrigation
daily; 2. “Their usual
treatment”
QoL questionnaires Improved sinus-related QoL
with irrigation; improved
symptom severity
TABLE V-14. Evidence for herbal treatments in ARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Guo215 2006 1a Systematic review of RCTs Some evidence for benefit with
bromelain and Sinupret R© in
ARS
Bachert210 2009 1b Multicenter prospective DBRCT 1. Pelargonium sidoides
drops; 2. Placebo
Sinus severity score.
Radiologic changes;
SNOT-20, activity level,
ability to work
Every result was statistically
significant in favor of
Pelargonium sidoides
Tesche211 2008 2b DBRCT; no placebo control Patients with ARS and viral RS
randomized to: 1. Cineole;
2. Combination of 5
different components
Clinical and endoscopic
assessment
Cineole was more effective
complications can occur at any age, with predilection for
the second and third decade of life.225,231
V.E.1. ARS Complications: Orbital Complications
Chandler et al.’s232 classification of orbital complications
included preseptal cellulitis, orbital cellulitis, subperiosteal
abscess, orbital abscess, and cavernous sinus thrombosis.
However, the orbital septum is the anterior limit of the
orbit, hence “preseptal cellulitis” could be considered as an
eyelid, rather than an orbital, infection.233,234 Cavernous
sinus thrombosis228 is an intracranial complication and not
necessarily the end stage of orbital infection, so it will be
discussed in Section V.E.2.235
Typical signs of orbital cellulitis include conjunctival
edema (chemosis), a protruding eyeball (proptosis), ocular
pain and tenderness, and restricted and painful movement
of the extraocular muscles.228,236,237 In most series, high
fever and raised leucocyte count as well as an increased
number of immature neutrophils in peripheral blood were
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strongly associated with (subperiosteal or intraorbital) ab-
scess formation.238
A subperiosteal abscess forms between the periorbita and
the sinuses and is extraconal (located outside the extraoc-
ular muscles). The clinical features of a subperiosteal ab-
scess are similar to orbital cellulitis; however, as a conse-
quence of extraocular muscle involvement, the globe may
become fixed (ophthalmoplegia) and visual acuity may be
impaired.
An orbital abscess is intraconal (contained within the
space defined by the extraocular muscles) and generally
results from diagnostic delay or immunosuppression of
the patient239 with a frequency of between 13%229 and
8.3%240 in pediatric studies of orbital complications. The
predictive accuracy of a clinical diagnosis has been found
to be 82% and the accuracy of CT to be 91%.241 If a
concomitant intracranial complication is suspected or in
cases of uncertainty, magenetic resonance imaging (MRI)
can provide valuable additional information.229,241–244
Management is with intravenous (IV) antibiotics and
drainage of subperiosteal or intraorbital abscess. Evidence
of an abscess on the CT scan or absence of clinical im-
provement after 24 to 48 hours of IV antibiotics are in-
dications for orbital exploration and drainage,229 as well
as drainage of the paranasal sinuses.245 In small children
with subperiosteal abscesses, there have been a number of
studies showing good outcomes with IV antibiotics alone
and no surgical drainage in selected cases. 246–249
V.E.2. ARS Complications: Intracranial
Complications
These complications include epidural or subdural abscesses,
brain abscess, meningitis, cerebritis, superior sagittal and
cavernous sinus thrombosis, and isolated oculomotor or
abducens nerve palsy.222,226–228,231,250–252
The clinical presentation of these complications can be
nonspecific, characterized simply by high fever with se-
vere, intractable headache, or even be silent.228,253 The
majority, however, present with more specific signs and
symptoms that suggest intracranial involvement, such as
nausea and vomiting, neck stiffness, and altered mental
state.227,228,254–256 Intracranial abscesses are often heralded
by signs of increased intracranial pressure, meningeal irri-
tation, and focal neurologic deficits, including third, sixth,
or seventh cranial nerve palsies.228,254,257 Although an in-
tracranial abscess can be relatively asymptomatic, subtle af-
fective and behavioral changes often occur, showing altered
neurologic function, altered consciousness, gait instability,
and severe, progressive headache.252,258
A CT scan is essential for diagnosis because it allows
an accurate definition of bone involvement. MRI uti-
lization is increasing, being more sensitive than CT,259
as well as having an additional value in cavernous si-
nus thrombosis.227,256 Magnetic resonance angiography
(MRA) may be useful in cavernous sinus thrombosis as
well.260 Moreover, if meningitis is suspected, a lumbar
puncture could be useful256 after imaging excludes an
abscess.
High-dose IV antibiotic therapy with burr hole ab-
scess drainage, craniotomy, or image-guided aspiration as
needed, are usually required for successful treatment.261,262
There is evidence that combined drainage of the paranasal
sinuses can be performed endoscopically.259,263 Pathogens
most commonly involved in the pathogenesis of intracra-
nial complications are Streptococcus and Staphylococcus
species and anaerobes.222,261
Cavernous sinus thrombosis may present as bilateral lid
drop, exophthalmos, ophthalmic nerve neuralgia, retrooc-
ular headache, complete ophthalmoplegia, papilledema,
and/or signs of meningeal irritation associated with spiking
fevers.264 The cornerstone of diagnosis is MR venogram,
demonstrating absence of venous flow in the affected cav-
ernous sinus. The use of anticoagulants in these patients
remains controversial.264,265 Corticosteroids may help to
reduce inflammation and are likely to be helpful, adminis-
tered with concomitant antibiotics. Drainage of the offend-
ing sinus (almost always the sphenoid) is indicated.
V.E.3. ARS Complications: Osseous
Complications
Sinus infection can also extend to the bone producing
osteomyelitis, especially the frontal bones. On the ante-
rior wall of the frontal sinus it presents clinically with
“doughy” edema of the skin over the frontal bone produc-
ing a mass (Pott’s puffy tumor) whereas from the posterior
wall spread occurs directly or via thrombophlebitis of the
valveless diploic veins leading to meningitis, epidural ab-
scess, or brain abscess.264 Therapy includes a combination
of broad-spectrum, IV antibiotic administration, surgical
debridement of sequestered bone, and (endoscopic or open)
drainage of the frontal sinus.264
VI. RARS
VI.A. RARS: Incidence/Prevalence
The annual incidence of recurrent RARSwas obtained from
MarketScan Commercial Claims and Encounters database
(2003-2008) and was estimated to be 0.035% (3.5/10,000
per year).37
VI.B.1. RARS: Physiologic Contributing Factors
Similar to ARS, several factors predispose an individual to
developing RARS and include viral infection, AR, environ-
mental factors, and immunologic deficiency. Few authors
specifically delineate RARS as a separate entity and much
of what follows is extrapolated from studies on ARS and/or
CRS.
Viral infections are a common cause of RARS and com-
monly precede bacterial infections. Although the average
adult experiences 2 to 3 URIs a year, these URIs typi-
cally resolve spontaneously. Between 0.5% and 2% of indi-
viduals with URIs develop ABRS.130,266 Viruses including
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rhinovirus, adenovirus, influenza, and parainfluenza are the
most commonly associated with URIs.267 Rhinovirus is the
predominant cause of the common cold and has been found
within the respiratory epithelium in patients with ARS.268
It has been shown that 50% of these patients possessed
rhinovirus in mucosal biopsies.269
There has been some debate about the influence allergy
has on the development of RARS. Although a number of
studies provide evidence that allergy is a predisposing fac-
tor, others have disputed this. Similar to viral infections,
the inflammation and obstruction associated with allergic
disorders cause mucosal edema, ostial obstruction, and re-
tained sinus secretions. As a result, the sinus environment
becomes conducive to bacterial overgrowth.266,270,271 Not
only is there a reported increased coexistence of AR in 25%
to 31% of adults with acute maxillary sinusitis compared
to healthy controls, there is also an association between
AR and abnormal sinus CT scans.112,272 In an attempt to
understand a potential effect that AR has on a patient’s
innate immunity, 1 study found higher levels of eosinophil-
derived neurotoxin (EDN) and decreased levels of lysozyme
in the nasal fluids of patients with AR with RARS com-
pared to patients with AR alone or control patients.273 It
was suggested that the alteration in antimicrobial peptides
and proteins predisposes patients to recurrent infections.
In contrast, another study of innate immunity found that
Toll-like receptor 9 (TLR9) expression in sinonasal epithe-
lial cells was significantly increased in patients with AR
and RARS compared to the AR-only group. Indeed, rather
than a TLR9 defect increasing susceptibility to recurrent
RS, there was actually an upregulation, perhaps in response
to repeated antimicrobial insults.274
Another predisposing factor for the development of
RARS is immunodeficiency.275,276 The majority of primary
immune deficiencies (PIDs) associated with RARS are hu-
moral in nature and include Ig deficiency and common vari-
able immunodeficiency (CVID).277–279 Additionally, other
types of immune deficiencies such as human immunodefi-
ciency virus–acquired immunodeficiency syndrome (HIV-
AIDS), ataxia telangiectasia, Wiskott-Aldrich syndrome,
and C3 deficiency may also present with recurrent RS.275
One significant limitation in evaluating the role of immun-
odeficiency in RARS is that many studies do not discrimi-
nate RARS from CRS.
In conclusion, there is a paucity of information regarding
predisposing factors for RARS. As a result, there is some
controversy on its etiology. Although limited, the available
data suggest that viral infections, allergy, and certain im-
munodeficiencies can predispose patients to develop RARS
(Table VI-1).
 Aggregate Grade of Evidence: C (Level 2a: 1 study; Level
2b: 8 studies; Level 2c: 1 study; Level 3b: 3 studies; Level
4: 4 studies).
 Benefit: Ability to identify predisposing factors for the
development of RARS, which may allow a more tailored
and targeted therapeutic approach.
 Harm: Falsely identifying conditions that may not have
a significant association with the development of RARS.
 Cost: Cost associated with allergy and immune testing.
 Benefits-Harm Assessment: Preponderance of benefit
over harm.
 Value Judgments: Identifying predisposing factors for
RARS will allow for a more targeted therapeutic ap-
proach and improve outcomes.
 Policy Level: Recommendation
 Intervention: Consider viral, allergic, and immunodefi-
ciency as a cause for RARS.
VI.B.2. RARS: Anatomic Contributing Factors
The literature that evaluates the impact of anatomic vari-
ants on RS is largely composed of radiographic studies that
evaluate CT scans for anatomic variants in patients with
and without RS. Most of these studies have small numbers
of patients and usually combine all forms of RS or mucosal
thickening and do not specifically examine a specific type
of RS such as RARS. However, there is 1 study that did
assess RARS with regard to sinonasal anatomic variants
(Table VI-2). This was a small, retrospective radiographic
study comparing adult RARS patients to control patients
without RS,17 with 36 RARS patients and 42 patients in
the control group. In the study, the RARS group had a
mean Lund-Mackay (LM) score of 2.25, whereas the con-
trol group had a mean LM score of 1.27. There was sta-
tistically higher number of infraorbital (Haller) cells and
a smaller infundibular diameter in the RARS group com-
pared to the control group. There was a trend toward asso-
ciation with NSD and concha bullosa in the RARS group;
however, the study numbers were small and may have been
insufficiently powered.
 Aggregate Grade of Evidence: not applicable.
VI.C. RARS: Diagnosis
Correct diagnosis of RARS necessitates that there be a com-
plete resolution of the signs and symptoms of ARS between
episodes of recurrence. Diagnosis of this condition can
therefore be challenging because patients may present with
longstanding, episodic histories of common RS symptoms
such as sinus pain, pressure, congestion, and PND without
an abnormal CT or abnormal endoscopic exam between
acute episodes. The clinician is therefore mandated to take
a detailed history so the recurrent pattern of ARS can be
identified and the diagnosis of RARS clinched.
There is evidence to support that due to the lack of
characterization of this particular form of RS, a signifi-
cant burden of cost is incurred by the healthcare system.37
Bhattacharyya et al.37 demonstrated that in a population
with RARS, only 2.4% of patients received a nasal en-
doscopy over the course of the first year and only 9.2%
after 3 years from the onset of RARS. As for imaging ex-
ams, only 40% had received at least 1 CT scan after 4
years of the onset of symptoms. It is important to point
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TABLE VI-1. Evidence for physiologic contributing factors for RARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Wise276 2007 2a Systematic review of
cohort studies
Patients with recurrent or
chronic RS
Impact of CF, sarcoidosis,
AFRS, and aspirin
sensitivity
Recommended treatment of
comorbidities accordingly
Kirtsreesakul270 2004 2a Systematic review of
cohort studies
Systematic review of the
literature regarding AR and
RS
RS and AR share common
feature. The mechanisms
explaining how AR leads to
RS remain unclear
Melvin274 2010 2b Prospective cohort study 1. 8 AR (AR) patients; 2. 13 AR
+ RARS patients
TLR9 expression in sinonasal
epithelial cells
AR+RARS had a significant
increase in TLR9
expression compared with
that of AR-only patients
Edwards278 2004 2b Individual retrospective
cohort
127 IgA-deficient patients
referred to an immunology
clinic
Relationship between
vaccination and recurrent
infections
There was no relationship
between recurring
infections and
pneumococcal vaccine
responses
Kalfa273 2004 2b Prospective cohort study 1. 15 patients with PAR with
recurrent RS; 2. 16 patients
with PAR alone; 3. 16
controls
1. Lysozyme levels; 2. EDN
levels; 3. Lactoferrin levels;
4. HBD-2 levels
Decreased lysozyme and
increased EDN levels in
PAR+RS patients. No
differences in lactoferrin
and HBD-2 levels
Chee275 2001 2b Retrospective cohort study 1. 79 patients with RARS 1. Results of immunological
evaluation for atopy;
2. Ig levels
40% of patients were anergic.
Low IgG was found in 18%,
low IgA in 17%, and low
IgM in 5.%. CVID was
diagnosed in 9.9%
Savolainen112 1989 3b Case-control 1. 224 young adults with
acute maxillary sinusitis; 2.
Age-matched controls
Occurrence of allergy in the
2 groups
Higher occurrence of allergy in
the sinusitis group
Carr277 2011 3b Individual case-control
study
129 patients with CRS who
underwent ESS
Prevaccination and
postvaccination IgG and IgA
titers for Streptococcus
pneumoniae
72% had low baseline
anti-pneumococcal titers;
11.6% had an inadequate
response to the vaccine
Ramadan272 1999 3b Retrospective case-control 42 patients with RS who
underwent CT scan and
RAST testing
CT sinus findings in patients
with and without allergies
Allergic patients had higher
Lund-Mackay scores than
nonallergic patients
Pitkaranta269 2001 4 Prospective case series 14 adult patients with ARS Detection of HRV in maxillary
sinus tissue
HRV RNA was detected inside
the epithelial cells of the
maxillary sinus in 50% of
patients with ARS
Pitkaranta268 1997 4 Prospective case series 20 adults diagnosed with
acute community-acquired
RS
Detection of HRV and/or HCV.
Bacterial cultures
HRV infection was found in
40% and HCV in 15% of
patients with ARS
Gwaltney23 1994 4 Prospective case series 110 patients with
self-diagnosis of URI
for 48 to 96 hours
Viral cultures Rhinovirus was detected in
27% of patients
Turner280 1992 4 Prospective case series 19 adults exposed to
rhinovirus
MRI abnormalities of the
paranasal sinuses
33% showed sinus MRI
abnormalities that are
reversible without
antimicrobial therapy
HCV = human coronavirus; HRV = human rhinovirus; PAR = perennial AR; RAST = radioallergosorbent test.
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TABLE VI-2. Evidence for anatomic contributing factors for RARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Alkire17 2010 3b Retrospective
case-control
36 patients meeting strict
criteria for RARS; 42
control patients
Anatomical variants
seen on CT
Higher presence of infraorbital ethmoid
cells and smaller infundibular widths in
RARS patients
out that the delay and inappropriate use of diagnostic tools
for RARS yielded a direct healthcare cost of approximately
US$1000 per year per patient. This amount is similar to the
one usually presented for CRS patients. Taken into perspec-
tive, it highlights the importance of early and appropriate
diagnosis of RARS.
Because a complete resolution in between episodes must
be achieved, and is part of the diagnostic criteria, the sep-
aration of RARS from CRS remains difficult. There are
even proposals that patients with RARS may represent a
distinct phenotype, representing a separate disease entity
altogether.18
Although the diagnostic evaluation of these patients is
clinical, it is important to evaluate for CT findings of
anatomic obstruction in RARS, and to assess for allergy
that may be the instigating factor for RARS.17 It may also
be important to recommend that patients return for clini-
cal evaluation during an acute episode for documentation,
sinus culture (often most accurately obtained via nasal en-
doscopy), and evaluation of the ARS episodes, so that a
proper diagnosis can be made and appropriate treatment
initiated early. It is highly desirable to obtain microbio-
logical evidence of bacterial infection during an episode to
help confirm the diagnosis.44 Evaluation may include CT
imaging to aid objective assessment.
VI.D. RARS: Management
VI.D.1. RARS Management: INCS
A total of 3 studies were identified with the primary objec-
tive of assessing the effect of INCSs on symptom outcomes
of patients with RARS (Table VI-3). All study designs were
double-blinded RCTs (DBRCTs). All studies reported im-
provement in symptoms in the treatment groups. In ad-
dition, a recent systematic review by van Loon et al.199
summarized the impact of INCS use on symptom relief
in patients with RARS. Dolor et al.192 demonstrated sig-
nificant improvement in median days to clinical success
(6 in treatment group vs 9 in placebo group; p = 0.01)
with intranasal fluticasone. Meltzer et al.193 demonstrated
that mometasone resulted in improvement of total symp-
tom scores and specific symptoms of headache, congestion,
and facial pain. One major limitation of the available data
is that none of the studies defined RARS according to the
commonly accepted definition of 4 or more episodes per
year with absence of intervening symptoms. This may limit
applicability to RARS patients, and is considered a limita-
tion of the RCTs. Dolor et al.192 included a heterogeneous
population of patients with a history of RARS or chronic
rhinitis, whereas Qvarnberg et al.281 included a small
(n = 40), heterogeneous population of patients with recur-
rent acute maxillary RS (defined as 2 episodes per year for
2 years) and CRS. The study by Meltzer et al.193 included
only patients with RARS, defined as at least 2 episodes per
year for 2 years. Another limitation of all studies was inclu-
sion of additional therapeutic agents in addition to INCSs.
All studies included antibiotic therapy, and 1 included nasal
decongestant therapy. Finally, INCSs were used in these
studies during periods of acute exacerbation, and thus ef-
ficacy as a preventative therapeutic measure in this popu-
lation is unknown. No serious side effects were reported
from INCS use.
 Aggregate Grade of Evidence: B (Level 2b: 3 studies).
 Benefit: Generally well tolerated. May decrease time to
symptom relief. May decrease overall symptom severity,
as well as specific symptoms of headache, congestion,
and facial pain.
 Harm: Mild irritation.
 Cost: Moderate depending on preparation.
 Benefits-Harm Assessment: Balance of benefit and harm.
 Value Judgments: Patient populations studied did not
adhere to the AAO-HNS clinical practice guidelines def-
inition of RARS, and therefore conclusions may not be
directly applicable to this population.
 Policy Level: Option.
 Intervention: Option for use of INCS spray for acute
exacerbations of RARS.
VI.D.2. RARS Management: Antibiotics
Although the symptom burden in RARS is similar to CRS,
antibiotic utilization is higher.44 RARS patients average 4
courses of antibiotics per year.282 Current guidelines on
adult RS do not provide recommendations regarding antibi-
otic use in RARS.4 A recent, exhaustive systematic review
investigated the effectiveness of short-course antibiotics on
the severity and duration of symptoms and recurrences in
patients with RARS, and failed to identify any placebo-
controlled studies.282 Based on this lack of evidence, the
authors of the systematic review concluded that uncom-
plicated ARS in patients with RARS should be prescribed
antibiotics based on the same criteria used to manage pri-
mary or sporadic episodes of ARS. After careful exami-
nation of the methodology of this exhaustive review, and
with no available data subsequent to this, it is not possi-
ble to provide additional recommendations for the use of
antibiotics in RARS different from recommendations for
treating ABRS.
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TABLE VI-3. Evidence for INCS in the management of RARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Dolor192 2001 2b DBRCT 10-day cefuroxime, 3-day
xylometazoline, and: 1.
21-day INCS; 2. 21-day
placebo
Symptoms; QoL scores
(SNOT-20 and SF-12)
INCS with xylometazoline and
cefuroxime improves
clinical success rates and
accelerates recovery
Meltzer193 2000 2b DBRCT 21 days amoxicillin
clavulanate and: 1. 21
days of INCS; 2. placebo
Symptoms INCS produced a more rapid
and greater relief of
specific individual and
overall symptoms
Qvarnberg281 1992 2b DBRCT Erythromycin for 7 days
plus: 1. Budesonide for
3 months; 2. Placebo
Symptoms Budesonide group had greater
reduction in facial pain and
sensitivity
TABLE VI-4. Evidence for ESS in the management of RARS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Levine285 2013 3b Case-control Balloon dilation in RARS and CRS SNOT-20, RSI Mean improvement in
SNOT-20 and RSI scores in
RARS group comparable to
the CRS group
Bhandarkar284 2011 3b Case-control ESS in RARS and CRS Antibiotic utilization 61.2% reduction in antibiotic
utilization in RARS patients
Poetker18 2008 3b Case-control ESS in RARS and CRS CSS, RSDI; endoscopic exam,
CT scores
Significant reduction in CCS
and RSDI domain scores.
Reduction in sinus
medications use based on
CSS scores
Bhattacharyya283 2006 4 Case series ESS in RARS RSI Significant decrease in RSI
scores. Decreased
antihistamine use,
workdays missed, and
acute episodes
VI.D.2. RARS Management: ESS
A total of 3 studies were identified looking at patient out-
comes after ESS in patients with RARS (Table VI-4). Two
looked at patient-basedQoL scores and objective measures,
whereas a third study looked specifically at antibiotic uti-
lization following ESS. All 3 studies used standardized in-
clusion criteria and disease definitions for RARS as defined
by the Rhinosinusitis Task Force criteria.15
Bhattacharyya283 reported on 19 patients undergoing ESS
for RARS with a mean follow-up of 19 months. Signifi-
cant improvement was noted for this cohort in Rhinosi-
nusitis Symptom Inventory (RSI) domains, antihistamine
use, number of workdays missed, and number of acute in-
fectious episodes. However, declines in weeks of antibiotic
use and number of antibiotic courses were not significant.
Poetker et al.18 reported outcomes after ESS in 22 patients
with RARS. Their cohort wasmatched to CRSsNP patients.
Fourteen patients were available for postoperative follow-
up at a mean of 30 weeks. Their RARS cohort showed
significant improvement in the RSDI and Chronic Sinusi-
tis Survey (CSS) total and symptom domains, and patients
used significantly fewer sinus medications postoperatively
as measured by the CSS. A third study looked at antibi-
otic utilization following ESS in patients with CRS and
RARS.284 Patients with RARS (n = 21) reported a 61.2%
reduction in the average time on antibiotics postoperatively.
Through direct comparison to the CRS group, the reduction
in antibiotic utilization was shown to not be significantly
different between these patient cohorts (RARS vs CRS).
Two studies involving balloon dilation in RARS patients
were identified. Levine et al.285 reported results using the
transantral/canine fossa puncture technique for balloon
dilation of the maxillary sinus ostium in the office set-
ting. They reported significant mean improvement in the
SNOT-20 and RSI scores at 1 year in the RARS cohort
of 17 patients. Mean number of antibiotic courses, sinus-
related physician visits, and number of acute sinus infec-
tions were decreased. Patient use of INCSs, patient use of
antihistamines, and workdays missed were not found to
change significantly in the RARS group. In another study,
9 patients with RARS were treated as part of a larger
cohort using an office-based multi-sinus balloon dilation
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tool/technique.286 Unfortunately, outcomes data specific to
this small RARS group were not provided.
Limitations with these studies include small sample sizes
and the inherent difficulties in studying RARS related to
accurate diagnosis. These patients represent a small sub-
group of RS patients and do not necessarily adhere to strict
postoperative long-term follow-up. The fluctuating disease
pattern, both subjective and objective, also introduces sig-
nificant problems in studying this population.
 Aggregate Grade of Evidence: C (Level 3b: 3 studies;
Level 4: 1 study).
 Benefit: Postoperative improvement in patient symp-
toms. May reduce postoperative antibiotic utilization,
number of acute episodes, and missed workdays. Results
appear comparable to CRS cohorts.
 Harm: Surgery is associated with potential complica-
tions.
 Cost: Significant costs are associated with ESS.
 Benefits-Harm Assessment: Balance of benefit and harm.
 Value Judgments: Properly selected patients with RARS
may benefit both symptomatically and medically from
ESS. This option should be assessed and utilized cau-
tiously, however, because data remains limited.
 Policy Level: Option.
 Intervention: ESS is an option for properly selected pa-
tients with RARS.
VII. CRSsNP
This discussion of CRSsNP pertains to adults with this con-
dition only. Pediatric RS is discussed in Section XII.
VII.A. CRSsNP: Incidence/Prevalence
Based on an analysis of the Medical Expenditure Panel Sur-
vey (MEPS) for 2007 encompassing 225.1 million Ameri-
cans, Bhattacharyya35,287 estimated the prevalence of CRS
(with or without polyps) to be 4.9% ± 0.2% (490/10,000).
In contrast to this prevalence data of CRS overall, Tan
et al.288 examined the incidence of CRSsNP. They used
electronic health records from 307,381 adults who received
care from the Geisinger Clinic primary care from 2007
through 2009 and found the incidence of CRSsNP to be
105 (± 7.0) cases per 10,000 person-years.
VII.B. CRSsNP: Comorbid Asthma
CRS and asthma are both common manifestations of an in-
flammatory process within the contiguous upper and lower
airway system. Although the etiology and pathogenic mech-
anisms underlying the development and progress of these
2 conditions are not fully known, it is clear that the upper
and lower airways are influenced by common risk factors.7
Both CRS and asthma are multifactorial diseases caused
by multiple interactions between genetic background, en-
vironmental factors, and the specific host reaction of the
airway mucosa. Eosinophilia and airway remodeling are 2
major histological hallmarks that suggest the same patho-
logic disease process.289–292
Epidemiological and clinical studies have consistently
shown that CRS and asthma frequently coexist in the same
patient. In a recent random sample survey study with over
52,000 adults aged 18 to 75 years in 12 European coun-
tries, the prevalence of self-reported current asthma (5.1-
16.8%) was found to be strongly associated with CRS
appropriate symptoms (adjusted OR, 3.47; 95% CI, 3.20
to 3.76) in all ages, in both men and women, irrespective
of smoking behavior.293 The reported incidence of asthma
varies from 2% to 38% in patients with CRS,294–299 2%
to 66% in CRSwNP,289,294–314 and 68% to 91% in refrac-
tory CRSwNP.290,299 Among these reports, the prevalence
of asthma in patients with CRSsNP or CRSwNP appears
to be lower in Asians than whites. In patients with CRS,
the coexistence of asthma is associated with a higher inci-
dence of CRSwNP (47%) than CRSsNP (22%)315 Asthma
is often underdiagnosed in CRS patients and is more com-
mon in patients who subsequently are diagnosed with
CRS.288,295,306,315,316
CRS has been postulated as a risk factor for the develop-
ment and severity of asthma. Asthma severity may have a
significant correlation with the presentation of CRS.317 In a
survey study, the prevalence of CRS was found to be 36.7%
in patients with well-characterized asthma, and there was
a significant correlation between the severity of the asthma
and sinus CT scan abnormalities.318
Treatments for CRS or asthma could potentially allevi-
ate the coexisting condition. Both CRSsNP and CRSwNP,
when suboptimally controlled, worsen the course of lower
airway disease. For example, asthmatic patients resistant
to drug therapy need frequently revision surgeries because
of their CRS recurrences, but their asthma symptoms and
pulmonary function improve after both medical and sur-
gical treatments.314 In a retrospective database analysis of
9105 CRS patients who had undergone ESS in 2008 (in the
United States), asthma was found to be associated with an
increased total number of surgeries, increased rate of inpa-
tient admissions, increased number of outpatient visits, and
increased drug utilization when compared to patients with
CRS without asthma.298,315
Summary of evidence for CRSsNP and asthma
(Table VII-1).
Statement (Grade of evidence)
 CRS and asthma frequently coexist in the same patient
(A)
 Asthma is underdiagnosed in CRS patients (C)
 The etiology and pathogenic mechanisms underlying the
development and progress of these 2 diseases largely
overlap (C)
 Treatments for CRSsNP or asthma could potentially al-
leviate the coexisting condition (B).
VII.C.1. CRSsNP: Pathophysiology
VII.C.1.a. CRSsNP Pathophysiology Contributing
Factors: Allergy. It is commonly accepted that the
pathophysiology of CRS is persistent inflammation and the
cause of this inflammation varies from patient to patient.
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TABLE VII-1. Evidence for CRSsNP and asthma as a comorbidity
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Jarvis293 2012 1a Population-based
survey
Adults from 19 centers in 12
European countries
Self-reported current CRS
and asthma
Asthma is associated with CRS
Ragab319 2006 1b Randomized,
prospective study
with 1-year
follow-up
35 patients with CRSwNP; 55
patients with CRSsNP; 43
patients with CRS and
asthma
Objective sinonasal
assessments; lung
function test
Treatment of CRS, medical or
surgical, benefits
concomitant asthma
Klossek307 2005 1b Population-based
random sample
survey
French population (adults,
aged 18 years)
Presence of NP and
asthma
The number of asthmatic
subjects was significantly
higher among NP (26.1%)
than controls (6%)
Benninger298 2014 2b Retrospective cohort
study
8329 adult patients with CRS
after ESS; 776 pediatric
patients with CRS after ESS
Medical history of
respiratory
comorbidities
CRS patients with asthma
(20.7%) received
significantly more
healthcare for CRS than
patients without asthma
Ponikau290 2003 3a Prospective study 22 patients with refractory
CRS; 4 healthy controls
Medical history Asthma was found in 11
patients with CRS (68.29%)
Tanaka295 2014 4 Case series study 170 patients with CRSwNP
after ESS; 40 patients with
CRSsNP after ESS
Asthma history; lung
function test
13% of CRSwNP and 20% of
CRSwNP had obstructive
lung dysfunction yet no
history of asthma
Batra299 2013 4 Cross-sectional (case
series) study
CRSwNP: 109; CRSsNP: 116 Medical history; sinus CT
scan assessment;
serum IgE
measurements
High prevalence of NP, asthma
(48.4%), inhalant allergy,
aspirin sensitivity is found
in patients with refractory
CRS
Fan294 2012 4 Case series study 309 patients with CRSwNP; 42
patients with CRSsNP
Questionnaire; lung
function test; oral
aspirin challenge
AERD was found 0.57% in
Chinese patients with CRS;
2.3% had asthma
Matsuno318 2008 4 Case series study 188 asthmatic patients
(survey): among them, 104
patients had had sinus CT
performed
Clinical findings; CT scan
abnormalities
Asthma is closely related to
RS; onset age of asthma is
important when
considering AR frequency
Staiku¯niene296 2008 4 Case series study 84 patients with CRSwNP; 37
patients with CRSsNP; 23
healthy controls
Nasal endoscopy; sinus CT
scan; absolute
eosinophil count;
allergy testing; asthma
history
CRS associated with NPs and
asthma is the most severe
form of unified respiratory
tract disease
Seybt315 2007 4 Retrospective clinical
date review study
34 patients with CRS with
asthma; 111 patients with
CRS without asthma
Medical history; CRS
symptoms; need for
surgical treatment
CRS patients with asthma did
require significantly more
revision sinus procedures
overall
Dunlop320 1999 4 Case series study with
a 1-year follow-up
50 asthmatic patients with
either CRSwNP or CRSsNP
Overall asthma control;
peak flow
measurements;
medication
requirements
Aggressive management of
sinonasal pathology can
improve asthma status
However, there are no controlled studies of the role of al-
lergy in the pathophysiology of CRSsNP. Nor are there any
controlled trials of treatment options which show that the
treatment of allergy alters the course of CRSsNP. There are
no studies to show how treating CRS affects the outcome of
AR patients and vice versa, and few studies have compared
patients with CRS with allergy to those patients with CRS
without allergy. The majority of studies are epidemiologic
and these provide our current state of knowledge about this
relationship.
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In CRSsNP the vast majority of patients show a Th1-
skewed inflammatory response whereas in the CRSwNP
group it is rather heterogeneous and often shows Th-2 type
inflammation.321 Data from a 12-country European study
of 52,000 adults showed a strong association of asthma
with CRS, and this association with asthma was stronger
in those reporting both CRS and AR (adjusted OR, 11.85;
95% CI, 10.57 to 13.17).293 Because the pathophysiology
of CRSsNP is in many ways still unclear, it is difficult to
evaluate the role of allergies in this type of CRS when there
are no controlled studies published.7
In 2014, Wilson et al.322 reviewed the role of allergy in
CRSwNP and CRSsNP. They considered only studies that
delineated the presence of polyps or not, so that studies ex-
amining “CRS” alone were excluded. In both CRSsNP and
CRSwNP, they found the aggregate LOE linking allergy to
these forms of CRS to be level D due to conflicting preva-
lence data, complemented by expert opinion and reasoning
from first principles. In CRSsNP specifically, they found 9
epidemiologic studies that addressed the role of allergy in
CRSsNP. Four of these studies (1 small level 1b, 3 level 3b)
supported an association, whereas 5 (all level 3b) did not.
They concluded that allergy testing should be considered
an option in CRSwNP and CRSsNP patients, inasmuch as
there was a theoretical benefit of finding inflammatory trig-
gers, there is little harm, and the low aggregate LOE did
not support a strong recommendation either for or against
this practice.
 Aggregate Grade of Evidence: D (Conflicting epidemio-
logic data [1 small level 1b, 7 level 3b, 1 level 4], expert
opinion, and reasoning from first principles).
 Benefit: Management theoretically reduces triggers and
could potentially modify symptoms of CRS. Robust data
on benefits are lacking.
 Harm: Mild local irritation associated with testing and
immunotherapy and mild sedation seen with some anti-
histamine drugs. Severe complications are rare.
 Cost: Moderate direct costs for testing and treatment;
some tests and therapies require significant patient time
(eg, office-administered skin testing and subcutaneous
immunotherapy).
 Benefits-Harm Assessment: Preponderance of benefit
over harm has not been demonstrated for avoidance
or immunotherapy. Benefits are largely theoretical and
should be balanced against the significant cost of testing
for allergies and instituting avoidance measures.
 Value Judgments: None.
 Policy Level: Option
 Intervention: Allergy testing and treatment are an option
in CRSsNP.
VII.C.1.b. CRSsNP Pathophysiology Contributing
Factors: Biofilms. Many organisms in the sinonasal tract
have the ability to form a biofilm, which is a community
of bacteria or fungi that surrounds itself with a protec-
tive extracellular matrix (ECM).323 Using “quorum sens-
ing” molecules, the bacteria communicate density status
and begin to form a biofilm once an appropriate microbe
concentration has been reached.324 The protection of the
biofilm renders the bacteria or fungus much more resis-
tant to external insults, including host defenses. The organ-
isms themselves also undergo a phenotypic change325 to
require less oxygen and nutrients, which confers additional
resistance to conventional antimicrobials.326 Microbes that
would normally be vulnerable to typically effective antibi-
otics are up to 1000 times more resistant in the biofilm
state.327 Antibody action, phagocytosis, and complement
binding can be equally unsuccessful in this setting.324
Biofilms in vivo can often be difficult to detect and cul-
ture. Reliance on conventional media results in an “enrich-
ment bias” in which the organisms with the fastest growth
rates are overrepresented.328 Identification of a biofilm-
forming pathogen in diseased mucosa therefore requires
special techniques to obtain an accurate result.329 Biosen-
sor molecular detection and fluorescent in situ hybridiza-
tion (FISH) have both proven to be effective.330,331 Interest-
ingly, a study comparing FISH to culture technique showed
very little overlap in the identities and relative quantities of
bacteria detected.331
The precise relationship between biofilm formation and
CRS pathogenesis is poorly understood. However, biofilm
presence in the sinonasal tract is correlated with concur-
rent CRS,332 and outcomes after ESS are worse in patients
who have biofilm colonization.333 Specifically, endpoints
of postoperative symptoms, ongoing inflammation, and
recurrent infections were all increased in biofilm-positive
surgery patients.323,334–337 Biofilm formation in CRS may
also be associated with increased need for surgical inter-
vention. Although around 20% of patients with CRS show
biofilm formation,323 up to 50% of CRS surgical can-
didates are biofilm-positive.334 Importantly, biofilms can
also be found in control patients without CRS, showing
that they are neither necessary nor sufficient to cause the
pathology.338
Treatment of biofilm-positive CRS is difficult, and ther-
apeutic strategies are far from fully elucidated. Antibiotics
such as ceftazidime, piperacillin, ciprofloxacin, and van-
comycin are ineffective when given systemically at typical
concentrations, and higher concentrations of these com-
pounds are often not clinically safe, sometimes requir-
ing a 60-fold to 1000-fold increase in dosing to achieve
an effect.339,340 Topical therapy may be a more effective
approach. Mupirocin has been shown to reduce biofilm
mass,340 but it is unclear if there is a maintained effect
after antibiotic application has ceased.341 Macrolides in-
hibit quorum sensing in Pseudomonas aeruginosa, and
these may become a useful therapeutic strategy for treat-
ing biofilm-associated CRS.334 Furosemide, which acts as a
cation channel blocker, also reduces biofilm size.342 Corti-
costeroids have shown some effect against Staphylococcus
aureus biofilm formation specifically.343
Other less conventional treatments have been attempted
with varying degrees of success. Detergent agents have
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appreciable biofilm-disrupting effects, but currently are
not in use because of several side effects, including ciliary
toxicity.344–347 Photodynamic therapy is a new and promis-
ing treatment that shows tremendous biofilm reductions in
vitro, and preliminary tissue studies have not shown dele-
terious side effects.348,349 Last, low-frequency ultrasound
treatments also seem effective in reducing biofilms, also
without observed side effects.350
A promising new approach to understanding biofilms
involves bitter taste receptors in the upper respiratory
tract. Acyl-homoserine lactones (AHLs) produced by
gram-negative bacteria serve as biofilm “quorum-sensing
molecules,” and these molecules are ligands for airway bit-
ter taste chemoreceptors.351 Detection of these molecules
allows the host to mount an innate defensive response
before the bacteria reach the density required for biofilm
formation.352 One of these bitter taste receptors, T2R38,
is activated by AHLs and has downstream effects of in-
creased MCC and bactericidal nitric oxide (NO) produc-
tion. CRS patients with a nonfunctional mutation in the
T2R38 gene are at a higher risk for needing surgical inter-
vention for their disease.353 Bitter-taste testing for the pres-
ence of T2R38 could potentially predict CRS severity or
necessary treatment,354 and bitter compounds themselves
could serve as therapeutic agents that activate the host im-
mune response against biofilm formation in CRS.355
VII.C.1.c. CRS Pathophysiology Contributing Fac-
tors: Fungus. Because of limited data, CRSwNP and
CRSsNP are combined in this analysis.
The potential pathogenic role for fungus as a trig-
ger of CRS first emerged in 1983 following a report
by Katzenstein et al.356 A key observation of this study
was the presence of noninvasive Aspergillus species within
eosinophilic mucin recovered from patients with CRS. Sub-
sequent reports of phenotypically similar patients eventu-
ally led to the disease entity “allergic fungal rhinosinusi-
tis” (AFRS).357–359 Given its histopathologic similarity to
allergic bronchopulmonary aspergillosis, AFRS was origi-
nally thought to represent a clinical manifestation of IgE-
mediated response to fungus within the nose and sinuses.360
When Ponikau et al.361 later found that eosinophils and
fungi could be recovered from essentially all patients with
CRS, a broader role for noninvasive fungi in the pathogen-
esis of CRS with and without polyposis was considered.
A number of recent studies illustrate potential mecha-
nisms through which fungi might induce inflammatory re-
sponses within the nose. One such example is that of fungal
proteases capable of binding to protease-activated receptors
on host vessels, leukocytes, and epithelial cells. These pro-
teases trigger release ofmediators responsible for damage of
host tissue.362–364 Further, Alternaria can directly activate
eosinophils leading to production of IL-8 and surface ex-
pression of eosinophil receptors key to cellular adhesion.365
Immunologic responses to fungi have been observed in
patients with CRS. Production of cathelicidins and de-
fensins, 2 key antimicrobial peptides associated with mu-
cosal innate immunity, is upregulated in CRS without
eosinophilic mucin in the presence of Aspergillus fumiga-
tus and Alternaria tenuis.366 Pulmonary surfactant protein
(SP-D), another important mechanism of innate immunity
expressed within respiratory mucosa, serves an important
role in the immune response to Aspergillus fumigatus in the
lung. SP-D is noted to be absent in patients with CRS with
eosinophilic mucin and fungal allergy.367
Systematic IgE-mediated allergy to fungus is axiomatic
to the diagnosis of AFRS and has been felt to represent a
key component in the pathophysiology of that disease.360
In attempting to expand the role of fungus to all types
of CRS, other types of reactions must be considered.
Non–IgE-mediated adaptive responses to fungi in CRS
have been identified. Shin et al.368 showed that peripheral
blood monocytes from patients with CRS cultured in the
presence of Alternaria extract produced significantly more
IL-5 and interferon γ (IFN-γ ) as compared to healthy con-
trols, suggesting that fungi can induce a specific peripheral
blood monocyte Th2 cytokine profile. This response was
independent of IgE sensitivity to fungi. Orlandi et al.,369
however, replicated the methods of Shin et al.368 and had
opposing results. They found that IL-5 levels correlated
strongly with fungal-specific IgE, but did not correlate
with fungal-specific IgG as described by Shin et al.368 In a
study performed by Pant et al.,370 IgG1 and IgG3 isotypes
to fungi were identified in CRS patients with eosinophilic
mucin. The effect was independent of IgE sensitivity to
fungus.
Despite the interesting laboratory findings regarding im-
munologic reactions to fungus, the clinical evidence is not
as supportive of an etiologic role. Fungal spores are ubiq-
uitous and continuously presented to the nasal respiratory
mucosa.371 Aspergillus, Cladosporium, Candida, Aureoba-
sidium, and Alternaria are most frequently recovered from
both CRS patients and normal controls.372,373 The pres-
ence of fungi seen in the sinuses of CRS patients may be
explained by delayed MCC, and may therefore be a down-
stream effect of inflammation rather than a cause. Although
some studies have shown increased fungal loads in some
CRS patients compared to controls,374,375 others have re-
vealed no difference in either prevalence rates of fungus or
number of different fungi recovered.361,376
Numerous studies, including multiple RCTs, have ex-
amined the role of antifungal treatment in CRS and none
have shown a clinically meaningful improvement.377–381 Al-
though not directly addressing fungus as an etiologic fac-
tor, these clinical studies cast significant doubt on the role
of fungus in the etiology of CRS.
Despite the well-recognized coexistence of fungus with
CRS, its role as a direct cause in the pathophysiology re-
mains uncertain.
 Aggregate Grade of Evidence: C (Level 3: 8 studies; Level
4: 2 studies; Table VII-2)
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TABLE VII-2. Evidence for CRS and fungus as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Porter374 2014 3 Case-control study 1. CRSsNP (n = 21); 2.
CRSwNP (n = 37); 3. AFRS
(n = 26); 4. Controls (n =
15)
Positive fungal culture of sinus
lavage
Fungal cultures were more
frequently positive in
CRSwNP and AFRS patients
compared to CRSsNP and
controls
Orlandi369 2009 3 Case-control study 1. CRS (n = 10); 2. Controls
(n = 7)
1. Cytokine production
following fungal exposure;
2. Fungal-specific serum
IgG and IgE levels
Cytokine levels did not
correlate with presence of
CRS. Fungal-specific IgE,
not IgG, levels strongly
correlated with IL-5
production
Murr373 2006 3 Case-control study 1. CRS (n = 37); 2. Controls
(n = 37)
1. Fungal recovery on QPCR;
2. Correlation of QPCR and
QoL measures
Fungal recovery rate was the
same between the 2
groups. Fungal results did
not correlate with SNOT-20
or SF-36
Kim372 2005 3 Case-control study 1. CRS (n = 82); 2. Controls
(n = 40)
Fungal culture and PCR results 93% of CRS patients and 98%
of controls were positive for
fungus on PCR. Fungal
culture rates were similar
Pant370 2005 3 Case-control study 1. Eosinophilic mucin CRS; 2.
AFRS; 3. AFRS-like; 4.
Nonallergic fungal
eosinophilic RS; 5.
Nonallergic, nonfungal
eosinophilic RS; 6. AR with
fungal allergy; 7. Control
Alternaria and Aspergillus
fungal-specific IgG and IgA
levels
Fungal-specific IgG and IgA
levels were higher in
eosinophilic mucin CRS
patient groups compared to
healthy controls.
Fungal-specific IgG and IgA
levels were not different
from AR and
non-eosinophilic mucin
CRS patients
Scheuller376 2004 3 Case-control study 1. CRS (n = 19); 2. controls
(n = 19)
Fungal recovery on PCR and
QPCR
Fungal PCR recovery rates did
not differ. For those with
positive fungal results,
quantitative PCR was
identical for the 2 groups
Shin368 2004 3 Case-control study 1. CRS (n = 18); 2. controls
(n = 15)
1. Cytokine production
following exposure to fungi;
2. Fungal-specific serum
IgG levels
Blood cells from 90% of CRS
patients but 0% from
control patients produced
more IL-5, IL-13, IFN-γ.
Fungal-specific IgG was
elevated in CRS patients
but not controls
Ponikau361 1999 3 Case-control study 1. CRS (n = 210); 2. controls
(n = 14)
Fungal culture results 96% of CRS patients had
positive fungal cultures;
100% of controls had
positive fungal cultures
Tosun382 2007 4 Case series CRS patients with and
without intranasal fungi
determined by PCR
Laboratory and clinical
parameters
Multiple laboratory and clinical
parameters did not differ
between the 2 groups
Taylor383 2002 4 Case series CRS patients Presence of chitin All specimens were positive
for chitin
IFN = interferon; QPCR = quantitative PCR.
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VII.C.1.d. CRS Pathophysiology Contributing
Factors: Osteitis. Because of limited data, CRSwNP
and CRSsNP are combined in this analysis.
Osteitis may play a role in the pathogenesis of CRS, par-
ticularly in patients with recalcitrant disease.384–387 No-
tably, some have questioned whether the changes seen
are truly inflammatory and have suggested the term
“neo-osteogenesis” may be more appropriate.388 Animal
and human studies examining histopathologic changes
of paranasal sinus mucosa and bone support its role in
CRS.389–398 Early studies by Kennedy et al.391 described
the histomorphometry and histology of the ethmoid bone
to better understand the pathogenesis of disease. Ethmoid
bones harvested from patients with and without CRS were
labeled with tetracycline and found to have significant ac-
tivity by histologic evaluation (new bone formation, fibro-
sis, and inflammatory cell presence). Similar histopatho-
logic results were obtained by other investigators.390,392 Lee
et al.392 found an increased incidence of osteitis according
to pathologic features in patients with CRS undergoing a
revision sinus surgery (58%) compared to those with CRS
undergoing primary surgery (6.7%), but did not differen-
tiate between CRSsNP and CRSwNP patients. The esti-
mated prevalence of osteitis in CRS patients based on radio-
graphic criteria or histopathology is 32.5% to 79%,399,400
which underscores the potential clinical impact of this
finding.
Although there is no standard diagnostic test for osteitis,
CT is currently the modality of choice.384–386,401,402 CT
imaging offers availability, good bony detail, and excellent
sensitivity and specificity for detecting mucosal abnormali-
ties and thickening.401 Single photon emission CT (SPECT)
has been suggested as another modality, but is costly, not
readily available, and exposes the patient to larger doses
of radiation.401,402 A variety of grading systems using CT
imaging have also been proposed, including the Kennedy
Osteitis Score, Global Osteitis Scoring Scale (GOSS), scor-
ing based upon Hounsfield units (HU), thickness of bony
partitions, as well as systematic examinations of separate
reference points in the sinuses.387,389,392,403,404 As with di-
agnostic testing for osteitis, these grading systems have not
been standardized.
Mounting evidence indicates that osteitis is a contribu-
tor to disease progression and indicator of worse clinical
outcomes when compared to CRS without osteitis. Gi-
acchi et al.390 found a strong correlation between higher
LM CT staging and the presence of osteitis. Importantly,
pathologic change may precede radiographic findings be-
cause only 67% of patients with pathologic evidence of os-
teitis had corresponding changes noted on CT imaging.392
Telmesani and Al-Shawarby398 found that in CRSwNP pa-
tients, the presence of osteitis was correlated with an in-
crease in disease recurrence rate. Osteitis may also predict
QoL measurements or response to surgical intervention.
Saylam et al.400 showed markedly worse subjective scores
for patients with osteitis (as determined by higher SPECT
scan) compared to a non-osteitis cohort. Bhandarkar et al.78
found no difference on Rhinosinusitis Outcome Measure
(RSOM), RSDI, or CSS in patients with and without os-
teitis. Nonetheless, fewer patients with osteitis achieved im-
provement from ESS after controlling for baseline disease-
specific factors. Of note, previous surgery has been associ-
ated with worsened osteitis scores in several studies, sug-
gesting osteitis may be a marker of more severe disease
and/or possibly a reaction to previous surgery.386,399,401,402
The causality and relationship of bacterial biofilms, mu-
cosal pathology, and bacterial infection is not well un-
derstood in relationship to osteitis. Bacterial infection of
the bone is an unlikely cause of osteitis in CRS pa-
tients. Wood et al.405 noted small colonies of bacte-
ria within the bone of both CRSsNP and CRSwNP pa-
tients and normal controls. Bacterial microcolonies were
found in 1 CRSsNP and 2 CRSwNP cases, as well as
in 2 of 6 control cases. 405 Dong et al.406 demonstrated
that 85% of CRS patients with mucosa with bacterial
biofilms had some form of osteitis present. Additionally,
the histopathologic grade, GOSS score, and HU value in
patients with bacterial biofilms were greater than those
without biofilms. Snidvongs et al.407 evaluated the asso-
ciation of osteitis with systemic eosinophilic markers of
eosinophilic CRSwNP, a more severe disease subgroup of
CRS patients likely to have polyposis, and found a signif-
icant correlation between tissue and serum eosinophilia to
osteitis.
In conclusion, osteitic bone is recognized as a manifesta-
tion of inflammatory changes in paranasal sinus bone that
may play a role in refractory CRS. Additional high-level ev-
idence is needed to determine a cause and effect relationship
between osteitis and both CRSsNP and CRSwNP.
 Aggregate Grade of Evidence: C (Level 1b: 1 study; Level
2b: 5 studies; Level 3a: 5 studies; Level 3b: 13 studies;
Table VII-3).
VII.C.1.e. CRS Pathophysiology Contributing Fac-
tors: Reflux. Because of limited data, CRSwNP and
CRSsNP are combined in this analysis.
Laryngopharyngeal reflux (LPR) is theorized to con-
tribute to the pathophysiology of CRS in 3 possible
ways: direct gastric acid exposure to the nasal cavity and
paranasal sinuses causing mucosal inflammation and im-
paired MCC408; a vagal-mediated response in the nasal
mucosa from esophageal stimulation409; and Helicobacter
pylori infection.410
Ulualp et al.411 demonstrated more pharyngeal acid re-
flux events in patients with medically refractory CRS (7/11,
64%) vs healthy controls (2/11, 18%). Pincus et al.412 re-
ported that 25 of 30 patients with refractory CRS had pos-
itive pH studies, and 14 of 15 positive pH study patients
treated with proton pump inhibitors (PPIs) had improve-
ment of their RS symptoms after 1 month. DiBaise et al.413
found modest improvement in CRS symptoms in 67% of
18 medically and surgically refractory CRS patients after
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TABLE VII-3. Evidence for CRS and osteitis as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Saylam400 2009 2b Prospective cohort study CRS patients with and without
osteitis
SPECT scores, subjective
evaluation of treatment and
prognosis
Poorer subjective scores of
patients with higher SPECT
scores, presence of osteitis
Sethi385 2015 3a Systematic review of
literature
CRS patients Osteitis has been found to
correlate with mucosal
eosinophilia. Only a
suggested association
exists of CRS and osteitis
Bhandarkar401 2013 3a Systematic review of
literature
CRS patients Osteitis is associated with
worse treatment outcomes
and with worse disease
Georgalas402 2013 3a Systematic review of
literature
CRS patients Correlation between radiologic
severity and extent osteitis
exists. No correlation
between clinical severity
and osteitis
Videler386 2011 3a Systematic review of
literature
CRS patients CT is recommended for
identification of osteitis. No
evidence of bacteria in
paranasal sinus bone.
Surgery may incite osteitis
Chiu384 2005 3a Systematic review of
literature
CRS patients The cause of bone remodeling
is unknown
Dong406 2014 3b Prospective cohort study 84 CRS patients undergoing
ESS and 22 control patients
Tissue samples: biofilm
volume, biofilm score,
histopathologic bony grade,
GOSS, and HU value
The rate of osteitis in CRS was
higher by CT and by
histopathologic grading.
Biofilms were associated
with osteitis
Wood405 2012 3b Prospective case control CRSsNP (n = 8); CRSwNP
(n = 8); controls (n = 6)
Presence of bacteria and
immune cells in bone
removed during ESS or
skull base surgery
Bacteria colonies and immune
cells in bone were
identified in similar number
of CRS and controls
Georgalas403 2010 3b Prospective, case control CRS (n = 102) and controls
(n = 68) undergoing sinus
CTs
GOSS, LM grading scale Osteitis was more common in
CRS. Strong correlation
between previous surgery
and osteitis
Telmesani398 2010 3b Prospective case control CRSwNP (n = 82, divided into
primary vs revision surgery
Histopathologic examination of
ethmoid bone and mucosa.
Disease recurrence
Higher risk of osteitis with
worse mucosal pathology
and revisions surgery.
Osteitis predicted higher
recurrence
Cho399 2008 3b Retrospective case control CRS patients having primary
ESS (n = 25); CRS patients
having revision ESS (n =
15); controls (n = 25)
Ethmoid NBF; HU; LM scores;
bone thickness on CT
NBF higher in revision cases
and higher LM scores. CRS
groups had increased bone
thickness
Giacchi390 2001 3b Prospective case control CRS patients with ESS (n =
20); controls having CSF
leak repair (n = 5)
Ethmoid mucosa and bone
evaluated by pathology for
mucosal and bone changes
Bone resorption and
osteoneogenesis noted in
CRS
Kennedy391 1998 3b Prospective case control CRS having ESS (n = 24);
controls (n = 9) undergoing
ethmoid surgery
Ethmoid tissue grouped
according to histologic
appearance of bone and
mucosa
Bone remodeling activity was
increased in the CRS group
compared to controls
(Continued)
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TABLE VII-3. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Snidvongs404 2013 4 Retrospective cohort CRSwNP (53%) and CRSsNP
(47%) patients receiving
surgery
CT, histopathology, endoscopy,
and QoL measures. KOS,
GOSS
51% of patients had osteitis;
higher prevalence with
revision surgery. No
correlation between QoL
and osteitis
Snidvongs407 2012 4 Retrospective case study 88 patients with CRSwNP or
CRSsNP undergoing ESS
LM scores histopathology,
SNOT-22 scores, asthma,
aspirin sensitivity
51% of patients had osteitis;
tissue and serum
eosinophilia correlated with
osteitis
Bhandarkar78 2011 4 Prospective case series 190 patients with CRS
undergoing ESS
LM CT scores, SIT, endoscopy,
presence of osteitis on CT,
RSDI, CSS
Osteitis correlated with
increased age, revision
surgery, NPs, asthma, and
ASA intolerance, and less
postoperative QoL
improvement
Lee392 2006 4 Prospective case series Patients undergoing ESS for
CRS
Presence of concurrent
osteitis based on imaging
and histopathology
CT showed osteoneogenesis
in 36%, with 53% showing
signs of osteitis on
pathology
Cho389 2006 4 Retrospective case series Patients undergoing primary
ESS for CRS
LM CT scores, HU of ethmoid
region on CT,
histopathologic analysis of
ethmoid mucosa and bone
HUs increased with higher LM.
Histopathologic bony
grades increased with
higher mucosal grades
Kim387 2006 4 Retrospective case series Patients undergoing primary
ESS for CRS
CT scans for evidence of
hyperostosis, postoperative
endoscopic outcomes
60% of patients showed
hyperostosis, associated
with poorer postoperative
outcome
KOS = Kennedy Osteitis Score; NBF = new bone formation.
6 months of PPI treatment for reflux. Neither the Pincus
et al.412 nor the DiBaise et al.413 study had a control group.
Ozmen et al.414 showed a higher prevalence of pharyn-
geal reflux events (29/33) and positive nasal pepsin assay
(26/33) in medically refractory CRS patients, as compared
to controls (11/20 for each). Loehrl et al.415 found positive
pharyngeal pH probes in 19 of 20 surgically refractory CRS
patients, and positive nasal pepsin assays were found in all
5 patients tested.
In a prospective case control study, DelGaudio416 re-
ported statistically significant higher incidences of reflux
events in the distal esophagus (p = 0.007), hypopharynx
(p = 0.006), and nasopharynx below pH 4 (p = 0.004)
and pH 5 (p = 0.00003) in 38 surgically refractory CRS
patients as compared to 10 successful ESS patients and 20
normal controls. Wong et al.417 detected over 800 reflux
events at a pH cutoff of <4 in 37 medically refractory CRS
patients who were candidates for ESS: 596 at the distal
esophagus, 187 at the proximal esophagus, 24 at the hy-
popharynx, and only 2 at the nasopharynx. Based on their
results, Wong’s group concluded that nasopharyngeal re-
flux is a rare event in CRS, and that the pathophysiology
of reflux in CRS is likely an alternative mechanism than
direct contact with nasal mucosa.417 Comparing this study
to the DelGaudio study,416 the patients in the cohort in
Wong et al.417 were medically (and not surgically) refrac-
tory CRS patients, thereby resembling the successful ESS
control group in the DelGaudio study, having significantly
less nasopharyngeal reflux events than the patients with
refractory CRS. Another significant difference is that the
pH cutoff in the Wong et al.417 article was <4, which may
have missed reflux events that occurred between pH 4 and
5. The findings in these studies therefore suggest a larger
role for reflux directly affecting the nasal mucosa in more
severe cases of CRS that are refractory to surgical manage-
ment, as compared to less severe CRS cases which can be
controlled either medically or surgically.
Jecker et al.418 reported that 20 surgically refractory
CRS patients had significantly more reflux events in the
esophagus than 20 healthy control patients. Interestingly,
this was not observed in the hypopharynx, suggesting
that refractory CRS is associated with gastroesophageal
reflux disease (GERD) but not with extra-esophageal
reflux (EER).418 This may suggest a vagally-mediated
response.
Vcˇeva et al.410 reported that Helicobacter pylori DNA
was identified in the NP tissue of 10 of 35 study group
patients, but it was not detected in the concha bullosa
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with normal mucosa specimens of 30 control patients, even
though H. pylori DNA was found in the gastric mucosa
samples of all study and control subjects. Ozdek et al.419
illustrated the presence ofH. pylori RNA by PCR in 4 of 12
ethmoidal tissue samples in patients with CRS and in none
of 13 concha bullosa specimens in patients without CRS.
Although these studies suggest that H. pylori is associated
with CRS, evidence of a causal relationship has not been
demonstrated.
PND is a symptom frequently attributed to both reflux
and RS. In a randomized-controlled double-blind crossover
study of 75 patients with complaints of PND, Vaezi et al.420
reported improvement of symptoms in 50% of patients
treated with a PPI compared to 5% in the placebo arm.
The authors concluded that these findings support a role
for reflux in PND symptoms.
Data in the published literature are frequently conflict-
ing. A recent evidence-based approach concluded weak
support for causation between GERD and RS.421 There
is significant evidence demonstrating a coexistent relation-
ship between reflux and CRS, although causation cannot
be clearly demonstrated. It is not entirely clear with the
evidence currently available whether extraesophageal re-
flux of gastric acid directly injures the sinonasal mucosa,
whether reflux events cause vagally-mediated neuroinflam-
matory changes, or if it is a combination of both of these
factors.
 Aggregate Grade of Evidence: B (Level 1b: 1 study; Level
2b: 6 studies; Level 4: 3 studies: Table VII-4).
VII.C.1.f. CRSsNP Pathophysiology Contributing
Factors: Vitamin D Deficiency. Vitamin D (VD3) cir-
culates in its inactive form (25VD3) and is converted to
its active form (1,25VD3) by 1α hydroxylase in periph-
eral tissues. This active form has anti-inflammatory and
antibacterial actions,422–424 thus prompting studies on its
potential role in CRS, especially CRSwNP, the eosinophilic,
Th2-skewed form of the disease. CRSsNP typically rep-
resents a different immunologic profile than CRSwNP,
with less eosinophilia and less of a Th2 cytokine pro-
file. The literature on the effects of VD3 on CRS con-
sists primarily of studies comparing CRSsNP to CRSwNP
and is limited to case series, case-control, and in vitro
studies.
Clinical studies show that VD3 may not be low in
CRSsNP in the absence of smoking exposure. A series of
case-control studies have consistently found no significant
difference in circulating or sinonasal tissue 25VD3 levels
of CRSsNP patients vs controls in both adult and pediatric
patients.425–427 Pinto et al.428 found that African Americans
with severe CRS—diagnosed by consensus on symptoms,
nasal endoscopy, and CT scan results—had significantly
lower serum 25VD3 levels than both Caucasian patients
and race/sex matched controls. However, the composition
of CRS patients was not defined and may have included
a heterogeneous group of CRSwNP and CRSsNP. While
systemic 25VD3 levels are normal in CRSsNP patients, ac-
tive or passive smoke exposure is associated with decreased
systemic and local 25VD3 levels in these patients.427 Con-
sistent with the CRS studies, active smoking was previ-
ously shown to decrease serum 25VD3 and 1,25VD3 in
perimenopausal women.429
In considering immunologic studies, both Sultan430 and
Mulligan427 found that CRSsNP sinonasal epithelial cells
have the ability to convert 25VD3 to 1,25VD3. Mulligan
et al.427 found that exogenous cigarette smoke exposure
impairs this conversion step. In contrast to CRSwNP, there
does not appear to be any relationship between systemic or
local dendritic cells and VD3 in adult or pediatric CRSsNP
patients.425,426
Others have examined osteoblasts and VD3 in CRS. Sug-
imoto et al.431 showed that ethmoid bone osteoblasts in
CRS produced greatest mineralization and secreted great-
est osteocalcin (a marker of bone mineralization) when in-
cubated in a VD3/vitamin K culture solution. Additionally,
VD3/vitamin K–cultured cells produced significantly more
transforming growth factor beta 2 (TGFβ2), a cytokine in-
volved in osteoneogenesis. However, the specific form of
VD3 used was not stated and these effects were not appar-
ent when using VD3 alone. The authors proposed that VD3
may have a role in modulating optimal sinus bone turnover
and speculated whether it might reduce the sinus bone ero-
sion observed in some CRS cases. This work may partly
explain the inverse correlation between 25VD3 levels and
bone erosion noted in some clinical studies.426,432,433
Two statements can be made about VD3 in CRSsNP:
1. CRSsNP is not associated with systemic 25VD3 deficien-
cies
 Aggregate Grade of Evidence: C (Level 3b: 4 studies;
Table VII-5).
2. Smoke exposure in CRSsNP patients can lower systemic
and local 25VD3 levels
 Aggregate Grade of Evidence: C (Level 3b: 1 study;
Table VII-5)
VII.C.1.g. CRSsNP Pathophysiology Contributing
Factors: Superantigens. At this time, a single article re-
ports an association between toxic shock syndrome toxin
(TSST-1) superantigen and CRS patients.434 In this article,
CRS patients with and without polyps are noted to have
significantly increased S. aureus nasal carriage rates and
TSST-1 vs controls. Some questions have been raised by
experts in the field regarding the reliability of TSST-1 de-
tection in tissue by passive latex agglutination and PCR, as
described.
In summary, unlike CRSwNP, there is little to no evi-
dence supporting the role of superantigens in the etiology
or pathogenesis of CRSsNP.
VII.C.1.h. CRS Pathophysiology Contributing
Factors: Microbiome Disturbance. Because of limited
data, CRSwNP and CRSsNP are combined in this analysis.
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TABLE VII-4. Evidence for CRSsNP and reflux as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Vaezi420 2010 1b RCT (n = 75) Chronic PND patients
randomized to
lansoprazole 30 mg BID
or to placebo
PND symptoms at 8 and 16
weeks
Therapy significantly improved
PND symptoms, suggesting
reflux as a causative factor
in PND
Loehrl415 2012 2b Case-control 1. Post-ESS with
inflammation (n = 38);
2. Post-ESS with no
inflammation (n = 10);
3. Controls (no CRS, no
ESS; n = 20)
PARE with 24-hour
triple-probe pH monitoring
at the NPx (events of pH <4
and <5), UES, and the
distal esophagus
Patients with persistent CRS
after ESS have more reflux
at the NPx, UES, and distal
esophagus than controls;
largest difference is NPx
reflux
Ozmen414 2008 2b Case-control 1. CRS (n = 33); 2.
Controls (n = 20)
PARE with 24-hour dual-probe
pH monitoring
Higher prevalence of PARE
and nasal pepsin in CRS
suggests an association
between CRS and LPR
Jecker418 2006 2b Case-control 1. Recurrent CRS (n =
20); 2. Healthy
volunteers (n = 20)
24-hour pH probe monitoring:
number of reflux events,
fraction of time pH < 4
CRS patients had more
esophageal but not
hypopharyngeal reflux
events
DelGaudio416 2005 2b Case-control 1. Post-ESS with
inflammation (n = 38)
patients; 2. Post-ESS
with no inflammation (n
= 10); 3. Controls (no
CRS, no ESS; n = 20)
PARE with 24-hour
triple-probe pH monitoring
at the NPx (events of pH <4
and <5), UES, and the
distal esophagus
Patients with persistent CRS
after ESS have more reflux
at the NPx, UES, and distal
esophagus than controls;
largest difference is NPx
reflux
Ozdek419 2003 2b Case-control 1. Mucosa from 12 CRS
patients; 2. Mucosa
from 13 controls
Helicobacter pylori DNA/RNA H. pylori found in 4/12 CRS
patients and 0/13 patients
without CRS
Ulualp411 1999 2b Case-control 1. Refractory CRS (n =
11); 2. Healthy controls
(n = 11)
PARE documented around UES
and lower esophageal
sphincter
Higher prevalence of PARE in
CRS, suggests GERD
contributes to pathogenesis
of CRS
Pincus412 2006 4 Cohort 30 refractory CRS patients
tested for reflux; 15 of
25 patients with reflux
treated with PPI
Sinus and GERD symptoms Improvement in sinus and
GERD symptoms, suggests
a role for reflux in the
pathophysiology of CRS
Wong417 2004 4 Cohort 40 patients with CRS Incidence of PARE with
24-hour 4-probe pH
monitoring at the NPx,
hypopharynx, proximal
esophagus, and distal
esophagus
NPx reflux events are rare in
patients with CRS;
pathogenesis of CRS and
reflux likely not direct acid
contact
DiBaise413 2002 4 Cohort 11 CRS patients tested for
GERD and then treated
with PPI
Individual sinus symptoms
and global satisfaction
measured at 12 weeks
High prevalence of GERD in
CRS, with symptom
improvement after GERD
treatment
LPR = laryngopharyngeal reflux; PARE = pharyngeal acid reflux event; UES = upper esophageal sphincter.
Newer methods for bacterial detection have demon-
strated that healthy sinuses are not sterile.435 The Hu-
man Microbiome Project has revealed a broad spectrum
of microbes associated with human function in health and
disease,436 and the microbiome is proposed to exist as a
functional bacterial community437 rather than a transient
assemblage of organisms. The significance of these con-
cepts with respect to CRS is not yet understood. Although
the presence of bacteria in sinus cultures continues to be
considered pathologic, it is possible that some microbes
may serve beneficial roles at the epithelial surface, includ-
ing pathogen exclusion, production of local antimicrobial
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TABLE VII-5. Evidence for CRSsNP and vitamin D as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Mulligan427 2014 3b Case-control 1. 21 control (CSF
leak/pituitary tumor
patients); 2. 40
CRSsNP; 3. 45 CRSwNP
1. 25VD3 level; 2. CYP27B1
gene expression; 3. 25VD3
to 1,25VD3 conversion
No difference in 25VD3
between CRSsNP and
controls. Cigarette smoke
associated with lower
25VD3 level
Wang433 2013 3b Case-control 1. 25 CRSwNP;
2. 20 CRSsNP
1. 25VD3 level; 2. Polyp grade;
3. LM score; 4. Total IgE
No difference in 25VD3 level
between CRSsNP and
controls
Mulligan425 2012 3b Retrospective case-control 1. 14 control patients;
2. 17 CRSsNP; 3. 5
CRSwNP; 4. 14 AFRS
1. 25VD3 level; 2. Number of
CD209+ dendritic cells in
nasal biopsy/high-powered
field
No difference in 25VD3
between CRSsNP and
controls
Mulligan426 2011 3b Retrospective case-control 1. 14 control (CSF leak);
2. 20 CRSsNP; 3. 9
CRSwNP; 4. 14 AFRS
1. 25VD3 level; 2. Dendritic
cells as percentage of total
peripheral blood
mononuclear cells
No difference in 25VD3
between CRSsNP and
controls
Pinto428 2008 4 Case-control 1. 68 controls; 2. 86 CRS 1. 25VD3 level 25VD3 levels are lower in
urban African Americans
with CRS than controls or
whites with CRS
Sultan430 2013 5 In vitro 1. 8 patients including
healthy, CRSwNP and
CRSsNP subjects
1. 1α hydroxylase
mRNA/protein staining;
2. 1,25VD3 level;
3. Cathelicidin mRNA
expression
Human sinonasal epithelial
cells express 1α
hydroxylase, can generate
the active 1,25VD3 and
cathelicidin
Sugimoto431 2007 5 In vitro 1. 6 patients with CRS 1. Osteocalcin concentration;
2. TGFβ concentration;
3. Mineralization area
Vitamin D3/vitamin K
combination creates
greatest osteoneogenesis
by ethmoid bone
osteoblasts
factors, barrier fortification, immune system development,
and metabolic functions. To date, much research has fo-
cused on bacteria, but host and bacterial interactions with
viruses and fungi also are likely at play in shaping the sinus
microbiome.
Literature exploring the role of microbes in CRS has his-
torically relied primarily on culture-based methods in both
the clinical and research realm. Culture remains the clin-
ical standard, but research into genetics-based techniques
has shown that bacterial culture detects only a small per-
centage of resident bacteria.438,439 Even dominant bacteria
may be identified by culture in less than 50% of cases. 440
Previous culture-independent methods, such as organism-
specific PCR assays and immunostaining, provide only lim-
ited ability to characterize the microbial community as a
whole. This limitation has been recently overcome by 16S
ribosomal DNA (rDNA) sequencing.
In health, the anterior nasal cavity, middle meatus,
and sphenoethmoidal recess are populated by a tem-
porally stable microbiome441 that appears to be highly
individualized.442 Yan et al.441 demonstrated differences
between microbiota of the anterior nares vs the deeper
anatomic subsites, but a thorough comparison within the
sinuses has yet to be published. In contrast to the rich assem-
blages of bacteria that populate the sinuses in the healthy
state, CRS patients are colonized by a similar quantity of
bacteria overall, but display qualitatively different micro-
bial communities than their healthy counterparts.439,443–445
For instance in CRS, next-generation bacterial sequenc-
ing methods have noted a larger relative abundance of
anaerobes than had previously been identified, perhaps
because of the difficulty in growing these species in
culture.330,438,439 Particular species (namely Lactobacillus
and Corynebacterium spp) may be more abundant in the
healthy or diseased state, although these preliminary find-
ings have yet to be replicated.444,446 A preliminary bac-
terial metagenomics study showed that community-wide
alterations in bacteria and their extracellular vesicles were
associated with CRS. In this study, CRS patients exhib-
ited more bacterial abundance but less diversity in nasal
lavage specimens.447 In a large cohort of patients, Ramakr-
ishnan et al.445 examined microbiome alterations by phe-
notype and noted that CRS patients with asthma or puru-
lence had markedly different microbiota. In this study, the
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authors did not find differences in overall diversity indices
of CRS patients when compared to controls but demon-
strated that bacterial diversity was a predictor of surgical
outcome, suggesting that a diverse microbiomemay be ben-
eficial to restoration of sinus health.
Although CRS could be associated with shifts in micro-
biota and may be associated with decreased bacterial di-
versity, it is unclear whether there is a causal relationship
between these alterations and disease progression or if they
are a byproduct of either the pathogenic process or ensuing
medical therapies.448 For instance, antibiotic administra-
tion results in a dramatic decrease in richness and diversity
of resident bacterial communities, as observed in the gut of
healthy subjects and in a study of AECRS.449,450 Observed
alterations in local microbiota in CRS may result from re-
peated and prolongedmedical therapies.439,451 In the Feazel
et al.439 study, prior sinus surgery and the presence of
S. aureus were also associated with less diversity, but this
observation requires further exploration to determine if this
is a disease-association or a result of the extensive medical
and surgical therapies used in recalcitrant CRS.
In addition to the bacterial dysbiosis that may be present
in CRS, the host reaction to microbiota may also be dys-
functional. For example, Aurora et al.452 found minimal
differences between the bacterial and fungal microbiomes
of CRS vs healthy subjects, but when peripheral leukocytes
were exposed to microbiota, CRS patients produced signif-
icantly more IL-5.
Although microbiome studies are in their infancy in CRS,
overall composition and diversity disturbances have been
observed. It is worth noting that some of these findings
have not been replicated, because of small study cohorts
and variable experimental methods. The results in the lit-
erature are varied and difficult to interpret in aggregate.
Although there are common taxa present in both healthy
and CRS patients, no consistent enrichment of a particular
species has been uniformly identified, although the role of
Staphylococci remains curious. There is considerable inter-
est and functional relevance in the microbial community
that may contribute to sinus health and disease. Further
investigations of the sinonasal microbiome may promote
better understanding of the disease, leading to novel thera-
peutic interventions with potential opportunity for person-
alized medicine.
VII.C.1.i. CRSsNP Pathophysiology Contributing
Factors: Anatomic Variation. Anatomic variations that
may contribute to the pathophysiology of CRSsNP (os-
tensibly by narrowing sinus ostia) are generally divided
into those that affect the OMC or those that affect
frontal sinus drainage, although both pathways may be
affected.16,99,101,102,108,453–459 Examples of OMC varia-
tions include concha bullosae, paradoxical curvature of the
MT, infraorbital ethmoid (Haller) cells, and NSD. Frontal
sinus drainage obstruction may be caused by Type 1–
4 frontal sinus cells, supraorbital cells, suprabullar cells,
frontal bullar cells, and intersinus septal cells. However, the
presence of these anatomic variations in the general popu-
lation suggests other or additional factors are required to
develop CRSsNP and underscores the difficulty of defin-
ing anatomic contributions to pathophysiology. Studies re-
viewing paranasal sinus CTs of patients with and without
sinus symptoms are contradictory about whether anatom-
ical variants correlate to sinus disease (typically defined
using LM scores). Much of the literature on anatomic vari-
ations is older and does not strictly differentiate CRSwNP,
CRSsNP, and ARS, but uses CT evidence of RS rather than
more accurate symptomatic definitions.
Caughey et al.101 found patients with infraorbital eth-
moid cells had overall increased LM CT scores for the
frontal, ethmoid, and maxillary sinuses, but only the eth-
moid and maxillary sinuses had increased scores when
comparing individual sinuses. In the same study, patients
with a concha bullosa had increased LM scores for maxil-
lary sinuses only. The form of RS (CRS vs ARS) was not
delineated.
Jain et al.16 found a significantly higher average num-
ber of anatomical anomalies (accessory ostia, conchae bul-
losae, infraorbital ethmoid cells, lateralized uncinate pro-
cesses, and paradoxical MTs) in patients with limited sinus
involvement on CT compared to a cohort with pansinusi-
tis or control group without disease. They proposed that
these anatomical variants are only related to impairment of
the OMC and primary mucosal abnormality is responsible
for individuals with more global disease. Sedaghat et al.458
found sinonasal anatomic variants predispose to progres-
sion to CRS in patients with underlying AR. In contrast,
Nouraei et al.457 and Bolger et al.99 found no relationship
between anatomical variations of the MT or other struc-
tures that could affect the OMC and impact on LM score.
Similarly, Cho et al.102 noted no correlation between MT
variations or NSD and presence of sinus inflammation on
CT scan.
Frontal cells are thought to contribute to the development
of frontal sinus disease, but are noted to be prevalent in pa-
tients without symptoms of CRSsNP.460–462 In 2 studies of
patients with a history of CRS, the presence of frontal recess
cells and agger nasi cells were not associated with a higher
incidence of frontal sinusitis.462,463 Additionally, no asso-
ciation was found by DelGaudio et al.463 between frontal
sinusitis and size of the frontal recess. When specifically
studying frontal sinus anatomy, DeConde et al.464 showed
that the frontal sinus outflow dimensions, presence of an
intersinus septal cell, and an anterior ethmoid artery on
the mesentery did not impact QoL gains from endoscopic
frontal sinus surgery. However, Lien et al.461 demonstrated
an increased incidence of frontal sinusitis in cells that affect
the posterior or posterolateral aspect of the frontal recess
(suprabullar, supraorbital, and frontal bullar cells) with
no association found with type 1–4 frontal cells. Langille
et al.465 showed a significant relationship between the pres-
ence of frontal cells andmucosal thickening on CT imaging.
In conclusion, evidence indicates anatomic variations
may contribute to CRSsNP, although some of the data are
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conflicting and many studies do not differentiate between
CRSsNP, CRSwNP, and ARS. Although there appears to
be a causal association in some studies, sinus anatomical
abnormalities do not likely play a large role in the patho-
genesis of CRSsNP.
 Aggregate Grade of Evidence: C (Level 2b: 3 studies;
Level 3b: 4 studies; Level 4: 7 studies). Results of studies
are conflicting (Table VII-6).
VII.C.1.j. CRS Pathophysiology Contributing Fac-
tors: Septal Deviation. Because of limited data, CR-
SwNP and CRSsNP are combined in this analysis.
NSD is difficult to compare among patients and stud-
ies because it may change along the anterior-posterior
axis and may be quantified by investigators in different
ways.103,466–469 Moreover, like many studies of anatomic
sinus variants and RS, CRS and ARS are often not differ-
entiated in studies on NSD.
Two large reviews have examined the role of NSD and
RS. Collet et al.109 performed a nonsystematic review of
25 papers and found methodologies and results were often
contradictory. This review could not establish a definite
role for the nasal septum as a pathogenic cause of, nor as
a contributing factor, for CRS. More recently, Orlandi108
systematically reviewed 13 papers and concluded that many
of the previous studies were insufficiently powered to estab-
lish any association between RS andNSD. By systematically
combining the studies, he concluded that NSD is associated
with an increased prevalence of RS, although the impact of
this anatomic anomaly is limited. Interestingly, the risk of
RS increased on both the convex and concave sides, sug-
gesting airflow alterations rather than simple “crowding”
of the sinus anatomy may play a role.
Several studies have been published after these reviews.
Kamani et al.470 examined histopathological changes in
septal and nasal mucosa of patients with NSD. This study
determined significantly higher rates of squamous meta-
plasia and lymphocytic infiltration in septal mucosa oppo-
site the deviation compared to the control group, imply-
ing NSD may render patients susceptible to CRS. Poorey
and Gupta471 found patients with increasing septal angles
were associated with a higher incidence of maxillary si-
nus mucosal changes. The study reemphasized the concept
that NSD may lead to obstruction at the OMC. Mundra
et al.472 also found a strong association of increasing an-
gles of NSD with corresponding patterns of disease in the
OMC. They concluded that obstruction at the OMC and
anterior ethmoid secondary to NSD is a key factor causing
CRS. Fadda et al.473 also found that NSD—as well as other
anatomic variants—correlates with the presence of sinus
mucosal disease.
In 2008, Mladina et al.474 classified NSDs into 7 different
types and suggested that the degree and the type of septal
deformity has importance in nasal and systemic diseases.
Poje et al.475 performed a multicenter comparative study
to elucidate whether or not some of the Mladina types of
septal deformities are more frequent in CRS patients. The
incidence of 1 type of deviation (the “Passali” deformity474)
was found to be significantly higher in the CRS patient
group than in the control group. Similarly, Cingi et al.476
demonstrated an increased prevalence of so-called vertical
septal deformities (Mladina types 2 to 4) among those with
CRS.
Contrastingly, Kaygusuz et al.477 examined patients with
CRS who had undergone ESS and found no statistically
significant correlation between sinonasal anatomical vari-
ations and paranasal sinuses pathologies. They concluded
that sinonasal anatomical variation did not increase the
possibility of developing CRS and/or increase the severity
of preexisting CRS. Prasad et al.478 similarly found no sig-
nificant relationship between NSD and CRS.
The aggregate LOE for publications evaluating the cor-
relation of NSD with CRS is grade C, with most studies at
level 3 or 4. It should be noted that the apparent limited
effect, many studies with small sample sizes, the hetero-
geneity of the definition of NSD, and the limitations of the
univariable analysis complicate drawing firm conclusions
on the role of NSD in CRSsNP (Table VII-7).
 Aggregate Grade of Evidence: Grade C (Level 1b: 1
study; Level 3b: 3 studies; Level 4: 6 studies).
VII.C.1.k. CRSsNP Pathophysiology Contributing
Factors: Innate immunity. Multiple innate immune
mechanisms exist at the sinonasal mucosa surface to defend
the host against environmental organisms and pathogens.
Innate immunity includes nonspecific innate immune mu-
cosal defense and pathogen-specific innate mechanisms that
are directed against shared microbial patterns. Nonspecific
innate immune mucosal defense includes but is not limited
to sinonasal MCC, secreted antimicrobials, and comple-
ment. One example of a pathogen-specific innate immune
mechanism is pattern recognition receptors (PRRs). The 2
best-characterized classes of PRRs are the TLR family and
the nucleotide-binding oligomerization domain-like recep-
tors (NLR) family.480 It has been hypothesized that dys-
regulation of PRR pathways and innate immune effectors
likely contribute to the inflammatory state in CRS.
Studies that have examined the activity of innate immu-
nity in CRSsNP are summarized in Table VII-8. The ev-
idence is presented in 2 categories: (1) key antimicrobial
proteins and peptides in innate immunity; and (2) PRRs in
innate immunity.
(1) Key antimicrobial proteins and peptides
Five studies revealed that the activities of select innate an-
timicrobial proteins and peptides are increased in patients
with CRSsNP. Only 1 study showed that the activity of an
antimicrobial protein was decreased in innate immunity of
patients with CRSsNP.
Lee et al.481 showed that surfactant protein A (SP-
A) messenger RNA (mRNA) and protein levels were
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TABLE VII-6. Evidence for CRSsNP and anatomic variants as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
DeConde464 2015 2b Prospective cohort 63 CRS patients undergoing
frontal sinus surgery
Frontal recess anatomic
variants, preoperative to
postoperative SNOT-22 score
change
Anatomic measurements and
variations did not correlate
with changes in SNOT-22
scores
Sedaghat458 2013 2b Cohort study 59 patients treated over 7
years for AR
Presence of anatomic variants
and progression to CRS
Faster progression to CRS in AR
patients with at least 1
anatomic variant
Jain16 2013 3b Retrospective
case-control study
22 patients with limited RS,
28 patients with diffuse
disease, 27 controls
Presence of anatomic variants Frequency of total anatomical
variants in the limited group
was significantly higher than
in the pansinusitis and
control groups
Cho102 2011 3b Case-control study Sinus CTs of 73 healthy
controls; 461 CTs of
patients with rhinologic
symptoms
Presence of anatomic variations
of MT and NSD correlated to
presence of rhinologic
symptoms
MT abnormality or NSD were not
associated with increased
incidence of RS
Caughey101 2005 3b Case-control series 250 consecutive sinus and
orbital CT scans
Presence and size of concha
bullosa, infraorbital ethmoid
cells, NSDs, and severity of
mucosal thickening
Concha bullosa, infraorbital
ethmoid cells, narrow nasal
cavities associated with sinus
disease. No associations of
frontal sinus disease and
anatomic variants
Jones466 1997 3b Case-control 100 CT scans from patients
with CRS compared to 100
CT scans from patients with
orbital disease
Presence of anatomic variants
and mucosal thickening on
CT
No significant bony anatomical
differences between CRS
group and controls
Eweiss462 2013 4 Retrospective case
series
CT scans of 70 patients Presence of frontal and ethmoid
anatomic variants and the
presence of frontal sinusitis
No significance found between
presence or absence of
frontal recess/sinus cells or
agger nasi cells and frontal
sinusitis
Langille465 2012 4 Retrospective case
series
CT scans of 328 patients Presence of frontal sinus cells
and presence of mucosal
thickening
Frontal cells had a significant
association with the presence
of mucosal thickening
Lien461 2010 4 Retrospective case
series
CT scans of 192 patients Presence of anatomic variants
within the frontal and
ethmoid regions and the
presence of frontal sinusitis
Frontoethmoid cells posterior
and posterolateral to the
frontal recess were
associated with frontal
sinusitis
Nouraei457 2009 4 Retrospective case
series
300 CT scans from patients
with symptoms of CRS
Anatomic variants and LM
scores
No relationship was a found
between anatomical
variations and LM score
DelGaudio463 2005 4 Retrospective case
series
117 patients seen at a tertiary
rhinology center
Presence of anatomic variants;
anterior-posterior diameter
and area of the frontal
isthmus
Frontal sinusitis and diameter
and area of frontal isthmus
was not different for patients
with and without frontal cells
Sirikci459 2004 4 Case series 1450 paranasal sinus CTs
examined over a 5-year
period
Presence of EMS (an enlarged
posterior ethmoid cell
occupying the superior
portion of the maxillary sinus)
EMS was present in 0.7% of
patients. No relationship
between EMS and RS
Stallman103 2004 4 Retrospective case
series
CT scans of 1095 consecutive
patients with sinus
complaints
Presence of concha bullosa,
sinus mucosal thickening,
and NSD
Concha bullosa significantly
correlated to contralateral
nasal NSD but not paranasal
sinus disease
EMS = ethmomaxillary sinus.
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TABLE VII-7. Evidence for CRSsNP and septal deviation as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Orlandi108 2010 1b Systematic analysis Review of 13 previously
published studies
Presence and angle of NSD
and presence of RS
NSD is associated with RS. The
clinical effect was modest,
with OR of 1.47
Kamani470 2014 3b Case-control 20 CRS patients,
10 controls
Squamous metaplasia and
lymphocytic infiltration in
septal mucosa
NSD predisposes to chronic
mucosal inflammation and
squamous metaplasia
Poje475 2014 3b Case-control 127 CRS patients,
64 controls
Mladina NSD classification;
diagnosis of CRS
Mladina type 7 deformities were
found to be significantly
higher in the group of CRS
patients
Kaygusuz477 2014 3b Case-control 65 CRS patients,
34 controls
Mladina’s NSD classification
associated to CRS
There was no significant
relationship between NSD
and CRS
Cingi476 2014 4 Case series 505 patients Mladina NSD classification,
diagnosis of CRS
Patients with CRS have a high
prevalence of vertical
deformities (types 2, 3, and 4)
Mundra472 2014 4 Case series 61 CRS patients OMC disease and anterior
sinus mucosal disease in
relation to direction of NSD
Strong association of increasing
angles of NSD with disease in
OMC; no side predilection
Poorey471 2014 4 Case series 67 CRS patients Degree of septal angles,
maxillary sinus mucosal
changes
Higher degree of NSD
associated with obstruction
at OMC
Prasad478 2013 4 Case series 120 CRS patients Mladina’s NSD classification,
diagnosis of CRS
There was no significant
relationship between NSD
and CRS
Fadda473 2012 4 Case series 200 CRS patients Association between NSD and
sinus mucosa disease
assessed by CT imaging
Statistically significant
association was found
between NSD, and the
presence of sinus mucosal
disease
Li479 2012 4 Case series 56 CRS patients Differences in aerodynamics
in patients with mild,
moderate, or severe NSD
No aerodynamic differences
around the OMC could be
detected with increasing
severity of NSD
significantly increased in sinonasal tissue of CRSsNP com-
pared to that of normal controls. This study indicated con-
stitutive expression of the SP-A gene in the paranasal sinus
mucosa; this expression was upregulated in patients with
CRSsNP.
Woods et al.482 found that immunostaining of lysozyme
was significantly increased in mucosal biopsy specimens of
CRSsNP compared to control, but not the mRNA level.
Schlosser et al.483 demonstrated that factor B and com-
plement components C3 and C5 mRNA levels were signifi-
cantly higher in sinus mucosa biopsy specimens of CRSsNP
compared to that of control patients. Interestingly, Cui
et al.484 also showed that serum C3 level was significantly
increased in CRSsNP compared to controls.
Trefoil factor family (TFF) proteins are involved in ep-
ithelial protection and repair. Li and Turner485 showed that
TFF1 and TFF3 mRNAs and protein levels were significant
higher in ethmoid tissue of CRSsNP compared to control
patients. They concluded that the putative role of TFF pep-
tides may be important regulators of the sinonasal epithelial
barrier in patients with CRSsNP.
Cumulatively, these studies suggest that enhanced innate
responses may play important roles in the inflammatory
response seen in CRSsNP.
On the contrary, another study shows decreased innate
peptide activity in CRSsNP, although in a different fam-
ily of proteins. Richer et al.486 analyzed the expression
of epithelial genes involved in epithelial barrier mainte-
nance and repair in CRS. They collected epithelium from
inferior turbinates and uncinate processes and examined
mRNA levels of cell-surface proteins S100A7, S100A8, and
S100A9. They found that mRNA levels were significantly
decreased in CRSsNP when compared with controls. This
study indicates that reduction of epithelial genes involved
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in epithelial barrier maintenance and repair may contribute
to the development of CRSsNP.
(2) PRRs
Although investigations have demonstrated altered reg-
ulation and downregulation of PRRs in CRSsNP, all
studies to date have shown decreased PRR activity in
this condition, with no study yet demonstrating an up-
regulation of PRRs. Van Crombruggen et al.487 exam-
ined the receptor for advanced glycation end products
(RAGE) in CRSsNP and controls. They found sinus mu-
cosal protein levels of the soluble form of RAGE to be
elevated in CRS, whereas the membrane form was de-
creased. Zhang et al.488 showed that TLR4 and TLR7
mRNAs and protein levels were significantly lower in
sinonasal tissue of CRSsNP compared to that of CRSwNP
and controls. Similarly, Detwiller et al.489 revealed that
patients with CRSsNP showed lower mean expression of
TLR2 mRNA in mucosal biopsy specimens compared to
controls. These studies suggest that altered PRR responses
may play a role in CRSsNP.
Summary
In patients with CRSsNP, the data demonstrate that key
innate immune mediators are differentially expressed. The
current evidence is relatively sparse, with no cohesive pic-
ture yet forming. Additional work in this area will shed
meaningful light on the pathophysiology of CRSsNP.
VII.C.1.l. CRS Pathophysiology Contributing Fac-
tors: Epithelial Barrier Disturbance. Because of lim-
ited data, CRSwNP and CRSsNP are combined in this
analysis.
The sinonasal mucosa functions as an epithelial barrier
to an array of exogenous agents, serving to limit and reg-
ulate secondary stimulation of the immune response. The
basic components consist of a mechanical barrier and an
innate immune barrier. When the barrier fails to exclude a
pathogen, epithelial-derived cytokines and chemokines act
to shape the subsequent immune response. Broadly speak-
ing, CRS has been proposed to be a disease characterized
by dysfunctional sinonasal mucosa in which defects at the
epithelial surface may underlie the etiology and pathogene-
sis of the disorder.490 It has been further suggested that the
various phenotypes of CRS, including with or without NPs,
may be associated with distinct upstream epithelial defect
patterns.486,491,492
The mechanical component of the barrier consists of 2
parts, respiratory mucus and underlying epithelium. Respi-
ratory mucus traps foreign material and it is moved toward
the nasopharynx. The physical and chemical properties of
the mucus likely play a significant role in the efficiency and
selectivity of this process. Genetic and acquired defects in
mucociliary flow are associated with a high incidence of
CRS, and these entail variations in viscosity and ciliary
activity.493–496 Beneath the mucus reside the epithelial cells
(ECs), which are linked by tight and adherens junctions.
Tight and adherens junctions comprise the apical junctional
complex (AJC), creating a relatively impermeable barrier.
Exogenous agents often possess protease activity allowing
them to degrade the junctional proteins, making the barrier
more permeable.497 The barrier is maintained via ongoing
production of AJC proteins as well as protective antipro-
tease molecules. The polypoid form of CRS and a Th2
cytokine milieu have been associated with significantly de-
creased levels of AJC proteins498–501 as well as diminished
intrinsic protective antiprotease activity.486,502 Functional
studies have also documented increased barrier permeabil-
ity in CRSwNP.500,501,503 It has been further proposed that
the protein oncostatin M may play a key role mediating
a leaky barrier in polyps.503 Furthermore, a global gene
microarray meta-analysis indicated that polyp epithelia ex-
hibited a less mature gene signature typically associated
with an epithelial to mesenchymal transition, which would
predict a loss of barrier integrity.504 Taken together, these
studies suggest that mucociliary dysfunction may play a
role in the pathogenesis of CRS broadly, whereas a porous
barrier is more closely linked to CRSwNP.
The mechanical barrier provides the first line of defense,
limiting access of foreign material. A second line of defense
is provided by multiple cells types that express PRRs capa-
ble of recognizing pathogen associated molecular patterns
(PAMPs) present on microbes.505,506 In order to incite a
sustained immune response, cell damage is typically also
necessary, and this is associated with the release of endoge-
nous cell products collectively termed damage-associated
molecular patterns (DAMPs).507–509 Multiple classes of
PRRs recognize PAMPs and DAMPs (eg, TLRs), and al-
though abnormal receptor signaling has been proposed to
contribute to the development of CRS, data are thus far
inconclusive.506,510–513 In addition to classical PRRs, recent
evidence has indicated that bitter and sweet taste receptors
are also present on ECs, functioning as PRRs by detect-
ing microbial products and triggering enhanced MCC and
release of host defense molecules.354,514
Nasal ECs, which are typically the first cells to en-
counter PAMPs, secrete host defense molecules into the
nasal mucus at baseline, with levels augmented upon PRR
stimulation.515–517 The pattern of host defense molecule se-
cretion exhibits regional specialization, with high levels of
the antibiofilm protein palate, lung, and nasal epithelium
clone protein (PLUNC) present at the uncinate process.518
Presumably, this regional pattern of host defense molecules
is mirrored by a complementary regional variation in the
local nasal microbiome. Decreased expression of some host
defense molecules has been associated with CRS.334,519–521
A precise molecular pathway for this defect has not been
proposed, but the cytokine IL-22 and its receptor IL-22R
are key regulators of mucosal host defense,522 acting in
large part through the transcription factor STAT 3.523,524
Diminished expression of IL-22R525 and blunting of the
STAT 3 pathway526 have been reported; these defects
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appear to be associated with CRS broadly, and are not
specific for the presence or absence of NPs.527 Taken to-
gether, these data provided support for the hypothesis that
a primary sinonasal innate immune defect may predispose
to the development of CRS.528
In addition to host defense molecules, ECs respond
to PRR stimulation with the secretion of cytokines and
chemokines that foster inflammation and attract and acti-
vate innate effector cells.362,515,529–532 In addition, the EC
cytokines play a key role in shaping any subsequent adap-
tive immune response. Cytokine crosstalk between ECs,
innate lymphoid cells (ILCs), and dendritic cells matches
the appropriate innate and adaptive response to particular
foreign stimuli. In health, this maintains mucosal home-
ostasis with (1) tolerance of allergens and commensals and
(2) defense against pathogens. In CRS, the mucosal inflam-
mation remains chronic, with a persistent innate cellular
and adaptive response. CRSwNP in whites is most com-
monly characterized by an excessive Th2 inflammation.
In asthma, the specific epithelial cytokines IL-25, IL-33,
and thymic stromal lymphopoietin (TSLP) have been impli-
cated in pathogenesis via effects on dendritic cells and type
2 ILCs.533–535 In support of this hypothesis in CRSwNP,
polyps exhibit large numbers of type 2 ILCs536,537 and den-
dritic cells.538,539 The critical upstream epithelial cytokine
is not completely clear, but high levels of TSLP activity
have been identified in polyp homogenates.540,541 Some ev-
idence suggests that IL-33 may play a role as well, but
these studies have yet to demonstrate increased expression
of this cytokine at the protein level in NP tissue.374,542–544
In regard to IL-25, evidence in CRS is scant. As mentioned
earlier in this section EC chemokines also play a major role
in the attraction and activation of innate effector cells in-
cluding eosinophils, mast cells, neutrophils, macrophages,
and likely ILCs. Local release of factors from these effector
cells is widely believed to be the proximate cause of the tis-
sue damage and remodeling changes associated with both
forms of CRS. In regard to pathogenesis, most interest has
centered on eosinophils545 and mast cells,546,547 although
elevated levels of neutrophils and macrophages are also
present and phagocytic activity may be impaired in CRS.548
ECs express enzymes involved in the generation of re-
active oxygen species and reactive nitrogen species that
are important in multiple epithelial processes, including
mucin production, epithelial repair, innate immunity, and
response to environmental toxins.549 Variations in activ-
ity of these enzyme systems have been proposed to im-
pair barrier function and innate immunity in CRS.550–554
EC enzyme systems also likely contribute to tissue lev-
els of eicosanoids, which have been implicated in sub-
types of CRSwNP.321,555 The overall relevance of these en-
zymes to CRS remains unclear but at least theoretically,
underactivation could predispose to microbial coloniza-
tion and overactivation could trigger barrier damage and/or
inflammation.
CRS has been most frequently characterized by the
adaptive immune response present in the tissue, yet it
is unclear that these downstream signatures are critical
from the standpoint of etiology and pathogenesis. From
this latter perspective, CRS has been proposed as a broad
disorder characterized by an upstream dysfunctional
host-environment interaction at the sinonasal interface.490
Similar concepts have been proposed with regard to
asthma pathogenesis535 and although the association of
asthma and CRS is well established, the prevalence of other
chronic inflammatory disorders within the CRS population
is close to background.288,556 These observations suggest
that host defects in CRS will be centered in the airway
mucosa, giving rise to the “immune barrier hypothesis,”
which proposes that genetic and epigenetic variation in the
coordinated mechanical barrier and/or the innate immune
response of the sinonasal epithelium manifests as CRS.530
Diminished innate host defense coupled with a porous
barrier should theoretically lead to altered microbial colo-
nization, accentuated barrier damage, and a compensatory
adaptive immune response.491,528 Although somewhat
distinct, CRSsNP and CRSwNP both exhibit innate im-
mune and mechanical barrier defects. The immune barrier
hypothesis does not specifically address the Th1 or Th2
subset skewing observed in many CRS subtypes, including
the Th2 pattern and B cell infiltrate observed in Western
CRSwNP patients.557,558 This implies additional, as yet
undetermined, mechanisms that may be centered on TSLP
and ILC signaling and which may foster an inappropriate
local adaptive response. An excessive and/or inappropriate
Th2 adaptive response in this setting may further com-
promise barrier function and diminish innate immunity,
thereby creating a self-perpetuating cycle of disease.
VII.C.1.m. CRSsNP Pathophysiology Contribut-
ing Factors: Ciliary Derangements. Proper MCC is of
paramount importance in eradicating pathogens and debris
from the sinonasal tract. Cilia beat in a directional fashion
to move mucus to the sinus natural ostia and ultimately
to the nasopharynx/oropharynx, where it can be cleared
by expectoration or swallowing.559 A variety of choliner-
gic, adrenergic, and peptidergic pathways are involved in
the regulation of ciliary beating, and ciliary beat frequency
(CBF) can be dynamicallymodulated formaximal efficiency
of mucociliary transport. Substances that are introduced to
the surface of the respiratory epithelium bind to receptors
that have potent downstream effects on CBF.560,561 During
infection, CBF increases to stimulate mucus clearance562
as well as to disseminate innate immune products.563 Mi-
crobes directly impact ciliary function, and can often “hi-
jack” normal ciliary regulation to prevent appropriate mu-
cus movement.560
In CRS, patients may have dysfunctional ciliary beating
from direct effects of the organisms or from an inappropri-
ate inflammatory response. Mucociliary stasis is a common
finding of CRS, which propagates the disease because
the stagnant mucus can harbor infection and sustain
inflammatory mediators.494 Although there does not seem
to be a detectable difference between baseline CBF in
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CRS patients and control patients, cilia from CRS patients
show an attenuated response to substances that reliably
increase CBF in controls.564,565 This blunted response to
ciliostimulatory substances may underlie the perpetuation
of pathology in CRS. Pathogens such as P. aeruginosa,
H. influenzae, Streptococcus pneumoniae, and S. aureus
secrete toxins that directly suppress ciliary motion.566–569
Pyocyanin, a toxin produced by P. aeruginosa, not only
causes progressive slowing, but also makes the cilia
unable to respond to mechanical simulation by other
factors.570 H. influenzae toxins destroy cilia entirely at
high concentrations, resulting in mucus stasis from ciliary
loss.571 These toxins, when present chronically, create an
environment that is very favorable for CRS development.
An overactive inflammatory environment or defects in
cellular transport may also be causing some of the CRS
ciliary pathology. TNF-α, IL-1β, IL-5, and IL-8 are consis-
tently elevated in CRS cases, 572 and chronic elevation of
these factors often blunts ciliary response. TNF-α has been
shown to prevent CBF increases in response to mechanical
stimulation,573 whereas cycles of inflammation can cause
ciliary loss or ciliary abnormalities in a chronic setting.560
Sodium and chloride transport play a large role in MCC as
well. Sodium absorption is increased in nasal cell culture
from CRS patients, resulting in greater mucus viscosity
and more difficult clearance, because the cilia have to work
harder to transport the same load.574 Cigarette smokers
have increased rates of CRS575,576 in part because of the
reduction in chloride transport caused by compounds in
cigarette smoke precipitating a reduction in CBF.577,578
Treatment of ciliary dysfunction in CRS involves the
respiratory epithelium returning to normal excitability
and the establishment of an appropriately regulated
inflammatory environment. It appears that the cilia are
capable of recovering their excitability and normal activity
in a healthy state. In 1 study, ciliated cells that were
removed from the inflammatory milieu of CRS regained
their ability to be stimulated and again functioned in a
normal fashion.495 Therefore, most effort clinically should
be in treating the underlying CRS, as opposed to treating
the dysfunctional cilia separately. Topical antimicrobial
therapy results in not only symptomatic improvement,
but in 1 study of 10 patients also showed an increase in
CBF back to expected levels.579 In cases of irreversible
ciliary dysfunction, structural components of the cilia may
be abnormal. Increased expression of CP110, a negative
regulator of ciliogenesis, has been observed in CRS patients
and may contribute to the poor ciliary recovery.580 Other
studies have hypothesized that the ciliogenesis process may
be dysregulated.304 If the cilia that are generated are in any
way functionally abnormal or absent, there is increased
risk of biofilm formation and other CRS risk factors.581–584
VII.C.1.n. CRSsNP Pathophysiology Contributing
Factors: Immunodeficiencies. In the subset of adult pa-
tients who have CRS that is refractory to usual therapy, PID
should be considered. The most common clinical manifes-
tations of PID include chronic otitis media, RS, and chronic
lung disease such as pneumonia and bronchiectasis.585–589
An association between hypoimmunoglobulinemia and
CRS has been described in the literature and multiple
studies have demonstrated PID as a risk factor for the
development of CRS.15,155,590–596 The association is fur-
ther strengthened by other studies that show an increased
incidence of RS in patients with immune dysfunction.586,587
CVID, X-linked hypogammaglobulinemia, and several
other disorders of humoral immunity are frequently
referenced as contributing factors to chronic or recurrent
recalcitrant RS.15,588,589,596–599 A number of selective Ig
deficiencies, specifically those involving IgG3 subclass, IgA,
and IgM, have been consistently identified in this group of
patients.585,586,590,593,594,596–598,600–602 Preimmunization
antipneumococcal titers have been shown to be decreased
as well, particularly in patients with the more severe forms
of immunodeficiency such as CVID.
The studies in this literature review demonstrate the
significance of PID in the development of chronic sinus
disease, with up to 50% of those with recalcitrant CRS
found to have primary immune dysfunction.596 The
included studies are somewhat limited given the relatively
inferior aggregate grade of evidence. Areas of further study
include the degree to which the severity of hypogamma-
globulinemia results in clinically significant RS and exactly
which CRS patients benefit most from investigation and
treatment of immunodeficiency. Additional research may
also define optimal medical and immune supplementation
therapy in those with PID and CRS (Table VII-9).
 Aggregate Grade of Evidence: C (Level 2b: 1 study; Level
3b: 8 studies; Level 4: 8 studies).
 Benefit: Identifying patients with PID allows for the op-
portunity to treat a subset of patients whowill respond to
Ig replacement therapy. Morbidity associated with CRS
may be minimized.
 Harm: There is a potential for increased cost associated
with unnecessary or premature testing.
 Cost: Associated costs consist of the direct costs of labo-
ratory testing.
 Benefits-Harm Assessment: The benefits of identifying
patients with immune dysfunction outweigh any associ-
ated risks.
 Value Judgments: Otolaryngologists may be the first
providers to see these patients given the frequent coexis-
tence of immunodeficiency and RS. This provides for the
opportunity to identify patients with a treatable under-
lying disorder. “Refractory CRS” is not well defined.
 Policy Level: Recommendation in cases of refractory
CRS.
 Intervention: PID should be considered in patients with
refractory CRS.
VII.C.1.o. CRSsNP Pathophysiology Contributing
Factors: Genetic Factors. With a few notable excep-
tions, studies of the genetic basis of CRS have mainly
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focused on CRS regardless of NP status, making it difficult
to determine precisely whether similar genetic variations
underlie the CRSwNP and CRSsNP phenotypes. A genetic
basis to CRS has long been suspected from aggregation
studies showing clustering of CRSwNP in families604–606
and by monogenic disorders that include CRSwNP in
their phenotype. The concept of a genetic basis to CRS
is further supported by genetically modified (knockout)
mouse studies where altered function of certain specific
genes are associated with development of signs and nasal
findings reminiscent of human CRS.607
In cystic fibrosis (CF), mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene are
associated with development of CRS in a high proportion
of affected individuals.608 However, disease evolution
cannot be predicted according to identified genotype.609
Other monogenic diseases include CRS in their phenotype.
Primary ciliary dyskinesia (PCD) is associated with RS as
1 of the elements of disease presentation.610,611
Although genetic syndromes with CRS implicate genes
logically linked with disease such as epithelial function612
and defects in innate and adaptive immunity,7 this is not
always the case. Numerous genetic associations have been
suggested that are difficult to link mechanistically to CRS
development.613 This underlines both the potential power
of these technologies to identify novel mechanisms and
pathways implicated in CRS development and the need for
more research in this promising area.
Screening for genetic associations has been dramatically
simplified by the use of single-nucleotide polymorphisms
(SNPs) as markers of gene variation and position.614 Un-
fortunately, all published gene association studies in CRS
lack the power to conclusively demonstrate association
at a significance approaching that seen in other diseases.
Investigators have nevertheless suggested a number of
candidate genes associated with CRS, which has led to
some interesting observations with intriguing implications.
Reviews of genetics of CRS615–617 have been presented
elsewhere and identified genes are presented as a tabulated
list (Table VII-10).
In the sole article assessing CRSsNP separately from CR-
SwNP, Zhang et al.,618 in Han Chinese in China, compared
genetic variations in the acetyl hydroxylase (AOAH) gene
in 300 CRSwNP, 300 CRSsNP, and 300 control subjects.
Differences in the p value and risk for both CRSwNP
and CRSsNP populations, as well as genetic variations in
the AOAH gene, were only seen in the CRSsNP group
(CRSsNP: OR, 0.30, p = 8.11 × 10−11; CRSwNP: OR,
0.96, p = 0.64). This suggests that different mechanisms
may underlie the development of CRSsNP and CRSwNP,
again highlighting the need for more studies in other
populations.
Three candidate SNPs have been replicated in separate
publications: TNF,619–623 IL1A,619,624 and AOAH.613,618
TNF and IL1A are important proinflammatory cytokines,
and AAOH inactivates lipopolysaccharides.625 This sug-
gests that dysregulated inflammatory responses may play
TABLE VII-10. Genes implicated in the pathogenesis of CRS
Phenotype
Gene name Reference Year (if delineated)
Immune function
ALOX5 Al-Shemari628 2008
ALOX5AP Al-Shemari628 2008
AOAH Bosse´613 2009
AOAH Zhang629 2011 CRSsNP
BDKRB2 Cormier630 2014
CD58 Pasaje631 2011 CRSwNP
CD8A Alromaih632 2013
CDH23 Cormier630 2014
CNTN5 Cormier630 2014
COX2 Sitarek633 2012
CYSLTR1(X)* Al-Shemari628 2008
HLA-DQB1 Schubert634 2004 CRSwNP
IL10 Bernstein635 2009
IL10 Zhang618 2012
IL1A Karjalainen636 2003
IL1A Mfuna Endam624 2010
IL1A Erbek619 2007
IL1B Bernstein635 2009
IL1B Erbek619 2007
IL1RL1 Castano637 2009
IL1RN Cheng638 2006
IL22RA1 Endam639 2009
IL33 Buysschaert640 2010
IL4 Zhang641 2012
IRAK-4 Tewfik626 2009
IRAK-4 Zhang629 2011 CRSwNP
K6IRS2 Cormier630 2014
K6IRS4 Cormier630 2014
K6IRS4 Cormier630 2014
MET Sitarek633 2012
MET1 Castano637 2009
MMP9 Wang642 2010
NOS1 Castano637 2009
NOS1 Zhang629 2011
NOS1AP Zhang629 2011
PDGFD Cormier630 2014
PI3Kγ Bojarski621 2013
(Continued)
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TABLE VII-10. Continued
Phenotype
Gene name Reference Year (if delineated)
PRKCH Cormier630 2014
RAC1 Cormier630 2014
TGFß1 Kim643 2007
TAS2R38 Adappa353 2014
TAS2R38 Mfuna Endam644 2014
TNFA Batikhan620 2010
TNFA Bernstein635 2009
TNFA Erbek619 2007
TNFAIP3 Cormier645 2009
TP73 Tournas646 2010
Epithelial/extracellular matrix function
IGFBP7 Cormier630 2014
LAMA2 Bosse´613 2009
LAMB1 Bosse´613 2009
LF Zielinska-Blizniewska647 2012
Solute carriage
CACNA1I Bosse´613 2009
CACNA2D1 Cormier630 2014
CACNG6 Lee648 2010
KCNAM1 Purkey627 2014
KCNQ5 Purkey627 2014
KIAA1456 Bosse´613 2009
SLC13A3 Cormier630 2014
Other/unknown function
C13orf7 Cormier630 2014
CIITA Bae649 2013 CRSwNP
DCBLD2 Pasaje650 2012 CRSwNP
DPP10 Kim651 2015 CRSwNP
FAM79B Cormier630 2014
GFRA1 Cormier630 2014
MSRA Bosse´613 2009
MUSK Bosse´613 2009
NARF Cormier630 2014
NAV3 Bosse´613 2009
OSF-2 Zielinska-Blizniewska647 2012
PARS2 Bosse´613 2009
PHF14 Cormier630 2014
(Continued)
TABLE VII-10. Continued
Phenotype
Gene name Reference Year (if delineated)
PIGT Cormier630 2014
RPGR Bukowy-Bieryllo652 2013
RYBP Bosse´613 2009
RYBP Cormier630 2014
SERPINA1 Kilty653 2010
TOMM34 Cormier630 2014
TRHDE Cormier630 2014
TRIP12 Bosse´613 2009
UBE3A Cormier630 2014
UBE3A Cormier630 2014
UBE3C Pasaje654 2011 CRSwNP
a role in genetically-determined CRS. It is unclear whether
the gene variation(s) associated with CRS favors increased
or reduced inflammation.
Relevance of other reported candidate genes may be
supported by demonstration of a functional impact of the
candidate genotype. Studies with functional impact include
interleukin-1 receptor-associated kinase 4 (IRAK-4), where
candidate SNPs identified in the CRS population are
associated with genotype-specific variation in IgE level.626
Gene variations in the TAS2R38 taste receptor353,354 are
associated with gram-negative bacterial carriage and poor
response to surgery.
Certain SNPs not associated with immune function
may also be implicated. Among possible candidates are
epithelial and ECM dysfunction. Top candidate SNPs in a
modified genomewide association study of refractory CRS
identified SNPs in 2 genes coding for elements of ECM
as top candidates.613 This suggests that dysfunction in
ECM composition or of ECM–integrin interactions may
be implicated in CRS.
In the only study of pediatric CRS, Purkey et al.627
demonstrated variations in the KCNAM1 and KCNQ5
genes, suggesting that potassium channel genes may play
a role in early developing CRS. The role of potassium
channel dysfunction in development of CRS remains to be
described, but may involve altered solute balance and/or
focal adhesion mechanisms important for epithelial cell
regulation. This underlines the power of these evolving
technologies for identifying new mechanisms.
Although clearly still in its infancy, identification
of genetic components will continue to progress with
discovery of novel genes and gene mechanisms through
advances in technology and sequencing of the genome.
Intriguing concepts continue to emerge that anticipate
further exciting developments.
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TABLE VII-11. The diagnostic criteria for CRSsNP
Greater than or equal to 12 weeks of:
2 or more of the following symptoms:
Mucopurulent discharge (rhinorrhea or PND)
Nasal obstruction and congestion
Decreased or absent sense of smell
Facial pressure or pain
AND
1 or more of the following findings:
Evidence of inflammation on paranasal sinus examination or CT
Evidence of purulence coming from paranasal sinuses or OMC
AND
Lack of polyps
VII.D. CRSsNP: Diagnosis
CRSsNP is defined in Section IV.B. The symptoms asso-
ciated with CRS can be grouped into 4 categories9: nasal
symptoms (obstruction, discharge, absence or impairment
of sense of smell); facial symptoms (facial pressure, facial
pain, headache); oropharyngeal symptoms (ear pain, hal-
itosis, PND, dental pain, cough); and systemic symptoms
(general malaise, fatigue). The most common symptom
is nasal obstruction.617 These symptoms are highly sen-
sitive individually, but not specific.655,656 Evidence has
shown combining 2 or more symptoms together along
with objective findings of disease (imaging, endoscopy)
substantially increases diagnostic specificity and positive
predictive value.9,15,657 Although the original guidelines
used major and minor criteria,11 there has been no
consensus or evidence whether this categorization is based
on prevalence, sensitivity, or specificity of symptoms. As
a result, the present definition includes the most sensitive
symptoms as part of the diagnosis. Other symptoms such
as halitosis, dental pain, and cough may be present and
related to the patient’s CRS, but are not included in the
diagnosis definition. The evidenced-based definition of
CRSsNP is shown in Table VII-11.
Dividing CRS into categories of polyposis and no poly-
posis is supported by histologic and inflammatory cytokine
findings in CRSwithout polyposis.9,658 Differences in treat-
ment responses and recurrence rates of the disease also sup-
port separating the categories,659 with CRSsNP showing
improved outcomes to standard treatments and a decrease
in recurrence rate. However more precise biomarker-based
categorization may be possible in the near future.
VII.D.1. CRSsNP Diagnosis: Differential Diagnosis
Because of the broad differential for CRSsNP, it is fre-
quently not easy to differentiate it from other diseases
without diagnostic modalities including nasal endoscopy
and radiologic examination.660,661 AR is a hypersensitivity
of the nasal mucosa to foreign substances mediated through
IgE antibodies.662 In most cases, sneezing and itching are
clues to distinguish AR from CRS, though not in all cases.
663 Another symptomatic mimic of CRSsNP is non-AR,
which includes non-AR with eosinophilia syndrome
(NARES), hormonal rhinitis, drug-induced rhinitis, irritant
rhinitis, atrophic rhinitis, and idiopathic rhinitis.271,664
Although only a small proportion of patients with purulent
CRS without coexisting chest disease complains of cough,
CRS should be differentiated from GERD and asthma by
physical examination.
In the case of CRS with recurrent acute facial pain
and pressure episodes, it is not easy to differentiate
it from primary headache disorders, such as migraine
and tension-type headache, because they are commonly
accompanied by sinus-related symptoms like rhinorrhea
and nasal congestion.665–667 To rule out the primary
headache and similar disorders, such as myofascial pain
and temporomandibular joint pain, an accurate history
and physical exam are needed. Chronic dental infection,
foreign body, and both benign and malignant sinonasal
neoplasia must be included in the differential diagnosis
as well. Most of these conditions can be eliminated by a
thorough physical exam including nasal endoscopy along
with appropriate imaging (CT or MRI).
If nasal discharge is unilateral and clear, clinicians should
rule out cerebrospinal fluid (CSF) rhinorrhea.668 History
of trauma and surgery, and salty taste of discharge are im-
portant clues for diagnosis.669 Detection of β2-transferrin
in nasal secretions confirms CSF.670
VII.D.2. CRS Diagnosis: Cost Effective Work Up
Because of limited data, CRSwNP and CRSsNP are
combined in this analysis and recommendation.
Prior evidence-based reviews have generally lacked
recommendations for the cost-effective diagnosis of adult
CRS. Since 1997, expert groups on RS have proposed
different diagnostic criteria for RS, with varying combi-
nations of symptoms and symptom duration, but more
recent iterations require confirmation with CT imaging or
endoscopy to arrive at a CRS diagnosis.7,15,21,155,202,671,672
Despite the requirement to document objective findings
of sinonasal inflammation, few studies have addressed the
timing and sequence of testing used to validate a CRS di-
agnosis in an accurate and cost-efficient manner. Published
algorithms recommend establishing a symptom-based defi-
nition of CRS through the patient history, followed by nasal
endoscopy.673–675 Diagnostic imaging, especially CT imag-
ing, has been recommended for symptomatic patients with
equivocal or normal findings on endoscopy.676 A discussion
of the cost efficiency of CRS diagnosis is highly dependent
on healthcare system–specific direct costs and availability of
professionals, diagnostic modalities, and therapeutic regi-
mens for CRS. Indirect costs, including radiation exposure,
time lost from work, and potential complications related to
International Forum of Allergy & Rhinology, Vol. 6, No. S1, February 2016 S76
International Consensus on Rhinosinusitis
therapeutic interventions, are more difficult to measure and
will generally be excluded from this analysis. The following
recommendations focus on diagnostic algorithms within
the context of the cost and availability of modalities in the
United States, based on existing evidence (Table VII-12).
VII.D.2.a. CRS Diagnosis Using “Symptoms Alone”
The symptom-based component for CRS diagnosis cur-
rently emphasizes the 4 cardinal symptoms of nasal
obstruction, nasal discharge, facial pain or pressure, and
reduction or loss of smell and no longer utilizes minor
symptoms (headache, fever, halitosis, fatigue, dental pain,
cough, and ear symptoms) because of their frequent
absence in CRS and overlap with other medical conditions.
11,655,656,661 Of the cardinal symptoms, prior studies con-
sistently show that discolored nasal discharge and smell
loss—individually and especially in combination—enhance
the positive predictive value of symptom criteria for CRS
diagnosis.656,660,676,677 Nasal obstruction is almost univer-
sal and has the highest average severity among patients with
CRS, but its absence in the presence of other cardinal symp-
toms may be indicative of a non-CRS etiology.660,675,678,679
Other studies suggest that facial pain (but not pressure) is
not universal and its presence may also decrease the like-
lihood of a CRS diagnosis.676–678 Together, these studies
suggest that refining symptom wording and increasing the
emphasis of specific symptoms (eg, smell loss) can change
the probability of CRS diagnosis. They also demonstrate
that using symptoms alone to diagnose CRS is not a
cost-efficient strategy for most patients given the expected
pretest probability of CRS among an appropriately symp-
tomatic population. Prior studies comparing symptoms
against a CT gold standard have suggested the specificity
of symptoms in the range of 2% to 12% and positive
predictive values ranging between 35% and 54%.7,655,657
 Aggregate Grade of Evidence: B (Level 2b: 8 studies;
Level 4: 2 studies).
 Benefit: A “symptoms alone” strategy is a patient-
centered andwidely available means for establishing pos-
sible diagnosis of CRS.
 Harm: High rate of false-positive diagnoses may prevent
or delay the establishment of correct underlying diag-
noses and potential for inappropriate interventions re-
sulting in direct and indirect healthcare costs (eg, time
lost from work and potential adverse effects from treat-
ments).
 Cost: Low–performed at all specialist and nonspecialist
visits.
 Benefits-Harm Assessment: Harm over benefit, if used as
the sole clinical method for CRS diagnosis, because there
is a significant risk of misdiagnosis.
 Value Judgments: Assessing patient-reported symptoms
is an important component of the patient encounter, but
is too inaccurate to be the only means used to diagnose
CRS.
 Policy Level: Recommend against.
 Intervention: Recommendation against using a
“symptoms-alone” strategy to make the diagnosis
of CRS.
VII.D.2.b. CRS Diagnosis with Nasal Endoscopy
The diagnostic utility of nasal airway examination to eval-
uate for CRS is well established in the literature.676,680–682
Although anterior rhinoscopy may reveal mucopurulent
drainage or severe nasal polyposis, this examination
technique may not consistently provide sufficient illumi-
nation and visualization of structures beyond the inferior
turbinate. Nasal endoscopy provides a more thorough ex-
amination of sinus drainage pathways in themiddlemeatus,
sphenoethmoidal recess, and nasopharynx. Applicable find-
ings for CRSsNP include purulent mucus in the sinonasal
cavities or less specifically, mucosal edema of the middle
meatus or ethmoid regions. Additionally, nasal endoscopy
can assist with obtaining cultures of targeted sinonasal
locations and evaluating for alternative pathologies that
may be symptomatically similar to CRS, such as intranasal
tumors, adenoid hypertrophy, or posterior NSDs. In post-
surgical patients, the surgical alterations of the anatomy
also facilitate a thorough examination of the sinuses using
nasal endoscopy alone. Bhattacharyya and Lee657 deter-
mined that compared to using a symptom-based criteria
alone to predict the presence of CRS (specificity and
positive predictive value of 12% and 39%, respectively,
using a CT-based gold standard), the addition of nasal
endoscopy to a symptom-based assessment substantially
increases the diagnostic accuracy of CRS, with specificity
and positive predictive values estimated at 84% and 66%,
respectively.
From a cost-efficiency standpoint, nasal endoscopy
is an important diagnostic tool in individuals with a
high pretest probability for CRS, as determined by their
symptoms. When performed by experienced specialists,
nasal endoscopy is regarded as a safe and effective method
to evaluate patient symptoms that are concerning for CRS.
If appropriate endoscopic findings are found for CRS
diagnosis, additional imaging for diagnostic confirmation
may not be unnecessary, although it may still be indicated
for preoperative planning or evaluation of complications
arising from RS. It is also cost-inefficient to obtain a
CT to confirm the diagnosis if the nasal endoscopy is
suggestive of CRS.676 Alternatively, a negative endoscopy
in a symptomatic patient also decreases the likelihood
of CRS to about 20%.657,676 Therefore, although nasal
endoscopy entails significant upfront costs related to the
purchase, maintenance, and processing of equipment
along with the expertise of specialists, the evidence
supports its use as a cost-effective strategy related to
potentially avoiding the need to obtain a CT scan of the
sinuses.
Despite the high specificity and positive predictive
value of nasal endoscopy in confirming a CRS diagnosis,
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endoscopy is notably less sensitive and thus has a high
false-negative rate compared to CT. Published estimates of
sensitivity and false-negative rates are 30% to 46%
and 35% to 70%, respectively, when compared to
CT.657,675,680–682 The lower sensitivity is related to the
difficulty or inability of rigid and flexible endoscopy to
assess the interior of all of the sinonasal cavities, especially
in unoperated patients.
 Aggregate Grade of Evidence: B (Level 2a: 1 study; Level
2b: 3 studies).
 Benefit: Higher positive predictive value and specificity
for a CRS diagnosis compared to using symptoms alone,
allowing for the avoidance of CT utilization costs and
potential radiation exposure of imaging.
 Harm: If the clinician still suspects CRS, a negative en-
doscopy exam will still require a CT scan of the sinuses
because of the potential for a false-negative endoscopy.
Mild discomfort associated with the procedure.
 Cost: For 2014, the Centers for Medicare & Medicaid
Services (CMS) in the United States set a national pay-
ment average for a diagnostic nasal endoscopy (Cur-
rent Procedural Terminology code 31231) at US$212.07,
which accounts for both service and facility reimburse-
ments for the diagnostic intervention. This cost reflects
the specialists’ time to perform and review findings of en-
doscopy, capital needed to purchase the essential equip-
ment, and expenses related to sterilizing and maintaining
the endoscopes.
 Benefits-Harm Assessment: Preponderance of benefit as
the initial technique to objectively establish CRS diagno-
sis by trained endoscopists, but the technique is limited
by a reduced sensitivity relative to CT imaging.
 Value Judgments: Endoscopy is an important diagnos-
tic intervention that should be used in conjunction with
a thorough history and physical exam for patients sus-
pected of having CRS. It should be complemented with
other diagnostic testing in the event of a negative en-
doscopy where CRS is still suspected.
 Policy Level: Recommendation.
 Intervention: Nasal endoscopy is recommended in con-
junction with a history and physical examination for a
patient being evaluated for CRS. CT is an option for
confirming CRS instead of nasal endoscopy.
VII.D.2.c. CRS Workup with Diagnostic Imaging
Practice guidelines acknowledge that CT imaging, as
opposed to the plain radiography or MRI, is the diagnostic
modality of choice for confirming CRS683 or as an alterna-
tive to nasal endoscopy.4 Some guidelines, however, suggest
that CT imaging as a diagnostic modality is not essential
in all cases, but should only be considered in situations
with disease that is refractory to maximal medical therapy,
or for surgical planning.7,202,671 Other studies examining
costs and expected treatment outcomes for correct and
incorrect CRS diagnosis suggest that upfront CT imaging
for specialty care patients with a negative endoscopy or
primary care patients is less costly than an extended course
of symptom-based empiric antibiotic therapy.675,684 Based
on CMS costs and published drug cost information in the
United States, an extended course of antibiotic therapy is
similar to that of obtaining a CT, and adopting an upfront
CT results in substantially reduced antibiotic utilization
in symptomatic patients with alternate diagnoses such as
rhinitis or atypical facial pain.685,686 These benefits are
traditionally weighed against additional imaging-related
concerns such as radiation exposure and access. The
availability of alternative CT imaging modalities such as
cone beam technologies mitigates some of these concerns
by facilitating CT availability at the point of care and
lowering radiation exposure while maintaining the quality
of diagnostic information necessary for CRS. In a recent
study, patients demonstrated a poor understanding of
radiation exposure involved in imaging, but the majority
of patients expressed a preference for accurate treatment
for CRS symptoms even if this care entailed additional
costs associated with imaging.687 Despite this, it is still
important that practitioners obtain imaging when patients
are not having an isolated acute URI, because radiologic
changes in ARS and CRS are similar. The utility of MRI for
diagnosis of CRS is furthermore limited; MRI is generally
useful only in specific instances such as delineation of
mucoceles, AFRS, concern over skull-base integrity, or
tumor-associated sinonasal inflammation.
 Aggregate Grade of Evidence: B (Level 1b: 1 study; Level
2c: 2 studies).
 Benefit: CT imaging is more sensitive than nasal en-
doscopy, and obtaining imaging earlier in the diagnostic
algorithm reduces antibiotic utilization.
 Harm: Concerns regarding radiation exposure.
 Cost: For 2014, the CMS-based national average pay-
ment for CT imaging without contrast material of
the maxillofacial area (Current Procedural Terminology
code 70486) was US$208.85. This reimbursement fee
for CT imaging accounts for costs for capital equipment,
technical execution of the scan, and the professional fee
associated with interpretation of the CT scan.
 Benefits-Harm Assessment: Variable, dependent on the
pretest likelihood of disease, access to CT scan, and find-
ings of physical exam and endoscopy.
 Value Judgments: A patient’s history of radiation expo-
sure and preferences should be taken into account when
deciding to confirm CRS with CT. Nasal endoscopy is
another method of confirming CRS but is less sensitive
and cannot delineate anatomy for surgical planning.
 Policy Level: Recommendation.
 Intervention: CT scanning is recommended for all pa-
tients meeting symptom-based criteria for CRS with a
lack of objective clinical findings on anterior rhinoscopy
or nasal endoscopy, or for preoperative planning. It is an
option for confirming CRS instead of nasal endoscopy.
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VII.E. CRS: Management
This discussion focuses on CRSsNP management (Fig. VII-
1). Themanagement of AECRS is discussed in Section IX.C.
VII.E.1. CRS Management: Saline Irrigation
Because of limited data, CRSwNP and CRSsNP are
combined in this analysis and recommendation.
Nasal saline irrigation is a common treatment adjunct in
the management of CRS. The favorable safety profile, lack
of systemic pharmaceutical absorption risk, and patient
acceptance make it an appealing long-term topical therapy
strategy.690 Although irrigation solutions often include
either isotonic (ie, normal) or hypertonic saline, there is
substantial variability in the volume (low or high), pressure
(passive or active), and frequency of saline irrigation pro-
tocols. Adverse effects of saline irrigations are rare, but in-
clude local irritation, ear pain, nose bleeds, headache, nasal
burning, nasal drainage, and bottle contamination.690,691
This review identified 12 studies evaluating saline irriga-
tion for the management of CRS (10 RCTs, 1 systematic
review, and 1 meta-analysis).206,209,692–701 (Table VII-13).
Five RCTs evaluated saline irrigation in patients who
had not undergone surgery. All 5 demonstrated improved
symptoms and QoL outcomes in patients with CRS. The
randomized trials by Bachmann et al.692 and Hauptman
and Ryan206 evaluated the effects of isotonic and hy-
pertonic saline irrigations and demonstrated that both
solutions improve sinonasal symptoms, although there
were no significant differences between groups. The study
by Rabago et al.209 randomized patients into 2 groups
(hypertonic saline irrigations and no treatment) and eval-
uated CRS-specific QoL, general QoL, symptom scores,
and medication usage. The results demonstrated that daily
hypertonic nasal saline irrigations significantly improved
CRS-specific QoL, symptom scores, and decreased med-
ication usage. However, there was no difference in the
general QoL outcomes using the SF-12 questionnaire.
The randomized trial by Heatley et al.697 compared
isotonic saline irrigations, using both bulb syringe and
pot irrigations, to reflexology as a control. The results
demonstrated that all groups received CRS-specific QoL
improvements, and surprisingly there were no difference
between the reflexology and saline irrigation groups. The
highest quality randomized trial by Pynnonen et al.700 com-
pared high-volume (240 mL) low-pressure isotonic saline
irrigation to low-volume saline spray and evaluated CRS-
specific QoL (SNOT-20) and symptom scores at 2, 4, and
8 weeks posttreatment. The results demonstrated that both
groups received improvement in QoL at 8 weeks; however,
there was a significantly larger improvement in both
outcome measures in patients using high-volume saline
irrigations.700
Two randomized trials by Friedman et al. in evaluated
the effectiveness of Dead Sea salt (DSS) irrigations on
QoL.694,695 The salt and mineral content of DSS has been
reported to have beneficial anti-inflammatory effects. The
2006 study failed to report the CRS cohort surgical history
and the 2012 study included CRS patients with and with-
out prior ESS. The 2006 study evaluated DSS irrigations
(did not state the volume or delivery device) compared to
hypertonic saline irrigations and demonstrated that DSS
irrigations were superior to hypertonic saline irrigations
in symptom and QoL improvement. The 2012 study
compared DSS irrigations (syringe 20 mL per naris BID)
to hypertonic saline irrigations plus INCS. The outcomes
demonstrated that the DSS irrigations alone were as
effective as hypertonic irrigations plus once daily INCS.
The systematic review and meta-analysis by Harvey
et al.696 included 8 studies that evaluated the following
designs: saline vs no treatment; saline vs placebo; saline
as an adjunct to INCS therapy; saline vs INCS therapy;
and isotonic vs hypertonic saline irrigations. A few studies
included pediatric patients with CRS and AR. The results
showed that saline irrigations improve symptom outcomes
when used as the sole CRS treatment modality; however,
saline was shown to be less effective compared to INCS
therapy. There is evidence to support that saline can im-
prove symptoms when used as an adjunct to INCS therapy.
Isotonic and hypertonic saline solutions appear to have
similar effects on patient symptoms and QoL; however, hy-
pertonic solutions may improve objective outcomes, such
as radiographic imaging. van den Berg et al.701 reported
in their systematic review that the 2007 RCT by Pynnonen
et al.700 was the only study of high enough quality to
discuss, and therefore concluded that high-volume normal
saline irrigations may provide better outcomes compared
to low-volume saline sprays in the management of CRS.
There is substantial evidence to support the use of nasal
saline irrigations in the management of CRS. Because of
the excellent safety profile of saline irrigations and low cost
(approximately US$0.24 per day),702 there is a preponder-
ance of benefit over harm. Isotonic saline irrigations may
produce minor adverse events in 5% to 10% of cases, in-
cluding nasal burning, ear plugging, and nausea. Evidence
suggests that hypertonic saline irrigations may result in a
higher rate of minor adverse events (10-25% of cases). No
major adverse events were recorded from a meta-analysis
of 22 trials.696 However, in 2011, there were 2 deaths from
amoebic meningoencephalitis suspected to be related to
irrigating with Naegleria fowleri–contaminated water.703
Until further research elucidates the safety of using tap
water, it is recommended to use a clean water source
(avoiding well water) for irrigation solution.
Bacterial contamination of saline irrigation bottles has
been reported in up to 50% and 80% of bottles after 1 and
2 weeks, respectively.691 Although there is no association
between irrigation bottle contamination and clinical
infection for patients with CRS, it has been suggested to
regularly disinfect and replace bottles. A recent review
suggests that postirrigation microwave decontamination is
an effective disinfecting strategy.704
Given the preponderance of benefit in combination
with an aggregate grade A of evidence, a “Strong
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TABLE VII-13. Evidence for CRSsNP and CRSwNP management with saline irrigation
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Harvey696 2007 1a Meta-analysis CRS patients 1. QoL; 2. Symptom; 3.
Radiologic
Saline irrigations improve CRS
symptoms as a sole
modality and as an adjunct
to INCS. Not as effective as
INCS
Friedman694 2012 1b RCT, double-blind 1. Dead sea salt irrigation;
2. Hypertonic saline +
INCS
1. QoL (SNOT-20); 2.
Endoscopy
Dead sea salt irrigation alone
was equally as effective as
INCS + hypertonic saline
Liang698 2008 1b RCT, no blinding CRS patients after ESS
treated with: 1. NS plus
debridement; 2.
Debridement alone
1. Symptoms; 2. Endoscopy Mild CRS had better symptom
and endoscopy scores with
irrigations added. No
difference in
moderate-severe CRS
Hauptman206 2007 1b RCT 1. NS; 2. Hypertonic saline 1. Symptoms; 2. Acoustic
rhinometry; 3. Saccharine
clearance
Both treatments improved
nasal stuffiness and
obstruction. NS improved
nasal airway patency
Pynnonen700 2007 1b RCT 1. High-volume,
low-pressure NS
irrigation; 2. NS
low-volume spray
1. QoL (SNOT-20); 2.
Symptom
SNOT-20 improvement in both
groups. High-volume
low-pressure irrigation
group received more
Friedman695 2006 1b DBRCT 1. Dead Sea salt irrigation;
2. Hypertonic saline
irrigation
RQLQ Dead Sea salt irrigations
received better symptom
relief compared to
hypertonic saline irrigations
Pinto699 2006 1b DBRCT 1. NS; 2. Hypertonic
saline; 3. No irrigations
Symptoms No difference in symptoms
between NS and no
irrigation. Worse pain and
nasal drainage with
hypertonic irrigation
van den Berg701 2014 2a Systematic review Saline therapy for CRS Only included and discussed 1
study with high enough
quality
High-volume NS irrigation
provides better QoL
improvement then
low-volume NS spray
Freeman693 2008 2b RCT, no blinding 1. NS (low volume
atomized spray); 2. No
irrigations
Endoscopy NS provided early (3 weeks)
endoscopic improvement.
No difference in long-term
(3 months) endoscopic
findings
Rabago209 2002 2b RCT, no blinding 1. Hypertonic saline; 2. No
treatment
1. QoL (RSDI; SF-12);
3. Symptom score)
Hypertonic saline irrigation
improved RSDI and
symptom scores. No
improvement in SF-12
Heatley697 2001 2b RCT, no blinding 1. NS in bulb syringe; 2.
NS in pot irrigation; 3.
Reflexology as placebo
RSOM-31; SNOT-20; SF-36 All groups had improvement in
RSOM-31 and SNOT-20
scores. No difference
between NS irrigation
groups and reflexology
Bachmann692 2000 2b RCT, no blinding 1. NS; 2. Hypertonic saline 1. Symptoms; 2. Endoscopy;
3. Mucociliary clearance;
4. Rhinomanometry; 5.
Olfactometry
No difference between NS and
hypertonic irrigation
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Recommendation” for its use in the management of CRS
is provided. Although nasal saline irrigations can improve
symptom and CRS-specific QoL outcomes, it is important
to recognize that it is often implemented as an adjunct to
other topical therapy strategies. Isotonic and hypertonic
saline irrigations appear to provide similar subjective
outcomes and high-volume saline irrigation appears to be
superior to low-volume nasal saline spray techniques.
 Aggregate Grade of Evidence: A (Level 1a: 1 study; Level
1b: 6 studies; Level 2a: 1 study; Level 2b: 4 studies).
 Benefit: Improved QoL, symptoms, and endoscopic, and
radiologic outcomes. Well tolerated. No risk of systemic
adverse effects. Low cost.
 Harm: Local irritation, nasal burning, headaches, and
ear pain/congestion. Low risk of infection from contam-
ination.
 Cost: Minimal (US$0.24/day). Patient time for applica-
tion.
 Benefits-Harm Assessment: Preponderance of benefit
over harm.
 Value Judgments: Important to use nasal saline irrigation
as an adjunct to other topical therapy strategies. Higher-
volume (>200 mL) irrigations appear to be superior to
low-volume nasal sprays, but further trials are required.
 Policy Level: Strong recommendation.
 Intervention: High-volume (>200 mL) nasal saline irri-
gations are strongly recommended as an adjunct to other
medical therapies for CRS.
VII.E.2.a. CRSsNP Management: Topical Cor-
ticosteroids. Topical corticosteroids may be delivered
using standard sprays or using irrigations and other
nonstandard methods. These delivery methods will be
discussed separately.
VII.E.2.a. CRSsNP Management with Topical
Corticosteroids: Standard Delivery (Sprays). INCSs
have been used extensively in the treatment of CRSsNP;
however, clinical evidence supporting their use in this
patient cohort has been variable both in quality, de-
livery mechanism, and type of corticosteroid. A search
strategy was performed based on that used in Snidvongs
et al.’s705 2011 Cochrane Review on INCS use in CRSsNP
(Table VII-14).
Two high-quality systematic reviews with meta-analyses
were included. In 2009, Kalish et al.706 combined 5
trials281,707–710 reporting overall response to treatment.
There was no significant benefit found, with significant
variability between studies noted (relative risk [RR], 0.75;
95% CI, 0.50 to 1.10; p = 0.14). Three trials708,710,711
reported change in symptom scores, and showed a stan-
dardized mean difference (SMD) favoring INCS (RR, 0.63;
95% CI, 0.16 to 1.09; p = 0.009). Snidvongs et al.705
published a Cochrane Review in 2011 that combined 5
trials708,710–713 reporting symptom scores. A significant
improvement in SMD of symptom scores was found in the
treatment arm (SMD, −0.37; 95% CI, −0.60 to −0.13;
p = 0.002), with no evidence of significant heterogeneity.
Both meta-analyses included 1 article (Lavigne et al.710)
using direct sinus corticosteroid delivery via maxillary
antrostomy sinusotomy tubes (MASTs) This article favored
corticosteroids, and thus may act as a confounder for a
conclusion on spray delivery methods alone. This was
accounted for by Snidvongs et al.,705 where the significant
improvement was preserved with subgroup analysis of
nasal delivery methods alone.
Two further randomized control studies were identified
in a systematic review published after the July 2010 cutoff
date for the Snidvongs meta-analysis.705 Mosges et al.714
randomized 60 CRSsNP patients in a double-blinded study
to receive either mometasone furoate spray 200 μg BID
or placebo for 16 weeks. Total symptom scores improved
in both groups during treatment, with no significant
difference seen (−7.27 vs −5.35, p = 0.51). A significant
improvement was seen in endoscopy scores in the treatment
arm throughout the treatment course (p = 0.002). The
authors noted their small sample size may limit the ability
to detect a significant difference, and no power calculation
was reported. Zeng et al.715 randomized 43 patients in
a single-blinded treatment comparison study to receive
either mometasone furoate 200 μg daily or clarithromycin
250 mg daily for 12 weeks. Significant improvements in
both symptom and endoscopy scores were seen in both
treatment groups, with no significant difference noted
between the groups. The lack of a placebo control and
small sample size weakened the quality of this study.
All of the above studies utilized spray as a delivery
method for INCS. No studies meeting inclusion criteria
were identified utilizing drops.
 Aggregate Grade of Evidence: A (Level 1a: 2 studies,
Level 1b: 2 studies).
 Benefit: Improved symptom scores, improved endoscopy
scores.
 Harm: Epistaxis, headache.
 Cost: Low to moderate (US$0.61 to US$4.80 per day
depending on medication).
 Benefits-Harm Assessment: Preponderance of benefit
over harm.
 Value Judgments: Direct sinus delivery methods showed
greater effects on symptom scores, therefore should be
considered in more complex cases of CRS, or following
failure of treatment with simple sprays.
 Policy Level: Recommendation.
 Intervention: Standard metered dose INCS should be
used in treatment of CRSsNP.
VII.E.2.b. CRSsNP Management with Topical
Corticosteroids: Nonstandard Delivery. As discussed
in the previous section, the use of standard INCS is recom-
mended for the treatment of CRSsNP. Penetration of sprays
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TABLE VII-14. Evidence for CRSsNP management with topical nasal corticosteroids (standard delivery with sprays)
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Snidvongs705 2011 1a Meta-analysis INCS 1. Symptom scores; 2.
QoL; 3. Adverse events
INCS improved symptom
scores. No change in QoL.
No adverse events
Kalish706 2009 1a Meta-analysis INCS 1. Overall response to
treatment; 2.
Symptoms
Insufficient evidence to
demonstrate a clear benefit
with INCS. Possible
improvement in symptom
scores
Mosges714 2011 1b DBRCT 16-week course: 1.
Mometasone furoate 200
μg BID; 2. Placebo
1. Total symptom score; 2.
Patient evaluation
treatment response; 3.
Endoscopy score; 4.
Adverse events
No difference in total symptom
score between groups.
Significant improvement in
endoscopic score
Zeng715 2011 1b RCT,
single-blinded,
treatment
comparison
study
12-week course: 1.
Mometasone furoate 200
μg once daily;
2. Clarithromycin 250 mg
once daily
1. Symptom score; 2.
Endoscopy score; 3.
Overall symptom
burden score
Improvement in symptom
scores and endoscopy
scores in both groups
Jorissen712 2009 1b DBRCT 6-month course, starting 2
weeks postsurgery:
1. Mometasone furoate 200
μg BID; 2. Placebo
1. Endoscopic score; 2.
Symptom scores; 3.
Adverse events
No significant difference in
total endoscopic score or
symptom scores between
groups
Dijkstra707 2004 1b DBRCT After ESS: 1. Fluticasone
propionate 400 μg BID;
2. Fluticasone propionate
800 μg BID; 3. Placebo
1. Symptom scores (VAS);
2. Endoscopy score; 3.
CT score (LM)
No reduction in recurrence
rate of CRS after ESS
Lund708 2004 1b DBRCT 20-week course: 1.
Budesonide 128 μg BID;
2. Placebo
1. Combined symptom
scores; 2. Individual
symptom score; 3.
HR-QoL (SF-36); 4.
Peak nasal flow
Budesonide improved
combined symptom score,
individual symptom scores
and peak nasal flow. No
change in HR-QoL
Giger716 2003 1b DBRCT 1. Beclomethasone
dipropionate 200 μg BID;
2. Beclomethasone 400 μg
morning, saline placebo
evening
1. Symptom score; 2.
Active anterior
rhinometry; 3. Acoustic
rhinometry; 4. Morning
serum; cortisol; 5.
Adverse events
Significant reduction in
symptom scores in both
groups, along with other
outcome measures
Parikh711 2001 1b DBRCT 16-week course: 1.
Fluticasone propionate 200
μg BID; 2. Placebo
1. Symptom score; 2.
Acoustic rhinometry; 3.
Endoscopy scores; 4.
Middle meatal swabs;
5. Blood tests
No difference between groups
in any outcome measures
Qvarnberg281 1992 1b DBRCT 12-week course: 1.
Budesonide 200 μg BID; 2.
Placebo
1. Symptom scores; 2.
X-ray changes; 3.
Microbiology
No significant differences in
treatment outcomes
between groups
Sykes709 1986 1b DBRCT 2-week course: 1. 20 μg
dexamethasone + 120 μg
tramazoline + 100 μg
neomycin; 2. 20 μg
dexamethasone, 120 μg
tramazoline; 3. Placebo
1. Proportion of patients
with improved
symptoms; 2. Nasal
airway resistance; 3.
Mucociliary clearance;
4. Sinus X-ray; 5.
Bacteriology
Significant increase in patients
with improved symptoms in
both treatment arms. No
difference between active
treatment groups
HR = health-related.
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beyond the nasal cavities into the paranasal sinuses has been
shown to be limited, however, particularly in preoperative
patients.717,718 This fact has led to an increased use of novel
delivery devices to attempt to improve intrasinus corticos-
teroid deposition, and thus potentially clinical outcomes.
Thirty articles were reviewed that addressed nonstandard
nasal corticosteroid delivery, with 9 articles included in the
final analysis (Table VII-15). Three article addressing the
use of corticosteroid/saline sinus irrigations met inclusion
criteria, all prospective cohort studies. In the largest study
to date, Snidvongs et al.719 published a prospective cohort
of 111 patients, 49 of whom had a diagnosis of CRSsNP
(analyzed separately). Treatment was with once-daily nasal
irrigations of 1 mg budesonide/betamethasone in 240 mL
of normal saline in the immediate postoperative period.
Significant improvements were seen in SNOT-20 scores
(2.3 ± 1.1 vs 1.2 ± 0.9), symptom scores (2.5 ± 1.1 vs 1.4
± 1.0), and Lund-Kennedy endoscopy scores (4.3 ± 2.0
vs 1.9 ± 1.6). No adverse outcome analysis was reported.
Two smaller studies were published by Sachanandani
et al.720 and Steinke et al.,721 of 9 and 5 patients, respec-
tively. Improvements in disease-specific QoL (SNOT-20),
symptom scores and endoscopy scores were shown, but
the small patient numbers limit the significance of the
conclusions. There have been concerns about the potential
for increased systemic absorption with subsequent adrenal
suppression with corticosteroid irrigation use, yet 2
studies published to date have shown no evidence of this
problem. 722,723
Two studies were identified investigating the use of
MASTs for corticosteroid delivery. Lavigne et al.710 ran-
domized 20 patients to receive either 256 μg budesonide or
placebo via a unilaterally placed MAST for 3 weeks. The
budesonide treatment group had a significant improvement
in clinical response scores, as well as significant reductions
in tissue biopsy eosinophil counts and IL-4 and IL-5 levels
compared with placebo. Reported complications were
tube migration (3 patients), epistaxis (3 patients), and
1 case of tube infection. Moshaver et al.724 reported a
prospective pilot cohort study of 13 patients who had
bilateral MAST tube placement and once daily irriga-
tions of tobramycin (10 mL of 0.8 mg/mL) and 0.4 mL
of a mixture containing ciprofloxacin (2 mg/mL) and
hydrocortisone (10 mg/mL). Significant improvements in
both SNOT-16 and endoscopy scores were seen, which
were maintained until the final 16-week follow-up. No
treatment complications were noted. A significant issue
with this method of drug delivery is the invasive nature of
the tube insertion via a surgical inferior antrostomy, and
the increased treatment time and cost associated with tube
placement.
Hansen et al.725 published a DBRCT of 20 patients using
a bidirectional spray device. Patients received a 12-week
course of either fluticasone propionate 400 μg or placebo
twice daily. Significant improvements in subjective patient
symptom scores and peak nasal flow were seen in the corti-
costeroid group. Overall RSOM-31 and endoscopy scores
showed no statistically significant changes, however. The
main weakness of this study was the small sample size (only
one-half of the subjects required by power calculation).
Adverse effects were limited to mild epistaxis, cough, and
rhinorrhea. No evidence of adrenal suppression was found.
One article was identified investigating the use of
mucosal atomization devices (MADs). Thamboo et al.726
randomized 20 patients in an unblinded treatment compar-
ison study to a 12-week course of either 1 mg budesonide
via MAD, or 1 mg of budesonide in 120 mL of saline ir-
rigations. Clinically significant improvements in SNOT-22
scores were seen in both arms, although only in the MAD
group did this reach statistical significance. Importantly,
a statistically significant difference in stimulated cortisol
was seen in the MAD group at 60 days, although this
did not reach formal threshold for diagnosis of adrenal
suppression.
Shikani et al.727 randomized 17 patients in a small
unblinded trial to a 6-week course of either a combination
of nebulized mometasone and culture-directed antibiotics
plus weekly endoscopic-guided placement of mometasone
and antibiotic-impregnated hydroxyethylcellulose gel or
“standard treatment” of oral culture-directed antibiotics
and mometasone sprays. Both treatment groups showed
equivalent effects, making it difficult to assess the relative
impact of corticosteroids vs the antibiotics from this
treatment regime, however.
Finally, Furukido et al.713 reported a single-blinded
RCT utilizing the YAMIK sinus catheter. Twenty-five
patients were treated with a 1-month course of weekly
irrigations of either betamethasone (0.4 mg/mL) or saline.
No difference was seen between treatment groups in either
symptom scores or sinus X-ray scores. Treatment-related
epistaxis was reported in 4 patients.
 Aggregate Grade of Evidence: Irrigations – C (Level 4: 3
studies), MAD – N/A (Level 1b: 1 study), MAST tubes
– B (Level 1b: 1 study, Level 4: 1 study), YAMIK – N/A
(Level 1b: 1 study).
 Benefit: Irrigations – Improvement in health-related
(HR)-QoL, subjective symptom scores and endoscopic
appearance in postoperative patients. MAD – Improve-
ment in HR-QoL. MAST – Improvement in HR-
QoL, subjective symptom scores, and endoscopy scores.
YAMIK – No benefit seen.
 Harm: Irrigations – minor (epistaxis, nasal irritation).
No evidence of adrenal suppression at studied doses.
MAD – Trend toward reduced stimulated cortisol levels.
MAST – Invasive insertion, epistaxis. YAMIK – Patient
discomfort, epistaxis.
 Cost:Moderate to high (fromUS$2.50 per day for budes-
onide respules, MAST US$100 for each tube + variable
costs associated with insertion).
 Benefits-Harm Assessment: Irrigations – Preponderance
of benefit over harm, with relatively high cost. MAD –
Balance of benefit and harm. MAST – Balance of benefit
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TABLE VII-15. Evidence for CRSsNP management with topical nasal corticosteroids (nonstandard delivery)
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Thamboo726 2014 1b RCT, unblinded Twice daily treatments: 1. 1 mg
budesonide via mucosal
atomization device; 2. 1 mg
budesonide in 120 mL saline
via large volume irrigation
1. SNOT-22; 2. ACTH stimulation
test; 3. Plasma cortisol levels
MAD-delivered budesonide
improved SNOT-22. A slight
reduction in ACTH-stimulated
cortisol levels was seen
Hansen725 2010 1b DBRCT Bidirectional spray 12-week
course: 1. Fluticasone
propionate 400 μg BID;
2. Placebo
1. RSOM-31; 2. Subjective
symptoms; 3. Nasal
endoscopy; 4. Peak nasal
flow; 5. Acoustic rhinometry;
6. MRI sinuses
Fluticasone improved nasal
symptom scores, endoscopic
nasal edema, and peak nasal
airflow
Furukido713 2005 1b RCT,
single-blinded
1-month course of once-weekly
irrigations via YAMIK sinus
catheter: 1. Saline solution; 2.
Betamethasone (0.4 mg/mL)
solution
1. Clinical symptom score; 2.
Radiologic (sinus X-ray
score); 3. Sinus effusion
cytokine levels
No difference between clinical
or radiological scores in study
groups
Lavigne710 2004 1b DBRCT Unilateral MAST catheter with
3-week daily irrigation with
either: 1. 256 μg budesonide;
2. Placebo control
1. Nonvalidated clinical
response score; 2. Tissue
eosinophil counts; 3. Tissue
IL-4 and IL-5 levels
Treatment improved clinical
response scores and reduced
eosinophil counts and
IL-4/IL-5 levels
Shikani727 2013 2b RCT, unblinded 6-week course of oral culture
directed antibiotics and
mometasone spray and: 1.
Weekly intrasinus
administration of gel
impregnated with mometasone
and culture-directed
antibiotics; 2. nothing
1. Symptom scores; 2.
Endoscopy scores; 3.
Mucosal biopsy inflammation
scores
A combined antibiotic and
corticosteroid topical
administration protocol is
equivalent to standard
treatment. Topical treatment
did not impact histological
score
Snidvongs719 2012 4 Prospective
case-series
Once-daily irrigations of 1 mg
budesonide/betamethasone in
240 mL saline
1. Symptom score; 2. SNOT-22;
3. Lund-Kennedy endoscopy
score; 4. Need for revision
surgery; 5. Need for oral
corticosteroids
Improvement in symptom score
and SNOT-22 scores in
CRSsNP. High tissue
eosinophilia predicted better
response
Moshaver724 2010 4 Prospective,
cohort, pilot
study
Bilateral MAST catheter insertion
with 3 weeks’ daily irrigation of
Tobramycin (10 mL of
0.8 mg/mL) and CiproxinHC R©
(0.4 mL of ciprofloxacin
2 mg/mL and hydrocortisone
10 mg/mL)
1. HR-QoL (SNOT-16); 2.
Endoscopy scores
Significant reduction in both
SNOT-16 and endoscopy
scores, continuing to
16-week follow-up
Sachanandani720 2009 4 Prospective
case-series
30-day course of 250 μg
budesonide diluted into 5 mL of
isotonic saline each nostril QID
1. SNOT-20; 2. Adrenal function Topical budesonide improved
SNOT-20 scores, and did not
affect adrenal function
Steinke721 2009 4 Prospective, pilot,
cohort study
3-month course of twice-daily
budesonide irrigations (500 μg
into >100 mL saline)
1. Endoscopy score Budesonide irrigations may
improve endoscopy scores
ACTH = adrenocorticotropic hormone; HR = health-related.
and harm. YAMIK – Limited evidence shows preponder-
ance of harm over benefit.
 Value Judgments: Early evidence for irrigations is low
level and there is a higher cost compared to sprays.
Strongest evidence of improvement is seen in postop-
erative patients.
 Policy Level: Irrigations – Option in postoperative pa-
tients. MAD – Option. MAST – Option. YAMIK – Rec-
ommendation against.
 Intervention: Corticosteroid nasal irrigations are an op-
tion in CRSsNP. They may be most beneficial in postop-
erative patients. The use of MAD or MAST is an option.
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Use of the YAMIK device is not recommended based on
current evidence.
VII.E.3. CRSsNP Management: Oral
Corticosteroids
There are 4 level-4 studies that evaluate the benefit of oral
corticosteroids in patients with CRSsNP. All 4 include oral
corticosteroids in a treatment regimen with other interven-
tions such as antibiotics, topical corticosteroids, and saline
irrigations. Three of the 4 include CRSwNP patients.
Lal et al.728 reported on 145 patients, 82 of which had
CRSsNP. All patients received 4 weeks of antibiotics, a 12-
day corticosteroid taper, INCS, topical decongestants, and
saline irrigations. Posttreatment, patients were followed
for a minimum of 8 weeks. Of the CRSsNP cohort, 55%
of patients were successfully treated, defined as complete
resolution of symptoms. Forty-five percent failed medical
therapy, defined as persistent symptoms, and 22 (31%)
remained symptomatic enough to elect to pursue surgery.
Combined therapy of oral corticosteroids, antibiotics, and
INCS together did not allow assessment of benefit due to
oral corticosteroids alone.
Subramanian et al.729 reported on 40 patients (23
CRSsNP) treated with a 10-day prednisone taper, 4 to
8 weeks of antibiotics, saline irrigations, and INCS.
They reported significant improvements in symptom
scores and LM CT scores posttreatment (p = 0.0005);
however, no specifics were provided as to the timing of the
posttreatment CT or symptoms scoring in these patients.
Additionally, there was no way to determine the benefit
from each component of the therapy.
Hessler et al.730 prospectively followed CRS patients us-
ing the SNOT-20+1 (SNOT-20 plus olfaction). Fifty of the
patients who completed the study had CRSsNP. Patients
were treated with a combination of medical therapy (an-
tibiotics, oral corticosteroids, nasal corticosteroids, antihis-
tamines, antileukotrienes, herbal medications, and saline)
without a universal treatment algorithm. Improvement in
the SNOT-20+1 scores in patients using prednisone for
11 days failed to reach statistical significance (p = 0.29).
Ikeda et al.731 evaluated the effect of corticosteroids
alone on CRS symptoms. Twelve patients with nonallergic
CRSsNP based on nasal endoscopy and imaging who had
failed INCS underwent olfactory testing before and after a
10-day to 14-day taper of prednisone. The authors found
significant improvements in both detection and recognition
thresholds following the prednisone course (p < 0.05, p <
0.01, respectively).
Despite the common use of oral corticosteroids for
CRSsNP, there is a lack of evidence supporting their use.
Their inclusion in a multidrug regimen in all 4 studies limits
the ability to draw any conclusions. Dosage and duration
of therapy need to be elucidated, especially because higher
doses are associated with more side effects.732 The cost of
oral corticosteroids itself is low, but potential costs accrued
due to adverse effects must also be kept in consideration.
A recent economic analysis of oral corticosteroid use in
CRSwNP patients that took the cost of adverse events
into account found that the breakeven threshold, favoring
surgery over medical therapy, occurred when more than 1
corticosteroid course was given every 2 years in CRSwNP
patients. Of note, CRSsNP patients were not included in
the analysis.733
Given the potential risks of systemic corticosteroids,
clearer evidence addressing the use of corticosteroids in
CRSsNP patients is crucial to balance these risks. No
published studies exist to determine the benefit of oral
corticosteroids alone in CRSsNP, other than 1 study ad-
dressing olfaction. There are no current studies evaluating
the benefit of oral corticosteroids in the perioperative
period, representing a large gap in evidence and a potential
area for future study. Because of the lack of clear evidence
on the benefits of oral corticosteroids in CRSsNP, no
recommendation can be made.
 Aggregate Grade of Evidence: not applicable.
VII.E.4. CRSsNP Management: Antibiotics
VII.E.4.a. CRSsNP Management with Antibiotics:
Oral Nonmacrolide Antibiotics for <3 Weeks. For
treatment of CRS with antibiotics for less than 3 weeks,
the majority of the literature is focused on the treatment of
AECRS. Despite the high utilization of this class of pharma-
cotherapy in CRS, there is a surprising paucity of evidence
in the literature. Recent high-quality prospective studies
are lacking, but a total of 6 studies were found addressing
the short-term treatment with antibiotics of CRSsNP.
Two studies identified were observational cohort studies.
Gehanno and Cohen734 observed 198 patients treated with
ofloxacin for 12 days, whereas Matthews et al.735 observed
44 patients on a 10-day course of cefixime. Both studies
had cohorts achieving a >90% “improvement rate,” but
unfortunately there was no measurable objective outcome.
There were a total of four736–739 double-blind random-
ized trials comparing 2 individual antibiotic regimens head
to head without the inclusion of a placebo arm. Clinical
resolution of RS was the main endpoint in each study,
and there was no identifiable difference between treatment
arms. One study,739 however, did note a significant
increase in the rate of relapse in patients treated with
cefuroxime vs amoxicillin.
Within the general literature and cited in the previous
6 trials, there are well known side effects with oral
antibiotics, mandating caution when considering their use.
Although the courses of treatment in each of these studies
were short (ie, <3 weeks), side effects were nevertheless
noted. The most common included gastrointestinal com-
plaints, genitourinary infections, cutaneous rashes, and
Clostridium difficile colitis.
In the age of cost containment and cost-effective
medicine, attempts have been made to determine the
appropriate number of courses of antibiotics before
surgical intervention is warranted. Unfortunately, suitable
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cost modeling is lacking because of the lack of appropriate
prospective data available in the literature.
The lack of rigorous clinical studies and the combination
of AECRS and CRS in most studies precludes the ability to
make recommendations regarding the use of nonmacrolide
antibiotic for less than 3 weeks in CRSsNP.
 Aggregate Grade of Evidence: not applicable.
VII.E.4.b. CRSsNP Management with Antibiotics:
Oral Nonmacrolide Antibiotics for >3 Weeks.
Although there is significant literature on the role of
prolonged treatment with macrolide antibiotics for
CRSsNP, there is a paucity of literature with respect
to similar treatment with nonmacrolide therapies. Two
early studies729,740 were observational, utilizing “maximal
medical treatments” including antibiotics for 4 weeks in
a total of over 240 patients, but with no classification of
outcomes between the polyp and nonpolyp patients.
One more recent observational study by Dubin et al.741
examined the treatment duration of oral antibiotics
in CRSsNP patients. A total of 35 patients with CT
scan–confirmed CRSsNP were prescribed culture directed
antibiotics for a total of 6 weeks. Sequential CT scans were
obtained at weeks 3 and 6 and compared to the baseline
for any improvement using the LM scoring system. Only
45% of the patients (n = 16) completed the full 6 weeks of
therapy and obtained the 2 interval CT scans. The authors
noted a significant improvement in average CT scores
between the baseline scan (LM score= 8.9) and the interval
scan at week 3 (LM score = 4.38). Although there were no
significant improvements between week 3 and week 6 (LM
score = 4.125), the authors noted that 38% of patients
did have an improvement in CT scan scores. The safety
profile of longer treatment was good, with the only event
noted being gastrointestinal upset in 8% of patients. There
were no cases of allergic reactions or super infection with
Clostridium difficile. Based on the solely objective CT data
in the study, the authors concluded that a longer course
of therapy is safe and may be indicated to help patients
achieve radiographic improvement and disease resolution.
With only 1 study in the literature and only 38% of the
patient population showing improvement in the extended
treatment duration, recommendation of nonmacrolide oral
antibiotics for longer than 3 weeks in treatment of CRSsNP
is limited by lack of appropriate evidence. Although the
risks of adverse events in extended antibiotic treatment
were not seen in this small observational study, prescribers
must keep in mind the possibility when larger cohorts are
treated.
 Aggregate Grade of Evidence: not applicable.
VII.E.4.c. CRSsNP Management with Antibiotics:
Macrolide Antibiotics. Macrolides are known to have
anti-inflammatory as well as antimicrobial properties and
may therefore have a role in the treatment of CRS. The
treatment of CRS with macrolide antibiotics stems from
early studies of lower airway disease, where erythromycin
was used in panbronchiolitis to improve clinical symptoms
and 5-year survival rates.742 Current understanding of the
macrolides’ mechanism of action suggests both antibacte-
rial and immunomodulatory roles and the proposed effects
of macrolides are diverse.743,744 They are known to de-
crease proinflammatory cytokine production while altering
leukocyte reaction by decreasing IL-8 and also inhibit a key
proinflammatory transcription factor, nuclear factor kB
(NF-kB).745–748 Significant literature also suggests a role for
macrolide disruption of neutrophilic action, particularly in
limitingmigration, adhesion, and oxidative response.749,750
In 2004, Ragab et al.751 published an RCT that compared
CRS patients randomized to surgery or medical therapy.
Both CRSwNP and CRSsNP were included and analyzed
separately. The medical therapy arm for CRSsNP patients
was comprised of INCS, alkaline nasal irrigations, and
long-term low-dose oral macrolide therapy. Erythromycin
500 mg BID was administered for 2 weeks, followed
by 250 mg BID for 10 weeks. At the conclusion of the
12-week trial, patients treated with medical therapy and
those treated with surgery had similar subjective and
objective outcomes.
In 2013, Soler et al.752 published a review of macrolides
in CRS as part of a larger work on antimicrobials in
CRS. They identified 17 studies that evaluated the use of
macrolide antibiotics in CRS for their anti-inflammatory
properties. The aggregate quality of the evidence was found
to be B, with 2 placebo-controlled RCTs, 1 retrospective
case-control study, and 14 observational cohort studies
with no controls. The 2 RCTs753,754 used robust CRS
definitions and the duration of therapy was 3 months in
both studies. Wallwork et al.754 treated CRSsNP patients
with roxithromycin 150 mg daily and found improved
SNOT-20 and endoscopy scores compared to placebo, but
no difference in other metrics, including olfactory function,
peak nasal inspiratory flow (PNIF), saccharine transit time,
and nasal lavage markers. These results were not sustained
after cessation of treatment. Interestingly, patients without
elevated IgE appeared to have better results.
Videler et al.753 examined CRSsNP patients and CR-
SwNP patients with low-grade polyps using a similar
combination of patient-reported outcome and objective
measures and found that azithromycin 500 mg/week after
an initial loading dose showed no benefit over placebo.
Notably, CRSwNP patients comprised 52% of the 60
subjects. Limitations of this study beyond the mixing of
CRSwNP with CRSsNP is the possible higher severity of
disease, inasmuch as all patients had failed prior antibiotic
or INCS treatments, and patients with prior ESS were
eligible, averaging 2.5 prior ESS procedures.
Of the remaining 15 studies examined by Soler et al.,752
three specifically examined CRSwNP, 1 was a nonclinical
study examining rheologic properties of mucus, and 10 did
not delineate polyp status. Interestingly, 1 study combined
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both CRSwNP and CRSsNP patients and found that those
without NPs responded better to macrolides.755
Soler et al.752 provided a summary of the evidence
and recommendations for macrolide use in CRS, finding
a balance between benefit and harm and considering
macrolides an option in the treatment of CRS. Unfortu-
nately, like much of the literature on which their review
and recommendations were based, Soler et al.752 did
not differentiate CRSwNP from CRSsNP. Others have
more recently examined this same published data and
have similarly found a general lack of high-level evidence,
a propensity to combine CRSwNP and CRSsNP, and
significant harms to balance benefits.756–758
Since these systematic reviews and meta-analyses were
published, 2 additional studies have been published exam-
ining macrolide treatment in CRSsNP and 1 in CRSsNP
combined with low-grade CRSwNP. Zeng et al.715 com-
pared oral clarithromycin to mometasone topical nasal
spray in 43 patients with CRSsNP. They found compa-
rable improvement in total symptoms, nasal obstruction,
headache, and rhinorrhea, as well as endoscopic findings of
mucosal swelling and nasal discharge at 4 weeks of therapy.
As has been seen previously,754 patients with AR did not
have as robust a response tomacrolide therapy. Luo et al.759
treated CRSsNP patients with clarithromycin and found
improved nasal symptom scores, as well as reductions in
IL-8 and myeloperoxidase in nasal secretions. Macrolide
therapy was found to bemore effective in patients with high
IL-8 levels prior to treatment. Majima et al.760 examined
the effect of clarithromycin in CRSsNP patients and CR-
SwNP patients with limited polyps. Subjects were treated
with clarithromycin or clarithromycin and carboxymethyl-
cysteine. Clarithromycin-treated patients showed statisti-
cally significant improvement in SNOT-20 and CT after
12 weeks of treatment.
One additional study of CRSsNP and CRSwNP patients
examined the use of erythromycin following ESS, with
evaluation of patient-reported outcomes and physiologic
measurements.761 Both CRSsNP and CRSwNP patients
treated with erythromycin had better endoscopy scores
than control patients, but CRSsNP patients demonstrated
a greater improvement with erythromycin compared to
similarly treated CRSwNP patients. CRSsNP patients also
showed trends toward greater improvement than CRSwNP
patients in SNOT-20 scores, olfaction, and saccharin
transit times.
Maniakis et al.762 performed a retrospective audit on a
cohort of 21 patients who did not respond to topical budes-
onide irrigations. Twelve of the 21 received azithromycin
250 mg three times weekly, with 8 of the 12 showing
a favorable response. The authors postulated topical
corticosteroid-unresponsive CRS patients may represent
a distinct clinical entity that may respond to macrolide
therapy. Polyp status was not reported for these 12 patients.
Although most macrolide studies have utilized treatment
duration of approximately 12 weeks, no specifications
exist for ideal treatment length. Nakamura et al.763 eval-
uated treatment duration using daily clarithromycin for
12-week or 24-week treatment courses in post-ESS CRS
patients. CRSwNP and CRSsNP patients were included.
Although both 12-week and 24-week treatment groups
showed reduction in symptoms at early time points,
only the 24-week treatment group demonstrated durable
suppression of rhinorrhea and PND 12 months after ESS.
Few adverse events were noted in any published trials.
Gastrointestinal disorders including mild diarrhea, vague
abdominal discomfort, or nausea and vomiting were most
common, reported in less than 5% of all patients.753,754,761
In non-sinus studies, macrolides have been implicated in
causing ototoxicity764 and liver dysfunction.765 Concerns
about overuse resulting in host antibiotic resistance have
been raised.766 Perhaps most importantly, a growing
body of literature has associated macrolide antibiotic
use with ventricular arrhythmias and cardiac arrest,
including azithromycin, which has a perceived lower risk
of cardiotoxicity.767,768 These findings have resulted in
an FDA advisory cautioning against the use of macrolides
in patients with high baseline cardiovascular risk.769
Finally, macrolides are metabolized by the liver and have
known interactions with other medications, predominantly
due to their inhibition of CYP 3A4–mediated activity
of cytochrome P-450.765 Warfarin, cisapride, benzodi-
azepines, cyclosporine, antihistamines, and statins all have
previously reported minor interactions with macrolides.757
In summary, a few RCTs concerning macrolides in
CRSsNP have been published and 2 have rather compelling
findings about the short-term efficacy, whereas 1 shows no
benefit. Careful review of the evidence demonstrates that
most systematic reviews are based on these RCTs with
conflicting results and a large number of noncontrolled
cohort studies. The subgroup of CRSsNP patients that best
benefit from macrolides is not currently known. Various
drugs and dosages have been studied so that the optimal
drug and dosages are also not currently known. Macrolides
have significant side effects and contraindications. More-
over, the long-term outcomes of macrolide-treated patients
are not entirely known, with some evidence showing a lack
of permanent effect. The efficacy of macrolides appear
to differ by CRS phenotype, so that additional work will
need to be performed in order to better clarify the balance
between benefit and harm of macrolide therapy in CRSsNP
(Table VII-16).
 Aggregate Grade of Evidence: B (Level 1a: 2 studies;
Level 1b: 2 studies; Level 1a-2a: 2 studies; Level 2b: 3
studies).
 Benefit: Reduction in endoscopy scores and some symp-
toms in patients with CRSsNP, particularly in patients
without elevated IgE. Effects appear to be comparable to
INCS. Benefit may not last long following cessation of
therapy.
 Harm: Significant potential for medication interactions.
Rare mild adverse events. Potential for severe cardiovas-
cular complications.
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TABLE VII-16. Evidence for CRSsNP management with macrolide antibiotics
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Cervin757 2014 1a Systematic review CRSsNP and CRSwNP: 2 RCTs;
22 open/cohort studies
Support for macrolide use in
refractory CRS in absence
of high IgE levels
Pynnonen756 2013 1a Meta-analysis of 3
RCTs
CRSsNP and CRSwNP: 183
(3 studies)
Insufficient evidence
demonstrating a clinically
significant impact of
long-term macrolide
therapy
Soler752 2013 1a Systematic review of
RCTs and cohort
studies
CRSsNP and CRSwNP: 2 RCTs;
15 open/cohort studies
Recommendation level: option
(especially patients with
low IgE)
Piromchai758 2011 1a Meta-analysis of 1
study, involving
macrolides
CRSsNP: 64 (1 study) 1. Clinical cure rate; 2.
Improvement scale;
3. Bacteriological cure rate;
4. Radiographic response
rate; 5. Relapse rate;
6. Adverse effects
Insufficient response to
recommend the use of any
kind of antibiotic in CRS
Haxel761 2015 1b RCT 1. Erythromycin 250 mg daily
(n = 29); 2. Placebo (n =
29)
1. ECP and MPO in nasal
secretions; 2. Multiple other
patient reported and clinical
measures
Improved nasal endoscopy
score. Duration or low-dose
of this trial not efficacious.
High chance of Type II error
Ragab751 2004 1b RCT 1. Surgical treatment (n =
45); 2. Erythromycin 500
mg BID, fluticasone 400 μg
BID (n = 45)
1. SNOT-20; 2. VAS for
symptoms; 3. Multiple
other patient-reported and
clinical measures
No difference in VAS or
SNOT-20 between groups.
CRSwNP better at 12
months in medical therapy
group
Majima760 2012 2b Cohort study 1. Clarithromycin 200 mg
daily (n = 158); 2.
Clarithromycin 200 mg
daily +
S-carboxymethylcysteine
daily (n = 159)
1. SNOT-20; 2. CT score; 3.
Subjective symptom score;
4. Nasal endoscopy findings
Combination group was more
improved at 12 weeks.
Improvement grew in both
groups with longer
treatment
Luo759 2011 2b Cohort study 1. Clarithromycin 250 mg
daily (n = 33)
1. Symptoms scores (VAS);
1. Nasal resistance; 2. IL-8,
MPO levels; 3. SNOT-20;
4. SF-36
Improved symptoms and QoL
CRSsNP patients.
Reduction in IL-8 and MPO
Zeng715 2011 2b Cohort study 1. Mometasone furoate 200
μg daily (n = 21); 2.
Clarithromycin 250 mg
daily (n = 22)
1. VAS; 2. Endoscopic score INCS and clarithromycin had
comparable effect for
CRSsNP
MPO = myeloperoxidase.
 Cost: Low.
 Benefits-Harm Assessment: Benefits appear to outweigh
harms. Benefit of treatment over placebo is seen in most
but not all studies. Harm, though rare is significant.
 Value Judgments: Macrolides appear to confer a benefit
in the short term. The benefit may not last following
cessation of therapy. Optimal drug, dosage, and length
of therapy are not known.
 Policy Level: Option.
 Intervention: Macrolides are an option for patients with
CRSsNP.
VII.E.4.d. CRS Management with Antibiotics:
Intravenous Antibiotics. Because of limited data,
CRSwNP and CRSsNP are combined in this analysis and
recommendation.
The evidence for IV antibiotics in the treatment of
CRS is sparse, with no differentiation of CRSsNP vs
CRSwNP in the literature. Three available studies were
identified, primarily retrospective and observational
cohorts (Table VII-17). Gross et al.770 reported outcomes
of 14 patients receiving culture-directed IV antibiotics
in conjunction with ESS. The indications to pursue IV
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TABLE VII-17. Evidence for CRSsNP and CRSwNP management with intravenous antibiotics
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Anand771 2003 4 Observational
cohort
1. IV antibiotics 1. Symptom scores; 2. RSDI No significant improvement in
symptom scores
Fowler772 2003 4 Case series 1. IV antibiotics
(culture-directed)
1. Resolution (defined by CT or
endoscopy); 2. Relapse rate
29% with resolution; 89%
with relapse at average of
11.5 weeks
Gross770 2002 4 Case series 1. IV antibiotics plus
surgery
1. Short-term response 50% showed complete
resolution
therapy included: (1) pathogen resistance to effective oral
antimicrobial agents, (2) patient intolerance or allergy
to effective oral antimicrobial agents, and (3) extranasal
complications of CRS. The duration of outpatient therapy
was 4 weeks delivered via peripherally inserted central
catheter. Clinical endpoints examined response to the
treatments. Of the 14 patients treated, 79% were noted to
show a partial or complete response. Adverse events were
reported in 5 patients (35%), including 3 catheter-related
events (2 patients with thrombophlebitis and 1 patient
with deep vein thrombosis) and 2 allergic drug reactions.
Anand et al.771 reported an observational cohort of
45 nonsurgical patients, diagnosed with osteitis of the
paranasal sinuses on CT scans. All patients were treated
with culture-directed antibiotics for a period of 6 weeks.
Clinical endpoints included patient-reported symptom
scores and RSDI scores. A variety of antibiotics were uti-
lized during the study period, with significant improvement
in patient reported symptom scores examined at 3 weeks
after cessation of therapy. RSDI was also noted to improve
but given the low number of available patients (n = 7) to
compare, a p value was not available for calculation. Minor
complications were reported in 16% of patients, which in-
cluded elevations in liver enzymes, neutropenia, septicemia,
bleeding, and rash. The authors conclude that given the
response noted, IV antibiotics would be a viable option.
Fowler et al.772 performed a retrospective case series of
31 patients with CRS failing 3 courses of oral antibiotics
and subsequently treated with an average of 4.8 weeks
of culture-directed IV antibiotics. CRS was defined by
continuous symptoms and positive findings on sinus CT
scan and/or sinus endoscopy lasting for greater than
3 months. Only 29% of patients were noted to have reso-
lution of disease on CT scan or nasal endoscopy following
treatment. Of these, 89% relapsed at an average of 11.5
weeks after cessation of therapy. Complications occurred
in 26% including thrombophlebitis, peripheral venous
thrombosis, catheter infection, diarrhea, and neutropenia.
Indeed, high complication rates have since been substan-
tiated in a subsequent larger patient series. Lin et al.773
examined 177 patients who underwent IV antibiotic ther-
apy for CRS, with the majority receiving a combination
of ceftriaxone and clindamycin. The overall complication
rate was reported at 18%, with 16% antibiotic-related
adverse events (ie, neutropenia, elevated liver function tests
[LFTs], and rash) and 2% catheter-related adverse events
(ie, thrombosis).
The high preponderance of adverse events noted in the
literature in the treatment of CRS with IV antibiotics
makes it difficult to recommend. Associated costs of line
placement and the treatment of the potential adverse
events preclude it from being a cost-effective option
in the uncomplicated CRS patient. However, for the
subset of patients with CRS complications or extrasinus
manifestations of CRS, the benefits of treatment outweigh
the cost and risk of possible adverse events.
 Aggregate Grade of Evidence: C (Level 4: 3 studies).
 Benefit: Possible improvement in patient-reported symp-
toms in cohort and case-controlled studies.
 Harm: Thrombophlebitis, neutropenia, sepsis, deep vein
thrombosis, elevated liver enzymes, drug adverse events,
rash, bleeding.
 Cost: High.
 Benefits-Harm Assessment: Risk of harm over the possi-
ble benefits noted.
 Value Judgments: Risk of adverse events and cost of
treatment greatly outweighs possible benefit for routine
use in CRSsNP.
 Policy Level: Recommendation against.
 Intervention: Intravenous antibiotics should not be used
for routine cases of CRS. For patients with complica-
tions or extrasinus manifestations of CRS, the benefits
of treatment may outweigh the cost and risk of possible
adverse events.
VII.E.4.e. CRS Management with Antibiotics:
Topical Antibiotics. Because of limited data, CR-
SwNP and CRSsNP are combined in this analysis and
recommendation.
The goal of topical antibiotic therapy in CRS is to
deliver a high concentration of antibiotics directly to the
diseased sinonasal mucosa, thereby increasing efficacy
and decreasing systemic absorption and associated side
effects. Disadvantages to topical antibiotic therapy include
user-dependent variations in delivery technique, topical
absorption, local adverse effects, and limited long-term
data. Studies on topical antibiotic delivery do not dis-
tinguish between those with CRSwNP and CRSsNP.
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TABLE VII-18. Evidence for CRSsNP and CRSwNP management with topical antibiotics
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Jervis-Bardy341 2012 1b DBRCT 1. Mupirocin rinses (n = 9); 2.
Saline rinses
(n = 13)
1. Bacterial culture; 2.
Symptoms; 3. QoL;
4. Endoscopy
Short-term effect on S.
aureus clearance with
mupirocin, but no effect
on long-term outcomes
Wei787 2011 1b DBRCT 1. Saline plus gentamicin; 2.
Saline alone
1. LM scoring of CT; 2. QoL No benefit seen with
topical antibiotic
Videler776 2008 1b DBRCT crossover pilot
study
Total (n = 14): 1.
Bacitracin-Colimycin with
oral antibiotics; 2. Saline
(placebo) with oral
antibiotics
1. Symptoms (VAS); 2. QoL
questionnaire; 3. Nasal
endoscopy
No benefit seen with
topical antibiotic
Desrosiers777 2001 1b DBRCT 1. Tobramycin-saline
nebulization; 2. Saline
nebulization
1. Symptoms; 2. QoL;
3. Histology
No benefit seen with
topical antibiotic
Sykes709 1986 1b DBRCT 1. Neomycin, tramazoline,
dexamethasone (n = 20);
2. Tramazoline,
dexamethasone (n = 20);
3. Placebo (n = 10)
1. Nasal MCC; 2. Sinus
X-ray; 3. Nasal
rhinomanometry;
4. Bacterial culture;
5. Nasal endoscopy
No benefit seen with
topical antibiotic
Lee781 2014 2a Systematic review with
heterogeneity
Topical antibiotic therapy
not recommended as
first-line therapy, but
may be considered for
recalcitrant CRS
Huang780 2013 2a Systematic review with
heterogeneity
Additional studies required
to evaluate efficacy of
topical antibiotics
Rudmik702 2013 2a Systematic review with
heterogeneity
Recommend against
topical antibiotic due to
insufficient clinical
research
Soler752 2013 2a Systematic review with
heterogeneity
Use of topical antibiotics
recommended against
due to lack of evidence
Woodhouse779 2011 2a Systematic review of RCT,
with heterogeneity
Nebulized antibiotics
cannot be
recommended due to
lack of evidence
Lim782 2008 2a Systematic review with
heterogeneity
Topical antibiotics may be
effective, but further
high level studies are
required
Additionally the majority of studies focus on the postsur-
gical recalcitrant CRS patient. Studies have shown that
ESS increases the penetration of topical irrigation therapy
from minimal absorption (<2%) to greater than 95%
absorption.717,774,775 Four RCTs and 6 systematic reviews
have examined topical antibiotics in CRS (Table VII-18).
Videler et al.776 conducted a randomized, placebo-
controlled, double-blind, cross-over pilot study in 14
people with refractory CRS post-ESS. Recalcitrant disease
was defined by positive nasal cultures for Staphylococcus
aureus after 2 treatments of oral antibiotics (>2 weeks
duration) and nasal saline irrigations. The patients were
initially randomized into 1 of 2 groups, either high-dose
nebulized bacitracin-colimycin (8 weeks) and oral lev-
ofloxacin (2 weeks) or nebulized saline (control) and oral
levofloxacin (2 weeks). Although the authors found that
nebulization improved CRS symptoms, they did not find
any added benefit of bacitracin/colimycin to the nebulized
solution. The authors acknowledged the inadequate
number of patients enrolled and calculated a minimum of
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126 patients to achieve statistical significance. Moreover
the use of oral levofloxacin may have confounded the
results, although patients had failed prior oral antibiotics.
Sykes et al.709 investigated the additive effective of
neomycin in conjunction with a nasal spray of trazoline
and dexamethasone compared to saline placebo. They stud-
ied 50 patients with symptoms of chronic purulent nasal
drainage although there was no mention of prior surgical
therapy. Their study utilized comprehensive outcome mea-
sures, which included nasal MCC, imaging, rhinomanome-
try, bacterial cultures, and endoscopy. Both therapy groups
showed improvement in objective measures of disease and
no added benefit was seen with topical neomycin.
Desrosiers and Salas-Prato777 looked at 20 patients
with a history of post-ESS recalcitrant CRS who were
randomized to nebulized tobramycin with saline compared
to saline placebo alone for a total of 4 weeks. After a
4-week washout period, they found that both groups
improved in symptoms, QoL, and histologic changes in
sinonasal mucosa and were unable to detect a significant
difference with the addition of tobramycin. Tobramycin
was found to improve pain more quickly than saline, but
also led to the side effect of nasal congestion.
One RCT investigated the use of mupirocin irrigations
in post-ESS patients to treat recalcitrant S. aureus. Jervis-
Bardy et al.341 performed a DBRCT study of 25 patients
with either 1 month of mupirocin-saline irrigations or
saline control irrigations. They found a short-term im-
provement in negative S. aureus cultures in those with
mupirocin, but no improvement in long-term outcomes
in regard to objective or subjective measures of CRS im-
provement. Interestingly, a subsequent study by the same
group found a high failure rate of mupirocin in eradicating
S. aureus and documented a case of mupirocin-resistanct
S. aureus in 1 of their patients following treatment.778
Six systematic reviews have summarized the evidence on
topical antibiotics in CRS. Woodhouse and Cleveland779
confined their review to the 4 published RCTs; however,
the RCTs were heterogeneous and therefore topical
antibiotic use could not be recommended. The 5 remaining
systematic reviews included lower-level studies, and all
consistently recommended against the use of topical
antibiotics because of the lack of evidence.702,752,780–782
Existing high-level evidence of topical antibiotics in CRS
fails to consistently demonstrate benefits. Their routine use
cannot be recommended. Some case series have reported ef-
fectiveness, particularly in recalcitrant cases of CRS,783–786
suggesting there may be a role in unusual cases.
 Aggregate Grade of Evidence: B (Level 1b: 4 studies;
Level 2a: 6 studies; Level 4: 4 studies).
 Benefit: RCTs failed to show any benefit from the use of
topical antibiotics.
 Harm: Nasal congestion, irritation, epistaxis. The-
oretical possibility of systemic absorption with
topical aminoglycosides. Possibility of developing bac-
terial resistance.
 Cost: Moderate to high (US$2.64 to US$7.64) per dose,
depending on antibiotic and formulation.
 Benefits-Harm Assessment: Relative harm over benefit.
 Value Judgments: Topical therapy may be a preferable
alternative to IV therapy for infections caused by organ-
isms resistant to oral antibiotics.
 Policy Level: Recommendation against.
 Intervention: Topical antibiotics are not recommended
for CRS.
VII.E.5. CRSsNP Management: Antifungals
VII.E.5.a. CRSsNP Management: Oral Antifun-
gals. Antifungal agents can be used as topical or systemic
treatment and systemic antifungals are given orally or
intravenously. It has been suggested by some that fungi
are a cause/contributing factor of CRS in a large subgroup
of patients, especially in those with eosinophilic inflam-
mation. Antifungals have therefore been suggested as a
potential treatment in this subgroup of CRS patients.
Only 1 study has examined the use of oral antifungals in
CRS.379 Kennedy et al.379 recruited 53 adult CRS patients
and randomized them into 2 groups in a DBRCT. Patients
who had sinus surgery within the 3 months prior to
screening were not considered for this study. There was no
indication in the study as to whether or not the included
patients had CRSwNP or CRSsNP. One group of patients
received 625 mg of terbinafine orally (n = 25) while the
other group received placebo tablets (n = 28) once daily for
6 weeks. At study initiation, all patients were required to
have a positive fungal culture. This entry criterion was later
relaxed so that any patient meeting the criteria for CRS was
enrolled. The primary outcome was the percentage change
from baseline in CT score using the LM scoring system.
Secondary outcomes included changes from baseline in
patient’s and physician’s evaluation of RS, patient’s and
physician’s evaluation of therapeutic response, as well as
RSDI scores. Four (16%) terbinafine patients and 5 (17%)
placebo patients did not complete the study. In this trial,
for both symptom and radiographic scores, there was no
significant benefit of terbinafine over placebo.
On the basis of the 1 available study there is no evidence
to support the use of systemic antifungal treatment in the
routine management of CRSsNP.
 Aggregate Grade of Evidence: not applicable.
VII.E.5.b. CRSsNP Management: Topical An-
tifungals. The Cochrane review conducted by Sacks
et al.788 synthesized all RCTs investigating the use of
topical antifungals in the management of CRS. They found
2 RCTs that address this topic. Liang et al.380 studied 70
CRSsNP patients with no history of previous ESS. The
patients were randomized into 2 groups that used nasal
irrigation (60 mL) with either amphotericin B solution
(5 mg/mL, daily amount of amphotericin B = 20 mg)
or placebo for 4 weeks. The primary outcome was the
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Chinese version of the RSOM-31 (CRSOM-31) and nasal
endoscopy scores using the Lund-Kennedy system. Six
(8.6%) patients did not complete the study: 4 (11.4%)
in the amphotericin B group and 2 (5.7%) in the placebo
group. The amphotericin B group showed no significant
improvement in CRSOM-31 scores when compared to
placebo. The amphotericin B group also showed no
significant improvement in nasal endoscopy scores.
Ponikau et al.378 studied 30 adult CRS patients, although
it was unclear whether these were CRSsNP, CRSwNP,
or both. Patients were randomized into 2 equal groups.
Twenty-five patients had prior ESS, 13 (86.7%) in the inter-
vention arm and 12 (80%) in the control arm. Both groups
received 20 mL amphotericin B solution (250 μg/mL) or
placebo in each nostril twice daily through a bulb syringe
for 24 weeks (daily amount of amphotericin B = 20 mg).
The primary outcome measure was to be the change from
baseline in the percentage of inflammatory mucosal thick-
ening measured by CT scan (proprietary scale). Secondary
outcomes included change from baseline of mucosal
thickening measured by endoscopic staging and the change
from baseline in patient symptoms using the SNOT-20.
Inflammatory mediators, intranasal Alternaria protein
and blood eosinophilia were also measured. Five (33.3%)
patients in the intervention group and 1 (6.7%) control
patient did not complete the study. The amphotericin B
group showed no significant improvement in SNOT-20
scores when compared to placebo. The amphotericin B
group showed a statistical improvement in radiographic
scores, though the clinical relevance was dubious.
On the basis of the available studies there is no evidence
to support the use of topical antifungal treatment in the
routine management of CRSsNP (Table VII-19).
 Aggregate Grade of Evidence: A (Level 1a: 1 study, Level
1b: 2 studies).
 Benefit: RCTs failed to show any symptomatic benefit
from the use of topical antifungal irrigations.
 Harm: The irrigations are generally well tolerated.
 Cost: Moderate.
 Benefits-Harm Assessment: No benefit with rare harm
and moderate cost.
 Value Judgments: None.
 Policy Level: Recommendation against.
 Intervention: Topical antifungal agents are not recom-
mended for CRSsNP.
VII.E.6.a. CRS Management with Topical Alter-
native Therapies: Surfactants. Because of limited data,
CRSwNP and CRSsNP are combined in this analysis and
recommendation.
The word surfactant is derived from “surface” “active”
“agent,” and refers to a group of amphipathic (both hy-
drophobic and hydrophilic) compounds that can be solvent
in both water and organic substrates. In the respiratory
system, naturally occurring surfactants decrease the surface
tension and viscosity of mucous. The orthopedic literature
has established the benefits of chemical surfactants,
commonly found in soaps and shampoos, as therapeutic
detergents to break up and assist in the eradication of
bacterial biofilms. These agents also have antimicrobial
potential as a result of their ability to cause cell membrane
disruption and loss of function. Therefore, in the setting of
CRS, chemical surfactant may have a therapeutic benefit
both as a mucoactive agent and a biocide with activity
against planktonic and biofilm associated microbes.789
The use of baby shampoo, citric acid zwitterionic sur-
factant, and a novel proprietary sinus surfactant solution
(Sinusurf R©; NeilMed Pharmaceuticals, Santa Rosa, CA)
have been evaluated in vitro, in animal models, and in vivo.
One percent baby shampoo in normal saline was
determined to be the optimal concentration for inhibition
of Pseudomonas biofilm formation, but it had no effect on
the eradication of already formed Pseudomonas biofilms.
A prospective study using 1% baby shampoo irrigation
in the post-ESS setting showed modest symptomatic
improvement, with 2 of 18 patients (11%) discontinuing
use due to nasal and skin irritation; there was no control
group.790 An RCT of 1% baby shampoo vs hypertonic
saline showed no significant differences in posttreatment
symptom scores; however, 20% of patients receiving the
surfactant irrigation solution discontinued use because
of side effects.791 The Sinusurf R© surfactant solution was
withdrawn from the market in 2011 because of adverse
effects, including olfactory disturbance.702
Data regarding the effects of surfactant irrigation on the
respiratory epithelium/cilia is mixed, with evidence of both
a transient increase in cilia beat frequency and an increase
in MCC time.789,792
In summary, 1 RCT has shown no benefit of baby
shampoo over control and patients in the treatment group
had higher rate of side effects and study discontinuation.
The benefits of surfactants are clearance of thick secretions
and interruption of biofilm formation. Harms include nasal
irritation as well as negative effects on cilia morphology,
CBF, and MCC time. Cost of surfactant therapy is low. Al-
though there appears to be a balance of benefit and harm,
because of the limited clinical data, no recommendation is
given for the use of surfactants in CRSsNP and CRSwNP.
 Aggregate Grade of Evidence: not applicable.
VII.E.6.b. CRS Management with Topical Alter-
native Therapies: Manuka Honey. Because of limited
data, CRSwNP and CRSsNP are combined in this analysis
and recommendation.
Manuka honey and its active component methylglyoxal
(MGO) have demonstrated in vitro effectiveness against
both the planktonic forms and biofilms of Staphylococcus
aureus and Pseudomonas aeruginosa.793–795 Kilty et al.793
demonstrated that higher effective concentrations of MGO
are needed for biofilms of S. aureus and P. aeruginosa
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TABLE VII-19. Evidence for CRSsNP management with topical antifungals
Study Year Study design LOE Study groups Clinical endpoint Conclusions
Sacks788 2011 1a Systematic review
with meta-
analysis
1. Topical antifungal therapy;
2. Placebo
1. Collated symptom scores;
2. QoL; 3. Adverse events
No benefit of topical antifungal
over placebo
Liang380 2008 1b RCT 1. 20 mg amphotericin B daily
(n = 51); 2. Placebo (n =
46)
1. Chinese RSOM; 2.
Endoscopic scores
No benefit of topical antifungal
over placebo
Ponikau378 2005 1b RCT 1. 20 mg amphotericin B daily
(n = 15); 2. Placebo (n =
15)
1. CT score; 2. SNOT-22 Improvement in CT over
placebo. No improvement
in symptom score
than for the planktonic forms. Jervis-Bardy et al.794
demonstrated that the biocidal activity against S. aureus
biofilms is enhanced when in a honey solution, suggesting
a role for both the honey component and the MGO.
In vivo animal studies have demonstrated the safety and
potential efficacy of Manuka honey in the sinonasal cavity.
To evaluate the effect on nasal respiratory epithelium, Kilty
et al.796 treated New Zealand rabbits with up to 14 days
of daily irrigations of 1.5 mL of 33% mixture of Manuka
honey with saline. The amount of MGO in the Manuka
honey was not stated in the study. No epithelial damage of
the nasal respiratory mucosa was seen on light microscopy
or transmission electron microscopy. Paramasivan et al.797
performed both a safety and efficacy study in an in vivo
sheep model by performing frontal trephinations and
irrigating the frontal sinuses with Manuka honey. In the
safety arm, they found that a concentration of MGO
up to 1.8 mg/mL did not cause any epithelial injury on
standard microscopy and scanning electron microscopy;
however, at an MGO concentration of 3.6 mg/mL, patchy
ciliary denudation of the epithelium was demonstrated. In
the efficacy arm, the frontal sinuses were infected with a
biofilm-forming strain of S. aureus. Twice daily irrigations
through 1 of the frontal sinus trephination were used for
5 days with the other sinus acting as the control. Biofilm
mass was found to be equally decreased at an MGO
concentration of 3.6 and 1.8 mg/mL. At a concentration
of 0.9 mg/mL, the biofilm mass was reduced less, and
at an MGO concentration of 0.5 mg/mL, there was no
reduction in biofilm mass. The authors conclude that
Manuka honey/MGO with MGO concentrations between
0.9 and 1.8 mg/mL is probably optimal.793
Only 2 clinical studies were found in the literature
pertaining to the use of topical Manuka honey in patients
with AFRS. Thamboo et al.798 performed a single-blind
study including 34 patients whomet Bent and Kuhn criteria
for AFRS who had failed standard medical treatments for
12 weeks post-ESS. Manuka honey–saline solution was
applied via an atomization device into 1 sinonasal cavity,
with the other cavity serving as the control. The authors
found no significant difference in endoscopic mucosal
scores after 30 days of treatments. Of note, 4 patients com-
plained of nasal burning and 1 complained of nausea.798
Wong et al.799 reported a case series of 2 patients with
AFRS who failed standard medical management post-ESS,
at which point Manuka honey irrigations were added
to their treatment regimen for 12 weeks. The authors
report a decrease in SNOT-22 score and improvement
endoscopically in both patients after addition of Manuka
honey irrigations. They do note that the Manuka honey did
increase the SNOT-22 score for 1 of the patients in the cat-
egories of need to blow nose, runny nose, and sneezing.799
Both studies used commercially available Manuka honey
but did not report the concentration of MGO.
In summary, there are no clinical studies on Manuka
honey use in routine CRSwNP or CRSsNP. The only
2 clinical studies thus far on Manuka honey are small
case series in AFRS. Extrapolating from in vitro and
animal studies, potential benefits include improvement
in endoscopic score, improvement in some domains of
SNOT-22, and bactericidal and biocidal properties against
S. aureus and P. aeruginosa. Nasal burning, irritation,
and potential respiratory epithelial injury are potential
harms. The cost is low (about US$10 for 250 g of Manuka
honey). The concentration of MGO in Manuka honey is
variable so that caution should be used in its use. Because
of the paucity of evidence, no recommendation for the use
of Manuka honey in CRSsNP and CRSwNP is possible.
 Aggregate Grade of Evidence: not applicable.
VII.E.6.c. CRS Management with Topical Alter-
native Therapies: Xylitol. Because of limited data,
CRSwNP and CRSsNP are combined in this analysis and
recommendation.
Xylitol is a 5-carbon sugar that has been shown to en-
hance the innate immune system. Its mechanism of action
occurs via xylitol’s effect on the thin layer of airway sur-
face liquid, enhancing the activity of innate antimicrobial
factors present in the respiratory secretions. Brown et al.800
demonstrated that simultaneous administration of xylitol
with Pseudomonas aeruginosa into the maxillary sinus of a
rabbit produced an increase in bacterial killing after 20min-
utes. However, they found that preadministration of xylitol
into the sinus or administration of xylitol in an infected si-
nus did not decrease bacterial counts when compared with
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saline. In a human study, Zabner et al.801 demonstrated that
xylitol nasal spray administered for 4 days in normal vol-
unteers resulted in greater reduction of coagulase-negative
Staphylococcus colony-forming units than did saline spray.
Weissman et al.802 performed the only human study
evaluating the effect of xylitol in patients with CRS.
This study was a prospective DBRCT crossover pilot
study. The subjects were adults with a history of CRS
who had undergone sinus surgery. After a 3-day washout
period, subjects were given either xylitol or isotonic saline
irrigations daily for 10 days. This was followed by another
3-day washout period, followed by 10 days of the other
treatment. There were 10 subjects in each group, and only
15 (75%) completed the study. The xylitol group showed
a greater improvement in the SNOT-20 score than the
saline group. There was no difference in the VAS score
between the groups. There were no adverse events with
only 1 patient reporting minor stinging.802
In summary, 1 small RCT with 25% dropout has shown
limited symptom benefit with xylitol. In vitro studies have
shown enhancement of innate immunity. Potential harm is
limited to minor irritation and cost of therapy is low. Due
to the limited amount of evidence, no recommendation
regarding xylitol therapy in CRSsNP and CRSwNP is
possible.
 Aggregate Grade of Evidence: not applicable.
VII.E.6. CRSwNP Management: Topical
Alternative Therapies
VII.E.6.d. CRS Management with Topical Alter-
native Therapies: Colloidal Silver. Because of limited
data, CRSwNP and CRSsNP are combined in this analysis
and recommendation.
Silver is known to possess broad antimicrobial prop-
erties, with effectiveness against gram-negative and
gram-positive bacteria, fungi, protozoa, and some viruses.
It is among the most toxic elements to microorganisms,
many of which do not develop resistance to its effects.
Because of this, silver is used in a number of medical and
nonmedical products including wound dressings, catheters,
water purification devices, and textiles.
Orally administered silver has been described to be
absorbed in a range of 0.4% to 18% and seems to be
distributed to all organ systems, with the highest levels
being observed in the intestine and stomach.803 Argyria
involves the deposition of silver granules in the skin,
mucous membranes, and internal organs, including the
central nervous system, resulting in the hallmark blue-
gray discoloration of the skin generally associated with
chronic low-dose exposure to silver-containing products.
Consumption of large doses of colloidal silver can result in
significant morbidity including gastrointestinal ulceration,
hemolysis, agranulocytosis, and neural toxicity.
Although colloidal silver (a colloidal solution of 33.23
ppm elemental Ag in 99.99% water) has been shown to
cause a 99% reduction in biomass of a S. aureus biofilm
compared to control in an in vitro study,804 it remains an
unregulated alternative medicine. Colloidal silver products
of unknown formulation were tested and found to vary
from ineffective to dangerous to possibly life threatening.
These findings led the FDA in 1999 to rule that all
over-the-counter drug products containing colloidal silver
ingredients or silver salts for internal or external use were
not generally recognized as safe and effective and were
misbranded.805
In addition to these safety concerns, no evidence ex-
ists regarding the efficacy of topical silver treatment in
CRSsNP or CRSwNP. Topical silver is not recommended
in CRSsNP and CRSwNP.
 Aggregate Grade of Evidence: not applicable.
VII.E.7 CRS Management: Distribution of Topical
Medications and the Influence of Head
Position, Device, Surgery, and Nasal
Anatomy
Because of limited data, CRSwNP and CRSsNP are
combined in this analysis and recommendation.
The evidence based review by Thomas et al.806 examined
how the distribution of topical therapies is affected by
surgery, delivery device, head position, and nasal anatomy.
Thirty-two studies published between 1987 and 2011
examining topical medication distribution in the nose and
sinuses were included. Only 1 further study807 has been
published since that time (Table VII-20).
The Influence of Sinus Surgery. Eight studies have
examined the effect of sinus surgery on the distribution
of topical medications in the nose and sinuses in both
CRSwNP and CRSsNP.806 Surgical interventions ranged
from sinus ostium dilation to modified Lothrop frontal
sinus surgery and medial maxillectomy. Unoperated si-
nuses appeared to receive little topical therapy, with more
extensive procedures resulting in increasing distribution
in general.774,808–810 Specifically, a 4-mm to 5-mm ostial
size has been shown to predict sinus penetration with
high volume irrigators.774 Standard sinus surgery increases
distribution of topical therapies to all sinuses, but has no
impact upon nasal cavity delivery.809,810 Although there
are both direct and indirect costs surrounding surgical
intervention, there is a preponderance of benefit over harm
to improve delivery of local topical therapies and avoid
systemic therapies.806
The Influence of Delivery Device. Delivery is best
achieved with large-volume devices.774 Previous studies
have shown that low-volume devices do not reliably pene-
trate the sinuses, although delivery into the nasal cavity has
been demonstrated. High-volume devices (>60 mL, but
generally >100 mL) or heavy irrigators have been found to
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TABLE VII-20. Evidence for influence of head position, device, surgery, and nasal anatomy on topical delivery
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Thomas806 2013 3a Systematic review Surgery; Device; Head
position; Nasal anatomy
Sinus distribution of topical
fluid from intranasal
deliveries
Surgery and high-volume
delivery devices are the
critical factors in sinus
delivery
Habib807 2013 5 Cadaver,
experimental
MAD delivery of saline in
the: 1. Head-Down and
Forward position; 2.
Lying-Head-Back
position
Endoscopic evaluation of
captured images
The Lying-Head-Back position
was superior
improve delivery into the sinuses.811,812 This definition of
“high-volume” is rather arbitrary, but clinical evidence sug-
gests it may play an important role for mechanical cleaning
or lavage and drug delivery.700 High-volume devices can
unfortunately carry unwanted side effects, with Eustachian
tube dysfunction and local irritation reported in up to
one-fourth of patients. However, these are often mild and
compliance is high.706 Low-volume devices such as drops,
sprays, and nebulizers are successful alternatives if nasal
cavity delivery is needed, but they do not reliably reach
within the sinuses and provide no mechanism for lavage.
The shear force achieved by high-volume irrigations, and
their ability to clear thick mucus, is poorly defined in many
studies. There is clinical evidence such a difference exits
between low-volume and high-volume devices.700
The Influence of Head Position. Head position im-
pacts delivery in the previously operated patient, especially
for low-volume devices. Very limited sinus delivery occurs
in the unoperated patient regardless of head position.
However, in the postoperative cavity, sinus delivery is
improved with the head down and forward position,
although the influence of head position is overcome with
high-volume devices, especially to the frontal sinus.811,812
The head down and forward position appears to be
optimal for topical delivery into the sinuses but may be
impractical or difficult for those with limited mobility. For
high-volume devices, proper head position is less critical
for solutions to reach the sinuses in the postoperative
state.
The Influence of Nasal Anatomy. Although it may
seem axiomatic that correcting local septal and turbinate
deformities would enhance local drug delivery, there is
little evidence to support this assumption. In evaluation of
the potential benefits and harms of altering nasal anatomy
and/or using longstanding decongestants to improve top-
ical medication delivery, Thomas et al.’s806 evidence-based
review did not find significant data supporting this practice.
Level C evidence supports that high-volume irrigations are
able to overcome minor anatomic variations in the nasal
cavity and still achieve sinus delivery for those with prior
sinus surgery. Nasal cavity delivery with low-volume de-
vices can be overcome with pharmacologic decongestion or
head positioning. Nasal surgery or a chronic topical vaso-
constrictor use, without documented airflow obstruction,
is unproven and increases the risk for harm and cost.
Summary. The goal of topical therapy in CRS is to
facilitate clearance of mucus and address the mucostasis
that characterizes this condition. Enabling effective local
pharmacologic management is also important as “sinus”
distribution of topical therapies, primarily corticosteroids,
antibiotics, and mucolytics. The mechanical shear force
that is provided by high-volume irrigations in the post-
operative state is underevaluated and may be a major
factor to manage the mucostasis. Advantages of direct
topical medical therapy include the potential for delivering
higher local drug concentrations and minimizing systemic
absorption. Current evidence suggests that optimal topical
sinus delivery occurs after surgery and with high-volume
irrigation devices.
 Aggregate Grade of Evidence: C (Level 3b: 5 studies,
Level 4: 39 studies).
 Benefit: Sinus surgery increases distribution of topical
therapies to all sinuses. High-volume (>100 mL) irriga-
tion or heavy irrigators improve both sinus and nasal
cavity distribution of topical treatments. Head position
has the greatest impact when using low-volume devices
but does not affect high-volume device delivery. No ben-
efit in altering nasal anatomy with surgery or deconges-
tants for high-volume delivery. Impact on low-volume
delivery is unknown.
 Harm: Surgery is associated with potential complications
and recovery. High-volume irrigation may be associated
with nasal irritation and Eustachian tube dysfunction.
 Cost: Costs for high-volume delivery devices are gener-
ally low. With regard to the impact of surgery on topical
therapy delivery: (1) Direct costs: High cost associated
with ESS. Topical delivery caries moderate costs depend-
ing on choice of device, (range, US$9.97 to US$149.00)
and preparation. (2) Indirect costs: Indirect costs may
occur from surgery due to missed work and decreased
productivity in the perioperative period.
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 Benefits-Harm Assessment: Benefit exceeds harm when
local therapies avoid systemic therapy risks.
 Value Judgments: The decision for topical therapies must
evaluate the risks and costs of surgery with ongoing sys-
temic medications. The ability to deliver topical medi-
cations and remove mucus may impact decision-making
when considering sinus surgery.
 Policy Level: Recommendation for large-volume irri-
gation to deliver topical medication following sinus
surgery. Recommendation to address head position if
using low-volume topical medication delivery following
sinus surgery. Recommendation against the alteration of
nasal anatomy with surgery or decongestants in order
to facilitate high-volume delivery into the sinuses in the
absence of nasal airway obstruction.
 Intervention:When topical medication delivery or mucus
evacuation is indicated, high-volume delivery following
sinus surgery is recommended. When using low-volume
delivery following sinus surgery, use the head down and
forward position. Alteration of nasal anatomy through
surgery or decongestants is not recommended for topi-
cal medication delivery in the absence of nasal airway
obstruction.
VII.E.8 CRS Management: Immune Workup and
Treatment
Because of limited data, CRSwNP and CRSsNP are
combined in this analysis and recommendation.
In patients with CRSsNP refractory to standard treat-
ment, immunodeficiency should be considered. Testing for
PID may include quantitative serum immunoglobulins, and
specific antibody responses.155,277,585,590–592,813 Certain
selective Ig deficiencies may be associated with other
diagnoses, such as the linkage between IgG3 deficiency and
atopy, stressing the importance of an adequate assessment
and treatment for allergies in these patients.595
A systematic review of the literature for immuno-
deficiency treatment in CRS identified 1 randomized,
double-blind cross-over trial, 2 level 2b and 3b studies
each, 1 level 4 study and 6 level 5 studies as follows:
 Prophylactic antibiotics
◦ Level 4: 1 study; Level 5: 4 studies
 Early culture-directed antibiotics
◦ Level 5: 4 studies
 Immunoglobulin replacement
◦ Level 2b: 2 studies; Level 3b: 1 study, Level 5: 4
studies
 Other immune therapy: thymic hormone preparation
thymostimulin
◦ Level 1b: 1 study; Level 5: 1 study
 ESS
◦ Level 3b: 1 study; Level 5: 1 study
Tas et al.814 performed a randomized control study using
thymic hormone preparation thymostimulin (TP-1) and
placebo in a crossover trial. TP-1 was proven to be effective
in patients with recurrent CRS who were immunologically
deficient in cell-mediated immunity.814 However, TP-1
was taken off the market and a related therapeutic target,
thymosin 1α (a 28–amino acid peptide isolated from
thymosin fraction 5), is under study.815 There is debate on
the role of Ig replacement. Roifman and Gelfand816 evalu-
ated sinopulmonary disease frequency after high-dose and
low-dose therapy with intravenous Ig (IVIG). High-dose Ig
achieved minimal trough serum IgG levels and decreased
symptoms and frequency of major and minor infections.816
However, after a long-term follow-up of a large cohort
of patients with common variable immunodeficiency,
Quinti et al.597 found Ig administration was associated
with increased prevalence of CRS and bronchiectasis. This
was supported by a study from Rose et al.817 in which the
inflammatory cytokines were markedly elevated in nasal
lavage, which had a discrepancy with serum IgG level. ESS
results were compared in CRS with immune dysfunction or
autoimmune disease vs controls. The results were similar
in both groups, which suggests that patients with immune
dysfunction may experience similar benefit from ESS.818
Prophylactic antibiotics and early culture-directed antibi-
otics were recommended by expert groups.815,819–823 Yet
there are no consensus guidelines on the use of antibiotics
in refractory CRS with immunodeficiency.
Overall, because the current studies were small in
scale and not based on controlled trials, the balance of
risk to benefit is unclear. Prophylactic antibiotics may
reduce infections in immunodeficient patients, but there
is an increased concern on antimicrobial resistance and
alterations to the sinus microbiome. Early culture-directed
antibiotics are theoretically advisable, but there is a lack of
definitive evidence to support this. ESS may have a similar
role as in patients with normal immune function, but a
strong indication for surgery is not clear. Larger future
studies will be required to confirm the safety and clinical
benefit of these studies.
The effect of Ig replacement is controversial; this is a
challenging issue on which to provide guidelines, because
IVIG carries the risk of significant side effects (petechial
bleeding, fatigue, headache, nausea, dyspnea, tachycardia,
abdominal pain, and even anaphylactoid reaction) and can
be expensive. The long-term benefit of Ig replacement in
controlling RS is less encouraging. Still, Ig replacement is
an approved treatment for CVID because it can prevent
pulmonary disease and complications from CRS, such
as subperiosteal and intracranial abscesses, meningitis,
and sepsis. The use of Ig replacement in other immune
disorders including specific antibody deficiency or IgG sub-
class deficiencies remains controversial. Thymic hormone
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preparation thymostimulin was shown to be effective
and safe in 1 study but it is now not available in the
market. Thus, thymostimulin cannot be recommended
(Table VII-21).
 Aggregate Grade of Evidence: C (Level 1b: 1 study; Level
2b: 2 studies; Level 3b: 2 studies; Level 4: 1 study; Level
5: 6 studies).
 Benefit: Unclear benefit from prophylactic antibiotics
and Ig replacement in immunodeficient patients.
 Harm: Potential for bacterial resistance with the use of
prophylactic antibiotics. Potential for side effects with
IVIG.
 Cost: Moderate to high, depending on regimen.
 Benefits-Harm Assessment: Balance of benefit and harm.
 Value Judgments: Most studies involving immune func-
tion testing are performed in “recalcitrant” patients who
have not responded to typical medical and surgical ther-
apy. This group is poorly defined. Moreover, the LOE is
low.
 Policy Level: Option.
 Intervention: Treatment of immunodeficiency is an op-
tion for “recalcitrant” CRS patients (Table VII-22).
VII.F. CRSsNP: Complications
Complications secondary to CRSsNP may be classified
into those which are major and often associated with
infection and those that are minor and typically associated
with localized tissue changes. Although complications
of CRSsNP can be indolent, acute exacerbations can
be life-threatening, particularly in immunocompromised
patients or those with altered sinus anatomy. It is difficult
to determine the true incidence of these complications
because most of the data stem from case reports.
Major complications of CRSsNP typically occur as a
result of worsening infection that involves the eye, brain,
and/or lungs. The microbiology of these complications
differs from that of ARS.825 Direct involvement or
chronic inflammatory changes near the orbit can lead to
enophthalmos,826 epiphora,827 diplopia,828 proptosis,829
optic neuropathy,830,831 and vision loss.832–834 Fungal
or bacterial invasion along the skull base can lead to
an epidural abscess or cavernous sinus thrombosis. The
chronic inflammatory response observed in CRS can
worsen existing airway hyperreactivity, but it can also
lead to adult-onset asthma.293 Although the paranasal
sinuses appear to act as a reservoir for chronic pulmonary
infections, this association has not been well documented.
When CRS is present concomitantly with recurrent
pneumonia, immunodeficiency should be suspected.
Minor complications associated with CRS tend to
occur with local tissue alterations and include mucocele
formation,835,836 and intrinsic narrowing and tortuosity of
the frontal recess appears to be a predisposing factor for
mucocele formation.836 Tissue remodeling can also lead
to osteitis,390,394,395 bone erosion and expansion,837,838 as
well as osseous metaplasia.839,840 Sinonasal mucosal re-
modeling, at times irreversible, can occur.841,842 The varied
medical therapies aimed at treatment of CRSsNP, including
antibiotics and systemic corticosteroids, can also cause seri-
ous complications and add morbidity to the disease.843–847
VIII. Chronic Rhinosinusitis with Nasal
Polyps (CRSwNP)
This discussion of CRSwNP pertains to adults with this
condition only. Pediatric RS is discussed in Section XI.
VIII.A. CRSwNP: Incidence/Prevalence
Larsen and Tos848 estimated the prevalence of NP to be
6.3 per 10,000 in Denmark. Interestingly, between 26%
and 42% (2600 to 4200 per 10,000) of autopsy specimens
contain NP.849,850 Tan et al.288 reviewed the electronic
health records from 307,381 adults who received care
at the Geisinger Clinic from 2007 through 2009 and
determined the average incidence rate of CRSwNP was 8.3
(±1.3) cases per 10,000 person-years.
VIII.B. CRSwNP: Comorbid Asthma
Since the introduction of the united airway concept,851
a large body of evidence from clinical epidemiology,
pathophysiology, histology, and treatment outcomes has
correlated asthma and nasal polyposis. CRSwNP and
asthma coexist frequently and share similar features
of inflammation and remodeling. This association has
been supported by numerous observations of similar
histopathological changes,852 the same primary effector
cell (eosinophil), and common inflammatory mediators.853
Moreover, there is evidence that markers such as
interleukin (IL)-5 and staphylococcal enterotoxin (SE) IgE
within the NP tissue are associated with comorbid asthma,
supporting the idea of systemic immunologic crosstalk.300
Kato,854 in a recent review, described evidence suggesting
that newly identified epithelial-derived cytokines (IL-25,
IL-33, and TSLP) help shape the local activation of Th2 im-
munity, and the exaggerated expression of these cytokines
induces Th2 inflammation, which is associated with
bronchial asthma and CRSwNP. There is evidence that,
apart from a similar immunologic environment, defects
in airway epithelial barrier function are associated with
asthma and CRSwNP. These defects in barrier function
could play a critical role in the pathogenesis of CRSwNP by
allowing an influx of foreign antigens into the submucosa
where they may trigger or exacerbate an inflammatory
response. In an attempt to phenotype patients with asthma,
Moore et al.855 performed a cluster analysis of asthmatic
patients. They found the subjects with concurrent asthma
and sinus disease had less atopy but a higher prevalence of
severe asthma, worse QoL, and later-onset disease.
Bronchial asthma is more prevalent in patients who suf-
fer from CRS than in patients without.7,293,856 Similarly,
patients with asthma have a greater prevalence of CRS.857
Three large epidemiological studies have demonstrated
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TABLE VII-21. Evidence for immunodeficiency treatment in CRSsNP management
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Tas814 1990 1b Randomized control
trial; double-blind
crossover trial (n =
20)
1. TP-1 then placebo; 2.
placebo then TP-1
Endoscopy, DTH skin test,
lymphocyte subsets, MIF
assay, and other
laboratory tests
R-CRS patients were
successfully treated with
TP-1, restoring some
laboratory parameters
Quinti597 2007 2b Multicenter
prospective study
CVID patients on IVIG for a
mean of 11.5 years
(n = 224)
Ig level, lymphocyte subsets,
culture test, CT
IVIG is more effective in
reducing lower
respiratory infections
than reducing RS
Roifman816 1988 2b Prospective crossover
study
6 months of: 1. High-dose (0.6
g/kg/month) IVIG; 2.
Low-dose (0.2 g/kg/month)
IVIG
Endoscopy, sputum cultures,
Ig level, chest and sinus
radiographs, spirometry
High-dose IVIG therapy was
more effective than
low-dose IVIG
Khalid818 2010 3b Case-control study 1. CRS with immune
dysfunction or autoimmune
disease (n = 22); 2. CRS
control (n = 22)
QoL measurement, nasal
endoscopy, sinus CT
Immune dysfunction CRS
patients had similar
outcomes as control CRS
patients
Rose817 2006 3b Case-control study 1. CVID (n = 13); 2. Selective
IgA deficiency (n = 10);
3. Control (n = 14)
1. MRI; 2. Blood and nasal
lavage after IVIG tested
for: IgG, IgA, IgM, ECP,
IL-8, TNF-α
In the sample patients, IVIG
was not sufficient to
prevent chronic sinus
inflammation
Buehring824 1997 4 Prospective case
series (open trial)
16 R-CRS treated with
azithromycin,
N-acetylcysteine, and
topical intranasal
beclomethasone
1. MRI; 2. Nasal lavage for
ECP, IL-8, TNF-α; 3. Nasal
culture
Treatment was of little
benefit in patients with
R-CRS with an underlying
immunodeficiency
Ocampo819 2013 5 Expert opinion Recommended prophylactic
antibiotics, Ig
replacement if indicated,
and early ESS
Kuruvilla823 2013 5 Commentary/review Approximately one-half of
the therapeutic dose is
proposed for prophylactic
antibiotics, with rotation
to avoid drug resistance
Dalm815 2012 5 Expert opinion Thymosin 1α may have an
effect on monocyte
function, a possible new
target for therapy in
R-CRS
Ryan820 2010 5 Expert opinion Recommended prophylactic
antibiotics; early,
aggressive,
culture-directed antibiotic
treatment; and possible
use IVIG
Ferguson821 2009 5 Expert opinion Culture-directed antibiotics
should be administered
more promptly than in
patients with normal
immunity
Ryan822 2008 5 Expert opinion Advocated prompt treatment
with culture-directed
antibiotics and the use of
IVIG
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TABLE VII-22. Recommendations for treatment of immune deficiency in “recalcitrant” CRS patients
Grade of Balance of
Treatment evidence benefit to harm Recommendation Protocol
Other immune therapy A Equal Recommendation against Thymic hormone preparation
thymostimulin
Immunoglobulin replacement B Equal Optional Common variable
immunodeficiency
Prophylactic antibiotics C Equal Optional
ESS C Equal Optional
Early culture-directed antibiotics D Equal Optional
the association between these 2 diseases. The first study
involved 52,000 subjects,857 the second 6037 asthmatic
patients,858 and the third 488 asthmatic patients.859 Re-
garding asthma severity in relation to CRSwNP, asthmatic
patients have more concomitant CRSwNP (7%) than the
general population (4%).858 In nonatopic asthma and late-
onset asthma, CRSwNP was found even more frequently,
reaching 53% to 63%.855 More than 60% of CRSwNP
patients have lower airway involvement.860 Often, CR-
SwNP and asthma patients show higher LM scores70 as
well as more severe nasal obstruction and hyposmia.856
Treatment of CRS decreases the severity of asthma
(Table VIII-1).319,861,862 Using objective and subjective
sinonasal and asthma outcome measures, studies have
demonstrated significant clinical improvement following
ESS.320,861,863–866 In patients with asthma and NPs, ESS
was shown to improve asthma severity scores, reduce the
need of inhaled corticosteroids and reduce the frequency of
asthma-related emergency room visits.863 Ehnhage et al.864
showed in a prospective randomized trial that patients
with CRSwNP had a significant improvement in nasal
and lower airway symptoms after ESS. But they failed
to show a benefit of postoperative INCS use. The same
authors recently followed a cohort of CRSwNP patients
after ESS and found an improvement in asthma symptoms
score, daily peak expiratory flow, and nasal inspiratory
flow.867 Zhang et al.868 observed in their retrospective
analysis that patients with both NP and asthma experience
a larger QoL improvement measured by SNOT-22 at 1
and 3 months, when compared to patients without asthma
or NPs. In a smaller series of patients with NP, ESS did
not affect the asthma state.866 Alobid et al.869 evaluated
different outcomes of patients with CRSwNP and found
that asthma, and especially persistent asthma, have an
accumulative impact on the loss of smell. These authors
suggested that CRSwNP could be used as a benchmark
tool to identify asthma severity. Other authors have also
found lower olfactory outcomes in patients who have
associated CRSwNP and asthma compared to controls.864
Despite the number of publications suggesting that
nasal conditions may trigger lower airway pathology in
susceptible individuals and vice versa, these views are not
universal.7 Asthma and CRSwNP are not always clini-
cally present together and Williamson et al.870 found no
correlation between nasal condition and spirometry results.
In conclusion, the preponderance of published evidence
demonstrates an association between CRSwNP and
asthma. Asthma as a comorbidity should be considered
during the evaluation of a patient with CRSwNP.
 Aggregate Grade of Evidence: B (Level 1b: 3 studies;
Level 2a: 3 studies; Level 2b: 5 studies).
 Benefit: Early diagnosis of asthma in patients with CR-
SwNP.
 Harm: Inconvenience of office visit and diagnostic test-
ing.
 Cost:Moderate for associated diagnostic testing and pos-
sible consultation.
 Benefits-Harm Assessment: Balance of benefits over
harm.
 Value Judgments: Asthma is highly prevalent in patients
with CRSwNP.
 Policy Level: Recommend.
 Intervention: Asthma screening should be considered in
all patients with CRSwNP.
VIII.C.1. CRSwNP: Pathophysiology
VIII.C.1.a. CRSwNP Pathophysiology Contribut-
ing Factors: Allergy. IgE-mediated allergy has been
among the multiple etiologies suggested to cause CR-
SwNP. Allergy is strongly associated with a Th2-mediated
response. Multiple studies suggest a prominent role
for Th2-mediated inflammation in the pathogenesis of
CRSwNP.875–880 Elevated levels of Th2 cytokines IL-5 and
IL-13 have been isolated in NP tissue and eosinophilic
inflammation is commonly identified in both atopy and
CRSwNP. In addition, mast cells and basophils are also
significantly increased in NPs and their counts correlate
with the increased eosinophils in polyp tissue. Inasmuch
as mast cells and basophils are the cells involved in
IgE-mediated allergic inflammation, their presence suggests
that eosinophils, mast cells, and basophils are associated
in the ongoing Th2 inflammatory response observed in
CRSwNP. This indirect evidence of an association between
International Forum of Allergy & Rhinology, Vol. 6, No. S1, February 2016 S102
International Consensus on Rhinosinusitis
TABLE VIII-1. Evidence for CRSwNP and asthma as a comorbidity
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Swierczyn´ska-
Kre˛pa871
2014 1b Prospective
randomized trial
1. AERD patients with NPs; 2.
Non-AERD patients with
NPs
1. Nasal clinical and
biochemical parameters; 2.
Lung clinical and
biochemical parameters
Only patients with AERD had
clinically beneficial effects
of ASA desensitization on
nasal and bronchial
symptoms
Ehnhage864 2009 1b Prospective
randomized trial
CRSwNP and asthma, after
ESS: 1, INCS; 2, placebo
1. Nasal symptoms; 2. Polyp
score; 3. Lower airway
symptoms
ESS improved nasal and lower
airway symptoms. No
significant differences
between INCS group and
placebo
Ragab319 2006 1b Prospective
randomized trial
1. Surgical group (CRSsNP and
CRSwNP); 2. Medical group
(CRSsNP and CRSwNP)
1. Asthma symptoms and
control; 2. FEV1 and peak
flow; 3. Medication use; 4.
Hospitalization
Improved symptoms in
medical group. Improved
FEV1. Lower medication
needs. Lower
hospitalization rate
Vashishta872 2013 2a Systematic review CRS patients with at least one
asthma outcome reported
1. Overall asthma control; 2.
Asthma attacks; 3. Number
of hospitalizations; 4. Use
of oral corticosteroids
ESS in patients with
concomitant bronchial
asthma improves clinical
asthma outcome measures,
but not lung function testing
Dejima574 2006 2b Prospective
controlled trial
1. CRS with asthma
undergoing ESS; 2. CRS
without asthma undergoing
ESS
1. Lower airway symptoms;
2. Sinonasal symptoms
Improved symptoms. Reduced
medication needs.
Improved FEV1
Ikeda862 1999 2b Prospective
controlled trial
1. CRSwNP undergoing ESS;
2. CRSsNP undergoing ESS
1. Sinonasal and pulmonary
symptoms; 2. Medication
use
Improved FEV1 and reduced
medication needs
Ehnhage867 2012 2b Cohort study CRSwNP patients with
asthma, after ESS
1. Dyspnea/cough scores; 2.
Mean daily peak expiratory
flow rate; 3. Spirometry; 4.
Butanol test; 5. Olfaction
score; 6. PNIF; 7. polyps
score
Improvement in asthma
symptoms score.
Improvement in daily peak
expiratory flow.
Improvement in all nasal
parameters
Uri866 2002 2b Prospective cohort CRSwNP and asthma patients
undergoing ESS
1. Asthma and nasal
symptoms; 2. Spirometry;
3. Medication use
Improved symptoms. Lower
medication needs. No
changes in FEV1
Lamblin873 2000 2b Prospective cohort CRSwNP and asthma patients
followed for 4 years
1. Nasal symptoms; 2. Lower
airway clinical and
biochemical parameters
CRSwNP patients requiring
surgery developed
nonreversible airflow
obstruction during the
observation period
Senior874 1999 2b Prospective cohort CRS with asthma undergoing
ESS
1. Symptoms score; 2.
Asthma exacerbations; 3.
Medication use
Improved symptoms. Fewer
asthma relapses. Lower
medication needs
Nishioka865 1994 2b Prospective cohort CRSwNP and asthma patients
undergoing ESS
1. Symptoms score; 2.
Medication use; 3. Number
of emergency visits
Improved symptoms
Zhang868 2014 4 Retrospective case
series
Adults with CRS after ESS SNOT-22 CRS patients with both
asthma and NP have a
larger QoL benefit after ESS
than CRS patients without
asthma or polyps
(Continued)
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TABLE VIII-1. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Batra861 2003 4 Retrospective case
series
CRSwNP and asthma patients
after ESS
1. Symptoms score; 2.
Medication use; 3. Number
of emergency visits; 4.
FEV1 change
Improved symptoms. Lower
medication needs. Lower
number of emergency
visits. Improved FEV1
Dunlop320 1999 4 Retrospective case
series
1. CRSwNP and asthma
patients after ESS; 2.
CRSsNP and asthma
patients after ESS
1. Symptoms score; 2.
Medication use; 3. Number
of emergency visits; 4.
FEV1 change
Improved symptoms. Lower
medication needs. Lower
hospitalization rates.
Improved FEV1
allergy and CRSwNP is not, however, confirmed with
direct clinical evidence, where the data are often unclear or
contradictory.
In 2014, Wilson et al.322 reviewed the role of allergy in
CRSwNP and CRSsNP. They considered only studies that
delineated the presence of polyps or not, so that studies
examining “CRS” alone were excluded. In both CRSsNP
and CRSwNP, they found the aggregate LOE linking al-
lergy to these forms of CRS to be level D, due to conflicting
prevalence data, complemented by expert opinion and
reasoning from first principles. In CRSwNP specifically,
they found 18 epidemiologic studies that addressed the
role of allergy in CRSwNP. Ten of these studies (1 level
2b, 9 level 3b) supported an association, 7 (3 level 3b, 4
level 4) did not, and 1 (level 3b) was equivocal.
Tan et al.881 found a higher number of inhalant sen-
sitivities in CRSwNP patients compared to CRSsNP and
rhinitis patients, although the overall sensitivity rates were
similar. Houser and Keen882 evaluated for allergy using in-
tradermal testing or radioallergosorbent testing in surgical
CRSwNP and CRSsNP patients. In CRSwNP patients, a
statistically significant association was identified only for
perennial allergens, most notably dust mites. Similarly,
Asero and Bottazzi883 identified higher prevalence of dust
mite sensitivity in polyp patients when compared with
non-polyp counterparts. Munoz del Castillo et al.884
further implicated dust mite allergy in CRSwNP patients.
Using skin-prick testing, they found 63.2% had at least 1
positive result, most frequently to dust and Olea europaea.
Pumhirun et al.885 found elevated dust and cockroach in
CRSwNP. Asero and Bottazzi886 found positive skin testing
to at least 1 fungal species at higher rates in CRSwNP
patients when compared to both allergic controls and
CRSsNP patients. Among these patients, the only genus to
reach statistical significance was Candida.
Other studies have not found a significant association
between CRSwNP and allergy based on either rates of
sensitivity or disease outcomes. Pearlman et al.887 found no
significant difference in atopic rates between CRSwNP and
CRSsNP groups. Keith et al.888 found that ragweed-allergic
CRSwNP patients did not have worse symptoms during
the ragweed season. Erbek et al.889 divided patients with
CRSwNP by atopic status. No difference was identified
in NP size, CT scores, symptoms, or recurrence of disease
based on atopic status.889 Similarly, Bonfils’ group890,891
did not identify any difference in the presenting symptoms
or postoperative course of CRSwNP patients regardless of
their allergic status.
Contradictory results in these studies likely reflect differ-
ences in study design, inclusion criteria, and populations
studied. Taken together, these data suggest that inhalant
allergy may be a disease-modifying factor in CRSwNP, but
a direct link to causation is lacking.
Taking the totality of these studies into account, Wilson
et al.322 concluded that allergy testing should be considered
an option in CRSwNP patients, inasmuch as there was a
theoretical benefit of finding inflammatory triggers, there is
little harm, and the low aggregate LOE did not support a
strong recommendation either for or against this practice.
Although food allergies have been postulated to play a
role in CRSwNP, there is no evidence that substantiates
this view. A few studies show higher sensitization rates to
foods in patients with CRSwNP compared to controls, but
the clinical implications are not known.892,893
Despite an overlap of immunologic pathways and of
symptoms, conflicting data in the literature prevents defini-
tive conclusion about the association between atopy and
nasal polyposis. Well-designed, prospective studies with
defined inclusion and exclusion criteria among defined pop-
ulations should shed additional light on this relationship.
 Aggregate Grade of Evidence: D (Conflicting observa-
tional studies—case control and cohort design).
 Benefit: Management of allergy symptoms is low risk
and may reduce 1 potential source of inflammation con-
tributing to CRSwNP.
 Harm: Discomfort from allergy testing, sedation from
oral antihistamine, epistaxis from INCS.
 Cost: Direct costs: diagnostic testing and treatment. Indi-
rect costs: time off work for immunotherapy, decreased
productivity during peak allergy seasons.
 Benefits-Harm Assessment: Low-risk treatment to
achieve improvements in allergic symptoms and QoL.
 Policy Level: Option.
 Value Judgments: Allergy testing and treatment (avoid-
ance, medication, immunotherapy) are an option for pa-
tients with CRSwNP.
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VIII.C.1.b. CRSwNP Pathophysiology Contribut-
ing Factors: Biofilms. Biofilms in general are addressed
in Section VII.C.1.b. With regard to CRSwNP, biofilm
presence and polyp status in CRS seem to have a rela-
tively insignificant relationship. One study showed no
association,323 whereas another study showed a trend
toward an increased number of bacterial species in CR-
SwNP; this result did not reach significance. Interestingly,
fungi were only detected in the presence of NPs, although
this was a rare finding.330 In CRSwNP, there was no qual-
itative difference in inflammatory cells between patients
with or without biofilms.894 Quantitatively, there is an
association between biofilms and increased eosinophilic
content, in accordance with other evidence that biofilms
encourage a more potent Th2 response of the immune
system.895,896
VIII.C.1.c. CRSwNP Pathophysiology Contribut-
ing Factors: Fungus. Because of limited data, CRSwNP
and CRSsNP are combined in Section VII.C.1.c.
VIII.C.1.d. CRSwNP Pathophysiology Contribut-
ing Factors: Osteitis. Because of limited data, CRSwNP
and CRSsNP are combined in Section VII.C.1.d.
VIII.C.1.e. CRSwNP Pathophysiology Contribut-
ing Factors: Reflux. Because of limited data, CRSwNP
and CRSsNP are combined in Section VII.C.1.e.
VIII.C.1.f. CRSwNP Pathophysiology Contribut-
ing Factors: Vitamin D Deficiency. VD3 is classically
known for its actions in bone and calcium homeostasis.
Recently, however, it has also been shown to be a potent
immunomodulatory steroid hormone involved in the
regulation of epithelial cell, dendritic cell, monocyte,
macrophage and T-cell functions.422,423 The literature
on VD3 in CRSwNP largely consists of case series,
case-control, and in vitro studies.
In the United States, several reports have linked CRSwNP
and low 25VD3. Adult CRSwNP and AFRS patients had
significantly lower 25VD3 than controls and low 25VD3
correlated with greater sinus bone erosion as measured on
CT scan.426 Likewise, in a pediatric population CRSwNP
and AFRS patients had significantly lower 25VD3 levels
than controls.425 CT findings were not reported in these
patients.
Recently, in a retrospective analysis of 70 CRSwNP
patients Schlosser et al.432 found 55% were 25VD3 insuf-
ficient (<30 ng/mL) and an additional 30% were 25VD3
deficient (<20 ng/mL). The lowest levels were found in
African American patients with nearly 80% insufficient.
Severity of mucosal disease (defined by LM score on CT)
also correlated with low 25VD3 level. Wang et al.433
found significantly lower 25VD3 in Taiwanese CRSwNP
patients compared to CRSsNP patients. Low 25VD3 also
correlated with more severe polyp grade. Although the
proportion with 25VD3 deficiency (<20 ng/mL) was higher
in CRSwNP (45.5%) than CRSsNP (6.3%), this was not
reported as statistically significant. 25VD3 was inversely
related to LM score, consistent with U.S. patients.432
With regard to allergic status, Ozkara et al.897 found
Turkish patients with concurrent CRSwNP and AR had
significantly lower 1,25VD3 than healthy controls. This
effect was not seen in CRSwNP without AR, implying
that allergy is a necessary condition. This contrasts
with U.S. reports where CRSwNP alone was associated
with low 25VD3. The 2 groups, however, measured
different molecules, with the Turkish work measuring the
active 1,25VD3 and the U.S. studies measuring 25VD3,
conventionally considered the more accurate marker of
VD3 status due to its longer half-life. The Taiwanese
study examining interplay of allergic factors in CRSwNP
reported an inverse correlation between 25VD3 and total
IgE, though this was not statistically significant.433
Passive or active cigarette smoke exposure appears to
decrease both systemic and local sinus tissue levels of
25VD3. This finding was consistent across CRSwNP and
control patients.427
In vitro studies also support the role of VD3 in CRSwNP
pathogenesis. Sultan et al.430 found in a heterogeneous
group (healthy, CRSwNP and CRSsNP) that human
sinonasal epithelial cells constitutively express 1α hydrox-
ylase, the enzyme responsible for converting 25VD3 to the
active 1,25VD3. Mulligan et al.427 confirmed that epithe-
lial cells convert 25VD3 to 1,25VD3 in a dose-dependent
manner, but that CRSwNP epithelial cells appear to have
lower levels of 1α hydroxylase and are less efficient at
25VD3 activation. Exogenous insults with smoke extract
further impaired epithelial cell conversion of 25VD3
into the biologically active 1,25VD3. Finally, addition of
1,25VD3 to smoke exposed cells inhibited their secretion of
proinflammatory cytokines (IL-6, IL-8, CCL20), alluding
to its potential to influence immune tolerance.
CRSwNP patients have 25VD3 deficiencies that correlate
with increased numbers of systemic and local dendritic
cells. This finding is consistent in both adults and children
with CRSwNP, independent of atopic status425,426 and
may explain the Th2 skewing noted in these patients.
Active 1,25VD3 and its analogue tacalcitol significantly
inhibit activated NP fibroblast proliferation.898 Fur-
thermore, combined tacalcitol/budesonide was better at
suppressing fibroblast proliferation than tacalcitol alone,
raising the possibility of an additive or synergistic action
between tacalcitol and corticosteroid.899 In addition to sup-
pressing fibroblast proliferation, 1,25VD3 and tacalcitol
inhibited production of the proinflammatory cytokines IL-
6, IL-8, and RANTES (an eosinophil/lymphocyte chemoat-
tractant) by activated human NP fibroblasts.900,901 With
regard to suppressing RANTES production, a synergistic ef-
fect was observed when budesonide was added to 1,25VD3
or tacalcitol as compared to monotherapy. Finally, studies
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on 1,25VD3 or tacalcitol-exposed fibroblasts did not show
a shift in BCL-2/BAX gene expression in a proapoptotic
direction.902
In summary, available evidence indicates that 25VD3
deficiency is common in CRSwNP and correlates with
severity of mucosal and bone disease in CRSwNP.
 Aggregate Grade of Evidence: C (Level 3b: 5 studies,
Level 4: 1 study; Table VIII-2)
VIII.C.1.g. CRSwNP Pathophysiology Contribut-
ing Factors: Superantigens. Superantigens are a class
of antigens that stimulate T cells less specifically than
normal antigens, causing nonspecific and polyclonal
activation of T cells with massive cytokine release. The
first description of a possible role of superantigens and
IgE-antibodies to superantigen in CRSwNP dates from
2001.875 The presence of IgE specific to staphylococcal
enterotoxins A and B (SEA and SEB) pointed to the
possible role of bacterial superantigens in the development
of inflammation, as it was associated with increased levels
of total IgE and eosinophilic inflammation in CRSwNP.
It was later demonstrated that at least 1 toxin was
detected in 14 of 29 patients with bilateral CRSwNP,
but in none of 11 healthy controls and in only 1 of 13
CRSsNP samples.903 Serum SEA-specific, SEB-specific,
and toxic shock syndrome toxin 1 (TSST-1)-specific
IgE antibodies were detected in 0% vs 75% of healthy
controls vs CRSwNP, respectively, and in about 60% of
CRSwNP evidence of superantigen effects on the T cell
receptor V-beta expansion in both CD4+ and CD8+
lymphocytes was noted.904 The expansion of lymphocytes
expressing T cell receptors with specific V beta-domains
was limited to the polyp tissue, whereas much less bias was
found in the blood.905 The findings of superantigens in
CRSwNP were independently confirmed by others,906,907
and the association of those findings with an eosinophilic
inflammation was also reported by multiple groups.908,909
Interestingly, there were no differences in superantigen
genes between S. aureus strains isolated from controls
compared with those from NP patients.910 To impact the
disease, S. aureus may have to pass the epithelial barrier
and release superantigens intramucosally.
Stimulation of mucosal tissue with SEB, the best studied
superantigen, over 24 hours induced a significant increase
of IL-1β, TNF-α, IFN-γ , IL-2, IL-4, IL-5, IL-10, and
IL-13 in CRSwNP and healthy patients, with this increase
significantly greater in NPs compared to controls.911 SEB
also downregulates the anti-inflammatory prostaglandin
PGE4912 in CRSwNP fibroblasts, and induces growth
factors and chemokines in nasal epithelial cells.913 Most
importantly, IgE antibodies to enterotoxins (SE-IgE) were
associated with significantly higher concentrations of IgG,
specifically of the IgG4 subclass, and IgE in NPs.914 In
CRSwNP, evidence for local IgE synthesis and class switch
recombination was also provided915; recombination acti-
vating genes RAG1 and RAG2mRNA concentrations were
increased in polyps and correlated with the magnitude of
inflammation and the presence of SE-specific IgE in the NP
mucosa, pointing to a very active local Ig production in SE-
IgE positive polyps. The locally formed IgE is polyclonal,
with IgE antibodies against several hundred or more aller-
gens, and functional, even in the absence of systemic IgE
antibodies or a positive skin-prick test.916,917 Among those
IgE specificities, only staphylococcal enterotoxins have
superantigenic activity. CRSwNP showed a significantly
higher S. aureus culture-positivity and a higher detection
rate of S. aureus superantigens and of specific SE-IgE in
a recent meta-analysis.918 This meta-analysis confirmed
that superantigens may be a risk factor for CRSwNP, and
the presence of superantigen also was related to disease
severity.
In a cluster analysis, SE-IgE in the NP tissue was the
best categorical value to predict comorbid asthma in
CRSwNP patients300; other positive determinants were
total IgE, eosinophilic cationic protein (ECP), and IL-5
in the continuous model, all representing Th2-associated
markers. Whereas SE-IgE in CRSwNP patients often is
undetectable in serum,919 it was associated with asthma
in a Europe-wide epidemiological study920 and associated
with severe, often nonatopic late-onset asthma.921,922
Staphylococcal enterotoxin IgE antibodies, but not IgE
against inhalant allergens, were found to be risk factors
for severe asthma, hospitalization, and oral corticosteroid
use, as well as limitations in lung function.922
In a study investigating the immune profiles of recurrent
vs nonrecurrent polyp disease at the first surgery, SE-IgE
was, with other factors (total IgE, ECP, IL-5), significantly
increased in recurrent polyps, whereas IFN-γ was increased
in nonrecurrent CRSwNPs.923
S. aureus also is frequently found in patients with
AFRS924,925 and could be demonstrated to coexist with
Aspergillus sp. in the sinuses, and to modulate the typical
IgE immune response in those patients.924
In summary, based on a wealth of in vitro and some
clinical data, superantigens appear to have a significant
role in the pathogenesis of CRSwNP.
VIII.C.1.h. CRSwNP Pathophysiology Contribut-
ing Factors: Microbiome Disturbance. Because of
limited data, CRSwNP and CRSsNP are combined in
Section VII.C.1.h.
VIII.C.1.i. CRSwNP Pathophysiology Contribut-
ing Factors: Anatomic Variation. Anatomical
remodeling occurs with increasing severity of CRSwNP
as judged by CT scan imaging.926 However, the degree
to which anatomic variation in the paranasal sinuses
might contribute to disease pathophysiology (ie, concha
bullosae, paradoxical positioning of the MT, infraorbital
ethmoid [Haller] cells, and NSD, among others) is less
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TABLE VIII-2. Evidence for CRSwNP and vitamin D3 deficiency as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Mulligan427 2014 3b Case-control 1. Control (CSF leak/pituitary
tumor patients) (n = 21); 2.
CRSsNP (n = 40); 3.
CRSwNP (n = 45)
1. 25VD3 level; 2. CYP27B1
gene expression; 3. 25VD3
to 1,25VD3 conversion
Lower 25VD3 in CRSwNP than
controls. Cigarette smoke
associated with lower
25VD3 level, impairs
conversion to 1,25VD3
Wang433 2013 3b Case-control 1. CRSwNP (n = 25); 2.
CRSsNP (n = 20)
1. 25VD3 level; 2. Polyp grade;
3. LM score; 4. Total IgE
CRSwNP have lower 25VD3
than CRSsNP. 25VD3 is
inversely correlated with
polyp grade severity
Ozkara897 2012 3b Case-control 1. Control (healthy volunteers)
(n = 40); 2. CRSwNP and
AR (n = 30); 3. CRSwNP
(n = 30)
1. 1,25VD3; 2. IL-4, IL-10,
IFNγ level
CRSwNP with AR have lower
1,25VD3 than control.
CRSwNP with AR have TH2
cytokine profile
Mulligan425 2012 3b Retrospective
case-control
1. Control patients (n = 14);
2. CRSsNP (n = 17); 3.
CRSwNP (n = 5); 4.
AFRS (n = 14)
1. 25VD3 level; 2. Number of
CD209+ dendritic cells in
nasal tissue
25VD3 is lower in pediatric
CRSwNP and AFRS. Low
25VD3 correlates with
increased dendritic cells
Mulligan426 2011 3b Retrospective
case-control
1. Control (CSF leak) (n = 14);
2. CRSsNP (n = 20); 3.
CRSwNP (n = 9); 4.
AFRS (n = 14)
1. 25VD3 level; 2. Dendritic
cells as percentage of total
peripheral blood
mononuclear cells
25VD3 is lower in CRSwNP
and AFRS. Low 25VD3
correlates with increased
circulating dendritic cells
Schlosser432 2014 4 Retrospective
case-series
1. CRSwNP (n = 70) 1. 25VD3 level 25VD3 insufficiency/deficiency
is common in CRSwNP,
especially in African
Americans
IFN = interferon.
clear.16,456,457,927 CRSwNP patient populations have rarely
been independently studied to determine the influence of
anatomic variation on disease. Any causality/relationship
of anatomic variation and disease burden is therefore not
well-understood in CRSwNP.
One study specifically examined CRSwNP patients. Le-
ung et al.928 investigated obstruction at the OMC in CR-
SwNP and CRSsNP and noted that OMC obstruction was
associated with increasing LM scores in both forms of CRS.
In CRSsNP, OMC obstruction was associated with adja-
cent sinus inflammation, whereas in CRSwNP, this corre-
lation was absent. The authors concluded that paranasal
sinus inflammation was not likely to be a postobstructive
phenomenon in the setting of CRSwNP. Jain et al.16 found a
significantly higher average number of anatomical anoma-
lies (accessory ostia, conchae bullosae, infraorbital eth-
moid cells, lateralized uncinated processes, and paradoxical
MTs) in patients with limited disease compared to a cohort
with pansinusitis or control group without disease. These
data again suggest that anatomical variants may be related
to impairment of the OMC, whereas a primary mucosal
abnormality contributes to more diffuse CRS disease.16
In conclusion, the relationship between anatomical vari-
ants and development of disease in patients with CRSwNP
is impossible to ascertain given our current literature
and understanding of this inflammatory disease. Studies
that independently evaluate this group of patients suggest
minimal influence on pathophysiology and instead favor a
systemic inflammatory process leading to sinonasal disease.
Aggregate Grade of Evidence: not applicable
VIII.C.1.j. CRSwNP Pathophysiology Contribut-
ing Factors: Septal Deviation. Because of limited data,
CRSwNP and CRSsNP are combined in Section VII.C.1.i.
VIII.C.1.k. CRSwNP Pathophysiology Contribut-
ing Factors: Innate Immunity. The topic of innate
immunity of the sinonasal cavity was introduced in Section
VII.C.1.k with regard to CRSsNP. Innate immunity’s role
in CRSwNP has been studied as well (Table VIII-3). The
evidence examining innate immunity in CRSwNP can be
divided into 2 categories: (1) key antimicrobial proteins
and peptides, and (2) pattern recognition receptors.
(1) Key Antimicrobial Proteins and Peptides
Seven studies provide evidence of increased activity of
antimicrobial proteins and peptides in innate immunity in
patients with CRSwNP whereas 4 studies provide evidence
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of decreased activity. In patients with CRSwNP only 2
studies report that antimicrobial proteins and peptides
levels were normal.
Woods et al.482 found that immunoreactivity of lysozyme
was significantly increased in mucosal biopsy specimens
of CRSwNP compared to control, but not the mRNA
level. Wang et al.929 found that SP-A mRNA and protein
were significantly increased in sinonasal tissue of CRSwNP
compared to controls. Conversely, another study did
not detect any difference in SP-A between CRSwNP and
controls nor did it find a difference in levels of SP-C or
SP-D. However, it did demonstrate that SP-B protein levels
were significantly increased in patients with CRSwNP.930
Cathelicidin (LL-37) is a peptide that regulates the
innate immune response at the mucosal surface as an
antimicrobial and as a proinflammatory peptide. LL-37
can be directly cytotoxic to epithelial cells and is thought
to regulate the inflammatory response through effector
cells such as mast cells, macrophages, and neutrophils.
Chen and Fang931 found that LL-37 is constitutively
expressed on the surface of sinonasal epithelial cells and is
significantly increased in patients with CRSwNP compared
to controls. The study suggests that upregulation of LL-37
plays an important role in the heightened inflammatory
response seen in patients with CRSwNP.
Cui et al.484 showed that serum C3 level was signifi-
cantly increased in CRSwNP compared to that of control.
Ramanathan et al.932 and Park et al.933 both reported
that acidic mammalian chitinase (AMCase) mRNA or
protein level was significantly increased in nasal tissue
of patients with CRSwNP compared to that of controls.
The latter study also found that chitotriosidase (ChT)
was significantly increased in NP tissue of CRSwNP. Last,
Claeys et al.512 found that human beta defensin (HBD)-2
expression is significantly higher in sinonasal tissue of
CRSwNP without CF than that of CRSwNP with CF and
control.
Two studies by Claeys et al.512,934 showed that there
were no significant differences in HBD2 and HBD3
mRNAs level between CRSwNP and control. In contrast,
Ramanathan and Lee935 found that HBD-2 protein level
was significantly decreased in the sinonasal epithelial cells
isolated from nasal tissue compared to that of control.
Seshadri et al.521 found that expression of antimicrobial
PLUNC family members PLUNC 1, PLUNC 2, and lacto-
ferrin proteins was significantly decreased in NP tissues
of CRSwNP compared to that of CRSsNP and control.
Two recent studies reported that patients with CRSwNP
have normal level of antimicrobial proteins TFF1, TFF3,
SP-A, and SP-D when compared to that of healthy
controls.485,936
Taken together, these studies provide significant evidence
of altered antimicrobial protein and peptide activity in
CRSwNP. Some protein families are increased whereas
others are decreased and some studies show contradictory
results.
(2) PRRs in Innate Immunity
Like studies in antimicrobial proteins and peptides, several
studies of PRRs provide evidence of downregulated PRRs
in CRSwNP whereas others show increased activity.
Zhang et al.488 showed that TLR2, TLR4, and TLR7
mRNAs and protein levels were remarkably higher in
sinonasal tissue of CRSwNP compared to that of CRSsNP
and controls. Zhao et al.937 found that both TLR-9 mRNA
and protein level were increased in NPs of CRSwNP
compared to nasal tissue of controls. Last, Ma˚nsson
et al.938 found that the NLR mRNA level was higher in
NPs than in normal nasal mucosa.
Four studies revealed that mRNA or protein level of
TLR9 and or TLR2 in epithelial cells isolated from nasal
tissue or sinonasal tissue was markedly decreased in
CRSwNP compared with controls.510,513,935,939 These
studies suggest that impaired innate immune responses via
TLR-9 on sinonasal epithelial cells may represent a critical
mechanism in chronic inflammatory process of CRSwNP.
One study showed that there is no significant difference in
TLR2 and TLR4 in sinonasal tissue between CRSwNP and
controls.512 Examination of soluble and membrane-bound
RAGE in CRSwNP patients demonstrated that tissue
protein levels of both forms were reduced.487
Summary. In summary, there is conflicting data suggest-
ing either an upregulation or downregulation of expression
of antimicrobial proteins, antimicrobial peptides, and
PRRs in CRSwNP.
VIII.C.1.l. CRSwNP Pathophysiology Contribut-
ing Factors: Epithelial Barrier Disturbance. Because
of limited data, CRSwNP and CRSsNP are combined in
Section VII.C.1.j.
VIII.C.1.m. CRSwNP Pathophysiology Con-
tributing Factors: Ciliary Derangements. Ciliary
derangements in general are reviewed in Section VII.C.1.m
in the context of CRSsNP. CRSwNP has more pronounced
ciliary dysfunction in some cases, and there are sev-
eral reasons that it manifests differently than CRSsNP.
The nature of NPs physically disrupts MCC patterns.
Additionally, histopathologic studies demonstrate that
some regions of NPs do not have ciliated surfaces, which
causes a disruption in flow of mucus in the sinonasal
tract.940 Interestingly, explants from CRSwNP patients
demonstrate a faster baseline CBF compared with control
explants, suggesting that a local epithelial compensation is
occurring to account for “blocked” mucociliary flow. This
baseline increase is not observed in CRSsNP explants.564
Chronically increased CBF has a potential consequence of
downregulating endogenous stimulatory pathways, and
the cell loses responsiveness to natural CBF stimulants
and cannot be modulated normally.495 Epithelial damage
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in CRSwNP has also been associated with squamous
metaplasia, and abnormal or absent cilia are often
associated with this metaplastic change.302,303,581–583
Scanning electron microscopy confirms the abnormal
architecture, with cilia in CRSwNP presenting as overly
dense, lengthened, and untidy. Ciliogenesis factors are
correspondingly upregulated.304
VIII.C.1.n. CRSwNP Pathophysiology Contribut-
ing Factors: Immunodeficiency. Little evidence exists
examining the role of immunodeficiency in CRSwNP. Tran
Khai Hoan et al.941 examined a prospective case series and
concluded that a link between IgG subclass deficiency and
CRSwNP seemed unlikely. Two case-control studies have
also examined this subject. Seppanen et al.591 compared
CRS (including two thirds with CRSwNP) or RARS to ARS
and controls. They demonstrated that low complement C4
levels were more associated with CRS or RARS than ARS
and concluded that the isolated low IgG subclass alone
had limited value in patient assessment.591 Cui et al.484
performed a case-control study in Chinese adult patients.
They found that increased levels of C3 and mannose-
binding lectin (MBL, a pattern-recognition molecule that
can activate the lectin pathway of complement system)
might play a modulatory role in CRS development. This
finding was especially true for MBL in CRSwNP compared
to CRSsNP. The study from Carr et al.,277 in which
42% of CRS subjects were CRSwNP, demonstrated that
patients with medically refractory CRS may have a high
prevalence of low preimmunization antipneumococcal titer
and specific antibody deficiency. However, no correlation
was identified specifically in CRSwNP.277 Baraniuk and
Maibach942 performed subgroup analysis and found that
Ig subclass deficiencies were more prevalent in CRSsNP
than CRSwNP although the small numbers of subjects per
group precluded statistical significance.
The evidence linking immunodeficiency to CRSwNP is
contradictory. In an effort to uncover all possible etiologies,
some experts have recommended testing for immunodefi-
ciency in refractory CRSwNP patients. The main reason for
this recommendation is that immunodeficiency may alter
treatment considerations. In addition, this knowledge of
an immune explanation alone may be a relief to the patient
with recurrent sinus problems. Further well-designed stud-
ies to evaluate the pathophysiology of immunodeficiency
and CRSwNP are needed (Table VIII-4).
 Aggregate Grade of Evidence: C (Level 2: 1 study; Level
3b: 2 studies; Level 4: 3 studies).
 Benefit: Identifying patients with PID allows for the op-
portunity to treat a subset of patients who will respond
to Ig replacement therapy.
 Harm: Procedural discomfort; identifying and treating
incidental findings or subclinical conditions that might
not require independent therapy.
 Cost: Procedural and laboratory cost.
 Benefits-Harm Assessment: Balance of benefit and harm.
 Value Judgments: Evidence for immunodeficiencies in
CRSwNP patients is contradictory and low-level.
 Policy Level: Option.
 Intervention: Patients with CRSwNP may be evaluated
for the presence of an underlying PID.
VIII.C.1.o. CRSwNP Pathophysiology Con-
tributing Factors: Genetic Factors. A lack of direct
comparison of genetic variation between CRSwNP and
CRSsNP makes it difficult to determine precisely whether
similar genetic variations underlie CRSwNP and CRSsNP
phenotypes. Early work on genetics of CRSwNP performed
on a Japanese CRSwNP population suggested a link with
human leukocyte antigen (HLA) types.943 This work was
extended upon by assessing a white CRSwNP population
affected with AFRS.634 This study described a clustering
of the HLA-DQB1*03 allele, implicating adaptive immune
responses in the development of CRSwNP. In this study, no
comparison with CRSsNP was performed so it is difficult
to state whether this is specific to CRSwNP or a feature of
CRS overall.
Differences between CRSwNP and CRSsNP have nev-
ertheless been suggested in at least 1 other study. In a
replication article, Zhang et al.618 compared populations
of Han Chinese in China with CRSwNP, CRSsNP, and
control subjects. They replicated previously published
associations in the RYBP, AOAH, IRAK-4, and IL1RL1
genes.613,626,637 When assessed according to subgroup,
and even with the loss of power afforded by the smaller
subgroup analyses, certain differences were apparent
between the 2 CRS populations. Although candidate SNPs
in the RYBP gene were similar in allelic frequencies as
well as p value and risk for both CRSwNP and CRSsNP
populations, genetic variations in the AOAH gene were
only seen in the CRSsNP group (CRSsNP: OR = 0.30,
p = 8.11 × 10−11; CRSwNP: OR = 0.96, p = 0.64). Con-
versely, weaker associations seen for SNPs in the IRAK-4
gene were mainly limited to the CRSwNP population.
This suggests that different mechanisms may underlie the
development of CRSwNP compared to CRSsNP.
Certain asthmatic populations have been assessed as to
presence or absence of CRSwNP. A large South Korean
asthmatic population has been characterized as to presence
or absence of nasal polyposis. The Park et al. group have
identified CRSwNP candidate SNPs in genes coding for ele-
ments of the HLA system,944 in UBE3C,654 in DCBLD2,650
and in CIITA.649 These 4 genes are implicated in regulation
of immune responses, suggesting a role in the development
of CRSwNP. Again, given the nature of the population
sampled, it is impossible to determine whether these are
specific to CRSwNP.
The CRSwNP population has been further subdivided
according to acetylsalicylic acid (ASA) intolerant and
ASA-tolerant CRSwNP phenotypes. The candidate genes
implicated (CD58, DPP10)651 are quite novel and may lend
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TABLE VIII-4. Evidence for CRSwNP and immunodeficiency as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Tran Khai Hoan941 2014 2b Prospective case
series
1. Operated (n = 118); 2. Not
operated (n = 43)
Ig and IgG subclass levels,
symptom scale, endoscopy
A link between IgG subclass
deficiency and CRSwNP
seems unlikely
Cui484 2009 3b Case-control study 1. CRSwNP (n = 95); 2.
CRSsNP (n = 72); 3.
Healthy control (n = 110)
Ig and IgG subclass level,
plasma C3, C4 level, MBL
Ig, C3, C4, and MBL deficiency
is not the main cause of
CRS in adult Chinese
patients
Seppanen591 2006 3b Case-control study 1. R-CRS (n = 48); 2. ARS
(n = 50); 3. Unselected
control (n = 150); 4.
Healthy control (n = 48)
Ig and IgG subclass level,
plasma C3, C4 level,
C4 immune typing
Isolated low IgG subclass had
limited value in patient
assessment. C4A null
alleles are associated with
CRS and RARS
Carr277 2011 4 Retrospective case
series
129 CRS (42% with CRSwNP) Incidence R-CRS associated with low
preimmunization
antipneumococcal titer and
specific antibody
deficiency. No difference
with CRSwNP
Baraniuk942 2005 4 Retrospective case
series
99 CRS (50% with CRSwNP) Incidence Ig subclass deficiencies were
more prevalent in CRSsNP
than CRSwNP
themselves to new leads in investigation of pathophysiology
of ASA intolerance.
An intriguing recent variation has been to assess genetics
of CRSwNP based on type of bacteria colonizing the sinus
surface. A pooling-based genomewide association study by
Cormier et al.630 compared CRSwNP patients according
to S aureus carriage. Even though limited to 39 candidate
SNPs, they identified several candidate genes, notably in the
area of pathogen engulfment and destruction. Their data
suggest alterations in immunity might predispose to colo-
nization with secondary environmental modulators that in-
fluence subsequent development and persistence of disease.
An example and final caveat is that gene function may
be altered in a transmissible fashion by means other
than genetic variation. Epigenetic modification of the
genome, which alters gene function in response to external
environment, may occur and may be transmitted to repli-
cating cells and progeny. Evidence of differences in gene
methylation between ASA-intolerant and ASA-tolerant
populations supports this concept.945,946
Taken together, these findings suggest that the genetic
underpinnings of CRSwNP may differ somewhat from
those of CRSsNP. Numerous genes have been implicated in
the pathophysiology of both CRSwNP as well as CRSsNP.
These genes, with their differential impact on phenotype
(where known), are listed in Table VII-10.
VIII.C.1.p. CRSwNP Pathophysiology Contribut-
ing Factors: Aspirin Exacerbated Respiratory
Disease. More often than previously thought, recurrent
nasal polyposis is discovered to be associated with aspirin
sensitivity and asthma. This clinical scenario, often referred
to as Samter’s triad, includes the presence of bronchial
asthma, nasal polyposis, and respiratory reaction to
aspirin and most nonsteroidal anti-inflammatory drugs
(NSAIDs). Eosinophilic airway inflammation is also now
accepted as part of the clinical presentation and defining
diagnostic factors. The NSAID sensitivity often manifests
as ASA intolerance, and the disorder is now generally
referred to as aspirin (or NSAID)-exacerbated respiratory
disease (AERD).947–949 Prevalence rates of AERD in the
general population have been estimated at 0.6% to 2.5%
and in CRSwNP patients at 9.7%.950,951 An incomplete
triad might be observed in patients with recurrent nasal
polyposis and asthma who do not yet report adverse
reactions to NSAIDs.
The first symptoms usually occur within the fourth
decade of life with rhinitis/RS followed by NPs. Asthma
often develops several years later but may take longer to
present, and then the clinical sensitivity to NSAIDs may
also be delayed by years. The exact pathophysiological
mechanism of AERD remains uncertain but previous data
suggest dysfunction in the arachidonic acid metabolism
pathway to be fundamental to disease development.
NSAIDs such as aspirin affect the arachidonic acid
pathway and cause inhibition of the cyclooxygenases
(COX), which are necessary for metabolizing arachidonic
acid into prostaglandins.952 Due to this inhibition, the
lipoxygenase pathway is further activated, which leads to
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an imbalance of anti-inflammatory prostaglandins (PGs)
and proinflammatory leukotrienes (LTs). On top of this
physiological inhibitory effect, individuals with AERD are
thought to be characterized by genetic polymorphisms that
lead to a reduced activity of the constitutively expressed
COX 1 isoenzyme as well as increased LT receptor affinity.
Due to these changes in arachidonic acid metabolism,
the PG/LT imbalance in these patients is altered favoring
a proinflammatory state, which fuels the eosinophilic
inflammatory changes characteristically seen in CRSwNP
and asthma. Key cytokines and chemokines such as IL-5
and eotaxin are also elevated, leading to intense airway
mucosal eosinophilic infiltration and activation.953 Com-
parative histopathological analysis reveals the strongest
tissue eosinophilia in patients with AERD, when compar-
ing different clinical subgroups in a patient population
with CRSsNP, inhalant allergies, and/or CRSwNP.954
However, much of the described pathophysiology of
AERD is likely explained by genetic variations, of which
a number of polymorphisms have been identified that
potentially play a causative role.955–957 These polymor-
phisms are thought to alter enzyme kinetics and receptor
sensitivity. As a result the activity of LT-synthase is
increased, leading to an overproduction of cysteinyl LTs
(cysLTs). Sensitivity of LT receptors is upregulated and so
is the expression of cysLT receptor 1. Also, the production
of PGE2 is reduced and COX-2 as well as E-prostanoid
receptor subtype-2 are downregulated.953 All of these
effects add to an aggravation of the eicosanoid imbalance.
Recently, gene profiling studies have suggested that pe-
riostin is the most upregulated gene in NP tissue of AERD
patients.953,957
The complexity in the interaction of inflammatory
mediators in AERD is underlined by the dysregulation of
the PG2-dependent control of LT production in peripheral
granulocytes. When compared to those of patients with
ASA-tolerant asthma or those of controls, granulocytes
of patients with AERD generate more LTB4 and cysLTs,
and are resistant to the PGE2-mediated suppression of
LT generation.958 This can be explained by an impaired
protein kinase A function in AERD, which can lead to
the deregulated control of 5-lipoxygenase activity by
PGE2.
These pathophysiological and immunological considera-
tions have become a key factor in understanding the nature
of AERD and have led to development of in vitro tests.
These tests may potentially evolve to be an alternative to
classic provocation testing in identifying this important
subgroup of CRSwNP patients.959 Several such tests have
been used in clinical trials, investigating their sensitivity and
specificity. These observations have revealed comparable
validity to provocation testing when mixed leukocyte cul-
tures are used to evaluate the eicosanoid and neuropeptide
release patterns.959 Further work is necessary to validate
in vitro testing as a reasonable alternative to current
practice.
 Aggregate Grade of Evidence: C (Level 2a: 1 study; Level
2b: 3 studies; level 5: 10 studies; Table VIII-5).
VIII.D.1. CRSwNP: Diagnosis
CRSwNP is defined in Section IV.B. Diagnosis of CRSwNP
is discussed in Section VI.D in general and the evidence-
based definition of CRSwNP is shown in Table VIII-6.
VIII.D.2. CRSwNP Diagnosis: Differential
Diagnosis
In addition to the differential diagnosis for CRSsNP (see
Section VII.D.2), several space-occupying lesions in the
nasal cavity appear like NPs and must be considered.
Sometimes normal structural variants, such as concha
bullosa and medialized uncinated process, are misdiag-
nosed as NPs. Severely hypertrophied turbinates may also
be mistaken as NPs. Although NPs have a characteristic
translucent gray-to-yellow–colored, teardrop-shaped mor-
phology, those characteristics could be seen in other benign
or malignant lesions. Alternatively, NPs may have different
morphology involving a significant fibrous component,
such that biopsy is needed to confirm the diagnosis.
Common benign tumors shaped like NP include inverted
papilloma, lobular capillary hemangioma, cavernous
hemangioma, and schwannoma.963 Juvenile angiofibroma
should be suspected in adolescent males. Malignant tu-
mors simulating polyps include squamous cell carcinoma,
salivary gland–type carcinoma, olfactory neuroblastoma,
and lymphoma. Key features distinguishing sinonasal
tumors from NPs are unilateral disease,964 lack of sinus
inflammation in some cases, and surface features, such as
easy bleeding and ulceration.
Encephaloceles can masquerade as NPs.965 This lesion
typically arises in the midline nasal and anterior skull
base and causes nasal obstruction. Characteristic signs are
pulsation and expansion of the mass with crying or com-
pression of the jugular vein. Biopsy or nasal polypectomy
based on the misdiagnosis as NP can cause intracranial
complications. Intracranial connection should therefore be
ruled out before any intervention in cases of a unilateral
nasal mass, especially in pediatric cases. Unilateral nasal
obstruction or rhinorrhea in the pediatric population
should also raise suspicion for a foreign body.271
An antrochoanal polyp differs from other NPs in that it
tends to be a large unilateral single mass comprised of cystic
and solid components. Removal of the base may decrease
the chance of recurrence. It usually originates from the
posterior wall of the maxillary sinus and extends into the
choana through an accessory maxillary sinus ostium.966
NPs can be associated with comorbid diseases including
ASA intolerance, asthma, AR, CF, and PCD.967–971 Because
NPs are usually secondary to continued inflammation
caused by these comorbid diseases, the clinician should
evaluate underlying conditions in order to more effectively
treat NPs.
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TABLE VIII-5. Evidence for CRSwNP and aspirin intolerance as a contributing pathogenic factor
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Baker950 2011 2a Systematic review Patients with AERD
undergoing high-dose
desensitization
GI side effects GI symptoms are the primary
risk in high dose
desensitization
Mendelsohn960 2011 2b Large
retrospective
cohort study
Patients undergoing ESS for
NP (n = 549)
Recurrence (measured by
Kaplan-Meier curves)
Revision rates are significantly
higher in AERD
Gosepath947 2002 2b Long-term cohort
study
Patients with AERD
undergoing long-term
low-dose desensitization
Recurrence of NPs and need
for surgical revisions
Long-term low-dose
desensitization is clinically
effective and can be
monitored in vitro
Amar961 2000 2b Case-control study 1.AERD; 2.CRS with and
without asthma
1. Clinical effect of ESS; 2.
Recurrent CRS; 3. Number
of surgical interventions
Surgery is less effective
long-term in patients with
AERD
Chang962 2014 5 Bench research No significant association
between the FABP1
polymorphisms and AERD
Choi953 2014 5 Nonsystematic
review/expert
opinion
Update on pathophysiology in
AERD
Kim957 2014 5 Bench research Serum periostin levels are
significantly elevated in
AERD patients and are
associated with disease
severity
Laidlaw958 2014 5 Bench research Impaired granulocyte PKA
function in AERD may lead
to dysregulated control of
5-lipoxygenase activity by
PGE(2)
Losol956 2013 5 Bench research A functional polymorphism in
IL5RA may contribute to
eosinophil and mast cell
activation in AERD patients
Park955 2013 5 Nonsystematic
review
Review on genetic variants
responsible for risk of AERD
after a genomewide
association study
Stevenson948 2009 5 Nonsystematic
review/expert
opinion
Update on pathophysiology in
AERD
Baenkler959 2008 5 Nonsystematic
review/expert
opinion
Update on pathophysiology in
AERD
Szczeklik952 2003 5 Nonsystematic
review/expert
opinion
Update on pathophysiology in
AERD
Kaldenbach954 1999 5 Bench research CRSwNP; inhalant allergies;
AERD
Role of eosinophilic
granulocytes
Strongest eosinophilia seen in
the group of patients with
AERD
PGE(2) = prostaglandin E(2); PKA = protein kinase A.
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TABLE VIII-6. The diagnostic criteria for CRSwNP
Greater than or equal to 12 weeks of:
2 or more of the following symptoms:
Mucopurulent discharge (rhinorrhea or PND)
Nasal obstruction and congestion
Decreased or absent sense of smell
Facial pressure or pain
AND
1 or more of the following findings:
Evidence of inflammation on paranasal sinus examination or CT
Evidence of purulence coming from paranasal sinuses or ostiomeatal
complex
AND
Presence of polyps
VIII.D.3. CRSwNP Diagnosis: Cost Effective
Work-Up
Because of limited data, CRSwNP and CRSsNP are
combined in Section VII.D.3.
VIII.E. CRSwNP: Management
This discussion will focus on CRSwNP management
(Fig. VII-1). The management of AECRS is discussed in
Section IX.C.
VIII.E.1. CRSwNP Management:-Saline (Spray
and Irrigation)
Because of limited data, CRSwNP and CRSsNP are
combined in Section VII.E.1.
VIII.E.2.a. CRSwNP Management with Topical
Corticosteroids: Standard Delivery (Drops and
Sprays). The use of INCS for CRSwNP has been
well studied. A systematic review of the literature was
performed in which in general only RCTs were con-
sidered, which compared topical corticosteroid against
placebo (35 studies).707,712,864,972–1004 Among these,
8 trials also compared low-dose to high-dose topical
corticosteroid707,981,984,987,989,990,994,997 and 3 trials also
compared 2 corticosteroid agents, fluticasone propionate
and beclomethasone dipropionate.983,985,993 In addition, 4
level 2b studies were included, 3 comparing active with no
intervention973,1005,1006and 1 comparing active treatment
with and without surgery.1007 For 28 trials all or most
of the patients had undergone sinus surgery immediately
prior to the administration of the corticosteroid or had
undergone surgery in the past. In 12 studies there was no
preceding operation or the population was mixed.
A wide range of corticosteroid preparations were
utilized, including: sprays, aerosols, or drops, in varying
doses and for periods ranging from 4 to 260 weeks:
 Fluticasone propionate was studied in 16 tri-
als.707,864,982,983,985–988,993,995,996,999,1001,1002,1006,1007
 Beclomethasone dipropionate was studied in 5
trials.973,983,985,993,1005
 Betamethasone sodium phosphate was studied in 1
trial.977
 Mometasone furoate was studied in 6
trials.712,992,994,997,998,1000
 Flunisolide was studied in 2 trials.975,976
 Budesonide was studied in 9 trials.974,978–981,984,989–991
 Triamcinolone was studied in 1 trial.1003
Outcomes included individual and overall symptoms
scores, endoscopic/polyp scores, QoL questionnaires,
objective assessments of olfaction and airway and occa-
sionally asthma score, number and time to relapse, or
prevention of reoperation. A summary of outcomes is pro-
vided in Table VIII-7, with the majority demonstrating a
significant benefit from the use of INCS as sprays or drops.
A number of critical reviews and meta-analyses have
been published.7,702,1008–1012 When compared to placebo,
pooled data analyses of symptoms, polyp size, polyp re-
currence, and nasal airflow have demonstrated significant
benefit in favor of the topical corticosteroid irrespective of
the variations in which these outcomes have been reported.
It has also been possible to do subgroup analysis7 on:
1. Surgical status comparing those patients with prior
sinus surgery vs those without sinus surgery. This
showed benefit from having had prior surgery.
2. Topical delivery method showed nasal aerosols and dry
powder inhaler were more effective than nasal spray in
controlling symptoms but did not improve on reduction
of polyp size or nasal airway. Both sprays and drops
were statistically effective.
3. Corticosteroid type. Modern corticosteroids (mometa-
sone, fluticasone, and ciclesonide) are not shown to
be more effective than earlier versions (budesonide,
beclomethasone, betamethasone, triamcinolone, and
dexamethasone) for final symptom score or polyp size
reduction.
No serious side effects are reported in any of the studies.
Epistaxis is the most common event together with nasal
irritation producing itching, sneezing, dryness, and rhinitis.
Headache is also frequently reported and usually the side
effects are found equally in the placebo arms suggesting
that local trauma due to poor technique with the device is
more relevant than the content. No increase in infection or
specifically candidiasis has been detected. These minor or
moderate adverse events are generally tolerated by patients.
No difference in intraocular pressure or serum/urinary
cortisol levels have been demonstrated in those few studies
considering these issues.
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Nasal biopsy studies after long-term administration
of INCS do not show any evidence of damage to the
nasal mucosa. Specifically, mucosal atrophy does not
occur because the mucosa is a single layer of epithelium
compared to keratin-producing multilayered skin and
has cilia whose action is enhanced by the corticosteroid,
facilitating its rapid removal.1013–1015 Finally the systemic
bioavailability of INCS varies from <1% to up to 40%
to 50%, which will influence the risk of systemic adverse
effects.1016
 Aggregate Grade of Evidence: A (Level 1b: 36 studies,
Level 2b: 4 studies).
 Benefit: Improved symptoms, endoscopic appearances,
polyp size, and QoL, objective tests of olfaction and air-
way and polyp recurrence.
 Harm: Epistaxis, nasal irritation, headache.
 Cost: Moderate depending on preparation
 Benefits-Harm Assessment: Benefit outweighs harm.
 Value Judgments: None.
 Policy Level: Recommended.
 Intervention: Topical nasal corticosteroids (sprays or
drops) are recommended for CRSwNP before or after
sinus surgery.
VIII.E.2.b. CRSwNP Management with Topical
Corticosteroids: Nonstandard Delivery (Irrigation
and Nebulizers). Nonstandard delivery of topical
corticosteroids has been studied in addition to standard-
ized delivery methods. In systematically reviewing this
literature, only 1 RCT1017 was identified and 5 further
noncontrolled studies were included. Three of the 5 were
prospective719–721 but 2 were severely underpowered.
The remaining 2 were retrospective.1018,1019 Most trials
included a mixed population of CRSwNP and CRSsNP,
and 4 mentioned ASA-tolerance status.719,721,1017,1018
There were 208 patients with CRSwNP and 1 mixed
study of 9 individuals did not give the number of
CRSwNP.
All 6 considered budesonide, either as irrigation or in 1
case in nebulized form.1019 A commercially available prepa-
ration of budesonide was used off-label that is available in
2 doses of 250 μg/2 mL or 500 μg/2 mL. In the included
studies, dosage varied from 128μg to 1 mg. One study used
either budesonide or beclomethasone, also 1mg but the per-
centage of patients using 1 or the other is not given.719 The
volume of saline ranged from 5 to 240mL orwas not stated.
For 4 trials all or most of the patients had undergone sinus
surgery immediately prior to the administration of the corti-
costeroid or had undergone surgery in the past.719,1017–1019
Outcomes included individual and overall symptoms
scores, endoscopic/polyp scores, QoL questionnaires
(SNOT-20, SNOT-21, SNOT-22), CT scores, oral corti-
costeroid use, and tissue eosinophilia. Adrenal function
was the primary outcome for 1 study.720 Because of
disparity of treatments and outcome measures, no
meta-analyses are possible.
A summary of outcomes is provided in Table VIII-8. The
single well-powered RCT showed no difference in outcome
for patient-based (QoL) or objective (endoscopy and CT
scores) assessments.1017 The rest of the results varied from
study to study, with some showing improvement and
others no difference. Most are substantially undermined
by their study design and there is a need for further
well-conducted RCTs.
With regard to adverse effects, concern has centered on
whether off-label utilization of budesonide might result in
systemic absorption and adrenal suppression.702,1020 No
RCTs have been done to adequately address this issue but
those studies that have considered this aspect have not
shown any overt problem. Bhalla et al.722 retrospectively
considered 18 patients receiving budesonide irrigation and
showed no reduction in morning cortisol, and in selected
patients an adrenocorticotropic hormone (ACTH) stim-
ulation test did not show hypothalamic-pituitary-adrenal
(HPA) axis suppression. Similar findings were reported in
a prospective study by Sachanandani et al.720 involving
9 patients using 250 μg/nostril daily for 4 weeks. Welch
et al.723 considered 10 patients who prospectively used 500
μg/2 mL in 250 mL of saline twice daily and showed no
change in serum or 24-hour urinary cortisol at this higher
dose.
Another prospective study considered the effects of
budesonide irrigation (500 μg/2 mL in 240 mL saline BID)
on intraocular pressure in 18 patients.1021 No significant
elevation of pressure was shown with an average duration
of use of 6.3 months in 10 of the patients. A relatively low
dose of active drug is probably delivered to the mucosa
using irrigation systems although the exact exposure is
undetermined at present.775,806,808 This may not be the
case with small-volume, high-dose nebulized devices for
which no safety data is as yet available. Longer-term
adequately powered RCTs are needed on these safety
issues.
 Aggregate Grade of Evidence: B (Level 1b:1 study, level
4: 5studies).
 Benefit: Overall not possible to statistically confirm ther-
apeutic improvement on present evidence.
 Harm: No evidence of adrenal suppression but cannot
be excluded with nonstandardized delivery and dosage
regimes.
 Cost: Moderate.
 Benefits-Harm Assessment: Off-label use, likely negligi-
ble side effects compared with oral corticosteroids.
 Value Judgments: Only one level 1B study so insufficient
data at present.
 Policy Level: Option.
 Intervention: Nonstandard delivery of topical corticos-
teroids is an option in CRSwNP, mainly after sinus
surgery.
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VIII.E.3. CRSwNP Management: Oral
Corticosteroids
Sixteen articles were identified that met criteria for
oral corticosteroids in the management of CRSwNP.
These studies examined different dosage, duration, and
combination regimens. They all evaluated subjective and
objective changes following corticosteroid courses of
varying lengths, with all the studies showing positive
changes in the majority of the parameters evaluated for
patients treated with corticosteroids.
Kroflic et al.1022 performed an RCT comparing 40
patients assigned to oral methylprednisolone or topical
furosemide nebulizer for 7 days prior to sinus surgery.
After 7 days, the oral corticosteroids significantly improved
subjective scores for nasal obstruction, olfaction, and nasal
secretions. Nasal endoscopy scores were significantly
improved and eosinophils were significantly reduced in the
polyp tissue after oral corticosteroids.
Van Zele et al.1023 randomized 47 CRSwNP patients
to receive oral methylprednisolone taper (20 days), doxy-
cycline, or placebo. They reported a significant reduction
of the size of the polyps on nasal endoscopy, a decrease
in nasal congestion, PND, and loss of sense of smell.
Polyp size was improved in the corticosteroid group up
to 8 weeks, but was not found to differ from baseline at
the 12-week follow-up. The corticosteroid group showed
no significant improvement on rhinorrhea compared to
placebo, but did demonstrate significant decreases in blood
eosinophil counts, IgE, ECP, and IL-5. There was no
difference in the matrix metalloproteinase (MMP)-9 levels
between the corticosteroids and placebo groups. Almost
one-half of the subjects reported at least 1 adverse event,
but there was no significant difference in the number or
type between the groups.
Hissaria et al.1024 randomized 41 subjects to receive
50 mg of prednisolone or placebo daily for 14 days. At
the completion of treatment, both groups showed signif-
icant improvement in symptoms based on the physician
interview and the RSOM scores, with the corticosteroid
group demonstrating a significant improvement over the
placebo group in each of these categories. The objective
measures, including nasal endoscopy and MRI, showed
significant improvements in the corticosteroid group over
the placebo. Insomnia was reported more frequently in the
prednisolone group, but no significant adverse reactions to
the corticosteroids were reported.
Vaidyanathan et al.1025 reported their RCT in which 60
CRSwNP patients were randomized to receive 25 mg of
prednisolone or placebo daily for 2 weeks. All patients
received fluticasone propionate nasal drops (400 μg BID)
for 8 weeks then fluticasone propionate nasal spray (200
μg BID) for 18 weeks. The authors reported significant
improvements in nasal endoscopy, hyposmia VAS, Pocket
Smell Test, total nasal symptom scores, mini Rhinoconjunc-
tivitis Quality of Life Questionnaire (RQLQ), PNIF, serum
EDN, and high-sensitivity CRP levels after the 2 weeks
of oral corticosteroids. During their follow-up period, the
polyp size showed statistically significant reduction at the
2-week (p < 0.001) and 10-week (p = 0.001) follow-ups.
At 28 weeks, the reduction in size was not statistically sig-
nificant (p = 0.11). The improvement in olfaction showed
similar trends at the 2-week, 10-week, and 28-week
follow-up. They also reported basal and dynamic adrenal
function suppression after the 2-week treatment with oral
corticosteroids. This returned to baseline after completion
of the oral corticosteroids. The markers of bone turnover
showed a similar trend with significant drops in the
procollagen studies following the corticosteroids. Similar
rates of adverse events were noted in each group, though
none were considered serious as defined by the protocol.
Kirtsreesakul et al.1026 included 109 patients, random-
ized to receive 50 mg of prednisolone or placebo daily
for 14 days. The authors found that subjective symptoms
improved in both groups, though the corticosteroid group
had significantly greater improvements in all subjective
measures over the placebo group. Only the corticosteroid
group had significant improvements in the peak expiratory
flows index and nasal endoscopy measures. Of note,
the corticosteroid group had more patients report GI
disturbances and dyspepsia than did the placebo group.
Finally, an evidence-based risk analysis of oral corticos-
teroid use in CRSwNP was performed by Leung et al.733
Using published complications rates, QoL changes, and
costs, their analysis simulated the economic impact of ad-
verse events from a Medicare patient perspective, societal
perspective, and a universal healthcare perspective. This
analysis found that a breakeven threshold favored surgery
over medical therapy when CRSwNP patients required
oral corticosteroids more than once every 2 years.
These data support the infrequent use of oral corticos-
teroids in CRSwNP patients in the immediate and short-
term period. The long-term efficacy of an oral corticosteroid
taper, followed by maintenance with INCS is likely 8 to
12 weeks. Two studies found no difference in longer-term
effect.1023,1025 Vaidyanathan et al.1025 found adrenal sup-
pression and alteration of bone metabolism to be transient.
Although no severe adverse events were reported in this
study, the higher doses of corticosteroids (50 mg/day for 14
days) may exceed the thresholds reported for osteonecrosis
(300 to 1000mg of oral prednisone).1027 Practitioners must
be aware of the relative benefits vs risks when developing
treatment plans with their patients (Table VIII-9).
 Aggregate Grade of Evidence: A (Level 1b: 5 studies;
Level 3: 2 studies; Level 4: 11 studies).
 Benefit: Significant short-term improvements in subjec-
tive and objective measures in CRSwNP patients. Dura-
tion of improvement may last 8 to 12 weeks in conjunc-
tion with INCS use.
 Harm:More GI symptoms in corticosteroid group, no se-
vere reactions reported. Transient adrenal suppression,
insomnia, and increased bone turnover. All established
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TABLE VIII-9. Evidence for CRSwNP management with oral corticosteroids
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Kirtsreesakul1026 2011 1b DBRCT 1. Prednisolone 50 mg daily
for 14 days; 2. Placebo
1. Nasal symptoms (Likert
scale); 2. Nasal peak
expiratory flow index; 3.
Polyp size
Greater improvement in
symptoms in corticosteroid
arm. Polyp size and nasal
patency were improved
Vaidyanathan1025 2011 1b DBRCT 1. Prednisolone 25 mg/day ×
14 days followed by INCS;
2. Placebo × 14 days
followed by INCS
1 Polyp size; 2. Olfaction; 3.
Total nasal symptom score;
4. mini-RQLQ; 5. PNIF; 6.
EDN and CRP; 7. Adrenal
suppression; 8. Bone
turnover indices
Improvement in all outcomes
(#1–#6) in corticosteroid
arm. Benefits of oral
corticosteroids faded by 28
weeks. Transient adrenal
suppression and decrease
in osteoblast activity was
observed
Van Zele1023 2010 1b DBRCT, multicenter 1. Methylprednisolone 32 mg
× 5 days, 16 mg × 5 days,
8 mg × 10 days; 2. Oral
doxycycline for 20 days; 3.
Placebo
1. Nasal polyps grade by nasal
endoscopy; 2. PNIF; 3.
Nasal symptoms; 4. Serum
eosinophil count; 5. Nasal
secretion of IL-5, IgE,
MMP-9, ECP
Improvement in polyp size,
PNIF, nasal symptoms, and
inflammatory markers in
the corticosteroid arm.
Return to baseline of
clinical endpoints at the
end of the study
Hissaria1024 2006 1b DBRCT 1. Prednisolone 50 mg daily ×
14 days; 2. Placebo
1. Nasal symptoms (VAS); 2.
RSOM-31; 3. MRI; 4. Nasal
endoscopy
Greater improvement in the
corticosteroid arm. MRI and
endoscopy showed
improvement in
corticosteroid arm
Kroflic1022 2006 1b RCT 1. Methylprednisolone 1
mg/kg daily for 7 days prior
to surgery; 2. Nasal
furosemide for 7 days prior
to surgery
1. Nasal symptoms; 2.
Endoscopic grading of
polyp size; 3. Histology; 4.
Intraoperative bleeding
Improved nasal symptoms and
polyp size in both groups
with no difference between
groups. Reduced NP size in
corticosteroid group
corticosteroid risks exist, particularly with prolonged
treatment.
 Cost: Low.
 Benefits-Harm Assessment: Preponderance of benefit to
harm in small, short-term follow-up and with use less
than once every 2 years.
 Value Judgments: Significant improvements in subjective
and objective measures based on high-quality data, low
risk, and low cost. Risks of oral corticosteroids outweigh
benefits relative to surgery with use more than once every
2 years.
 Policy Level: Recommendation.
 Intervention: Oral corticosteroids are recommended in
the short-term management of CRSwNP. Longer-term
or frequent use of corticosteroids for CRSwNP is not
supported by the literature and carries an increased risk
of harm to the patient.
VIII.E.4. CRSwNP Management: Antibiotics
VIII.E.4.a. CRSwNP Management with Antibi-
otics: Oral Nonmacrolide Antibiotics for <3 Weeks.
Antibiotics are prescribed in 26% of ambulatory visits
for CRSwNP.1028 This finding is based on a nationwide
database in the United States, which does not differentiate
between use in acute exacerbations of CRSwNP and the
chronic phase of this condition. Despite the common use
of antimicrobials in CRSwNP, surprisingly few studies
address this practice.
In the EBRR on antimicrobials in CRS published in
2013, Soler et al.752 found only 6 studies examining the
short-term (<3 weeks) use of antibiotics in CRS. Only 1
of these, Van Zele et al.1023 differentiated CRSwNP from
CRSsNP patients. This study examined doxycycline 200
mg once followed by 100 mg daily for 20 days using a
prospective RCT. The authors demonstrated a reduction in
visible polyp size following treatment with doxycycline but
no difference was seen in patient-reported nasal congestion
scores, PNIF, rhinorrhea, or hyposmia. The authors
pointed out that the intrinsic anti-inflammatory effects of
doxycycline may have been responsible for the polyp size
reduction in addition to or instead of the antimicrobial
effect.
Since the Soler et al.752 review identified this 1 study,
only 1 additional clinical trial examining antibiotics in
CRSwNP has been published. Hoza et al.1029 examined the
efficacy of erdosteine, a mucolytic agent with antibacterial,
antioxidant, and anti-inflammatory effects. Erdosteine was
administered alone or in combination with an INCS. There
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was no placebo control. Significant reduction of symptoms
based on SNOT-22 testing was seen in both groups, with
significantly better response seen in the group treated
without INCS. It is unclear whether the antimicrobial,
mucolytic, or other property of erdosteine was responsible
for the improvement seen in this study.
In summary, despite the widespread use of antibiotics
in CRSwNP, there is a paucity of evidence for their
efficacy (Table VIII-10). Antibiotics have a number of
potential harms so that their use in CRSwNP in a nonacute
exacerbation should be discouraged.
 Aggregate Grade of Evidence: B (1 Level 1b study, 1
Level 4 study).
 Benefit: Reduction in polyp size with doxycycline; but
no change in patient-reported outcomes; lack of placebo
in erdosteine trial makes it impossible to determine a
benefit for this therapy.
 Harm: GI upset and potential for resistance and for ana-
phylaxis.
 Cost: Variable, depending on antibiotic chosen.
 Benefits-Harm Assessment: Harm outweighs demon-
strated benefits.
 Value Judgments: Unclear/limited benefits with signifi-
cant harm and potentially significant cost
 Policy Level: Recommendation against.
 Intervention: Nonmacrolide antibiotics (<3-week
course) should generally not be prescribed for CRSwNP
in nonacute clinical situations.
VIII.E.4.b. CRSwNP Management with Antibi-
otics: Oral Non-Macrolide Antibiotics for > 3
Weeks. CRSwNP is thought to be primarily an inflam-
matory disease. Based on first principles, the potential
benefit of >3-week duration of antibiotics may be limited,
likely outweighed by the common risks of antibiotics, such
as gastrointestinal upset, Clostridium difficile colitis, rash,
and anaphylaxis, and the risk of antimicrobial resistance
(both individually and societally).
No studies examining the use of nonmacrolide antibiotics
for longer than 3 weeks in CRSwNP have been published.
Therefore, no evidence-based recommendations can be
made regarding this practice.
 Aggregate Grade of Evidence: not applicable.
VIII.E.4.c. CRSwNP Management with Antibi-
otics: Macrolide Antibiotics. The anti-inflammatory
properties of macrolides have led many to examine their
role in the treatment of CRSwNP. Numerous cohort
studies have evaluated the impact of macrolides on
polyp size and recurrence, specifically in a post-ESS
setting. Recently, higher level evidence has also been
published.
Macrolides have been pursued as treatment for CRS
because of proposed antibacterial and immunomodulatory
properties, as previously reviewed in Section VII.E.4.c. In
addition to modulating NF-kB proinflammatory cytokine
production,744–748 studies suggest a non–allergy-mediated
role for macrolides in reducing nasal fibroblast prolifera-
tion, differentiation, collagen production, and decreased
eosinophilic infiltration into nasal epithelium and lamina
propria.1030–1032
An EBRR by Soler et al.752 addressed the utility of
macrolide use in CRS. Neither of the 2 RCTs exclusively
evaluated CRSwNP patients and just 3 of the remaining
15 retrospective studies specifically assessed CRSwNP
patients. Results within these CRSwNP studies may be af-
fected by differences in polyp composition, where racial and
geographic factors have resulted in distinct neutrophilic
and eosinophilic polyp phenotypes. Katsuta et al.1033
treated CRSwNP patients with 3 months of roxithromycin
500 mg BID and found improvements in symptoms, en-
doscopy, and CT findings in greater than 50% of patients.
Yamada et al.1034 used clarithromycin 400 mg daily for 8
to 12 weeks and found improved polyp grade in 40% of
patients. Moriyama et al.1035 studied erythromycin 400 to
600 mg daily for 7 months in postoperative patients, show-
ing improved rhinoscopy findings without significant side
effects.
More recently, 1 RCT has examined macrolides specif-
ically in CRSwNP patients. To evaluate the effect of
macrolide dosing duration, Varvyanskaya and Lopatin1036
evaluated 66 patients with bilateral NPs on nasal en-
doscopy and CT imaging after ESS. They were randomized
to 3 treatment groups: clarithromycin 250 mg daily for 24
weeks (n = 22), clarithromycin 250 mg daily for 12 weeks
(n = 22), and control (n = 22). All participants received
mometasone furoate 400 μg daily and were evaluated at
6, 12, and 24 weeks after ESS. Both 12-week and 24-week
durations of clarithromycin treatment resulted in improved
SNOT-20 scores at each follow-up time point compared
to control. Both macrolide treatment groups demonstrated
significant reduction in polyposis as well. At the 24-week
time point, the 24-week treatment and 12-week treatment
groups had statistically significant 8-fold and 5.3-fold
reductions in polyp burden, respectively, compared to just
1.8-fold reduction in the control group of mometasone
furoate alone. Similarly, LM scores were significantly
improved after 24 weeks in the extended-duration treat-
ment group. Finally, levels of ECP were significantly
reduced at 12 and 24 weeks post-ESS in both treatment
groups, suggesting that macrolide reduction of eosinophilic
inflammation may reduce polyp recurrence.
Haxel et al.761 used a DBRCT to examine the efficacy
of macrolide in both CRSwNP and CRSsNP patients fol-
lowing sinus surgery. Both CRSwNP and CRSsNP patients
were found to have improved endoscopy scores following
3 months of erythromycin 250 mg daily compared to
controls. Interestingly, CRSsNP patients had a more robust
response than CRSwNP patients.
Additional lower-level evidence supports the use of
macrolides, with most using clarithromycin in varying
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TABLE VIII-10. Evidence for CRSwNP management with nonmacrolide oral antibiotics for <3 weeks
Study Year LOE Study design Study groups Clinical endpoint Conclusion
Van Zele1023 2010 1b RCT 1. Doxycycline; 2. Placebo 1. Polyp size; 2. Nasal
obstruction; 3. Olfaction; 4.
Rhinorrhea; 5. Postnasal
drainage
Reduction in polyp size at week
12; reduction in postnasal
drainage at week 2
Hoza1029 2013 4 Case series 1. Erdosteine; 2. Erdosteine
with INCS spray
SNOT-22 score Reduction in symptom score;
better response seen without
INCS
dosages and durations. A recent study by Dabirmoghad-
dam et al.1037 in 40 patients with severe polyposis
demonstrated a significant endoscopic response in 72% of
patients treated with clarithromycin 500 mg twice daily.
Peric et al.1032 reported statistically significant reduction
in polyp score in both allergic and nonallergic patients
and reduction in levels of IL-8 after 8 weeks of treatment
with clarithromycin 500 mg daily. Haruna et al.755
suggest that macrolide treatment may be less efficacious
in reducing symptoms in patients with predominant
eosinophilic disease or severe polyp burden if polypectomy
is not initially performed. Finally, Ichimura et al.1038
determined that roxithromycin improved NPs in 52% of
CRSwNP patients at a dose of 150 mg daily for at least
8 weeks.
Adverse effects and caution in using macrolides is
reviewed in Section VII.E.4.c.
Limited data from 1 RCT of macrolides and CRSwNP
as well as lower-level evidence demonstrate some benefit,
particularly following ESS (Table VIII-11). Existing studies
have utilized different drugs, dosages, and durations of
therapy. Risks of adverse events are significant so that
potential benefit must be balanced with potential harm.
 Aggregate Grade of Evidence: B (Level 1b: 2 studies;
Level 2b: 5 studies; Level 3b: 1 study; Level 4: 1 study).
 Benefit: Macrolides appear to reduce polyp burden in
post-ESS patients and improve CRS symptoms.
 Harm: Significant potential for medication interactions.
Rare mild adverse events, particularly potential for se-
vere cardiovascular complications.
 Cost: Low.
 Benefits-Harm Assessment: Benefits appear to outweigh
harm, though data are limited.
 Value Judgments: Limited data to determine benefit-
harm balance. Optimal drug, dosage, and duration of
therapy are not known.
 Policy Level: Option.
 Intervention: In CRSwNP, macrolides may be beneficial
after ESS to decrease recurrence of polyps.
VIII.E.4.d CRSwNP Management with Antibi-
otics: Intravenous Antibiotics. Because of limited data,
CRSwNP and CRSsNP are combined in Section VII.E.4.d.
VIII.E.4.e CRSwNP Management with Antibi-
otics: Topical Antibiotics. Because of limited data,
CRSwNP and CRSsNP are combined in Section VII.E.4.e.
VIII.E.5. CRSwNP Management: Antifungals
VIII.E.5.a CRSwNP Management: Antifungals:
Oral Antifungals. The Cochrane review conducted by
Sacks et al.788 synthesized all RCTs investigating the use
of oral antifungals in the management of CRS, of which
only 1 met inclusion criteria (see Table VIII-12).1039 In this
study, 50 adult CRSwNP patients who were diagnosed
with AFRS by clinical, radiologic, histopathologic, and
laboratory workup and who subsequently underwent
ESS were recruited and postoperatively randomized into
5 groups. This study was not blinded and there was
no discussion of the method of randomization in the
methods. In addition to conventional medical treatment
(CMT) consisting of oral antibiotics and oral and topical
corticosteroids, patients received oral itraconazole (group
A), fluconazole nasal spray (group B), combined oral
itraconazole and nasal fluconazole (group C), and irriga-
tion with a fluconazole solution through the nasal fossa
(group D); the control group (group E) received CMT
only. A total of 41 patients were available for follow-up
(9 months maximum). Recurrence rates in the 5 groups
were as follows: group A 66.7%; group B 10.0%; group
C 14.3%; group D 28.6%; and group E 75.0%. It was
not mentioned whether these differences were statistically
significant.
Kennedy et al.379 examined use of oral antifungal
treatment in CRS but did not delineate polyp status. They
found no improvement with the use of oral terbinafine. No
other RCTs using oral antifungals for CRSwNP have been
published.
On the basis of this 1 small randomized but not placebo-
controlled study in an AFRS subset of CRSwNP, there
is no evidence to support the use of systemic antifungal
treatment in the routine management of CRSwNP more
generally.
 Aggregate Grade of Evidence: A (Level 1a: 1 study, Level
1b: 1 study).
 Benefit: No demonstrated benefit of oral antifungals in
routine management of CRSwNP.
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TABLE VIII-11. Evidence for CRSwNP management with macrolide antibiotics
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Haxel761 2015 1b RCT 1. Erythromycin 250 mg daily
(n = 29); 2. Placebo (n =
29)
1. ECP and MPO in nasal
secretions; 2. Multiple other
patient reported and clinical
measures
Improved nasal endoscopy
score. Duration or low-dose
of this trial not efficacious.
High chance of Type II error
Varvyanskaya1036 2014 1b RCT 1. Clarithromycin 250 mg
daily × 24 weeks (n = 22);
2. Clarithromycin 250 mg
daily × 12 weeks (n = 22);
3. Control (n = 22)
1. SNOT-20; 2. Symptoms
(VAS); 3. Olfaction; 4.
Endoscopy; 5. Saccharin
transit; 6. Acoustic
rhinometry; 7. CT
SNOT-20, CT, and endoscopy
were improved in both
treatment groups compared
to control. VAS scores
improved, but
nonsignificant
Dabirmoghaddam1037 2013 2b Cohort study 1. Clarithromycin 500 mg BID
(n = 40)
1. Symptoms (VAS); 2. NP
size; 3. CT (LM score)
Improvement in nasal
obstruction, hyposmia,
rhinorrhea, NP size, and LM
score
Peric1032 2012 2b Cohort study 1. Clarithromycin 500 mg
daily (n = 40)
NP score Reduction in polyp score in
both nonallergic and
allergic patients
Haruna755 2009 2b Cohort study 1. Roxithromycin 150 mg daily
(n = 45); 2. Clarithromycin
200 mg daily (n = 23)
1. Change in CT score; 2.
Subjective symptom score
Improvement of symptoms in
most patients. Less
efficacious in some patients
if NPs not removed first
Katsuta1033 2002 2b Cohort study Roxithromycin 500 mg BID 1. Symptoms; 2. Endoscopy;
3. CT scores
More than 50% of patients
demonstrated clinical
improvement
Yamada1034 2000 2b Cohort study 1. Clarithromycin 400 mg daily
(n = 20); 2. Observation;
nonconcurrent (n = 18)
1. NP size; 2. IL-8 levels in
nasal lavage; 3. IL-4, IL-6,
IL-10, and MCP-1 levels in
nasal lavage
40% of patients showed
reduction in polyp size; IL-8
levels reduced with
treatment
Moriyama1035 1995 3b Retrospective
case-control
1. Erythromycin
postoperatively (600 mg
TID for 1–2 months, then
400 mg BID); 2. No
erythromycin
postoperatively
1. Symptoms; 2. Endoscopy Erythromycin demonstrated a
greater improvement in
symptoms and endoscopy
compared to no
erythromycin
Ichimura1038 1996 4 Case series 1. Roxithromycin 150 mg daily
(n = 20); 2. Roxithromycin
150 mg daily + Azelastine
1 mg BID (n = 20)
1. Subjective symptom score;
2. Serum IgE; 3. Serum
eosinophil count; 4. CT
scan score
Reduction in polyp size, with
greater impact on smaller
polyps
MCP-1 = monocyte chemoattractant protein 1; MPO = myeloperoxidase.
 Harm: Systemic side effects including derangement of
liver function tests have been reported.
 Cost: Moderate.
 Benefits-Harm Assessment: Risk of adverse effects out-
weigh potential benefit because evidence for use of oral
antifungal therapy is lacking.
 Value Judgments: Studies included are often a mix of
CRSwNP and CRSsNP.
 Policy Level: Recommendation against.
 Intervention: Oral antifungal agents should not be given
for the routine treatment of CRSwNP.
VIII.E.5.b. CRSwNP Management: Antifungals:
Topical Antifungals. The Cochrane review conducted
by Sacks et al.788 synthesized all RCTs investigating the
use of topical antifungals in the management of CRS. A
systematic search for RCTs using the same search strategies
as in the Cochrane database was conducted and 4 resulting
studies were reviewed and categorized as either CRSsNP
or CRSwNP depending on the major population.
Ebbens et al. recruited 116 adult patients with CRS (with
and without NPs) who had undergone ESS. These patients
from 6 European tertiary care otorhinolaryngology clinics
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TABLE VIII-12. Evidence for CRSwNP management with oral antifungals
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Khalil1039 2011 1b Nonblinded prospective
RCT (not placebo-
controlled)
AFRS patients: 1. Oral itraconazole; 2.
Fluconazole nasal spray; 3.
Combined (1) and (2); 4.
Fluconazole irrigation; 5.
Conventional medical therapy only
Recurrence rate (not
clearly defined)
Recurrence rates in the 5 groups
were 66.7%, 10.0%, 14.3%,
28.6%, and 75.0%,
respectively (no statistical
analysis was done)
had persistent clinical signs and symptoms for over 6
months.381 More than 80% of the patients had CRSwNP
(amphotericin B group 47/59 patients [80%] and placebo
group 48/57 [84%]; personal communication Ebbens).
These patients were randomized into 2 groups: 25 mL
amphotericin B solution (100 μg/mL) to each nostril twice
daily using a nasal irrigating device (daily amount of
amphotericin B = 10 mg) (n = 59) or a yellow-colored
placebo solution (n = 57) for 13 weeks. The primary
outcomes were symptom scores (using a total VAS) and
endoscopic scores. Secondary outcomes included change
from baseline in disease-specific QoL using the RSOM-31
and individual VAS scores, change in QoL using the SF-36,
change in PNIF, and change in polyp scores. Eight (13.6%)
treatment patients and 9 (15.8%) control patients did not
complete the study.
Gerlinger et al.1040 studied 33 adult patients presenting
with CRSwNP who had previous ESS. They were random-
ized into 1 group receiving amphotericin B nasal spray (5
mg/mL) (daily amount of amphotericin B = 4 mg, n =
16) or the other group receiving a placebo spray (n = 17),
2 sprays twice daily into each nostril for 52 weeks. The
primary outcome measure was a modified LM CT score.
Secondary outcomes included a nonvalidated sinonasal
assessment questionnaire and endoscopic assessment.
Two (12.5%) patients in the intervention group and 1
(5.9%) patient in the control group did not complete the
study.
The study by Khalil et al.1039 involved both topical and
oral antifungal treatment. Fifty adult CRSwNP patients
who were diagnosed with AFRS by clinical, radiologic,
histopathologic, and laboratory workup and who subse-
quently underwent ESS were postoperatively randomized
into 5 groups. This study was not blinded and there was no
discussion of the method of randomization in the methods.
In addition to conventional medical treatment consisting
of oral antibiotics and oral and topical corticosteroids,
patients received oral itraconazole (group A), flucona-
zole nasal spray (group B), combined oral itraconazole
and nasal fluconazole (group C), and irrigation with a
fluconazole solution through the nasal fossa (group D);
the control group (group E) received CMT only. A total
of 41 patients were available for follow-up (9 month
maximum). Recurrence rates in the 5 groups were 66.7%,
10.0%, 14.3%, 28.6%, and 75.0%, respectively. It was
not mentioned whether these differences were statistically
significant.
Weschta et al.377 studied 78 adult patients with CRSwNP
presenting for ESS who were recruited and randomized into
2 groups. Thirty-three patients had previous sinus surgery,
17 (43.6%) in the intervention arm and 16 (41.6%) in the
control arm. Following ESS, both groups were instructed
to spray twice (200 mcL) in each nostril 4 times a day
for 8 weeks. The intervention group (n = 39) received
amphotericin B nasal spray (3 mg/mL, daily amount of am-
photericin B = 4.8 mg) whereas the control group received
a placebo nasal spray (n = 39). Primary outcomes included
CT scores (modified LM), RS QoL scores (RQLQ), and
endoscopy scores. Ten (25.6%) amphotericin B patients
and 5 (12.8%) control patients did not complete the
study.
Of note, Ponikau et al.378 studied topical amphotericin
and found a radiologic change, but no symptom or
endoscopic change. They did not delineate polyp status.
Results of the 4 studies on CRSwNP patients are pre-
sented in Table VIII-13. The results of all studies showed
no significant improvement in QoL questionnaire scores,
or the radiographic scores when compared to placebo;
1 study favored the control group for symptoms377 and
another study favored the control group for the radio-
graphic scores.1040 In 1 study the amphotericin B group
showed no significant improvement in nasal endoscopy
scores.381 Khalil et al.1039 showed an improvement in
recurrence rates in AFRS with fluconazole nasal spray but
did not perform a statistical analysis on these patients. It
is difficult to know how generalizable the Khalil et al.1039
data are to CRSwNP patients overall. On the basis of the
available studies there is no evidence to support the use
of topical antifungal treatment in the routine management
of CRSwNP.
 Aggregate Grade of Evidence: A (Level 1a: 1 study, Level
1b: 4 studies).*
 Benefit: No demonstrated benefit of topical antifungals
in management of typical CRSwNP, but may have some
benefit in certain CRSwNP subsets, such as AFRS.
 Harm: Main side effect reported is local irritation. Meta-
analysis performed in the Cochrane Review did not
demonstrate a statistically significant difference in ad-
verse effects between treatment and placebo groups.
 Cost: Moderate.
 Benefits-Harm Assessment: With no benefit seen for CR-
SwNP patients generally, the benefits cannot outweigh
the risks and costs.
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TABLE VIII-13. Evidence for CRSwNP management with topical antifungals
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Sacks788 2011 1a Systematic review
with meta-analysis
combining CRSwNP
and CRSsNP
1. Topical antifungal
therapy; 2. Placebo
1. Collated symptom
scores; 2. QoL
questionnaire; 3.
Adverse events
No benefit of topical
antifungal over
placebo
Khalil1039 2011 1b Nonblinded
prospective RCT
(not placebo
controlled)
AFRS patients: 1. Oral
itraconazole; 2.
Fluconazole nasal spray;
3. Combined (1) and (2);
4. Fluconazole irrigation;
5. Conventional medical
therapy only
Recurrence rate (not
clearly defined)
Recurrence rates in
the 5 groups were
66.7%, 10.0%,
14.3%, 28.6%, and
75.0%, respectively
(no statistical
analysis was done)
Gerlinger1040 2009 1b RCT 1. 4 mg daily amphotericin
B (n = 16); 2. Placebo
(n = 17)
1. LM CT score; 2.
Questionnaire; 3.
Endoscopic score
No benefit of topical
antifungal over
placebo
Ebbens381 2006 1b RCT 1. 25 mL amphotericin B
(n = 59); 2.
Yellow-colored placebo
(n = 57)
1. Total and individual
symptom VAS; 2.
RSOM-31; 3. SF-36; 4.
PNIF
No benefit of topical
antifungal over
placebo
Weschta377 2004 1b RCT 1. 4.8 mg daily
amphotericin B
(n = 39); 2. Placebo
(n = 39)
1. CT score (modified LM);
2. RQLQ; 3. Endoscopic
score
No benefit of topical
antifungal over
placebo
 Value Judgments: None.
 Policy Level: Recommendation against.
 Intervention: Topical antifungal agents should not be
used in routine CRSwNP treatment.
*Studies included are often a mix of CRSwNP and
CRSsNP.
VIII.E.6. CRSwNP Management: Topical
Alternative Therapies
VIII.E.6.a CRSwNP Management with Topical
Alternative Therapies: Surfactants. Because of limited
data, CRSwNP and CRSsNP are combined in Section
VII.E.6.a.
VIII.E.6.b. CRSwNP Management with Topical
Alternative Therapies: Manuka Honey. Because of
limited data, CRSwNP and CRSsNP are combined in
Section VII.E.6.b.
VIII.E.6.c. CRSwNP Management with Topical
Alternative Therapies: Xylitol. Because of limited
data, CRSwNP and CRSsNP are combined in Section
VII.E.6.c.
VIII.E.6.d. CRSwNP Management with Topical
Alternative Therapies: Colloidal Silver. Because of
the limited data, CRSwNP and CRSsNP are combined in
Section VII.E.6.d.
VIII.E.7. CRSwNP Management: Distribution of
Topical Medications and the Influence of
Head Position, Device, Surgery, and
Nasal Anatomy
Because of limited data, CRSwNP and CRSsNP are
combined in Section VII.E.7.
VIII.E.8. CRSwNP Management: Immune Workup
and Treatment
Because of limited data, CRSwNP and CRSsNP are
combined in Section VII.E.8.
VIII.E.9. CRSwNP Management: Anti-LT Therapy
Upregulation of the cysLT pathway has been demonstrated
in asthma, AR, and CRSwNP. CysLTs are inflamma-
tory mediators synthesized by eosinophils and mast
cells through the breakdown of arachidonic acid. Both
increased cysLT production and upregulation of cysLT
receptors have been seen in these conditions, particularly
in AERD. Because of the known increase in cysLT activity
in CRSwNP, anti-LT therapy has been used in CRSwNP.
Few studies have examined the effectiveness of anti-LT
therapy in CRSwNP and these were recently summarized
by Wentzel et al.1041 and Smith and Sautter.1042
International Forum of Allergy & Rhinology, Vol. 6, No. S1, February 2016 S128
International Consensus on Rhinosinusitis
Wentzel et al.1041 performed a systematic review and
meta-analysis and found 12 studies that examined the
effectiveness of anti-LT therapy in CRSwNP: 5 RCTs and
7 case series. Of the 5 RCTs, which included a total of 179
patients, 2 RCTs compared montelukast, a CysLT receptor
antagonist, to placebo1043,1044; 2 compared montelukast to
INCS1045,1046; and 1 compared montelukast and INCS to
INCS alone following a course of oral corticosteroids.1047
Wentzel et al.1041 were able to combine 2 of the RCTs into
a meta-analysis. Their systematic review and meta-analysis
found that anti-LT therapy showed improvement in symp-
toms over placebo, but no difference compared to INCS.
They concluded that, although anti-LT therapy showed
limited benefit as an adjunctive therapy to INCS, additional
study was needed to determine the most beneficial strategy
for their use.
The Smith and Sautter review1042 confined itself to
English-language studies that addressed the efficacy of
montelukast in CRSwNP. They identified 5 such studies.
Three were RCTs (level 1b),1043,1046,1047 with 1 each of
a nonrandomized, noncontrolled study (level 3)1048 and
a basic science study (level 5).1049 Overall, they found
moderate evidence of efficacy as an adjunctive treatment,
used in conjunction with corticosteroids. Interestingly, they
cited 1 ex vivo basic science study that showed montelukast
combined with zileuton, a selective 5-lipoxygenase enzyme
inhibitor, better prevented mast cell activation in CRSwNP
tissue than montelukast alone.1049
Finally, 1 double-blinded placebo-controlled study
has examined zileuton as an addon therapy to inhaled
and/or oral corticosteroids in AERD patients.1050 Dahlen
et al.1050 demonstrated that 6 weeks of zileuton (600 mg
QID) not only improved pulmonary function but also
resulted in improvement in olfaction, rhinorrhea, and nasal
obstruction. The authors reported no adverse drug-related
events in the 40 patients studied.
In summary, 2 reviews have demonstrated a limited
benefit to anti-LT therapy (Table VIII-14). The risks of LT
therapy vary with the specific drug chosen. Montelukast
has a relatively limited adverse reaction profile, but other
anti-LT medications such as zileuton have been associated
with significant liver concerns.
 Aggregate Grade of Evidence: A (Level 1a: 2 studies).
 Benefit: Improvement in symptoms, comparable to
INCS. May have limited benefit as an adjunct to
INCS.
 Harm: Limited risks. Montelukast has been associated
with rare neuropsychiatric events in postmarketing re-
ports. Zileuton and other medications are associated
with elevated liver enzymes.
 Cost: Moderate.
 Benefits-Harm Assessment: Balance of benefit and harm.
 Value Judgments: Montelukast may be beneficial in pa-
tients who are intolerant or unresponsive to INCS.
 Policy Level: Option.
 Intervention: Montelukast is an option for CRSwNP pa-
tients either instead of or in addition to INCS.
VIII.E.10. CRSwNP and AERD Management:
Aspirin Desensitization
ESS today still is the treatment of choice for NP removal
in individuals suffering from AERD. However, in this
particular subset of patients, recurrence of inflammatory
mucosal changes and ultimately NPs are seen early on,
often within months, and a high percentage of patients
have to undergo revision surgeries.960,961 Consequently,
there is a need for additional treatment options to optimize
postoperative results and to minimize the recurrence rate of
NPs after sinus surgery. Several researchers have described
diverse adaptive aspirin desensitization protocols, the re-
spective impact on LT and prostaglandin (PG) release, and
their clinical results.1051,1052 Some of these protocols vary
in aspirin intake route, especially with regard to oral vs IV
application during the initial desensitization phase.1053–1055
Where controversy between authors is most prominent is
with regard to the best possible maintenance dose, one that
is both effective and yet well tolerated. There is agreement
between researchers that the best timing to start aspirin de-
sensitization is a few weeks after surgical removal of polyps
in an effort to calm down the inflammatory situation and
have the best possible impact on polyp relapse and QoL.
One caveat before initiating desensitization is a thorough
evaluation of the pulmonary function, which should not
be worse than 75% of the expected functional expiratory
volume within 1 second (FEV1) for the individual.
In several publications, including a level 1b trial in
the early 1980s, Stevenson et al.1053,1056 were able to
demonstrate the efficacy of aspirin desensitization using
a daily aspirin maintenance dose of up to 1300 mg. The
authors observed a significant reduction of sinus infections,
revision surgeries, and INCS use during this high-dose
aspirin desensitization. However, severe aspirin-related
side effects like gastric bleeding and gastric pain were
observed as well as impaired renal function, nausea, and
blood-clotting disorders.950,1056 These adverse effects led to
high dropout rates around 50% after just several months.
This is unfavorable, because desensitization only offers a
potential causative therapeutic option if given long enough
to normalize the pathologic shift in the arachidonic acid
pathway. Earlier clinical observations were able to demon-
strate that in most patients this effect takes 6 to 9 months
to become measurable in vitro.947 Even so, it is uncertain
whether any interruption of the maintenance dose for
longer than 48 hours might end the refractory state of the
metabolism and jeopardize the beneficial effect. Therefore,
successful long-term desensitization should be continued
over years, potentially decades, if benefits are to remain.
Data in the literature with regard to dosage during long-
term desensitization have been as variable as the respective
LOE. Rozsasi et al.1057 recommended a maintenance dose
of 300 mg daily to reduce NP recurrence and to improve
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TABLE VIII-14. Evidence for CRSwNP management with antileukotriene therapy
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Smith1042 2014 1a Systematic review of RCTs CRSwNP 1. Symptom improvement;
2. Other clinical
parameters
Moderate evidence for montelukast
improving symptoms as an adjunct
to INCS
Wentzel1041 2013 1a Systematic review and
meta-analysis of RCTs
CRSwNP 1. Symptom improvement;
2. Other clinical
parameters
Montelukast shows improvement in
symptoms over placebo, similar to
that seen with INCS
Dahle´n1050 1998 1b DBRCT using zileuton 600
mg QID
AERD 1. PFTs; 2. Symptoms
scoring; 3. PNIF
Zileuton resulted in improved PFTs as
well as nasal symptoms and PNIF
PFT = pulmonary function test.
sense of smell, whereas several earlier single-armed inves-
tigations could demonstrate an obvious reduction of NP
recurrence, an improvement of the sense of smell, and a re-
duction of asthma-related complaints with a maintenance
aspirin dose of 100 mg daily.947,1052 The most suitable pro-
tocol to establish efficacious and well-tolerable desensitiza-
tion with the lowest possible maintenance dose of oral as-
pirin still remains yet to be determined. Lee et al.1058 recom-
mend an aspirin intake dose of at least 325 mg twice daily
for optimal symptom control, but current reports showed
that even aspirin doses of 650 mg/day are associated with
a considerable risk of gastrointestinal bleeding.1059,1060
In 2013, the first double-blind placebo-controlled
clinical trial was published, investigating adaptive aspirin
desensitization with an initial challenge-dose reaching
800 mg aspirin over 1 day followed by a maintenance
dose of just 100 mg daily. This low-dose protocol was
revealed to be safe, with less than 3% of patients in the
treatment group complaining about gastric irritations,
all of which could continue the treatment after adding a
PPI.1061 With this unprecedented LOE it was shown that
100 mg as a maintenance dose could significantly reduce
the clinical key symptoms such as nasal obstruction,
discharge, and headache (p = 0.001). QoL was also
significantly improved over a 3-year follow-up period in
the treatment group (p = 0.03), along with a lower polyp
score after 36 months. Conclusions drawn from this first
study providing level 1b evidence on a 100-mg protocol
are that low-dose desensitization leads to a significant
decrease in underlying inflammatory activity and therefore
helps reduce the need for systemic corticosteroids in this
group of patients, leading to a reduced need for surgical
revisions.
In a recent review, Klimek et al.1062 concluded that
based on the currently available clinical and pathophysi-
ological data, aspirin desensitization has been proven to
be efficacious and safe and suitable to reduce the need
for other medications in AERD patients. Parikh and
Scadding1054,1063 have reported on the use of topical nasal
lysine in aspirin-sensitive patients. Interestingly, with only
75 mg applied intranasally, they were able to provide level
1b evidence for alterations of cysLT receptors and weaker
evidence levels for improved clinical outcomes using this
regimen1054,1063 (Table VIII-15).
In future trials, potential differences or clinical benefits of
100 mg vs 300 mg of aspirin or vice versa should be evalu-
ated by randomized double-blind prospective dose-finding
trials because the interpretation of the previously reported
data in the literature are limited by their open study design.
Such trials are needed in an effort to find agreement on
the lowest effective and practicable dosing. One of the
few reasons why patients with AERD fail desensitization
is that with their impaired pulmonary function they
cannot tolerate high doses. However, with more recently
elaborated evidence, low-dose desensitization has been
proven to be an effective therapeutic pathway and should
be recommended in patients with uncontrolled AERD.
 Aggregate Grade of Evidence: B (Level 1b: 4 studies;
Level 2a: 3 studies; Level 2b: 6 studies; Level 2c: 2 stud-
ies; Level 3b: 1 study; Level 5: 1 study).
 Benefit: Reduced polyp re-formation after surgery, in-
creased QoL and reduced CRS symptoms in AERD. Re-
duced need for systemic corticosteroids. Reduced num-
ber of surgical revisions.
 Harm: GI bleeding, increased morbidity in renal disease,
and blood clotting issues at high maintenance doses. Less
than 3% GI side effects with low-dose protocols.
 Cost: (1) Initial cost of desensitization. (2)Minimal direct
costs for 100 mg aspirin daily. (3) Potentially costs re-
duced if future surgical interventions reduced, less med-
ication use, fewer physician visits for asthma.
 Benefits-Harm Assessment: Clear benefit over harm.
 Value Judgments: Aspirin desensitization is 1 of the very
few causative medical treatment options available to pa-
tients with CRSwNP.
 Policy Level: Recommendation.
 Intervention: Aspirin desensitization should be consid-
ered in AERD patients after surgical removal of NPs to
prevent recurrence.
VIII.F. CRSwNP: Complications
Complications from CRSwNP fall into 2 broad pathophys-
iologic categories: (1) erosion and compression of the orbit
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TABLE VIII-15. Evidence for CRSwNP with AERD management with aspirin desensitization
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Fruth1061 2013 1b RCT, placebo-
controlled
Patients with AERD after ESS
undergoing low-dose
desensitization with 100 mg
ASA over 3 years
Symptom score,
medication score,
recurrence of polyps
over 3 years
Significant improvement in
symptoms and medication scores
after 3-year long-term low-dose
desensitization
Lee1058 2007 1b RCT 137 AERD patients randomized
to different
high-maintenance doses for
desensitization
Symptom and medication
scores after 1 year
Recommendation to start at 650 mg
twice daily and subsequently
decrease to 325 mg twice daily
Parikh1054 2005 1b Randomized
placebo-
controlled
crossover trial
22 AERD patients undergoing
desensitization with
intranasal lysine aspirin
1. Clinical improvement; 2.
Improvement of in vitro
parameters
Improvement only in tissue studies,
no clinical benefit after 6 months
Stevenson1053 1984 1b DBRCT Patients with AERD undergoing
oral desensitization
Nasal and pulmonary
symptom- and
medication scores
during desensitization
CRS symptoms significantly
reduced, asthma symptoms in
one-half of patients
Baker950 2011 2a SR Patients with AERD undergoing
high-dose desensitization
GI side effects GI symptoms are the primary risk in
high-dose desensitization
Lanas1059 2011 2a SR Patients with AERD and
low-dose desensitization
GI symptoms and bleeding Increased risk for GI bleeding in
low-dose desensitization,
decreased by PPI
Pfaar1055 2006 2a SR Patients with AERD undergoing
desensitization
Improvement for upper and
lower airway and in vitro
Desensitization proven effective as
the only specific treatment of
choice
Mendelsohn960 2011 2b Large
retrospective
cohort study
Patients undergoing ESS for NP
(n = 549)
Recurrence (measured by
Kaplan-Meier curves)
Revision rates significantly higher in
AERD
Rozsasi1057 2008 2b Comparative
cohort study
Patients with AERD undergoing
low-dose desensitization
with 100-mg vs 300-mg
maintenance dose
Polyp recurrence, symptom
and medication scores,
asthma control
Low dose is effective in reducing
polyp recurrence, less effective
for asthma control
Gosepath947 2002 2b Long-term cohort
study
Patients with AERD undergoing
long-term low-dose
desensitization
Recurrence of NPs and
need for surgical
revisions
Long-term low-dose desensitization
is clinically effective and can be
monitored in vitro
Gosepath1052 2001 2b Prospective cohort
study
Patients with AERD undergoing
low-dose desensitization
after surgery
Effectiveness of low-dose
desensitization and in
vitro monitoring after 1
year
Clinical success after 1 year with
100 mg; correlation between
clinical symptoms and in vitro
monitoring
Stevenson1056 1996 2b Large cohort study 65 AERD patients undergoing
desensitization up to 3 years
Long-term effectiveness Significant improvement for: CRS
symptoms, asthma, olfaction,
number of surgical revisions,
corticosteroid use
Lumry1051 1983 2b Cohort study Patients with incomplete AERD Improvement after aspirin
desensitization
77% of patients without asthma
showed clinical improvement
after desensitization
Klimek1062 2014 2c Outcome research
for aspirin
desensitization
Patients with AERD undergoing
different regimes of
desensitization
Oral, nasal, bronchial, and
IV application of aspirin
for desensitization.
Medication score
Aspirin desensitization has been
proven efficacious and safe in
AERD
(Continued)
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TABLE VIII-15. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Parikh1063 2014 2c Outcome research
for intranasal
lysine aspirin
desensitization
Patients with AERD undergoing
topical nasal lysine aspirin
desensitization
Evidence for the use of
intranasal
desensitization
Though desensitization has been
proven successful, the topical
nasal application is still under
debate
Amar961 2000 3b Case-control study 1.AERD; 2.CRS with/without
asthma
1. Clinical effect of ESS; 2.
Recurrent CRS; 3.
Number of surgical
interventions
Surgery is less effective long term in
patients with AERD
Moberg1060 2011 5 Online
questionnaire
1. Primary CV prevention; 2.
Secondary CV prevention
Adherence to low-dose
ASA in patients with GI
problems
Poor adherence in patients with GI
problems
CV = cardiovascular.
and skull base; and (2) sinus obstruction with mucocele
formation. Complications from CRSwNP can also be cat-
egorized in anatomic terms: (1) orbital complications that
manifest as loss of vision, proptosis, diplopia, and epiphora;
and (2) intracranial complications that manifest as menin-
gitis, altered mental status, and other neurologic deficits.
Although erosion of the lamina papyracea and skull base
can occur with longstanding polyp growth, compression
of the orbit and brain directly by polyps is rare. In a series
of 82 patients with AERD, 2 patients developed encroach-
ment and subsequent infections of the lacrimal apparatus,
and 2 patients had erosion of the medial orbital wall,
leading to orbital cellulitis in 1 and proptosis in the other.
No intracranial complications were reported.1064 Reports
of intracranial involvement in the setting of NPs, with
subsequent meningitis or intracranial abscess, are rare.
AFRS, which includes nasal polyposis as a hallmark
finding, poses a unique situation. Substantial involvement
of the skull base and lamina papyracea occurs in up to
50% of cases. 1065,1066 The role of gender and ethnicity is
unclear, but African-American males have been reported
to have a higher incidence of erosion.1067 Compressive
noninfective optic neuropathy with visual loss is less com-
mon (about 4%) but can also occur, with the possibility
of partial or complete recovery of vision.1068 Whether
a CRSwNP case is AFRS-related or not, orbital and
skull-base involvement in the absence of an acute infection
is an insidious process characterized by smooth expansion
without dural or periorbital invasion.
NPs can also cause sinus outflow obstruction, leading to
mucocele formation. In 1 large study of NP patients, the
incidence of mucocele in unoperated CRSwNP cases was
0.6%, whereas the incidence of mucocele in surgically-
treated patients was 2.5% per year.1069 The frontoethmoid
region was the most commonly affected, and patients with
AERD were at higher risk. In the same aforementioned
series of 82 patients with AERD,1064 3 of the 7 orbital
complications involved mucoceles encroaching on the
orbit. Of these 3, two developed blindness as a result of
optic nerve ischemia. A control group of aspirin-tolerant
patients did not have any orbital complications.1064
Overall, mucocele formation in CRSwNP is rare, but prior
surgery and aspirin sensitivity seem to be risk factors.
VIII.G. CRSwNP and AFRS: Differences in
Pathophysiology
AFRS is a subset of CRSwNP. It is a noninvasive,
eosinophilic, recurrent form of polypoid RS that, based
upon certain characteristics, is distinct from other forms
of CRSwNP.1070–1072 AFRS was originally described as
the sinonasal corollary to allergic bronchopulmonary as-
pergillosis, which involves Gell and Coombs type I and III
reactions to Aspergillus.1073,1074 In AFRS, inhaled fungal
spores are believed to trigger an escalating immunologic
reaction of the sinonasal cavities.1075,1076 The 1994 Bent-
Kuhn AFRS diagnostic criteria include: type I hypersensitiv-
ity, nasal polyposis, characteristic CT findings, eosinophilic
mucus without fungal invasion, and positive fungal
stain.358,1077 Aside fromNPs, these criteria collectively help
to differentiate AFRS from other forms of CRSwNP. Some
authors describe alternate AFRS criteria, specifying positive
fungal culture instead of fungal stain, and noting that not all
AFRS patients have fungal allergy.359,1078 This has stirred
debate regarding AFRS pathophysiology.370,1072,1076
CRSwNP, including AFRS, often involves a Th2-
predominant immune response with eosinophilic
inflammation.1071,1079,1080 Theoretically, the primary
stimulus in AFRS is a Type I IgE-mediated hypersensitivity
to ubiquitous fungal allergens. AFRS patients have elevated
serum total and fungal-specific IgE compared to CRSwNP
patients, and serum-specific IgE levels (to both fungal and
nonfungal allergens) have been shown to correlate with
clinical severity and recurrence.917,1073,1074,1077,1081,1082
Eosinophilic mucin, which is not present in all forms of
CRSwNP, is a byproduct of inflammation and contributes
to disease persistence or progression. Eosinophilic mucin
characteristic of AFRS is thick, tenacious, and consists
of necrotic and degranulating eosinophils in a back-
ground of mucin, Charcot-Leyden crystals, and fungal
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hyphae.1077,1083 Dematiaceous fungi and Aspergillus are
commonly identified, but fungi are diverse and vary
based on geographical region.1073,1075,1076,1081,1083,1084
Interestingly, correlation between fungal species in mucin
and systemic fungal allergy was poor in 1 Australian
study.370
Clinically, AFRS tends to be a more severe form
of CRSwNP. Characteristic CT scan findings include
increased density of material within sinus cavities and
expansion or erosion of paranasal sinus bony walls.
Unlike CRSwNP, greater than 30% of AFRS pa-
tients have skull-base or orbital expansion/erosion on
presentation,1066,1077,1082,1085–1088 potentially causing
visual disturbance or facial deformity.1070,1072,1083 Com-
pared to CRSwNP overall, AFRS patients are younger,
atopic, and often have unilateral disease.925,1073,1079,1089 In
the United States, associations with lower socioeconomic
status, Southern geographic region, and African-American
ethnicity have been identified.925,1085,1090–1092
Controversy exists over the importance of type I hyper-
sensitivity in AFRS pathophysiology, driving additional
investigation. Humoral immunity and Ig-independent
pathways may contribute. Fungal-specific IgG is typically
elevated in AFRS.1071,1073,1074 Elevated IgG3 levels spe-
cific to Alternaria alternata and Aspergillus fumigatus
distinguished eosinophilic RS, including AFRS, from
control groups.370 Staphylococcus aureus is a common
organism in polypoid RS, and may modify these dis-
ease processes as a direct pathogen or via superantigen
production.903,925,1084,1093,1094 S. aureus colonization is
more prevalent in AFRS vs other CRSwNP subtypes.925 Vi-
tamin D3 levels are also decreased in CRSwNP and AFRS,
with levels inversely correlating with bone erosion.426
Additionally, genetic analysis has demonstrated differential
gene expression and allelic variations in AFRS vs other
CRS subtypes.634,1095,1096
A local mucosal response also likely contributes to AFRS
pathogenesis. Respiratory epithelial cells can initiate a
local Th2 immune response.1094 NPs contain elevated
levels of dendritic cells, mast cells, eosinophils, and Th2
cytokines.538,1079,1080,1094,1097,1098 AFRS mucosa has a
predominance of CD8+ T cells vs CRSwNP mucosa,
which has elevated CD20+ B-cells.1086 Various studies
demonstrate elevation of fungal and nonfungal IgE within
AFRS mucosa, and local IgE correlates with sinonasal
eosinophilia.917,1079,1080,1093,1099,1100 Most AFRS patients
also have detectable fungal-specific IgE in their mucin.1077
AFRS is a distinct, often more severe, subclass of
CRSwNP. Although the precise AFRS pathophysiology
remains unclear, type I hypersensitivity, eosinophilic
inflammation, and Th2 cytokine profiles are impor-
tant. Environment, socioeconomic factors, and genetic
predisposition also likely contribute.
 Aggregate Grade of Evidence: Level 2b: 16 studies; Level
3a: 1 study; Level 4: 14 studies; Level 5: 10 studies
(Table VIII-16).
VIII.H. CRSwNP and AFRS: Differences in
Management
As a subtype of CRSwNP, there are significant similarities
in the management of AFRS and CRSwNP. Several reviews
on the management of AFRS often advocate the primary
role of sinus surgery to remove fungal-laden eosinophilic
mucin and extended courses of postoperative oral corti-
costeroids in AFRS.1094 Despite the widespread acceptance
of these treatment modalities, there are no studies that
have specifically addressed surgery as the recommended
initial step in the management of AFRS as compared to
medical therapy or the optimal duration of postoperative
oral corticosteroids.
Antifungal Therapy
Several studies support the role of fungi in the pathophys-
iology of AFRS. Although several clinical trials have ad-
dressed the role of oral antifungals in CRS, only a small
number of studies have specifically included AFRS. A re-
cent systematic review by Gan et al.1101 on the medical
management of AFRS evaluated studies on oral and topical
antifungals. This review only included studies that strictly
included AFRS patients that met the Bent and Kuhn diag-
nostic criteria. For oral antifungals, 5 clinical studies were
identified. Two studies, Chan et al.1102 and Khalil et al.,1039
were excluded for failure to specifically include fungal type I
hypersensitivity in the criteria for AFRS. These studies were
included in the review by Gan et al.1101 and are included in
this review and in Table VIII-17, but failure to require type I
hypersensitivity may bias the recommendations and results.
Rains and Mineck,1103 in a noncontrolled case series of
AFRS patients (n = 137) treated with an oral antifungal
(itraconazole 400 mg/day tapered to 200 mg/day for 3 to
6 months depending on response) found that the addition
of itraconazole to their usual postoperative low-dose
corticosteroids reduced reoperation rate from a range of
48% to 56% to 20.5%.
Kupferberg et al.1104 and Seiberling and Wormald1105
published 2 case series with small numbers. In Kupfer-
berg et al.’s study,1104 oral antifungals alone improved
symptoms in only 1 of the 3 patients who received them.
Seiberling and Wormald1105 reported on management of
postoperative recurrent NPs in AFRS patients treated with
6 months of itraconazole. Of the 9 AFRS patients included
in the study, 7 responded positively to itraconazole alone
but 2 experienced another recurrence that required another
course of itraconazole to clear.
Chan et al.1102 and Khalil et al.1039 defined AFRS by the
Bent and Kuhn criteria except for demonstration of fungal
Type I hypersensitivity. Chan et al.1102 reported a case
series with 32 recurrent patients postoperatively who failed
to respond to other medical therapies including prednisone
and topical antifungals. Eighteen of the 32 patients had
subjective significant or moderate improvement and 12 had
endoscopic improvement. The subjective and endoscopic
improvements did not correlate. Khalil et al.1039 performed
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TABLE VIII-16. Evidence for differences in pathophysiology between CRSwNP and AFRS
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Clinical description
Han1079 2013 2b Prospective
case-control
study
1. AERD; 2. AFRS; 3.
Asthmatic RS with allergy;
4. Asthmatic RS without
allergy; 5. Nonasthmatic
RS with allergy; 6.
Nonasthmatic RS without
allergy; 7. CF
1. Clinical data; 2. IHC of
sinonasal mucosa
AFRS pathophysiology involves
fungal-specific allergic reaction
whereas AScA is a more
undifferentiated allergic response.
IL-5 is important in pathogenesis of
AFRS, unlike other subclasses of
eosinophilic RS
Chakrabarti1083 2009 3a Consensus
panel/review
article
N/A N/A Suggested terminology for various
forms of fungal RS. Consensus to call
mucus in AFRS eosinophilic mucin
Uri1072 2013 4 Retrospective case
series
1. AFRS; 2. EMRS Clinical data AFRS and EMRS have similar clinical
presentations, but follow different
clinical courses. Unilateral disease
and orbital involvement are more
common in AFRS than EMRS
Marfani1087 2010 4 Retrospective case
series
Patients diagnosed with
AFRS
Clinical data The majority of patients were young,
male, and of low socioeconomic
status. Unilateral disease present in
over 59% of patients
Ghegan1066 2006 4 Retrospective case
series
Patients undergoing ESS for
inflammatory disease
Clinical data AFRS patients were >12 times more
likely to have bony erosion than CRS.
Patients with AFRS were younger.
Bony erosion was more common in
males and African American patients
Saravanan1078 2006 4 Prospective
comparative
study
Patients with CRS Clinical and pathologic
data
Reviewed diagnostic findings in patients
with AFRS
Ferguson1089 2000 4 Literature review
and
retrospective
case series
1. AFRS; 2. EMRS Clinical and immunologic
data
Unilateral disease, and elevated IgE
levels were more common in AFRS.
Adult-onset asthma and AIT were
more frequent in EMRS
Ferguson1092 2000 4 National survey;
literature review
Patients with AFRS Clinical data AFRS prevalence varied geographically,
with no correlation to environmental
mold counts
Mukherji1088 1998 4 Retrospective
review
Patients with AFRS Clinical data AFRS was more common in males and
in those from southern U.S. states
deShazo359 1995 4 Retrospective case
series
Patients diagnosed with
AFRS
Clinical data Proposal of 5 diagnostic criteria for
AFRS
Bent358 1994 4 Prospective case
series
Patients diagnosed with
AFRS
Clinical and pathologic
data
Defined diagnostic criteria for AFRS
Histopathologic evaluation
Laury1098 2014 2b Prospective
case-control
study
1. AFRS; 2. CRSsNP; 3.
Control group
Semiquantitative
reverse-transcription
PCR and
immunofluorescence of
sinus tissue
Periostin was significantly elevated in
AFRS compared to CRSsNP and
controls; correlated with bone erosion
Bakhshaee1081 2013 2b Prospective cohort
study
Patients with >1 year history
of CRSwNP
Clinical and
histopathological data
Prevalence of AFRS among patients
with NPs was 9.45%
(Continued)
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TABLE VIII-16. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Ragab1086 2013 2b Prospective
case-control
study
1. AFRS; 2. Mycetoma; 3.
CRSwNP; 4. CRSsNP
Histopathologic and IHC of
sinonasal mucosa
CD8+ T cells were the most common
cell type in AFRS. CD20+ B cells
were most common in CRSwNP and
CRSsNP
Ayers538 2011 2b Prospective
case-control
study
1. CRSwNP; 2. CRSsNP; 3.
AFRS; 4. Control group
IHC of mucosa from the
OMC
Dendritic cells and associated
chemokines are significantly
increased in the mucosa of AFRS and
CRSwNP
Ahn1100 2009 2b Prospective
case-control
study
1. CRSsNP; 2. AFRS; 3.
Control group
IHC of sinonasal mucosa More fungal and nonfungal IgE is
expressed in sinonasal mucosa of
AFRS patients, compared with
control and CRSsNP patients
Pant1097 2009 2b Prospective
case-control
study
1. CRS; 2. AFRS; 3. AFRS-like
(fungal allergy, but no
fungi in EM); 4. Nonallergic
fungal eosinophilic RS; 5.
Nonallergic nonfungal
eosinophilic RS
IHC and flow cytometry of
polyp, nonpolyp tissue,
and peripheral blood; 2.
Clinical characteristics
There is no significant difference
between AFRS and other forms of
EMCRS with respect to percentage of
cell populations and fungal-specific
lymphocyte proliferations. A higher
percentage of CD8+ T cells were
present in AFRS/EMCRS.
Fungal-specific lymphocyte
proliferation was greater in
AFRS/EMCRS regardless of allergy
Wise1099 2008 2b Prospective
case-control
study
1. Control group; 2. AFRS; 3.
CRSsNP
Immunohistochemistry of
mucosa biopsied from
the OMC assessing for
IgE
AFRS mucosa had significantly more IgE
compared to other groups. IgE was
increased more within subepithelial
sites when compared to epithelium;
Elevated IgE was not fungal-specific
Carney1080 2006 2b Prospective
case-control
study
1. Control group; 2. AFRS; 3.
Nonallergic eosinophilic
fungal RS (those patients
with NPs and positive
fungal culture or stain, but
without fungal allergy); 4.
CRS
Immunohistochemistry of
infundibular mucosa
AFRS, nonallergic eosinophilic fungal
RS, and CRSsNP patients have
elevated local mast cells, eosinophils,
and IgE+ cell numbers compared to
controls. There was no significant
difference in eosinophils, mast cells,
or IgE+ cell numbers between AFRS
and nonallergic eosinophilic fungal
RS, suggesting local IgE production
in all CRS subsets
Systemic immunologic response
Matsuwaki917 2013 2b Prospective
case-control
study
1. AFRS; 2. CRSwNP; 3.
Control group
Immunohistochemistry of
sinonasal mucosa.
Serum and local IgE
Serum and local total IgE were
significantly increased in AFRS
compared to other groups. Local total
IgE was increased in both CRSwNP
and AFRS. Local IgE correlated with
local ECP in all subjects, with
fungal-specific IgE more strongly
correlated compared to nonfungal IgE
Hutcheson1082 2010 2b Prospective
case-control
study
1.AFRS; 2. CRS 1.Serum total IgE and IgG
anti-Alternaria–specific
antibodies; 2. Serum
antifungal IgE by
Western
immunoblotting
Mean serum total IgE was significantly
higher in AFRS compared to CRS.
Mean serum IgG anti-Alternaria
antibodies were significantly elevated
in AFRS compared to CRS.
Statistically significant increase in
mean number of IgE antifungal bands
from AFRS compared to CRS
(Continued)
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TABLE VIII-16. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Pant370 2005 2b Prospective
case-control
study
1. EMCRS; 2. AFRS; 3.
AFRS-like; 4. Nonallergic
fungal eosinophilic RS; 5.
Nonallergic, nonfungal
eosinophilic RS; CRS; 6.
AR with fungal allergy; 7.
Control
1. IHC of sinonasal
mucosa; 2. Serum Ig
levels; 3. Clinical data
Fungal-specific IgG3 levels were
elevated in all EMCRS patients,
irrespective of the presence of fungal
allergy or fungi within eosinophilic
mucin
Other immune mechanisms
Seiberling903 2005 2b Prospective
case-control
1. CRSwNP; 2. CRSsNP; 3.
Control group
1. Presence of SEA, SEB,
SEC, SED, and TSST-1;
2. Pathologic evaluation
of tissue
Association between toxin detection and
CRSwNP. Higher eosinophil counts in
CRSwNP
Clark925 2013 4 Retrospective
case-series
1. CRSwNP; 2. AFRS Sinus culture There is a higher prevalence of S.
aureus in patients with AFRS vs
patients with other types of CRSwNP
Mulligan426 2011 4 Retrospective
case-series
1. AFRS; 2. CRSwNP; 3.
CRSsNP; 4. Control group
1. VD3 deficiency; 2.
Circulating levels of
immune cells; 3.
Degree of bone erosion
on sinus CT scan
CRSwNP and AFRS, but not CRSsNP,
have insufficient vitamin D3 levels.
Vitamin D3 levels inversely correlate
with circulating dendritic cells
Gene expression
Ebert1095 2014 2b Prospective
case-control
study
1. AFRS; 2. CRSwNP; 3.
Control group
Gene expression profiles
in mucosal tissue
assessed by microarray
analysis
Protease-activated receptor 3 gene
expression was elevated compared
to controls. No difference between
AFRS and controls
Orlandi1096 2007 2b Prospective
case-control
1. AFRS; 2. EMRS Gene expression profiles
in NP tissue using
microarray analysis
38 genes were overexpressed or
underexpressed in AFRS; 10 were
differentially expressed in EMRS
Schubert634 2004 2b Prospective
case-control
1. AFRS; 2. Hypertrophic
sinus disease
HLA DNA genotyping 66% of AFRS patients carried at least 1
HLA-DQB*03 allele. Allelic variants
differed between CRSwNP and AFRS
patients
Demographic and socioeconomic factors
Miller1091 2014 4 Retrospective
case-series
Patients who met 3 of 5
AFRS Bent-Kuhn
diagnostic criteria
1. Demographic and
socioeconomic factors;
2. Measures of disease
severity
Majority of patients were African
American. Higher prevalence of bone
erosion in males. Lower
socioeconomic status was
associated with more severe disease
Wise1090 2008 4 Retrospective
chart review
1. AFRS; 2. CRSwNP; 3.
CRSsNP
Demographic and
socioeconomic factors
Age of presentation was lower for AFRS
compared to CRSwNP and CRSsNP.
AFRS patients resided in counties
with higher poverty level compared
to CRSsNP, but not CRSwNP
Ghegan1085 2007 4 Retrospective
chart review
AFRS Demographic and
socioeconomic factors
Majority of patients were African
American. Higher prevalence of bone
erosion in males. Socioeconomic
factors did not significantly correlate
with bone erosion
AIT = aspirin intolerant; AScA = asthmatic sinusitis with allergy; EMCRS = eosinophilic mucus chronic rhinosinusitis; SEA, SEB, SEC, SED = staphylococcal enterotoxin A,
B, C, D.
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TABLE VIII-17. Evidence for AFRS management with oral antifungal therapy
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Khalil1039 2011 1b Nonblinded
prospective RCT
(not placebo-
controlled)
AFRS patients: 1. Oral itraconazole; 2.
Fluconazole nasal spray; 3.
Combined (1) and (2); 4.
Fluconazole irrigation; 5.
Conventional medical therapy only
Recurrence rate (not
clearly defined)
Recurrence rates in the 5 groups
were 66.7%, 10.0%, 14.3%,
28.6%, and 75.0%, respectively
(no statistical analysis was done)
Seiberling1105 2009 4 Case series Polyp recurrence treated with
itraconazole: 1. AFRS (n = 9); 2.
AFRS-like (n = 1); 3. Nonallergic
fungal eosinophilic RS (n = 13)
1. RS symptoms; 2.
Endoscopy
83% had improved symptoms and
endoscopy (7/9 with AFRS); 3/19
who responded had to stop due
to elevated liver enzymes
Chan1102 2008 4 Case series AFRS (n = 32) patients who had failed
other medical therapies
RSOM-31 56% had significant or moderate
improvement and 44% had little
or no change
Jen1107 2004 4 Pilot study Patients with “a history of AFRS” with
progression of symptoms treated
with fluconazole spray (n = 16)
1. Nasal endoscopy; 2.
Symptoms
75% had stabilization or decrease in
mucosal edema and symptoms
Rains1103 2003 4 Case series AFRS (n = 137) Recurrence 50.4% recurrence and reoperation
in 20.5%
Kupferberg1104 1997 4 Case series Postoperative AFRS patients
receiving: 1. No treatment (n = 9);
2. Oral corticosteroids (n = 100); 3.
Oral corticosteroids and oral
antifungals (n = 2); 4. Oral
antifungals only (n = 3)
Symptoms 1 of 3 patients receiving only oral
antifungals reported
improvement in symptoms
an unblinded randomized clinical trial evaluating both oral
and topical antifungals in 41 patients divided into 5 arms
postoperatively: (1) itraconazole; (2) topical fluconazole
spray alone; (3) itraconazole and topical fluconazole
together; (4) fluconazole irrigations; and (5) no antifungal.
All patients received conventional medical therapy which
consisted of high-dose oral corticosteroid tapered over 6
weeks, 14 days of amoxicillin-clavulanate, and 2 weeks of
saline irrigations. The primary outcome in this study was
recurrence of disease. The lowest recurrence rates were in
the groups treated with either topical fluconazole spray or
irrigation (10.0% to 28.6% vs 66.7% to 75%). However,
there are a number of limitations of this study, including
risk of bias from the unblinded nature of the study and
unclear definition of the primary outcome of recurrent
disease.
Although not designed to evaluate oral antifungals
specifically, and hence not formally included in Table VIII-
17, Rupa et al.1106 conducted a randomized controlled
study comparing 2 groups of AFRS patients. One group
(n = 12) was treated with oral itraconazole (200 mg/day
for 12 weeks) and the other group (n = 12) had oral
itraconazole plus oral corticosteroids (50 mg prednisone
× 6 weeks and then tapered off over 6 additional weeks.
Rupa et al.1106 found that although partial relief of
initial sinus symptoms was reported in all 12 patients
randomized to 12 weeks of oral itraconazole alone, the
nasal endoscopic evaluation revealed that only 1 of the 12
patients had no evidence of disease. This finding contrasted
with 8 of the 12 patients having no evidence of disease if
oral corticosteroids were added to the oral itraconazole.
Topical antifungals have been studied minimally in
AFRS patients. As mentioned above, Khalil et al.1039 found
beneficial effects of fluconazole sprays and irrigations on
recurrence rates. Jen et al.1107 performed an open-label
pilot study using topical fluconazole spray in patients
with history of AFRS. They did not define the inclusion
criteria, nor did they detail the outcomes measures used.
They reported that mucosal edema and patient symptoms
stabilized or improved in 75% of patients and worsened in
25%. These 2 studies, both with significant methodologic
flaws, provide the only evidence for topical antifungals in
the treatment of AFRS.
Overall, only a few studies examine oral or topical
antifungal therapy for AFRS and most are low-level, have
few subjects, and/or contain methodological flaws. Some
studies show promising results, but these are balanced by
significant numbers of nonresponders and adverse events.
At this point, there is insufficient evidence to recommend
for or against antifungal therapy in AFRS.
 Aggregate Grade of Evidence: C (Level 2b:1 study; Level
4: 5 studies).
Immunotherapy
Type I hypersensitivity to fungi is a criterion for AFRS di-
agnosis and may represent a significant component of the
pathophysiology of AFRS. As such, immunotherapy (IT)
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TABLE VIII-18. Evidence for AFRS management with immunotherapy
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Gan1101 2014 3a SR of level 3 and 4 studies AFRS patients N/A IT may reduce mucosal inflammation;
harm is similar to other IT
treatments; cost is high
IT = immunotherapy; N/A = not applicable; SR = systematic review.
represents a reasonable treatment option. Gan et al.1101 per-
formed an evidence-based review with recommendations
regarding IT for AFRS. They identified 2 level 3b stud-
ies and 3 level 4 studies that showed some value in treat-
ing AFRS with IT. Unfortunately, there were again signifi-
cant drawbacks in all of the studies, including small sample
sizes, mixture of IT with other medical treatments, and the
absence of standardized control groups. The authors con-
cluded that there was an equal degree of benefit and harm,
with IT as an option for postoperative AFRS patients. Given
the limited current evidence, additional clinical trials are
needed to examine this question (Table VIII-18).
 Aggregate Grade of Evidence: C (Level 3a: 1 study).
Anti-IgE
No studies have been performed evaluating anti-IgE (oma-
lizumab) in AFRS patients specifically. Given the Type
I fungal hypersensitivity and typical extremely elevated
serum IgE levels, anti-IgE may represent a treatment option
for AFRS patients but current evidence is lacking.
IX. Acute Exacerbation of Chronic
Rhinosinusitis (AECRS)
IX.A. AECRS: Incidence/Prevalance
There are no consistent data about the incidence of
AECRS in literature review. However, there are studies
suggesting that the underlying immunologic activity of
the chronic disease may directly correlate to the rate of
acute exacerbations and infections. For instance, clinical
follow-up in a subgroup of patients with AERD showed
markedly less frequent acute exacerbations after successful
desensitization (average of 4 episodes per year before vs 2
after desensitization).1052
IX.B. AECRS: Pathophysiology
Rank et al.1108 performed a pilot study that investigated
immunological changes in nasal secretion of CRSwNP
patients during clinical worsening of their CRS symptoms.
Interleukin (IL)-6, major basic protein, myeloperoxidase,
EDN, and uric acid were significantly elevated during
CRS exacerbation. However, this study was limited to the
immunology changes in patients suffering from CRSwNP.
The elevated IL-6 levels might suggest viral infection1109
or might be related to the altered IL-6 pathway described
in patients with CRS.526
Bacterial infection also contributes to acute exacer-
bations and acute purulent episodes in the scenario of
underlying chronic inflammatory changes associated
with CRS. The frequent presence of biofilm-forming
organisms represents a large reservoir for opportunistic
infections.1110 However, the low number of studies, the
diversity of the different study cohorts, and the missing
universal definition of AECRS make it difficult to draw
any conclusion concerning the role of bacteria in AECRS.
Clinical experience suggests antibiotics that cover the most
common organisms associated with both ARS and CRS
are likely effective in reducing the exacerbation of AECRS.
This again points to some role for bacteria in AECRS.
Brook1111 compared isolated organisms of the maxillary
sinus of patients with CRS with those suffering from an
AECRS. The identified organisms were predominantly
anaerobic and similar to those generally identified in
CRS (Prevotella, Porhyromonas, Peptostreptococcus,
and Fusobacterium subspecies). However, in addition to
the predominance of the anaerobic organisms, aerobic
bacteria that are usually found in acute infections were
also cultured. S. pneumoniae andH. influenzae were found
more frequently in patients with AECRS compared to
those with CRS without frequent acute exacerbations. It
is known that bacterial infection further leads to Th1 and
Th2 responses resulting in activation of neutrophils and
secondarily eosinophils in many cases. 1112
Substantiated studies focusing on the identification of
risk factors leading to an exacerbation of patients with
CRS are rare because the emphasis of prior studies was to
investigate the pathophysiology of the development of CRS.
Rank et al.1113 performed a retrospective cohort study
in 2010. Exacerbation of CRS was identified based on di-
agnosis coding and at least 1 of the following: prescription
for systemic antibiotics, systemic corticosteroids, plans for
surgical intervention, emergency department or urgent care
visit, or hospitalization for CRS.1113 After investigating
800 patients, 1 of the main observations was that AECRS
is more likely to occur during winter months, suggesting a
pattern similar to ARS without underlying chronic disease.
The authors discussed different hypotheses, including a
potential relationship between CRS disease activity and
viral infection, air quality, air temperature, air humidity, or
indoor allergen/irritant exposure as potential contributing
factors.
Although there are many contributing factors, CRS
is characterized by a dysfunctional host-environment
interaction.7 One might assume that the tissue changes
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associated with CRS predispose to AECRS. Therefore, it
could be concluded that AECRS is due to an imbalance
of host defense and environmental factors similar to the
pathophysiology of any ARS.
Besides immunologic changes at the level of receptors,
cytokines, interleukins, and other mediators, MCC is
considered crucial for the basic “first line of defense” of
respiratory mucosa. It has been described that MCC is im-
paired in a subgroup of patients with chronic inflammatory
mucosal changes. This appears not a result of impaired
beat frequency of the cilia themselves, but rather to a lack
of coordination of the motor arrays as well as altered vis-
cosity of the mucus blanket caused by the elevated levels of
mediators and cellular proteins within.1114 The prolonged
contact time of microorganisms to mucosal surfaces and
antigen-presenting cells appears to be another factor in the
individual susceptibility to acute exacerbations of CRS.
Last, atrophic rhinitis in combination with CRS has
been hypothesized to be another predisposing factor for
AECRS.1115
IX.C. AECRS: Diagnosis
Though the diagnosis of CRS is well codified in rhinology,
literature on the diagnosis of AECRS is scant, often
extrapolated from studies with a range of subjective and
objective measures with varied endpoints, and often in
post-ESS patients. Section IV.D defines AECRS as a sudden
worsening of symptoms in a patient previously diagnosed
with CRS, with a return to baseline symptoms after
treatment. There are no comparative studies of different
definitions or criteria.
Several studies have defined AECRS by worsened
sinonasal symptoms with accompanying presence of pu-
rulence corroborated by endoscopically-derived bacterial
cultures. Walgama et al.1116 based the diagnosis of AECRS
on acute worsening of sinonasal symptoms for at least
1 week and evidence of purulent secretions on nasal en-
doscopy. Bhattacharyya and Kepnes1117 diagnosed AECRS
based on 1 major or minor symptom of CRS in conjunction
with presence of mucopurulent secretions that predomi-
nantly demonstrated gram-positive cocci. Solares et al.1118
identified 24 AECRS patients based on worsened sinus
symptoms, purulence on nasal endoscopy and positive
culture of methicillin-resistant Staphylococcus aureus.
Rather than defining AECRS based on purulence,
Chaudhry et al.1119 defined 130 post-ESS patients with AE-
CRS based on an increase in SNOT-22 score and recurrent
NPs on endoscopic exam. These acute exacerbations did
not present with purulent drainage, and may represent a
separate subset of acute exacerbations.1119 Ikeda et al.1120
evaluated 42 subjects with AECRS and asthma post-ESS
and found that 38% of these patients developed a decline
in peak expiratory flow.
In summary, there exists a paucity of data on the diag-
nostic criteria of AECRS. Further, the data that does exist
suffers from a lack of consistency in reporting of endpoints.
Presumably, patients with established diagnosis of CRS
have symptoms at baseline. If history suggests an abrupt
worsening of these preexisting symptoms, diagnosis of AE-
CRS should be considered. Subjective features of AECRS
may include: (1) nasal blockage, congestion, or stuffiness;
(2) nasal discharge or PND; (3) facial pain, pressure, or
headache; and (4) reduction or loss of smell. Endoscopy
represents an important modality in the diagnostic al-
gorithm demonstrating presence of purulence, crusting,
edema, or polyps, thus providing supportive evidence. CT
imaging is reserved for select cases with equivocal diagnosis
based on endoscopy or concern for potential complications
of AECRS. Additional prospective studies are required to
better formalize definitive diagnostic criteria for AECRS.
IX.D. AECRS: Management
There are no trials to endorse an evidence-based treatment
of AECRS, though there is a tendency to treat AECRS like
an episode of ARS or RARS. Treatments are principally
extrapolated from ARS, whereas there is recognition
of the need to treat the underlying CRS as well. The
inflammation in CRS may impact the natural evolution of
an acute exacerbation, such that type of therapy, duration
of therapy, mode of delivery, and outcomes of therapy may
all differ in AECRS compared to ARS or RARS. There is
a significant gap in evidence for this topic and more robust
data to guide medical decision-making is needed.7,812
IX.E. AECRS: Complications
The orbital, intracranial, and osseous complications
related to AECRS are rare, but usually related to a
chronic refractory untreated or misdiagnosed CRS. These
complications are described elsewhere in this document
(Sections VII.F and VIII.F).
Mucoceles are relatively rare and grow slowly unless
AECRS produces a mucopyocoele. They occur most
often in the frontoethmoid region and the symptoms
presented in AECRS are related to an orbital complication
of ARS. The treatment usually includes antibiotics and,
in the majority of cases, ESS to promote drainage and
marsupialization.7,228,229,234,1121–1123
The most common osseous complication in adults is os-
teomyelitis of the frontal sinus, usually associated with the
progress of inflammation. It may be present as Pott’s puffy
tumor or frontocutaneous fistula. Eyelid and/or periorbital
edema is the most common finding in patients with orbital
involvement, and preseptal cellulitis is by far the most
prevalent orbital complication in Pott’s puffy tumor. Early
diagnosis and aggressive surgery treatment are essential to
avoid severe local or systemic complications.1124
X. Surgery for CRSwNP and CRSsNP
X.A. Surgery for CRSwNP and CRSsNP: General
Concepts
Surgery for CRS is generally indicated when symptoms
persist despite medical therapy, although what constitutes
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an appropriate trial of medical therapy remains ill-defined
(see Section X.B). Surgical techniques have evolved over
the last 3 decades, transitioning from open approaches to
microscopic approaches to endoscopic surgery, and more
recently to more minimal tissue-sparing techniques such as
balloon dilation.
The advent of the Hopkins rods in the 1960s paved the
way for more widespread use of nasal endoscopes and
helped revolutionize sinus surgery, offering more accurate
visualization of the natural drainage pathways of the
sinuses and associated sinonasal anatomy. The techniques
and discussions of Messerklinger and Wigand in the 1970s
further shaped the way sinus surgery was performed,
with an evolving surgical strategy away from radical
removal of all sinus mucosa toward more methodical,
targeted approaches. In the 1980s and 1990s, open surgical
approaches, such as Caldwell Luc surgery of the maxillary
sinus and obliteration of the frontal sinus, continued
to have their advocates, but their popularity waned as
endoscopic techniques became more broadly accepted.
Today, endoscopic approaches have become the stan-
dard for surgical treatment of CRSsNP and CRSwNP. The
tenets of contemporary sinus surgery emphasize mucosal
preservation and enlargement of natural sinus drainage
pathways. The degree to which the sinuses should be
opened and the extent of tissue removal have been a matter
of significant debate (see Section X.D.1).
Surgical treatment for CRSwNP places a greater empha-
sis on tissue removal compared to surgery for CRSsNP. In
CRSwNP, the primary surgical aims are the following: (1)
to establish a patent nasal airway and relieve sinus outflow
obstruction; (2) to decrease the overall inflammatory load;
and (3) to open the sinuses for postoperative topical drug
delivery.1125 Although ESS has become the mainstay for
achieving these aims, it is notable that strong evidence
for the superiority of ESS over simple polypectomy is
lacking.7,1126 Moreover, for CRSwNP specifically (as op-
posed to CRS overall), there is a similar lack of high-level
evidence for the superiority of surgery over medical ther-
apy for nasal polyposis.1127 To be clear, evidence can be
extrapolated from some studies, especially lower levels of
evidence, to support the superiority of surgery in CRSwNP.
Nonetheless, as in many cases of surgical treatments, RCTs
for the surgical treatment of CRSwNP are not available.
Nevertheless, a formal ESS using mucosal-preserving
technique addresses the aims of CRSwNP treatment,
and is generally advocated for patients with polyposis. A
complete ESS also allows for postoperative surveillance
and the ability to perform in-office polypectomy if polyps
recur, without needing to return to the operating room.
One study has shown that more aggressive, but mucosal
preserving, surgery in the frontal sinus leads to lower polyp
recurrence.1128 Although not widely utilized, a radical
approach to ethmoidectomy involving removal of ethmoid
mucosa and the MTs (“nasalization”) has also been shown
to have favorable outcomes. In 1 retrospective 5-year
study, patients who received nasalization ethmoidectomy
experienced better symptom relief and reduced polyp re-
currence than patients who underwent mucosal-preserving
ethmoidectomy.1129
Surgical interventions for CRSsNP encompass a wider
range of strategies. Mucosal-preserving endoscopic tech-
niques have largely replaced open approaches, although
outcomes comparisons between ESS with open sinus
surgery are limited. The 2012 EPOS guidelines7 found 3
studies comparing ESS with various conventional sinus
surgery techniques, such as Caldwell-Luc maxillary sinus
surgery and inferior meatal antrostomy with antral irri-
gation, and found that ESS was superior. Currently, open
approaches may still have utility to augment endoscopic ex-
posure or access in complex frontal or maxillary cases, via
frontal trephination or canine fossa puncture, respectively.
Although there are abundant level 4 studies asserting the
efficacy of ESS, well-conducted RCTs are less common.
Challenges of surgical study design include the difficulty
of completely blinding patients and assessors to the
interventions, thus introducing the potential for bias.
Developing a suitable control group is also a challenge, be-
cause incorporation of “sham” procedures may challenge
ethical standards. In addition, variances of technique for a
particular procedure may undermine the generalizability of
these trials. A Cochrane review, updated in 2009, reviewed
the evidence for ESS vs medical treatment and conventional
sinus surgery, and found only 3 RCTs. They concluded
from the pooled evidence that ESS was not superior to
either medical treatment or an inferior meatal antrostomy
as performed by traditional sinus surgery techniques,
although importantly admitted that the small sample sizes
could not exclude a type II error.1130 However, RCTs are
not always practical or ethical to perform, nor do they
always reflect daily practice. A recent multi-institutional
prospective study compared medical vs surgical therapy
for CRS in patients who had failed initial medical therapy.
Patients were followed for 1 year and were grouped in
nonrandomized fashion into 3 cohorts: medical therapy,
surgical therapy, or crossover from medical to surgical
treatment. Results from this study showed that patients
in the surgical cohort reported significantly higher levels
of symptomatic improvement than the medical cohort.
Additionally, patients in the crossover group had stagnant
or worsening QoL, which improved after ESS.1131
Balloon catheter dilation of the paranasal sinuses is a
relatively new surgical technique that aims for ostial dila-
tion without tissue removal. Current balloon technologies
are applicable to the maxillary, frontal, and sphenoid
sinuses, although there is some evidence that anterior
ethmoid disease may respond to dilation of the ethmoid
infundibulum which occurs in the course of maxillary
ostial dilation.285,286,1132 There have been many studies
looking at the safety and efficacy of this technology, but
few RCTs. The earliest RCT compared balloon dilation
of the frontal recess vs ESS and found no significant
difference in outcome.1133 A more recent study compared
Draf 2a frontal sinusotomy to a “hybrid” frontal approach
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combining balloon dilation of the frontal recess and tradi-
tional endoscopic techniques; the study found comparable
rates of ostial patency up to 1 year postoperatively, with
the hybrid technique having a slightly shorter surgical
time and less mean blood loss volume vs conventional
ESS.1134 A third RCT looked at maxillary sinus balloon
dilation vs ESS in patients with chronic maxillary sinusitis
with or without anterior ethmoid disease. Both techniques
were found to be equally effective in improving SNOT-20
scores, maintaining ostial patency, reducing RS episodes,
and improving work productivity at 1-year follow-up.1132
More recently, balloon dilation has been studied for
in-office treatment of CRS and RARS. A nonrandomized
prospective case series showed a high catheterization
success rate of 93% to 98% with satisfactory patient
tolerance of the procedure. Clinical outcomes showed
significant improvements in SNOT-20 scores sustained
through 1 year, as well as reduced episodes of ARS.285
As evidenced by the plethora of treatment methods for
CRS and the varied associated literature, it is difficult to
recommend 1 standard therapy for all patients. Treatment
often has to be customized to the individual patient,
depending on disease severity, patient comorbidities, and
surgeon expertise. As new techniques emerge, critical
assessment of outcomes is essential to understand the role
of these newer approaches in the surgical armamentarium.
X.B. Surgery for CRSwNP and CRSsNP:
Appropriate (“Maximal”) Medical
Management
Statements regarding indications for sinus surgery invari-
ably cite “failure of maximal medical therapy” (MMT)
as a prerequisite; surgery without a prior trial of medical
treatment is uncommon. However, although there is a
high level of consistency between guidelines regarding the
need for such a trial, there is much less consensus on what
MMT entails.
Recent work has examined how prolonging the time
between diagnosis and surgery for CRS may negatively
impact outcomes.1135–1137 The term “maximal” medical
therapy may thus not be entirely appropriate, inasmuch as
it implies surgery should be delayed until all available op-
tions have been exhausted. Therefore, instead of using the
term “maximal medical therapy,” this ICAR:RS document
will use the term “appropriate” medical therapy (AMT).
AMT is used in order to suggest striking a balance between
proceeding to surgery before appropriate nonsurgical
options have been tried and delaying too long so that
outcomes are negatively impacted. (In referring to past
work regarding “maximal” medical therapy in this review,
the MMT term will be retained.)
What is AMT?
Although there are numerous studies evaluating the efficacy
of individual drug classes in the treatment of CRS, dis-
cussed elsewhere in this ICAR:RS document (see Sections
VII.E and VIII.E), there are no clinical trials evaluating the
optimal combination of drugs. There are several guidelines
where recommendations are made, and these demonstrate
consistency with regard to inclusion of oral antibiotics,
INCS, and selective use of oral corticosteroids (Table X-
1).7,1138,1139 A recent systematic review demonstrated that
INCS, oral antibiotics, and oral corticosteroids were used
in 91%, 88%, and 62% of all MMT protocols for a mean
of 8 weeks, 23 days, and 18 days, respectively.1140
While incorporating the best available evidence into
a recommendation for AMT, including evidence from
this ICAR:RS document, a few key points should be
remembered. First, addition of surgery into the benefit-
harm assessment, with its own potential benefits, harms,
and costs, alters this balance. Second, AMT is typically
given as a combination of therapies and all of the above
recommendations for therapy in CRS address them as
single modalities. Third, as a result of the lack of trials of
optimal therapy combinations, the best we can provide at
this point are consensus recommendations extrapolated
from this best available evidence.
Intranasal Corticosteroid Sprays. Given the favorable
balance of benefit to harm for INCS use, there is little
debate to include this treatment in AMT protocols.
Saline Irrigations. The same is true of saline irrigations.
They should be included in AMT protocols.
Oral Corticosteroids. The inclusion of a short course
of oral corticosteroids should be considered separately
for CRSwNP and CRSsNP, based on differing amounts
of evidence and recommendations for each condition.
Interestingly, however, this modality was reported in 62%
of MMT protocols, with inclusion in previous MMT
protocols not differentiated based on NP status.
For CRSwNP, the best available evidence and balance
of benefits and harm appear to favor a single, short course
of oral corticosteroids. Section VIII.E.3 summarizes this
evidence and recommends their use. It should be noted,
however, that repeated or prolonged trials may not be bene-
ficial. Leung et al.’s733 recent economic analysis of potential
complications demonstrated that a breakeven threshold fa-
vors surgery over medical therapy when CRSwNP patients
required oral corticosteroids more than once every 2 years.
For CRSsNP, given the generalized lack of evidence
and risk of significant adverse events, it is challenging to
provide a recommendation to include oral corticosteroids
in an AMT protocol. The efficacy of oral corticosteroids in
CRSsNP is unknown (see Section VII.E.3). In comparing
the risks and benefits of surgery to medical therapy
including oral corticosteroids, it is evident that they may
be considered as an option in CRSsNP, particularly in
those patients displaying characteristics of an eosinophilic
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TABLE X-1. Maximal medical therapy defined by published guidelines
Guideline Antibiotics INCS Systemic corticosteroids Saline irrigation Other
AAOA Guidelines (2009)1138 Yes Yes Yes for CRSwNP or CRSsNP if
initial 2-week treatment
fails
Not specified Oral or topical
decongestants
AAO-HNS Guidelines (2015)4 Yes, culture-directed Optional Optional Optional Treatment of AR
Canadian Guidelines (2011)671 Yes, culture-directed Yes Yes in CRSwNP; Optional in
CRSsNP
Optional Leukotrienes optional in
AERD patients
EPOS (2012)7 Macrolides for selected
CRSsNP; doxycycline
for selected CRSwNP
Yes Yes in moderate/severe
CRSwNP; no for CRSsNP
Yes
BSACI (2008)202 Macrolide antibiotics Yes Yes in moderate/severe
CRSwNP; no for CRSsNP
Yes Leukotrienes optional in
AERD patients;
antihistamines for AR
phenotype. Clearly more work is needed to elucidate the
balance of potential benefit and harm in CRSsNP.
Oral Antibiotics. Although oral antibiotics were used
in approximately 88% of MMT regimens, robust evidence
to support a clear indication for their use is lacking. It is
not clear what role bacteria play in CRS and, interestingly,
in ARS, where they are known to play a role, antibiotic
use is not recommended but instead is an option (see
Section V.D.1). As in the case of oral corticosteroids, it is
helpful to differentiate recommendations for CRSwNP and
CRSsNP.
Antibiotic use in CRSsNP is reviewed in Section VII.E,
where insufficient evidence is found to recommend for or
against their use in the case of nonmacrolide antibiotics.
Macrolide antibiotics are found to be an option in CRSsNP.
As part of possible AMT, the benefit-harm assessment
for antibiotics changes once surgery is in the balance.
Antibiotics are therefore recommended for AMT in
CRSsNP.
Section VIII.E reviews antibiotic use in CRSwNP and
recommends against courses <3 weeks for non-AECRS.
No evidence was found regarding nonmacrolide courses
longer than 3 weeks and, as in CRSsNP, macrolides are
considered to be an option in CRSwNP. In balancing these
potential harms and benefits against those of surgery,
antibiotics should be considered an option for AMT in
CRSwNP.
There is divergence regarding the choice of antibiotics.
North American guidelines advocate the use of culture-
directed antibiotics, or in the absence of culture results, a
broad-spectrum antibiotic such as amoxicillin-clavulanate.
In contrast, EPOS recommends antibiotic choice to be
primarily linked to associated anti-inflammatory effects;
macrolides are recommended for CRSsNP for their
antineutrophilic effects, whereas doxycycline is recom-
mended in CRSwNP, where eosinophilic inflammation
predominates. This ICAR:RS statement finds insufficient
evidence to recommend 1 class of antibiotics over another
in an AMT protocol. Further trials are urgently required
to rationalize the appropriate indications and agents in the
face of increasing antibiotic resistance.
Surveys of prescribing habits of both U.S. and U.K.
ENT specialists (Table X-2) reveal broad adherence to
combination treatment recommendations. This does not
confirm the effectiveness of such regimens, but does suggest
acceptance of the published guidelines.
In summary, the evidence for what should constitute
appropriate medical therapy prior to surgical intervention
is very much lacking. Recommendations are given based
on available evidence, but the grade of evidence is D,
leading to weak strength of recommendation.
 Aggregate Grade of Evidence: D.
 Benefit: Symptomatic improvement and avoidance of
risks of surgical intervention.
 Harm: Risks of corticosteroids, GI side effects of antimi-
crobials, risk of cardiovascular toxicity with macrolide
antibiotics, potential for increasing antibiotic resistance.
 Cost: Direct cost of medications.
 Benefits-Harm Assessment: Differ for particular therapy
and clinical scenario.
 Value Judgements: Perceived lower risk of antibiotic
treatment vs risks of surgery, although recent evidence
has shown a low breakeven threshold for surgery vs oral
corticosteroids. Additional evidence is needed in assess-
ing antibiotic vs surgery benefit-harm balance. Clearly,
patient preference plays a large role in the decision to
continue medical therapy or to proceed with surgery.
 Policy level: Recommendation.
 Intervention:
◦ For CRSwNP: Appropriate medical therapy prior
to surgical intervention should include a trial of
INCS, saline irrigations, and a single short course
of oral corticosteroids. Antibiotics are an option.
◦ For CRSsNP: Appropriate medical therapy prior to
surgical intervention should include INCS, saline
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TABLE X-2. Results of surveys to establish medical therapy trial prior to surgery prescribing habits
Survey Antibiotics INCS Systemic corticosteroids Saline irrigation Other
ENT UK Survey (2013)
(n = 159)1141
92% 61% always, 27%
sometimes
4% always, 30% sometimes 23% always, 42%
sometimes
3% antihistamines, 4%
topical decongestants
AAO-HNS Survey
(2006) (n = 80)1142
94% 94% 34% 47% oral decongestants,
47% mucolytics
ARS Survey (2007)
(n = 308)1143
51% always, 30%
almost always
10% always, 20% almost
always
irrigations, and antibiotics. Oral corticosteroids are
an option.
How long should appropriate medical
management last?
There is 1 randomized trial currently listed on the U.S.
NIH website, clinicaltrials.gov (Identifier NCT01825408),
that intends to determine the optimal duration (3 vs 6
weeks) of oral antibiotics as part of a medical therapy trial
prior to surgery. There are no completed RCTs addressing
the optimal duration of a medical therapy trial prior
to surgery. One published nonrandomized uncontrolled
study suggests 6 weeks of culture directed oral antibiotics
to be more effective than 3 weeks.741 However, the 38%
improvement in CT staging from the 3-week to 6-week
scan has questionable clinical value and may have still
occurred without ongoing treatment.
Guidelines again diverge in recommendations, with
European guidelines recommending a prolonged course of
low-dose macrolides, whereas North American guidelines
recommend a longer course than would be prescribed in
ABRS, but up to a maximum of 4 weeks (Table X-3).
This is reflected in clinical practice, with 1 in 4 specialists
using a course of 6 weeks or more in the United Kingdom,
compared with less than 1 in 30 among U.S. rhinologists
(Table X-4).
There are multiple RCTs evaluating the benefits of INCS
in CRS. Studies where treatment duration is less than or
equal to 3 weeks show no benefit over placebo, whereas
studies of 4 weeks or more consistently favor INCS.
 Aggregate Grade of Evidence: D.
 Benefit: Symptomatic improvement and avoidance of
risks of surgical intervention.
 Harm: Risks of corticosteroids, GI side effects of antimi-
crobials, risk of cardiovascular toxicity with macrolide
antibiotics, potential of increasing antibiotic resistance.
 Cost: Direct cost of medications.
 Value Judgements: Low risk of treatment and delay of
surgery vs risks of surgery considered in recommending
a 3-week to 4-week trial.
 Policy Level: Recommendation
 Intervention: A trial of 3 to 4 weeks of AMT should be
considered as the minimum.
When should AMT be deemed to have failed?
Success of AMT should be defined by a symptomatic re-
sponse, such that symptoms are not sufficiently bothersome
to merit surgery. Although persistent radiological and
endoscopic evidence of disease do not itself define failure,
they may be predictive for subsequent relapse. Failure is
thus defined by insufficient symptomatic response to AMT,
in the presence of radiological or endoscopic evidence
of CRS.
What is the response rate and long-term control
rate after MMT/AMT?
The response rate to previous trials ofMMT varies between
30.4% and 90% (Table X-5).728,729,1144–1146 It is accepted
that CRS has a chronic relapsing course, but the long-term
fate following a successful trial of medical therapy is not
well reported. Subramanian et al.729 found a relapse rate
of 47.5% in those initially responding to medical therapy
trial prior to surgery, requiring a further course of medical
treatment. CRSwNP and previous sinus surgery were pre-
dictors of relapse. In contrast, Young et al.1146 found no
significant deterioration in the symptom scores of medical
responders from the end of a 3-month treatment period to
5 months (mean) of further follow-up. Ongoing medical
treatment was not defined in either study. Baguley et al.1145
identified a group of medical responders with persistent
radiological disease on completion of medical therapy but
resolution of symptoms. Despite ongoing INCS and saline
rinses, 43% suffered a symptomatic relapse between 3
and 23 months of further follow-up and 29% required
surgery.
Continued medical therapy following a failed trial of
1 MMT protocol (>3 weeks of antibiotics and INCS)
has been assessed in a nonrandomized multi-institutional
cohort study.1131 Ten percent of a cohort initially electing
continued medical therapy failed to receive continued
benefit and opted to cross-over and receive sinus surgery.
The crossover group of patients suffered from deterioration
in their QoL, which prompted the choice for surgery.
The 90% of patients who continued within the medical
therapy cohort had significant better baseline QoL scores
and reported stable QoL over a 6-month period, but failed
to report reductions in the use of rescue medication or
days of missed work/school.
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TABLE X-3. Duration of medical therapy trials prior to surgery recommended by major guidelines
Guideline Antibiotics INCS Systemic corticosteroids Saline irrigation
AAOA Guidelines (2009)1138 3–4 weeks At least 1 month 8–12 days Not specified
AAO-HNS Guidelines (2015)4 2–4 weeks Not specified Not specified Not specified
Canadian Guidelines (2011)671 “Slightly longer than for ABRS” Not specified 2 weeks in CRSwNP;
optional in CRSsNP
Not specified
EPOS (2012)7 12 weeks macrolides; 3 weeks
doxycycline
3 months, except 1 month
in severe CRSwNP
“short course” Yes
BSACI (2007)202 12 weeks of macrolide antibiotics Not specified 5–10 days Yes
TABLE X-4. Results of surveys to establish duration of prescribed medical therapy trials prior to surgery
Survey Antibiotics INCS Systemic corticosteroids
ENT UK Survey (2013)
(n = 159)1141
<2 weeks: 29%; 2–4 weeks:
26%; >6 weeks 26%
3–6 months: 67% 0–5 days: 42%; 6–10 days:
29%; 11–15 days: 29%
ARS Survey (2007) (n =
308)1143
0–2 weeks: 12%; 2.1–3 weeks:
37%; >6 weeks: 3%
Not specified 0–5 days: 7%; 6–14 days:
67%
AAO-HNS Survey (2006)
(n = 80)1142
Mean duration >5 weeks Mean duration 6 weeks Mean duration 1 week
TABLE X-5. Reported response rates to medical therapy trials prior to surgery
Study Intervention Outcome measured Response rate
Lal728 4 weeks amoxicillin-clavulanate, 12 days oral
corticosteroid, 4 weeks INCS, 4 weeks saline rinse
Complete resolution of
symptoms Partial response
51.03% 17.8%
Dilidaer1144 Not specified Complete control 30.4%
Young1146 3 weeks oral prednisolone, antibiotics, INCS, and
saline rinses
Improvement in symptoms
sufficient to avoid surgery
37.5%
Subramanian729 4 weeks antibiotics, INCS, saline rinses, 10 days
prednisolone
Improvement in symptoms
sufficient to avoid surgery
90%
Baguley1145 3 weeks prednisolone, 4–6 weeks INCS, saline rinse,
optional 20 days antibiotics
Control = symptoms resolved
or no longer bothersome
38%
Smith and Rudmik1147 evaluated the impact of contin-
uing medical therapy in patients with large reductions in
baseline QoL who chose sinus surgery but had to wait for
a mean of 7 months because of surgical waitlists. They
found that patients with large reductions in baseline QoL
who continued medical therapy failed to receive QoL
improvements and had increased absenteeism. It is worth
noting that all clinical outcomes improved after this cohort
received sinus surgery.1148
Data from a prospective cohort study and from 2 inde-
pendent electronic health records reviews1135–1137 suggest
that benefit from surgery, both in terms of symptomatic
response and ongoing healthcare utilization, is reduced if
surgical intervention is delayed. Therefore, surgery should
be considered once AMT has been deemed to have failed,
and further repeated courses should be avoided.
X.C. Surgery for CRSwNP and CRSsNP:
Preoperative Management
ESS has become the standard treatment modality for pa-
tients who do not respond to AMT. Since the introduction
of ESS, the technique has improved and been standardized.
Preoperative management is an essential part of ESS, and
optimal perioperative management including preoperative,
intraoperative, and postoperative care should be offered
to patients to help assure a positive surgical outcome.
The objective of preoperative management is not to cure
CRS, but rather to create the best conditions for ESS. The
outcome of ESS depends on several factors, and a clean
surgical field, especially a bloodless one, is the most im-
portant factor.1149 Impaired visibility due to a bloody field
can impair surgical dissection, prolong the length of the
procedure and increase the rate of complications.1149,1150
Accordingly, it could be said that the substantive objective
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of preoperative management is to create a unobscured
endoscopic view during ESS.
Preoperative disease extent appears to be a predictive
factor for bleeding during ESS. In a cohort study of 40
patients, preoperative LM CT scan score was significantly
correlated with intraoperative bleeding in primary cases,
and there was no correlation in revision cases. 1151 Simi-
larly, another study of 230 RS patients found that extent
of disease was a consistent predictor for intraoperative
bleeding.1152
In addition to disease extent, corticosteroid and antibi-
otic treatment are both commonly discussed as preoperative
treatment measures. Corticosteroids (systemic or topical)
and antibiotics have been proposed to decrease inflamma-
tion and vascularity of the sinus mucosa, leading to im-
proved visibility in the preoperative setting. However, there
is no uniform protocol for preoperative management before
ESS, mostly because of the paucity of available evidence.
X.C.1. CRSsNP: Preoperative Corticosteroids
There are no clinical trials investigating the role of
preoperative systemic or topical corticosteroid use in
CRSsNP patients alone. Several studies have included both
CRSsNP and CRSwNP patients. Albu et al.1150 reported
a double-blinded randomized, placebo control trial of 70
patients, of which 37 were CRSsNP and 33 were CRSwNP.
The treatment group received a 4-week course of intranasal
mometasone furoate 200 μg twice daily. The treatment
group had significantly less intraoperative blood loss, a
better surgical field, and shorter operation time. Subgoup
analysis was carried out on the CRSsNP patients, with
preservation of statistical significance of the above findings
(despite the study not being powered for the smaller
subgroup sample size). No studies regarding preoperative
systemic corticosteroid administration in CRSsNP patients
were identified. In a national survey of U.S. surgeons on the
use of preoperative systemic corticosteroids in ESS, only
26% of respondents prescribed them in CRSsNP cases. 65
It is well known that corticosteroid treatment has potential
morbidity. Although uncommon, oral corticosteroids are
associated with side effects such as Cushing’s disease,
blood sugar dyscrasias, gastrointestinal tract ulcer, and
avascular necrosis.1106 Topical corticosteroid use is also
related with mild adverse effects, such as nasal dryness,
bleeding, burning sense, and throat irritation.1153 In
conclusion, topical corticosteroid can be used as preop-
erative treatment for better surgical field. In case of oral
corticosteroid, there is no study to evaluate its efficacy as
a preoperative agent for CRSsNP. Therefore, there is not
enough benefit to outweigh the known risks (Table X-6).
 Aggregate Grade of Evidence: C (Level 1b: 1 study, Level
5: 1 study).
 Benefit: Objective improvement in surgical field, objec-
tive decrease in intraoperative bleeding, and objective
decrease in operation time seen with INCS. Subjective
improvement in surgical difficulty.
 Harm: Possible side effects of topical or systemic corti-
costeroids are known.
 Cost: Low.
 Benefit-Harm Assessment: Preponderance of benefit over
harm in INCS. Unknown for oral corticosteroids.
 Value Judgment: Improvement in surgical field (less
bleeding) is important.
 Policy level: Recommendation for INCS. No recommen-
dation in oral corticosteroids.
 Intervention: INCS are recommended in the preoperative
management of CRSsNP.
X.C.2. CRSsNP: Preoperative Oral Antibiotics
No studies were identified addressing the preoperative
use of systemic antibiotic treatment. Several studies did
describe short-term antibiotic use in CRSsNP patients.
Short-term (9 to 14 days) use of antibiotics improved
clinical symptoms such as nasal discharge and nasal block-
age, and there was no difference in the clinical efficacy of
several kinds of antibiotics.737–739 Although there has been
no trial directly investigating preoperative antibiotics and
intraoperative condition, patient-reported symptoms have
been shown to be correlated with intraoperative bleeding
and longer surgery time.1155 Therefore, preoperative oral
antibiotics may be beneficial in patients presenting with
acute exacerbation of symptom and purulent discharge on
endoscopic examination. Oral antibiotics are relatively safe
with very few side effects; however, like any medication,
adverse effects related to oral antibiotics may occur. Skin
rashes, drug fever, and gastrointestinal troubles such
as abdominal pain, diarrhea, and nausea/vomiting may
occur. In rare cases, patients may experience more serious
side effects, such as renal toxicity or liver toxicity.1156 In
conclusion, short-term, culture-directed, oral antibiotic
treatment for acute exacerbations of CRSsNP may be
beneficial before surgery. Because no studies examine this
issue directly, no recommendations are given.
 Aggregate Grade of Evidence: not applicable.
X.C.3. CRSwNP: Preoperative Corticosteroids
There have been many clinical trials about the effect
of corticosteroids on CRSwNP, but only a few of these
studies have tried to elucidate the role of corticosteroid
treatment as a preoperative measure in CRSwNP patients
(Table X-7). As described above in “CRSsNP: Preoperative
Corticosteroids,” there were 2 studies of preoperative
corticosteroid use in both CRSsNP and CRSwNP.65,1150 In
addition, Wright and Agrawal65 performed a randomized,
placebo-controlled trial comparing 26 patients randomly
assigned to receive 30 mg of oral prednisone or placebo
for 5 days, preoperatively. The results demonstrated a sig-
nificantly higher percentage of severely inflamed mucosa in
the placebo group, which was associated with a technically
more difficult surgery. Sieskiewicz et al.1149 reported their
open-label controlled trial in which 36 CRSwNP patients
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TABLE X-6. Evidence for preoperative corticosteroid administration in CRSsNP
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Albu1150 2010 1b Individual RCT CRSsNP and CRSwNP treated
with 4-week course of
mometasone furoate
Intraoperative
blood loss and
operation time
Statistically significant reduction
in blood loss and operation
time
Gonzalez-Castro1154 2013 5 Survey, expert
opinion
Only 26.17% of respondents
prescribed corticosteroid
TABLE X-7. Evidence for preoperative corticosteroid administration in CRSwNP
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Albu1150 2010 1b Individual RCT CRSsNP and CRSwNP treated with
4-weeks of mometasone
furoate
Intraoperative
blood loss and
operation time
Statistically significant reduction
in blood loss and operation time
Wright65 2007 1b Individual RCT CRSwNP treated with 5-day
course of
30 mg oral prednisone
Mucosal status
and difficulty
during surgery
Statistically significant
improvement in mucosal status
and surgical difficulty
Atighechi1157 2013 2b Individual
open-label
controlled trial
CRSwNP treated with 5-day
course or single dose of
systemic corticosteroid
Surgical field
quality
Better surgical field following
treatment
Sieskiewicz1149 2006 2b Individual
open-label
controlled trial
CRSwNP treated with 5 days of
30 mg oral prednisone
Blood loss and
condition of
surgical field
Statistically significant reduction
in blood loss
Grzegorzek1155 2014 4 Case series Treatment with systemic or topical
corticosteroid
Intraoperative
blood loss
INCS use was associated with
increased blood loss during
surgery
Gonzalez-Castro1154 2013 5 Survey, expert
opinion
96.64% of respondents
prescribed oral corticosteroids
were assigned to 30 mg of oral prednisone or no treatment.
Although total blood loss was only slightly less in the
corticosteroid-treated group, the visual condition of the
surgical field improved significantly. In a national survey
on the use of preoperative systemic corticosteroids in
ESS, 96.64% of respondents prescribed them in CRSwNP
patients.1154 In conclusion, preoperative treatment with
topical or oral corticosteroids is recommended to ensure
better intraoperative conditions in the absence of comor-
bidities that are aggravated with systemic corticosteroids.
 Aggregate Grade of Evidence: B (Level 1b: 2 studies;
Level 2b: 2 studies; Level 4: 1 study; Level 5: 1 study); 1
study shows contradicting results.
 Benefit: Objective improvement in surgical field, decrease
in intraoperative bleeding, and decrease in operation
time. Subjective improvement in surgical difficulty.
 Harm: No specific reports about side effect as preoper-
ative treatment, but possible risks of corticosteroids are
known.
 Cost: Low.
 Benefit-Harm Assessment: Preponderance of benefit over
harm.
 Value Judgment: Improvement in surgical field is impor-
tant. There is no evidence-based agreement on dosage
and duration. In case of oral corticosteroids, medium
dose (30 to 40 mg) for 4 to 7 days is the most commonly
prescribed regimen. Other techniques (eg, use of con-
centrated epinephrine) may be used to diminish bleeding
intraoperatively.
 Policy Level: Recommendation.
 Intervention: Recommendation for the use of oral and
topical corticosteroids in the preoperative management
of CRSwNP.
X.C.4. CRSwNP: Preoperative Oral Antibiotics
As with preoperative antibiotics in CRSsNP patients, no
studies regarding preoperative antibiotic use before ESS in
CRSwNP patients were identified. No recommendation is
therefore given.
 Aggregate Grade of Evidence: not applicable.
X.D. Surgery for CRSwNP and CRSsNP: Surgical
Principles
X.D.1. Surgical Principles/Techinques: Extent of
Surgery
Since the introduction of endoscopic techniques for the
surgical treatment of CRS in the 1980s, the goal of ESS
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has been to reestablish ventilation and drainage of the
paranasal sinuses through enlargement of the natural
ostia.1158 Conventional ESS involves opening of the OMC
with enlargement of the maxillary sinus otium1159 as well
as concurrent clearance of disease in the anterior and/or
posterior ethmoid cells to provide secondary drainage
of obstructed frontal and/or sphenoid sinuses. Direct en-
largement of frontal and sphenoid ostia are performed as
needed.
Modifications of conventional ESS techniques have been
described to match the extent and location of a patient’s
sinus disease, including minimally invasive sinus technique
(MIST) and balloon dilation of the sinuses. MIST is based
on the premise that transition spaces, not the natural
ostia, serve as bottlenecks for obstruction in the setting
of CRS. It is proposed that sinus surgery should address
the clearance of these transition spaces, rather than the
enlargement of sinus ostia. MIST addresses the ethmoid
infundibulum as the transition space where maxillary sinus
outflow obstruction occurs. Like conventional ESS, MIST
involves removal of the uncinate process in order to open
the infundibulum and expose the maxillary ostium, but
MIST does not include direct enlargement of the natural
ostium itself.1160 The contrasts between conventional
ESS and more conservative approaches, such as MIST,
have been studied in patients with chronic maxillary
sinusitis, and these findings have been interpreted to
generally translate to the other paranasal sinuses as
well.1160–1163
MIST and traditional maxillary antrostomy each have
their own set of potential advantages and disadvantages.
Because MIST involves less manipulation of mucosa and
bone, the likelihood for postoperative scar formation in
the region of the maxillary ostium may be reduced. On
the other hand, maxillary antrostomy not only eradicates
disease in the infundibulum, but also provides direct en-
largement of the natural maxillary sinus ostium. This latter
step may be beneficial in cases of more severe inflammatory
disease with ostial stenosis or anatomic variants, such as
an infraorbital ethmoid (Haller) cell. Ostial enlargement
may also be advantageous when the surgeon wishes
to clear disease within the maxillary sinus, such as in
AFRS.
Limited evidence in an animal model suggests that the
creation of an antrostomy that is too large may be lead
to detrimental effects such as osteitis and diminished
MCC.1161 On the other hand, clinical studies have shown
that a mega-antrostomy for recalcitrant chronic maxillary
sinusitis is effective in reducing sinonasal symptoma-
tology, objective endoscopic and radiographic evidence
of CRS, and corticosteroid and antibiotic use.1162,1163
Enlargement of the maxillary ostium may also be as-
sociated with decreased NO levels in the maxillary
sinus,1164 but the clinical impact of this decrease remains
unknown.
The primary concerns regardingMIST are whether it will
provide adequate ventilation of diseased sinuses and the
same clinical outcomes as traditional ESS. These issues have
been studied with respect to the maxillary sinus. Previous
work, utilizing xenon ventilation in a cadaveric sheep’s
head model,1165 has reported no significant difference in
maxillary sinus ventilation for sinuses that underwent
small antrostomies (approximated as 2 to 3 times the
natural ostium size) or large antrostomies (approximated
as 6 times the natural ostium size). Although it is unclear
whether this finding extends to simple removal of the unci-
nate process without enlargement of the maxillary ostium,
these results do suggest diminishing returns from the stand-
point of ventilation with increasing maxillary antrostomy
size.
Cohort studies of CRS patients undergoing MIST have
demonstrated postoperative improvements in sinonasal
symptoms.1166,1167 In 1 prospectively studied cohort,
78.8% of CRS patients (including those with and without
NPs) who underwent MIST maintained improvement
in their baseline CSS scores 2 years after surgery. Only
5.9% of patients required revision MIST during that same
period.1166 Postoperative improvement in sinonasal symp-
toms were found to be greater in patients who underwent
concomitant nasal polypectomy at time of MIST,1167
calling into question the extent that MIST-specific si-
nus ventilation contributed to the observed clinical
improvement.
Two RCTs have been reported with patients undergoing
a MIST procedure on 1 randomly-chosen side and tradi-
tional ESS, including maxillary antrostomy, performed on
the other.1168,1169 Nine months after surgery no significant
difference in radiographic LM score was detected between
the MIST or ESS sides,1168 although maxillary sinuses with
smaller postoperative ostia were associated with maxillary
sinus opacity or OMC obstruction.1168 Additionally,
there was greater endoscopic evidence of maxillary sinus
obstruction in the MIST group at 3 months, but not at 6,
9, or 12 months after surgery.1169 In another prospective
trial, patients with chronic maxillary RS were randomized
to receive either a small maxillary antrostomy, with mean
diameter of 6 mm, or a large maxillary antrostomy, with
mean diameter of 16 mm.1170 The creation of a small or
large maxillary antrostomy was not found to be associated
with symptomatic improvement in facial pain, nasal
obstruction, or rhinorrhea.1170
The necessary extent of ESS has also been addressed
through a recent study of balloon dilation for RS.1132 In
this prospective randomized trial, patients with chronic
maxillary sinusitis with or without concomitant anterior
ethmoid sinus disease who failed medical therapy received
either in-office balloon dilation of the maxillary sinus
ostium or ESS. For patients who had anterior ethmoid
disease, no further procedural intervention was performed
in the balloon dilation group, whereas concurrent eth-
moidectomy was performed in the sinus surgery group. At
1 year, no statistically significant differences were found
between the 2 cohorts with respect to study endpoints,
which included SNOT-20 scoring, maxillary ostium
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patency based on CT scan, reduction in RS episodes, and
improvement in work productivity and daily activity. The
applicability of this study’s results are limited, however,
because of the (1) exclusion of patients with posterior
ethmoid, frontal, or sphenoid sinus disease, and (2)
exclusion of patients needing other sinonasal procedures
such as septoplasty for deviated septum. The additional
expense of new technology must also be considered
with the utilization of balloon technology for treatment
of CRS.1171
As delivery of topical medications has become an increas-
ingly important treatment modality in the management of
CRS, the impact of sinus surgery to enhance such delivery
must be considered. Postoperative distribution of topical
medications to the paranasal sinuses may be limited by
utilization of more conservative ESS techniques, such as
MIST or balloon dilation. Studies have suggested that
maxillary antrum size correlates with airflow rates into
the maxillary sinuses,1172 as well as intrasinus delivery of
topical medications.1173 Recent evidence suggests that un-
operated sinuses receive little topical therapy compared to
sinuses which have been surgically opened. More extensive
enlargement could, in fact, result in increased distribution
of topical medications in general.812 These findings have
been summarized in an extensive EBRR, which suggests
that sinus surgery may be an effective means to increase
delivery of topical medications to the paranasal sinuses.806
Currently available data suggest that MIST may be
reasonable for some CRS patients, particularly those with
limited disease burden. The current evidence supports
the use of balloon dilation for patients with minimal
and focal sinus disease. Because of the lack of long-term
outcomes data and the potential for greater risk of sinus
(e.g. maxillary sinus) obstruction, which may lead to either
recurrent sinus disease or poor penetration of topical
medications, current evidence does not support the routine
application of limited techniques, such as MIST or balloon
sinus dilation, for all CRS patients (Table X-8).
 Aggregate Grade of Evidence: C (Level 1b, 3 studies;
Level 2b, 3 studies; Level 5, 1 study).
 Benefit: Although no studies have demonstrated a direct
benefit of more conservative (less extensive) surgical ap-
proaches for treatment of CRS compared to traditional
ESS, reducedmanipulation of sinonasal tissues with these
limited approaches, including MIST or balloon dilation,
has the potential to reduced postoperative scar formation
and surgical time.
 Harm: Potential harm of more conservative techniques
includes insufficient removal of obstructing sinonasal
disease, leading to persistent inflammation, faster relapse
of symptoms, and reduced delivery of topical medica-
tions.
 Cost: Although no studies have examined the issue of
cost related to modified-ESS techniques, shorter opera-
tive time could translate to lower costs in some circum-
stances. In contrast, balloon-dilation technology is asso-
ciated with increased equipment costs per case, which
needs to be considered in an environment of limited
healthcare resources.
 Benefits-Harm Assessment: Over the short term (up to
1 year postoperatively), conservative approaches do not
appear to increase harm from recurrence of inflamma-
tory sinus disease, particularly in patients with limited
sinus disease.
 Value Judgments: Conservative approaches (MIST or
balloon dilation) appear to provide short-term clinical
outcomes that are comparable to traditional ESS in pa-
tients with limited disease. For patients with moderate-
to-severe CRS, traditional ESS has the potential for
improved long-term sinus ventilation and delivery of
topical medications. There is no significant argument
for or against the use of less extensive sinus pro-
cedures. All studies to date have suggested equiva-
lent short-term outcomes as compared to traditional
large-hole technique in patients with minimal sinus
disease.
 Policy Level: Option.
 Intervention: Less extensive sinus interventions are likely
reasonable options in patients with minimal OMC or
maxillary sinus disease.
X.D.2. Surgical Principles/Techniques:
Concurrent Septoplasty
Rhinologic surgeons may perform septoplasty as an
adjunctive procedure in patients who are undergoing
ESS. The septal procedure may be performed to provide
access to the paranasal sinuses, or to address severe
nasal obstruction due to NSD. Because the 2 proce-
dures are often performed together, it may difficult to
separate the benefits of 1 procedure from the other.
Similarly, although some risks are clearly related to the
septoplasty (eg, septal perforation), attributing other
outcomes, such as postoperative pain or epistaxis, may be
problematic.
Descriptions of conventional septoplasty (CS) performed
in conjunction with ESS are sparse, although the procedure
combination seems quite common. Cantrell described the
technique and rationale for “limited” septoplasty, presum-
ably performed with traditional headlight illumination.1174
Most authors describe techniques for endoscopic septo-
plasty (ES) and report limited outcomes data in these case
series.1175–1178 Giles et al.1179 compared cohorts of patients
undergoing ESS alone, ESS and CS, and ESS and ES and
noted good outcomes in the ESS/ES group. Bothra and
Mathur1180 performed a similar comparison of ES and
CS in patients undergoing ESS and noted no differences
between groups.
In a prospective, multi-institutional study, Rudmik
et al.1181 compared ESS with septoplasty to ESS without
septoplasty, and noted no differences in various QoL
measures for CRS. Based upon these data, the authors
concluded that patients undergoing concurrent septoplasty
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TABLE X-8. Evidence for extent of surgery in CRSsNP and CRSwNP
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Bikhazi1132 2014 1b RCT Patients with chronic maxillary
sinusitis (with or without
chronic anterior ethmoid
sinusitis) that have failed
medical therapy who
received: 1. In-office
maxillary sinus balloon
dilation; 2. Maxillary
antrostomy with or without
anterior ethmoidectomy
At 1 year after the
intervention: 1. Change
in SNOT-20; 2.
Maxillary sinus ostium
patency by CT scan; 3.
RS episode frequency;
4. Change in Work
Productivity and Activity
Impairment survey
scores
Improvement in SNOT-20 and
subset scores, Work
Productivity and Activity
Impairment survey scores,
and RS episode frequency
in both cohorts. No
statistically significant
difference in outcomes
between the 2 groups
Myller1168 2011 1b RCT CRSsNP patients in whom: 1.
Wide maxillary antrostomy
was performed on 1 side
(2× natural ostium size);
and 2. Uncinectomy alone
was performed on the other
side
1. Postoperative CT scan
findings at 9 months; 2.
Postoperative maxillary
sinus ostium
cross-sectional area
Improvement in overall
ipsilateral LM for both
surgical treatments. No
difference in postoperative
overall ipsilateral LM score
between surgical
treatments
Wadwongtham1169 2003 1b DBRCT In patients with bilateral and
symmetric CRSwNP: 1.
Wide maxillary antrostomy
was performed on one side;
and 2. Uncinectomy alone
was performed on the other
side
Maxillary sinus ostium
obstruction at 3, 6, 9,
and 12 months
Less maxillary sinus
obstruction in the large
antrostomy group
compared to the
uncinectomy group at 3
months but not at 6, 9, or
12 months after surgery
Salama1167 2009 2b Prospective cohort
study
A consecutive series of
patients presenting with
CRS and undergoing
uncinectomy but not
antrostomy to address the
maxillary sinuses
1. Symptoms (VAS); 2. QoL
assessments at 1 and 3
years after surgery
Reduction in sinonasal
symptoms after MIST, more
pronounced in patients with
NPs. QoL after surgery was
sustained 3 years
postoperatively
Albu1170 2004 2b RCT (nonvalidated
means of
measuring
symptoms and
45% follow-up)
Surgical CRS patients who
underwent: 1. Small
maxillary antrostomy (mean
diameter 6 mm); 2. Large
maxillary antrostomy (mean
diameter 16 mm)
Patient-reported change in
symptoms of
obstruction, facial pain,
and rhinorrhea
Maxillary antrostomy size is
not associated with
postoperative changes in
patients’ symptoms of
obstruction, facial pain, and
rhinorrhea
Catalano1166 2003 2b Prospective cohort
study
Patients undergoing minimally
invasive sinus surgery for
CRS
1. CSS; 2. Need for
revision surgery
Postoperative CSS scores
were improved: 78.8% of
patients had improved CSS
score; 5.9% of patients
required revision MIST
Setliff1160 1996 5 Expert opinion Patients undergoing
uncinectomy but not
antrostomy to address the
maxillary sinuses
Surgical revision rate: 1.
To address the
maxillary sinus; 2.
Overall
Maxillary revision rate was
0.3%. Overall revision rate
was 7%
MIST = minimally invasive sinus technique.
should not be excluded from studies evaluating the impact
of ESS on CRS.1181
In a large retrospective case series, Chang et al.1182
compared ESS with septoplasty and ESS without septo-
plasty and noted a lower revision rate in patients who
underwent both procedures. This is the only study that
demonstrates a clear benefit of performing septoplasty
and ESS concurrently, but this conclusion is limited by the
retrospective study design1182 (Table X-9).
 Aggregate Level of Evidence: D (Level 2a: 1 study; Level
4: 8 studies; Level 5: 1 study).
 Benefit : Reduction in nasal obstruction, improved access
for ESS.
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TABLE X-9. Evidence for concurrent septoplasty with ESS in CRSsNP and CRSwNP
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Rudmik1181 2011 2a Prospective,
multi-
institutional
cohort study
ESS with septoplasty (n = 108);
ESS without septoplasty
(n = 113)
1. Rhinosinusitis
Disability Index; 2.
Chronic Sinusitis
Survey
No statistically significant
differences between groups
Chang1182 2014 4 Case series ESS with septoplasty (n = 876);
ESS without septoplasty
(n = 3608)
Need for revision
surgery
ESS with septoplasty
associated with a lower
revision rate
Bothra1180 2009 4 Case series ESS with CS (n = 40); ESS with
ES (n = 40)
1. Symptoms; 2.
Physical
examination; 3.
Complications
No statistically significant
differences between groups
Chung1176 2007 4 Case series ESS with ES (n = 96); ES alone
(n = 20)
1. Symptoms; 2.
Physical
examination; 3.
Complications
ES is an alternative to CS,
especially in patients
undergoing ESS
Su1178 2004 4 Case series ESS with ES (n = 81); ESS alone
(n = 152)
1. Symptoms; 2.
Complications
No statistically significant
differences between groups
Castelnuovo1177 1999 4 Case series ESS with CS (n = 89); ESS with
ES (n = 155); Rhinoplasty
with ES (n = 15)
Complications ES facilitates less extensive
manipulation of the septal
framework
Hwang1175 1999 4 Case series ESS with ES (n = 108); ES alone
(n = 3)
1. Physical
examination; 2.
Complications
ES is an adjunctive procedure
Giles1179 1994 4 Case series ESS without septoplasty
(n = 496); ESS with CS (n =
144); ESS with ES(n = 38)
1. Symptoms; 2.
Physical
examination
Good healing and no
obstruction in the
endoscopic septoplasty
group
Cantrell1174 1997 5 Report of
technique
ESS with “limited” septoplasty
(n = 100)
Not specified “Limited” septoplasty may be
performed with ESS
CS = conventional septoplasty; ES = endoscopic septoplasty.
 Harm: Bleeding, postoperative discomfort/pain, septal
hematoma, septal perforation, persistent obstruction, in-
tranasal scarring.
 Cost: Cost is related to increased operative time when
septoplasty is added to ESS.
 Benefit-Harm Assessment: Preponderance of benefit over
harm.
 Value Judgment: Septoplasty may be required during ESS
for surgical access. Patients with NSD and CRS may
experience reduced nasal obstruction when septoplasty
is performed at the time of ESS. Correcting an NSD has
an unknown impact on sinus disease.
 Policy Level: Option in patients with NSD undergoing
ESS.
 Intervention: Septoplasty (either ES or CS) is an option
to be performed at the time of ESS. Because the impact
on sinus inflammation is unknown, the decision to per-
form a septoplasty should be determined by anticipated
reduction in nasal obstruction or the need to access the
sinuses for ESS.
X.D.3. Surgical Principles/Techniques- MT
Preservation or Resection
Whether to routinely preserve or resect the MT during
sinus surgery has been a topic of debate for decades. Propo-
nents of preservation point to the MT’s role in sensation of
airflow, direction of airflow, humidification, and olfaction.
Risk of CSF leak and frontal sinus obstruction from a
lateralized MT stump as well as the loss of a landmark
for future revision surgery are also given as reasons for
preservation. Advocates for resection cite better access
during surgery, with better maxillary ostial patency and
reduced incidence of synechiae postoperatively.
These various arguments have been examined in the
literature over the last 2 decades and have shown limited
effects of both preservation and resection.
QoL. Two prospective nonrandomized cohorts have
used validated outcome metrics to compare QoL after
MT resection and preservation. Byun and Lee1183 studied
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CRSwNP patients and found no difference in SNOT-20
scores or symptoms using a VAS. Soler et al.1184 found
that although MT resection was associated with improved
endoscopy scores vs MT preservation, there was no
difference in RSDI, CSS, and SF-36 scores in CRS patients
with or without NP. Importantly, in both nonrandom-
ized cohorts, MT resection was associated with greater
disease burden preoperatively, assessed by endoscopy,
CT, olfaction testing, and symptom surveys. As a result,
it is difficult to fully assess the possible benefit of MT
resection.
Postoperative Frontal Sinusitis. Five studies looked at
this issue from different perspectives and came to varying
conclusions. In 1995, Swanson et al.1185 studied patients
presenting to a tertiary rhinologic practice with continued
CRS following previous surgery. They found a higher risk
of frontal sinusitis if the MT had been previously resected.
In their sample of 110 patients, 75% of MT resection sides
had frontal sinusitis compared to 45% of MT preservation
sides. Subsequent studies examined this issue in samples
of patients undergoing MT resection and found a 10% to
18% rate of frontal sinusitis.1186,1187 Two other studies
compared MT resection to preservation and found no
difference in the rate of frontal sinusitis, although both had
rather small sample sizes.1188,1189 These results cast doubt
on MT resection’s significance as a risk for postoperative
frontal sinusitis.
Recurrence of Nasal Polyps. Four studies have ex-
amined the effect of MT resection on recurrence of nasal
polyposis. Brescia et al.1190 found MT preservation to be
associated with lower endoscopy scores 12 months after
ESS. The authors reported, however, that the study was
too small (n = 48) to confidently conclude a true effect
and called for a larger study. Shortly thereafter Marchioni
et al.1191 found a trend toward a beneficial effect of MT
resection in their prospective cohort of 56 patients with
CRSwNP, though the effect was not statistically significant
in this small sample (p = 0.0589). Subsequently, Wu
et al.1192 retrospectively reviewed 299 CRSwNP patients
who underwent ESS and found that those who had MT re-
section had a longer median time to recurrence of NPs (4.56
vs 3.93 years, p = 0.048). Interestingly the beneficial effect
disappeared after 8 years. In a nonrandomized prospective
study, Byun and Lee1183 found MT preservation patients
to have better endoscopy scores at 12 months postoper-
atively. They noted, however, that MT resection patients
had a greater burden of disease preoperatively, based on
endoscopy, CT, and VAS assessment of symptoms. MT
resection appears to have a limited beneficial effect in
CRSwNP patients. This advantage may be due to better
topical medication access; future studies will need to exam-
ine the impact of corticosteroid irrigations following MT
resection.
Olfaction. Four studies have examined the effect of MT
resection on postoperative olfaction. Two prospective
cohort studies using objective testing have shown no
effect.1193,1194 Two additional studies have shown a ben-
eficial effect on olfaction following MT resection.1184,1195
Based on these studies, it appears the concern that MT
resection reduces olfactory ability is unwarranted, and
partial MT resection may in fact be associated with
improved olfactory outcomes.
Maxillary Ostial Stenosis. MT resection has been
studied as a method of preserving antrostomy patency
following ESS. One RCT, 1 prospective nonrandomized co-
hort study, and 1 retrospective analysis have all shown no
effect on maxillary patency.1188,1196,1197 One retrospective
study in 1992 initially found no effect, but when synechiae
that might lead to maxillary stenosis were included, there
was a positive effect for MT resection.1198 It appears from
these data that MT resection has no significant effect on
middle meatal antrostomy patency following ESS.
MT Synechiae. Two retrospective reviews from 1995
reviewed the effect of MT resection on synechiae formation
between the MT and the lateral nasal wall.1199,1200 Both
found no effect.
Loss of a Landmark for Revision Surgery. One
retrospective review in 1992 examined this issue and found
that MT resection is associated with an increased risk of
CSF leak, nasolacrimal duct stenosis, lamina papyracea
injury, and orbital hematoma.1201
Atrophic Rhinitis. One study has examined this issue
in 1106 matched patients with and without MT resection
and found that none of the 509 patients who underwent
MT resection had postoperative atrophic rhinitis.1202
The authors did note, however, that the median length
of follow-up was 4.2 years and may be too short to
definitively rule out this risk.
Summary. Rigid adherence to MT preservation or
routine MT resection is not supported by the cumulative
evidence. Even staunch preservationists must acknowl-
edge the role of conservative and/or partial resection in
cases of a concha bullosa, paradoxical curvature of the
MT, extremely narrow nasal cavity, or extensive polyp
involvement of the MT. On the other hand, routine MT
resection without consideration of alternatives, such as
complete uncinectomy and MT suture medialization to
prevent synechiae, must also be discouraged. At present,
management of the MT requires a thoughtful approach
with considerations of all potential risks, benefits, and
alternatives (Table X-9).
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 Aggregate Grade of Evidence: C (Level 1b: 2 studies;
Level 2b: 6 studies; Level 3b: 1 study; Level 4: 11 studies).
 Benefit: Lengthening of time to recurrence of NPs, pos-
sible improvement in olfaction, improved endoscopy
scores.
 Harm: Loss of landmark for revision surgery, leading to
increased risk of intraoperative complications.
 Cost: No additional cost beyond those associated with
ESS.
 Benefits-Harm Assessment: Most of the potential risks
and benefits postulated for MT resection are not sup-
ported in the literature.
 Value Judgments: MT resection may improve access to
the ethmoid cavity during ESS. Thoughtful consideration
must be given alternatives to removing a non-diseased
structure to improve access. The vast majority of the
literature purported to support both MT resection and
MT preservation is low level and most shows no effect.
 Policy Level: Option.
 Intervention:MT resectionmay be employed during ESS,
especially in cases of CRSwNP.
X.D.4. Surgical Principles/Techniques: Image
Guidance
Image-guided surgery (IGS) technology has found support
among sinus surgeons seeking to improve clinical out-
comes. In addition to preoperative imaging review, IGS
incorporates surgical navigation, which permits surgeons
intraoperatively to localize specific points in the operating
field against preoperative imaging data sets.1203 Since
2002, the AAO-HNS’s position statement on IGS has
emphasized the technology for complex procedures of the
paranasal sinuses and skull base, at the discretion of the
operating surgeon.1204
It must be remembered that the use of IGS is often
associated with more extensive surgery, presumably due
to the benefits of using the technology.1205,1206 Both in
practice and in published reports, ESS cases performed with
IGS tend to be more complex than those cases performed
without IGS; thus, a bias exists when interpreting some of
the literature on the use of IGS and its benefits.
IGS does seem to increase operative time.1205,1207–1210
This increase may reflect the time for IGS setup. Alterna-
tively, case selection bias may adversely influence operative
time. In contrast, IGS does not seem to be associated with
increased intraoperative blood loss.1206,1207
Numerous publications include complication rates. In
a comparison of 400 patients whose ESS was performed
with IGS and a historical cohort of patients in whom IGS
was not employed, Reardon1205 showed comparable com-
plication rates, despite more extensive surgery in the IGS
patients. Fried et al.1206 were able to associate a reduced
complication rate with the use of IGS through a comparison
of a patient cohort of ESS cases performed with ESS and
historical controls; of note, the IGS patients had greater
surgical complexity. A more recent publication also asso-
ciated reduced rate of complications with IGS.1209 Most
authors have not detected differences in complications with
IGS.1211,1212 A 2013 systematic review, by Ramakrishan
et al.1212 concluded that the peer-reviewed literature does
not support conclusions that IGS reduces complications
and improves clinical outcomes. These authors recommend
IGS as an option, because the consensus of practicing sur-
geons and expert opinion confirm the utility and acceptance
of IGS technology. Smith et al.1213 have estimated that
such a study designed to detect differences in complication
rates would require as many 35,000 enrolled patients.
Dalgorf et al.,1214 in an extensive meta-analysis, concluded
that IGS is indeed associated with fewer complications.
Although improvements in clinical outcomes associated
with the use of IGS have been difficult to confirm, Javer and
Genoway1215 were able to show improvedRSOM-31 scores
in patients whose ESS was performed with IGS. Masterson
et al.1216 found a reduction in revision surgery among
patients whose ESS was performed with IGS. Other studies
have not demonstrated similar benefits of IGS.1217–1220
Strauss et al.1221 proposed a novel strategy for assessing
the impact of IGS on surgical decision-making. In this
clinical series, IGS was associated with changes in surgical
technique and strategy, even for experienced surgeons.
Presumably, the information provided by IGS, as captured
in this study, translates to more complete/effective surgery
and greater operative efficiency.
IGS has also been combined with intraoperative
fluoroscopy,1222 CT-MR fusion,1223,1224 and 3D CT
angiography.1225 These reports emphasize technical fea-
sibility of these adaptations and explore potential clinical
applications. Furthermore, IGS also has specific uses for
skull-base surgery,1226 pediatric ESS,1227,1228 trephination
procedures, 1229 orbital surgery,1219 and osteoplastic
frontal sinus surgery.1230
Surgeon surveys suggest greater availability of IGS
technology in ENT operating rooms and confirm that most
surgeons are comfortable with the technology, especially
for more advanced sinus cases. 1231–1233 These data are
consistent with the theme of surgeon acceptance of IGS.
IGS technology entails incremental costs. One study has
proposed that IGS may reduce the overall cost of care, by
reducing the need for revision surgery.1216 From amedicole-
gal perspective, IGS has not been implicated as a factor in
litigation for ESS-related complications1234 (Table X-11).
 Aggregate Grade of Evidence: D (Level 2a: 1 study; Level
3b: 6 studies; Level 4: 33 studies; Table X-11).
 Benefit: Potential for reduction of complications and
more complete surgery.
 Harm: None identified.
 Cost: Moderate. Cost is due to additional equipment,
time for setup.
 Benefits-Harm Assessment: Benefits outweigh risks, po-
tentially outweigh costs.
 Value Judgments: Benefit is likely achieved in more dif-
ficult cases, with a higher risk of complication. Achieve-
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TABLE X-10. Evidence for middle turbinate resection with ESS in CRSsNP and CRSwNP
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Gulati1196 2010 1b RCT (n = 40) CRS patients undergoing
MMA: 1. MT resection;
2. MT preservation
Subjective symptoms
and endoscopy
Patients undergoing MT resection with
MMA were more likely to have
improvement in nasal obstruction
Havas1202 2000 1b RCT (n = 1106) Patients undergoing ESS:
1. MT resection; 2. MT
preservation
Atrophic rhinitis,
synechia, and need
for revision surgery
MT resection was associated with less
synechia and need for revision surgery.
Patients with MT resection had no
atrophic rhinitis after a mean of 4.2
years
Byun1183 2012 2b Prospective
nonrandomized
cohort (n = 187)
CRSwNP patients
undergoing ESS: 1. MT
resection; 2. MT
preservation
Endoscopy, QoL
(SNOT-20 and VAS)
MT preservation group had better
endoscopy outcomes. QoL
improvement did not differ between
groups. Greater burden of disease in
MT resection group based on
preoperative endoscopy, CT imaging,
and VAS
Albu1197 2010 2b Prospective
nonrandomized
cohort (n = 411)
Patients with chronic
maxillary RS
undergoing ESS: 1. MT
resection; 2. MT
preservation
Recurrence of RS Partial MT resection did not alter the risk
of recurrence
Soler1184 2010 2b Prospective
nonrandomized
cohort (n = 242)
CRS patients undergoing
ESS: 1. Bilateral MT
resection; 2. Bilateral
MT preservation
Olfaction, endoscopy,
and QoL (RSDI, CSS,
SF-36)
Patients with bilateral MT resection were
more likely to have asthma, AERD,
CRSwNP, and prior sinus surgery. No
differences in QoL improvement were
seen between the 2 groups
postoperatively
Federspil1193 2008 2b Prospective
nonrandomized
cohort (n = 52)
CRSwNP patients
undergoing ESS: 1. MT
resection; 2. MT
preservation
Olfaction (Sniffin’ Sticks) Partial resection of the MT had no effect
on olfactory threshold, discrimination
and identification
Marchioni1191 2008 2b Prospective
nonrandomized
cohort (n = 56)
CRSwNP patients
undergoing ESS: 1. MT
resection; 2. MT
preservation
Time to recurrence of
NPs
Trend toward faster relapse in patients
with MT preservation (p = 0.0589)
Unlu1189 2006 2b Prospective
nonrandomized
cohort (n = 61)
CRS patients undergoing
ESS: 1. MT resection; 2.
MT preservation
Postoperative frontal
sinusitis (by CT)
MT resection had no effect on
development of frontal sinusitis
Friedman1194 1996 3b Prospective
case-control study
(n = 64)
CRS patients undergoing
ESS: 1. MT resection; 2.
MT preservation
Olfaction (SIT) No difference was seen in postoperative
olfaction between the 2 groups
Wu1192 2014 4 Retrospective review
(n = 299)
CRSwNP patients
undergoing ESS: 1. MT
resection; 2. MT
preservation
Time to revision surgery Patients who underwent MT resection had
a longer median time to revision
surgery. The beneficial effect of MT
resection dissipated by 8 years
postoperatively
Brescia1190 2008 4 Retrospective review
(n = 48)
CRSwNP patients
undergoing ESS: 1. MT
resection; 2. MT
preservation
Endoscopy and
rhinomanometry
Patients who had MT preservation had
better endoscopy results. Nasal airway
resistance did not differ between
groups
Giacchi1188 2000 4 Retrospective review
(n = 50)
CRS patients undergoing
ESS: 1. MT resection; 2.
MT preservation
MT lateralization,
synechiae, maxillary
ostial stenosis,
recurrent ethmoiditis,
frontal sinusitis
Greater burden of disease in MT resection
group based on preoperative CT
imaging. Higher risk of recurrent
ethmoiditis in sides with MT resection.
No difference in other outcomes
(Continued)
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TABLE X-10. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Fortune1186 1998 4 Retrospective review
(n = 115)
Patients with CRS
undergoing MT
resection
Frontal sinusitis after
surgery
Patients with MT resection had a 10%
rate of frontal sinusitis postoperatively
Saidi1187 1998 4 Retrospective review
(n = 33)
Patients with CRS
undergoing MT
resection
Frontal sinusitis after
surgery
Patients with MT resection had a 18%
rate of frontal sinusitis postoperatively
when not present preoperatively
Jankowski1195 1997 4 Retrospective review
(n = 78)
CRSwNP patients
undergoing surgery: 1.
Nasalization, including
MT resection; 2.
Ethmoidectomy, with
MT preservation
Olfaction (VAS) Patients who underwent nasalization,
including MT resection, had better
olfaction than patients who underwent
traditional ethmoidectomy, with MT
preservation
Kinsella1199 1995 4 Retrospective review
(n = 193)
CRS patients undergoing
ESS: 1. MT resection; 2.
MT preservation
Middle turbinate
synechiae
Patients who had MT resection had the
same rate of synechia formation as
those who had MT preservation
Ramadan1200 1995 4 Retrospective review
(n = 337)
CRS patients undergoing
ESS: 1. MT resection; 2.
MT preservation
Middle turbinate
synechiae
Patients who had MT resection had the
same rate of synechiae formation as
those who had MT preservation
Swanson1185 1995 4 Retrospective review
(n = 110)
CRS patients undergoing
ESS: 1. MT resection; 2.
MT preservation
Frontal sinusitis
following surgery
Patients who had MT resection had a
higher rate of frontal sinusitis
compared to MT preservation
LaMear1198 1992 4 Retrospective review
(n = 283)
CRS patients undergoing
ESS: 1. MT resection; 2.
MT preservation
Either closed antrostomy
or significant
synechia formation
Patients who underwent MT resection had
a higher antrostomy patency or less
synechia formation
Vleming1201 1992 4 Retrospective review
(n = 593)
Patients with CRS who had
previously had surgery:
1. MT resection; 2. MT
preservation
Complications during
surgery
CSF leak, nasolacrimal duct stenosis,
lamina papyracea injury, and orbital
hematoma were all more likely in
patients who had undergone previous
MT resection
SIT = Smell Identification Test.
ment of high levels of evidence are complicated by the
need for very large sample sizes and possible ethical is-
sues involving clinical equipoise.
 Policy Level: Option.
 Intervention: Image guidance is an option for ESS for
CRSsNP and CRSwNP.
X.D.5. Surgical Principles/Techniques: Use of
Packing
Absorbable and nonabsorbable materials are commonly
used to pack the sinus cavities in the perioperative period.
Proponents of their use suggest that they facilitate hemosta-
sis and improve wound healing, whereas opponents argue
that they increase patient discomfort and may increase
scarring. This area has been well studied in recent years,
with numerous well-performed RCTs.
Evidence exists to support the position that packing
for hemostasis is not essential for the vast majority of
sinus cases. 1268–1271 Three RCTs comparing packing to
no-packing reported no evidence of significant postop-
erative bleeding requiring intervention in their unpacked
arms.1268–1270 This is further supported by a large retro-
spective series by Orlandi and Lanza1271 of 165 patients
undergoing ESS. This study observed that only 11.2%
of patients required packing at the end of their sinus
procedure, with no reports of significant postoperative
bleeding in those left unpacked.
Intraoperative Hemostasis. Level 1 evidence now
exists to support the findings of earlier case series that
packing with absorbable biomaterials can help achieve
rapid hemostasis within the sinuses.1272–1275 Both Floseal R©
(Baxter Inc, Deerfield, IL), an absorbable matrix of
bovine-derived gelatin with human-derived thrombin,
and HemoStase R© (CryoLife Inc, Kennesaw, GA), a
purified plant polysaccharide, resulted in complete ces-
sation of intraoperative bleeding within 5 minutes of
application.1272,1273 Although Jameson et al.1274 reported
a slower mean time to hemostasis of 16.4 minutes in their
RCT using Floseal R©, hemostasis was still considerably
faster than no intervention. When compared to Merocel R©
(Medtronic ENT, Jacksonville, FL), a nonabsorbable,
highly porous polyvinyl acetyl sponge, Floseal R© did not
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TABLE X-11. Evidence for use of image guidance with ESS in CRSsNP and CRSwNP
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Dalgorf1214 2013 2a Meta-analysis 14 controlled cohorts
(including 1
randomized trial)
Complications IGS reduces major
complication rates
Tschopp1235 2008 3b Prospective
case series
ESS procedures: with
IGS (n = 62);
without IGS
(n = 62)
Extent of surgery;
indications for
surgery; patient
symptoms (VAS);
surgeon satisfaction
IGS is associated with few
complications, but overall
outcomes are similar with
and without IGS
Javer1236 2006 3b Prospective
case series
ESS procedures: with
IGS (n = 80);
without IGS
(n = 15)
RSOM-31 IGS usage associated with
greater improvement in
QoL after ESS
Woodworth1237 2005 3b Prospective
case series
15 ESS cases with IGS:
laser registration;
touch registration
Time for registration;
TRE
Both laser and touch
registration produce
similar TRE (0.3–0.4
mm), but laser
registration is faster
Raabe1238 2002 3b Prospective
case series
34 consecutive
patients
Calculated TRE Laser surface registration
TRE was 2.4 ± 1.7 mm
Metson1239 1999 3b Prospective
case series
121 patients
undergoing ESS: no
IGS (n = 42)
TRE; operative time;
EBL; costs;
complication rates
IGS is associated with
greater costs and
operative time
Fried1240 1997 3b Prospective
case series
(multicen-
ter)
55 patients
undergoing ESS
Technical description of
new technology;
calculated TRE;
surgeon satisfaction;
case descriptions
Autoregistration TRE was
2.28 ± 0.91 mm. IGS is
an important new
technology for ESS
Sunkaraneni1241 2013 4 Case series ESS procedures: with
IGS (n = 333);
without IGS
(n = 47)
Complication rates; need
for revision sinus
surgery
IGS is associated lower
recurrences in the early
postoperative period; IGS
does not appear to
reduce complication rates
Eloy1242 2013 4 Medicolegal
case review
30 malpractice cases;
4 mentioned IGS
Mentions of IGS in
malpractice
judgments
IGS is not a factor in ESS
litigation
Ramakrishnan1358 2013 4 Database
query
62,823 patients
undergoing ESS
Complication rates Major ESS complications
seem to be decreasing;
impact of IGS is unclear
Masterson1216 2012 4 Case series 132 patients
underwent 147 ESS
procedures for CRS
and tumors
Complication rates; need
for revision surgery;
economic simulation
of potential savings
IGS is safe and may reduce
need for revision surgery;
IGS may also reduce
overall costs
Mueller1211 2010 4 Case series ESS procedures: with
IGS (n = 108);
without IGS
(n = 168)
Complications, need for
revision surgery
IGS is not associated with
lower rates of
complications and
revision surgery
Al-Swiahb1209 2010 4 Case series ESS procedures: with
IGS (n = 30);
without IGS
(n = 30)
Operative time,
complications,
recurrence rates
IGS is associated with
greater operative time
and fewer complications
Parikh1243 2009 4 Case series 33 pediatric patients
undergoing ESS
with IGS
Indications;
complications;
surgeon satisfaction
IGS can be used in children,
especially for more
complex procedures
(Continued)
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TABLE X-11. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Crawley1244 2009 4 Case series ESS with IGS
procedures
performed by
residents (n = 102)
Operative times, EBL,
case complexity
Residents may safely
perform ESS with IGS
Benoit1245 2009 4 Case series Pediatric patients
undergoing sinus
surgery (n = 28)
and skull-base
surgery (n = 5)
Complications, surgeon
satisfaction, accuracy,
uses per procedure
IGS is safe and effective in
children; surgeon usage
and comfort increases
with experience
Dubin1246 2008 4 Case series 24 patients
undergoing
endoscopic orbital
decompression with
IGS (45 orbits)
Ophthalmological
outcomes; surgeon
satisfaction
IGS did not improve
ophthalmological
outcomes after surgery,
despite surgeon
acceptance
Brown1247 2007 4 Case series 14 consecutive
patients undergoing
ESS with
fluoroscopy-
enhanced
IGS
Feasibility; concept
validation
Real-time IGS with
fluoroscopy is feasible;
additional development is
warranted
Zacharek 1248 2006 4 Case series ESS with trephination
and IGS (n = 13)
Feasibility; concept
validation;
indications; surgeon
satisfaction
IGS may be used to guide
trephination placement
Tabaee1249 2006 4 Case series ESS procedures: with
IGS (n = 60);
without IGS
(n = 179)
Complications; need for
revision surgery;
SNOT-20
IGS is not associated with
lower complication rates
and improved QoL
measures
Strauss1221 2006 4 Case series ESS with IGS (n = 29);
other ENT
procedures with IGS
(n = 13)
Change of surgical
strategy; surgeon
satisfaction; TRE;
costs; operative time
IGS usage is associated with
a change of surgical
strategy, especially at
specific subsites
Stelter1250 2006 4 Case series ESS with IGS (n = 368) TRE; surgeon
satisfaction;
complications
Risks associated with
inaccurate IGS are
minimal
Leong1224 2006 4 Case series ESS with IGS and
CT-MR fusion
(n = 25)
Image-to-image TRE;
feasibility; surgeon
satisfaction
CT-MR fusion provides
hybrid images that may
be used during IGS for
complex procedures of
the skull base and
sinuses
Knott1251 2006 NA Simulation
laboratory
Comparison of
contour-based
registration and
paired-point
registration
TRE Distribution of points for
contour-based
registration influences
TRE
Tabaee1252 2005 4 Case series Endoscopic CSF leak
repair: with IGS
(n = 16); without
IGS (n = 8)
Surgeon satisfaction;
surgical success rates
IGS enhances surgeon’s
confidence, but data
supporting improved
outcomes is lacking
Orlandi1233 2006 4 Physician
survey
Survey of practicing
ENT surgeons
(n = 340)
IGS availability; surgeon
satisfaction;
indications
Most surgeons have access
to IGS; most surgeons
limit use to more complex
cases
(Continued)
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TABLE X-11. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Leong1225 2005 4 Case series Patients undergoing
ESS with IGS and
3D-CTA (n = 18)
Feasibility; indications;
surgeon satisfaction
IGS with 3D-CTA offers
advantages over
conventional IGS in more
complex cases
Chiu1253 2005 4 Case series 2 patients undergoing
endoscopic
skull-base surgery
with IGS enabled
with CT-MR fusion
Feasibility, surgeon’s
satisfaction
IGS with CT-MR fusion
offers advantages over
conventional IGS in more
complex cases
Von Buchwald1254 2005 4 Case series 42 patients
undergoing
endoscopic inverted
papilloma resection
with IGS
Recurrence rates,
complications
Endoscopic inverted
papilloma resection with
IGS is safe
Chiu1255 2004 4 Case series Revision endoscopic
frontal sinus
surgery with IGS
(n = 67)
Frontal recess patency;
complications
IGS is a valuable tool for
revision ESS
Rombaux1256 2003 4 Case series 32 patients
undergoing ESS
Clinical accuracy;
complications;
preparation time
IGS accuracy is adequate for
ESS
Rassekh1257 2003 4 Case series 22 procedures in 21
patients
TRE; completion of
setup; complications
IGS carries a learning curve
for surgeons
Metson1258 2003 4 Case series 1000 IGS procedures
performed by 42
surgeons
Case volume; surgeon
satisfaction
IGS offers both benefits and
pitfalls
Eliashar1259 2003 4 Case series ESS procedures: with
IGS (n = 34);
without IGS
(n = 131)
Operative time;
surgeons satisfaction;
complications
IGS is associated with longer
operative time and
greater surgeon
satisfaction
Reardon1260 2002 4 Case series ESS procedures: with
IGS (n = 400);
without IGS
(n = 400)
Extent of surgery;
complications
IGS usage is associated with
more extensive surgery
Fried1261 2002 4 Case series Consecutive patients
undergoing ESS:
with IGS (n = 97);
without IGS
(n = 61)
Patient comorbidities;
extent of surgery;
complications; EBL;
operative time; repeat
surgery
IGS may reduce
complications and reduce
the need for revision
surgery
Olson1262 2000 4 Case series 62 ESS with IGS cases Indications for surgery;
surgeon satisfaction;
TRE
IGS is helpful at specific
subsites, especially in the
setting of anatomic
complexity
Metson1263 2000 4 Case series 754 IGS procedures
performed by 34
physicians
TRE; operative time;
surgeon satisfaction
IGS can be deployed in a
multisurgeon OR
Fried1264 1998 4 Case series;
cadaver
dissection
14 patients
undergoing ESS;
cadaver dissections
Feasibility;
complications;
surgeon satisfaction
IGS is suited to complex ESS
procedures; it is
anticipated to reduce
surgical complications
(Continued)
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TABLE X-11. Continued
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Roth1265 1995 4 Case series Patients undergoing
ESS: with IGS
(n = 12); without
IGS
(n = 208)
Indications for surgery;
operative time; costs;
surgeon satisfaction
IGS can be used for the
identification of key
structures
Klimek1226 1995 4 Case series 14 pediatric patients
undergoing
skull-base surgery
Technical description;
completion of
procedure
IGS has promise for
skull-base surgery
Ramakrishnan1212 2013 5 Evidence-
based
review
6 publications from
the peer-reviewed
literature
Complication rate;
clinical outcomes
IGS has not reduced
complications nor has it
improved clinical
outcomes
Fried1266 2008 5 Literature
review
NA Abstracted observations
and data from
published reports
Almost all experts agree that
IGS is a significant
advance for ESS
Smith1213 2007 5 Systematic
review
5 peer-reviewed
publications
Complications Studies intended to confirm
the impact of IGS on
complication rates are
not feasible
Justice1232 2012 NA Survey Physician survey
(n = 337)
IGS usage; surgeon
satisfaction
IGS technology is
increasingly available,
and surgeons favor its
use for specific surgical
challenges
Knott1251 2006 NA Simulation
laboratory
Comparison of
contour-based
registration and
paired-point
registration
TRE Distribution of points for
contour-based
registration influences
TRE
Hepworth1231 2006 NA Survey Survey of practicing
ENT surgeons
(n = 672)
IGS usage; surgeon
satisfaction
IGS usage is increasing;
surgeons favor usage for
more complex ESS cases
Hardy1267 2006 NA Cadaveric
dissection
1. Fiducial registration;
2. Landmark
registration; 3.
Contour registration
Time for registration;
TRE
TRE was best for fiducial
and worst for landmark
3D-CTA = Three-dimensional CT angiography; EBL = estimated blood loss; NA = not applicable; OR = operating room.
appear to achieve significantly faster hemostasis.1275
Other absorbable agents that have been evaluated include
chitosan-dextran (CD) gel, a biopolymer derived from the
treatment of crustaceans; Sepragel R©, a hyaluronan-derived
gel (Genzyme Co, Cambridge, MA); Quixil R©, a fibrin-
based glue (OMRIX Biopharmaceuticals Ltd, Nes-Ziona,
Israel); and Surgiflo R© hemostatic matrix (Johnson &
Johnson, Ethicon Division, Somerville, NJ) used in com-
bination with thrombin (King Pharmaceuticals, Bristol,
TN).1268,1269,1276,1277 An RCT by Valentine et al.1268
showed CD gel to achieve hemostasis in a mean time
of 2 minutes, which was significantly lower than the
average time of 10 minutes in untreated sinuses cavities.
Sepragel R© has also been compared to no intervention, but
did not appear to confer the same advantage in the time
to hemostasis.1269 Vaiman et al.1276 showed Quixil R© to be
significantly superior to Merocel R© in the control of intra-
operative bleeding and bleeding on pack removal, but no
significant difference was observed in postsurgical bleeding
>30 hours after the procedure. Although Surgiflo R© with
thrombin was shown in 1 case series to have an impressive
time to hemostasis (median = 61 seconds) and success in
95% of patients, these findings have not yet been validated
in a well-designed RCT.1277
Postoperative Hemostasis. For situations where pack-
ing is necessary, a number of trials have compared var-
ious materials. Vaiman et al.1276 reported significantly
less bleeding in sinus cavities treated with fibrin sealant
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(Quixil R©) compared to Merocel R©, within the first 24 hours
postsurgery, but not beyond. Yu et al.’s study1278 did not
replicate this finding in their study of an aerosolized form of
a fibrin sealant, but did report a decreased rate of bleeding
on pack removal in favor of the fibrin sealant. Floseal R©,1275
Surgicel R©,1279 Cutanplast R©1280 (Mascia Brunelli S.p.A.,
Milan, Italy), and oxidized cellulose1281 have also been
found in RCTs to be associated with less bleeding than
Merocel R© at the time of pack removal. Al-Shaikh et al.’s1281
study also showed oxidized cellulose to be associated with
significantly less bleeding thanMerocel R©, immediately after
surgery and on postoperative days 4, 6, and 7. Kim et al.1282
investigatedwhether glovingMerocel R© prior to its insertion
had any effect on posthemostasis and found that sinus cavi-
ties packed with the glovedMerocel R© had 40 g less bleeding
on removal than sides packed with ungloved Merocel R©.
Nasopore R© (Stryker, Hamilton, ON, Canada), a fully
synthetic absorbable dressing, has also been studied ex-
tensively. Two different RCTs comparing Nasopore R© to
Merocel R© have shown contrasting results. Although Verim
et al.1283 showed a benefit of Nasopore R© in all areas of
postoperative morbidity including bleeding on packing re-
moval, this was not replicated in Shoman et al.’s RCT.1284
More recently a DBRCT by Kastl et al.1285 showed no post-
operative hemostatic benefit of Nasopore R© over not pack-
ing at all. There is some evidence to suggest that presoaking
Nasopore R© with lidocaine may improve its hemostatic ef-
fect within the first 24 hours after surgery,1286 without caus-
ing adverse hemodynamic effects, but studies comparing
this treatment to no packing have not yet been performed.
Wound Healing. Critical to good surgical outcomes is
optimal wound healing. Various studies have investigated
the effects of different packing materials on adhesion for-
mation, crusting, mucosal edema, inflammation, and cilia
regeneration. Packing materials that have been evaluated
against not packing at all include Merocel R©1287 and ab-
sorbable materials such as Floseal R©,1274 HemoStase R©,1288
carboxymethylcellulose (CMC),1289 Merogel R© (Medtronic
ENT, Jacksonville, FL),1290 Sepragel R©,1291 and CD gel.1268
Only CD gel, Merocel R©, and Sepragel R© were shown to
confer any advantage over not packing at all, with both
showing lower adhesion rates in their active treatment
arms.1268,1287 CD gel was also shown, in another RCT, to
be associated with significantly larger sinus ostial sizes at 3
months, although this study did not report any difference in
adhesion rates between treated and untreated cavities.1292
A small noncontrolled study by Kim et al.1282 suggests that
gloving the Merocel R© pack prior to insertion may further
reduce its postoperative adhesion rate; however, this
finding has yet to be validated in a controlled study. Given
the perceived benefits of Merocel R© in reducing adhesion
formation, several RCTs have evaluated different packing
materials directly against Merocel R©. Floseal R©,1275 fibrin
sealant,1278 oxidized cellulose,1281 and Nasopore R©1283,1284
have all been found to have similar effects on postsurgical
wound healing, including rate of adhesion formation.
Contrasting results exist in RCTs comparing Merogel R©
to Merocel R©, however. Although an RCT by Berlucchi
et al.1293 suggested better early and long-term wound
healing for Merogel R©, no difference between these agents
was observed in 2 other independent RCTs.1294,1295
Interestingly an RCT by Shi et al.1296 evaluating a similar
hyaluronan-based gel, PureRegen Gel R© (BioRegen Bio-
medical, Changzhou, China), observed improved wound
healing in terms of adhesion formation, edema, and crust-
ing when the gel was applied toMerocel R© prior to packing.
This does suggest a possible benefit of hyaluronan gel.
Floseal R© and CMC have also been extensively investi-
gated for their effect on wound healing. Although studies
by Jameson et al.1274 and Baumann and Caversaccio1275
reported no difference in wound healing or adhesion
rates when Floseal R© was compared to no treatment
or packing with Merocel R©, concerns have been raised
regarding its possible proadhesion properties. Two studies
by Chandra et al.,1297,1298 suggest that Floseal R© may
actually incite early granulation tissue formation, with
a higher rate of symptomatic adhesion formation. Their
histopathological finding of incorporated foreign material
within a mature synechiae supports this concern.1298
Like Floseal R©, CMC has not been shown to confer any
significant benefit on wound healing compared to leaving
a cavity unpacked.1289 Two separate RCTs do suggest,
however, that CMC dressings may be associated to a lower
rate of adhesion formation when compared to commonly
used nonabsorbable dressings.1299,1300
Patient Comfort. Sinus surgery itself is not characteristi-
cally associated with significant amounts of pain, although
patients do frequently report discomfort from nasal
packing and its removal. Level 1 evidence suggests that
packing with absorbable dressings such as Nasopore R©,1285
HemoStase R©,1270 Sepragel R©,1291 and Floseal R©1274 are
not associated with any increased pain, compared to
unpacked cavities. In fact, in the studies that evaluated
Sepragel R© and Floseal R©, patients reported less subjective
discomfort on the treated side.1274,1291 Both studies were
small in number, however, and did not use validated
pain scoring systems. Bugten et al.1287 also reported no
significant difference in pain scores between patients
packed bilaterally with Merocel R© and those left unpacked,
although a patient self-controlled study has not yet been
performed to validate this observation. Several RCTs have
directly compared pain and comfort levels of packing using
absorbable vs nonabsorbable materials. Nasopore R© and
Merogel R© have both been found to better tolerated than
nonabsorbable Merocel R© while in situ,1283,1284,1293 with
Merogel R© causing less discomfort on removal.1293 Finally,
studies have also investigated whether modifications to
existing dressings can also improve their tolerance and
discomfort level during removal. The addition of lidocaine
to Nasopore R© intraoperatively and 8 hours postsurgery
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appeared to significantly reduce immediate postoperative
pain for up to 16 hours after surgery,1286 whereas gloved
Merocel R© packs were found to cause less discomfort on
removal than standard Merocel R© packs.1282
Summary. In summary, packing does not appear to be
necessary in the majority of ESS cases. If packing is chosen,
available evidence indicates packing achieves hemostasis
without significant adverse effects on postoperative wound
healing (Table X-12).
 Aggregate Grade of Evidence:
◦ Intraoperative Hemostasis: A (Level 1b: 5 studies;
Level 3b: 1 study; Level 4: 2 studies);
◦ Postoperative Hemostasis: A (Level 1b: 11 studies;
Level 3b: 1 study; Level 4: 1 study);
◦ Wound Healing: A (Level 1b: 21 studies; Level 3b:
1 study);
◦ Patient Comfort: A (Level 1b: 13 studies).
 Benefit: Rapid control of intraoperative bleeding. Poten-
tial reduction in adhesion formation with some materi-
als. CD appears to improve ostial sizes postoperatively.
 Harm: Potential for increased discomfort while in situ
and on removal. Rare risk of toxic shock syndrome. Po-
tential for an increased rate of clinically significant adhe-
sions with some materials.
 Cost: There is a cost associated with all packing mate-
rials, with absorbable materials being more costly than
nonabsorbable packing.
 Benefits-Harm Assessment: Balance of risks and benefits.
 Value Judgments: For the majority of sinus surgical cases
packing is not required for intraoperative hemostasis and
will not reduce the risk of postoperative epistaxis. Al-
though evidence does exist suggesting packing may re-
duce adhesion formation, it is limited and has not been
compared to studies employing early and frequent de-
bridement.
 Policy Level: Option.
 Intervention: When bleeding cannot be controlled, pack-
ing may help achieve hemostasis, without significant ad-
verse effects on postoperative wound healing.
X.D.6. Surgical Principles/Techniques: Drug
Eluting Packing, Stents, and Spacers
Although ESS is extremely successful in treating med-
ically resistant CRS, postoperative inflammation may
hamper the ultimate recovery of patients. Postoperative
failures may be caused by synechiae formation, ostial
stenosis, osteoneogeneiss, MT lateralization, and recurrent
polyposis.1302–1306 These complications are currently miti-
gated by saline irrigations to reduce crusting, postoperative
debridement, adhesion lysis, and topical and systemic
corticosteroids. Postoperative debridement can be painful
and the use of systemic corticosteroids carries potential side
effects. Topical corticosteroids can be useful in improving
healing but are limited by patient compliance due to the
requirement for multiple applications, and effectiveness
may be impacted by postoperative edema, discharge, and
crusting within the sinus cavity.1307
In order to improve postoperative healing, a wide variety
of techniques have been developed and include the use of
packing, stents, and spacers. Nasal packing is principally
designed for postoperative hemostasis and in animal mod-
els some packing materials demonstrate improved wound
healing. Stents and spacers on the other hand are designed
to maintain middle meatal patency and allow irrigation
without obstruction. If the stents are drug eluting, they can
also potentially provide local medical therapy to the sinus
mucosa, independent of patient compliance with minimal
systemic side effects.1308
Non–drug-eluting stents can act as spacers to prevent
adhesion formation and provide a scaffold for mucosal
regrowth. However, there has been conflicting evidence on
their effectiveness.1305,1309 Controversy remains regarding
their effectiveness, when they should be placed, duration of
placement, and type of stent employed.1308 Silastic stents
have been associated with biofilm formation postopera-
tively, which maybe counterproductive in the treatment of
CRS.1310
In an “off-label” use, nonbiodegradable spacers such as
the Relieva Stratus Microflow SpacerTM (Acclarent, Irvine,
CA) have been used as an drug-eluting stent by filling the
spacer with triamcinolone.1308,1311 However, these can be
difficult to remove, with a case report of retained spacers
leading to inflammation and infection 7 months after
initial insertion.1312,1313 There has also been a case report
of orbital violation leading to pain and a permanently
dilated pupil.1314
Biodegradable drug-eluting stents offer the benefit of
having both a mechanical spacer combined with precise
sustained release of medication into the sinus cavity over a
known period of time.1315 Unlike nonbiodegradable stents,
they may not require potentially painful postoperative
removal. Currently, the only drug-eluting stent approved
by the FDA is the PropelTMcorticosteroid-releasing im-
plant (Intersect ENT, Palo Alto, CA). It consists of a
self-expanding, bioabsorbable, drug-eluting stent with
the active ingredient of 370 μg mometasone furoate
embedded in a polymer matrix composed of polylactide-
co-glycolide that degrades over 30 days. Once inserted, its
springlike action helps maintain the patency of the middle
meatus allowing continued sinus irrigation. In animal
studies, this stent showed minimal mucosal inflammatory
reaction.1316
The PropelTM stent has been investigated in 1 cohort and
2 RCTs, which have demonstrated its efficacy and safety.
All 3 studies found similar outcomes in improvements
in symptom scores and endoscopic findings (decreased
polyposis and adhesions) as well need for postoperative
intervention when compared to the stent without corti-
costeroids. There was also no significant corticosteroid
systemic absorption or ocular toxicity.1307,1317,1318 A
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TABLE X-12. Evidence for use of packing with ESS in CRSsNP and CRSwNP
Study Year LOE Study design Materials Outcome measure Findings
Intraoperative hemostasis
Beyea1273 2011 1b RCT: 18 patients; 36
sides
Floseal R© vs
HemoStase R©
Total blood loss No significant difference
Valentine1268 2010 1b DBRCT: 40 patients;
80 sides
CD gel vs no packing Time to hemostasis Statistically significant
difference: CD gel 2 minutes;
no packing 10 minutes
Jameson1274 2006 1b DBRCT: 45 patients;
90 sides
Floseal R© with patties
vs patties alone
Time to hemostasis Statistically significant difference
with Floseal R© added to
patties (16.4 minutes vs 30.8
minutes)
Vaiman1276 2005 1b RCT: 91 patients
undergoing ESS; 48
sides Merocel; 43
sides Quixil
Merocel R© vs Quixil R© 1. All types of bleeding;
2. Bleeding after
removal; 3. Late
bleeding >30 hours
Quixil significantly better in #1
and #2. No significant
difference in #3
Frenkiel1269 2002 1b RCT: 20 patients; 40
sides
Sepragel R© vs no
packing
Intraoperative
hemostasis
No significant difference in total
blood loss
Baumann1275 2003 3b Individual
case-control: 50
patients; 100 sides
Floseal R© vs Merocel R© Hemostasis No significant difference (mean 3
minutes)
Woodworth1277 2009 4 Noncontrolled case
series: 30 patients;
30 sites
Gelatin-thrombin
matrix (Surgiflo R©)
with thrombin
Intraoperative
hemostasis
29/30 sites had complete
hemostasis within 10 minutes
Gall1272 2002 4 Cohort study: 18
patients; 30 sites
Floseal R© Time to hemostasis Average time 2 minutes. Unable
to stop bleeding 18 sites
Postoperative hemostasis
Al-Shaikh1281 2014 1b RCT: 47 patients, 94
sides
Oxidized cellulose
powder vs
Merocel R©
Postoperative bleeding Oxidized cellulose use had
significantly less bleeding
than Merocel R©
Kastl1285 2014 1b DBRCT: 47 patients;
94 sides
Nasopore R© vs no
packing
Postoperative bleeding No significant difference
Verim1283 2014 1b Partly blinded RCT: 56
patients, 112 sides
Nasopore R© vs
Merocel R©
Postoperative
hemostasis
Significantly better for
Nasopore R©
Yu1278 2014 1b Nonblinded RCT: 41
patients, 82 sides
Aerosolized fibrin
sealant vs
Merocel R©
Bleeding Increased in incidence in
bleeding on removal of
packing compared to fibrin
sealant but not on follow-up
Cho1280 2013 1b RCT: 100 patients, 200
sides
Cutanplast R© vs
Merocel R©
Bleeding and pain on
pack removal
Cutanplast R© had less bleeding
and pain on removal and less
time to control bleeding
following pack removal
Mo1286 2013 1b DBRCT: 63 patients,
123 sides
Nasopore R© soaked in
lidocaine vs
Nasopore R©
Postoperative bleeding
as determined by the
number of gauze
changes
The number of gauze changes at
1, 4, 16, and 20 hours was not
significantly different between
the 2 groups
Kim1282 2012 1b RCT: 15 patients, 30
sides
Gloved Merocel R© vs
Merocel R©
Bleeding on pack
removal
Gloved Merocel R© had 40 g less
blood loss than ungloved
Merocel R©
(Continued)
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TABLE X-12. Continued
Study Year LOE Study design Materials Outcome measure Findings
Antisdel1270 2009 1b Single-blinded RCT: 40
patients, 80 sides
Microporous
polysaccharide
hemospheres vs no
packing
Postoperative
hemostasis
Only significant difference on
postoperative day 1
Shoman1284 2009 1b RCT: 30 patients, 60
sides
Nasopore R© vs
Merocel R©
Postoperative
hemostasis
No significant difference
Vaiman1276 2005 1b RCT: 91 patients
undergoing ESS; 48
sides Merocel; 43
sides Quixil
Quixil R© vs Merocel R© 1. All types of bleeding;
2. Bleeding after
removal; 3. Late
bleeding >30 hours
Quixil R© significantly better for all
types of bleeding and bleeding
upon removal. No difference
in late bleeding
Shinkwin1279 1996 1b RCT: 60 patients,120
sides
Surgicel R© vs
Merocel R© or
petroleum ointment
gauze
Postoperative
hemostasis
Surgicel R© use had less bleeding
on pack removal compared to
Merocel R© or petroleum
ointment gauze
Baumann1275 2003 3b Individual
case-control: 50
patients, 100 sides
Floseal R© vs Merocel R© Hemostasis Removal of Merocel R© associated
with increased bleeding
Orlandi1271 2004 4 Retrospective case
series: 165
patients,169 sinus
surgical procedures
147 unpacked; 19
packed; 4
hemostatic agents
used
Significant postoperative
bleeding requiring
intervention
No significant postoperative
bleeding complications
reported
Wound healing
Akiyama1299 2014 1b RCT single-blinded: 44
patients, 88 sides
Silver CMC vs
chitin-coated gauze
Synechiae Silver CMC had significantly less
adhesions (0% vs 14%)
Al-Shaikh1281 2014 1b RCT: 47 patients, 94
sides
Oxidized cellulose
powder vs
Merocel R©
Crusting, adhesions,
infection
No significant difference
Verim1283 2014 1b Partly blinded RCT: 56
patients, 112 sides
Nasopore R© vs
Merocel R©
Edema, crusting,
secretions,
synechiae,
granulation tissue,
percentage
reepithelization
No significant difference in
wound healing at any time
point in the first 6 months
after surgery
Yu1278 2014 1b Nonblinded RCT: 41
patients, 82 sides
Aerosolized fibrin
sealant vs
Merocel R©
Endoscopic findings of
crusting, infection,
adhesions, frontal
stenosis, granulation
tissue
No significant difference for
infection, adhesions, or frontal
ostial size; fibrin sealant
showed less granulation
tissue at 2 and 4 weeks and
less crusting at 1 week
compared to Merocel R©
Ngoc1292 2013 1b Single-surgeon
DBRCT: 26 patients,
52 sides
CD gel vs no packing 1. Wound healing
including adhesion
rate; 2. Ostial size at 3
months for maxillary,
frontal, and sphenoid
No significant difference in
wound healing. Significantly
larger ostial sizes for
CD-treated cavities
Shi1296 2013 1b RCT: 54 patients, 108
sides
PureRegen R© gel plus
Merocel R© vs
Merocel R© alone
Reepithelization,
adhesions, edema,
and crusting
PureRegen R© gel had better %
reepithelization, Incidence of
nonobstructing adhesions,
edema, and crusting
Kim1282 2012 1b RCT: 15 patients, 30
sides
Gloved Merocel R© vs
Merocel R©
1. Adhesion rate; 2.
Postoperative
Lund-Kennedy
endoscopic score
Higher adhesion rate for
ungloved pack. Significantly
better endoscopic score at 4
weeks but no difference later
(Continued)
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TABLE X-12. Continued
Study Year LOE Study design Materials Outcome measure Findings
Antisdel1288 2011 1b RCT: 40 patients, 80
sides
Microporous
polysaccharide
hemospheres vs no
packing
1. Synechiae; 2. Edema; 3.
Infection
No significant difference in any
outcomes.
Szczygielski1300 2010 1b RCT: 60 patients, 120
sides
CMC packing
bilaterally vs latex
gloved cotton gauze
bilaterally
Synechiae at 8 weeks CMC packing had significantly
less synechiae (6.5% vs 35.7%)
Valentine1268 2010 1b DBRCT: 40 patients,
80 sides
CD gel vs no packing Adhesion formation Lower at all time points in first 3
months postoperatively for
CD-treated group
Berlucchi1293 2009 1b RCT: 66 patients, 88
sides
Merogel R© vs
Merocel R©
1. Adhesions; 2. %
Reepithelization; 3.
Granulation; 4. Edema; 5.
Crusting
Merogel showed superiority in
most outcomes and at some
time points
Kastl1289 2009 1b RCT: 26 patients, 52
sides
CMC mesh vs CMC gel
vs nothing
Wound healing No significant difference among
the groups
Shoman1284 2009 1b RCT: 30 patients, 60
sides
Nasopore R© vs
Merocel R©
Postoperative edema No significant difference
Franklin1295 2007 1b RCT: 35 patients, 70
sides
Merogel R© vs
Merocel R©
Lund-Kennedy endoscopic
score
No significant difference
Bugten1287 2006 1b RCT: 59 patients; 31
packed with
Merocel; 28
unpacked
Merocel R© for 5 days
vs no packing
Middle meatal adhesion
rate at 10–14 weeks
More bilateral adhesions in
unpacked patients. No
difference in unilateral
adhesions
Jameson1274 2006 1b DBRCT: 45 patients,
90 sides
Floseal R© with patties
vs patties alone
Wound healing Only significant difference was
that Floseal R© showed less
crusting at 1 week
postoperatively
Wormald1290 2006 1b Blinded RCT: 42
patients, 84 sides
Merogel R© vs nothing Adhesion, edema, infection No difference at 2, 4, and 6–8
weeks for any parameter
Chandra1298 2005 1b RCT: 13 patients, 36
sides
Floseal R© vs
thrombin-soaked
gelatin foam
Adhesions at 1 year Floseal R© showed a higher number
of adhesions overall and a
higher number requiring lysis
Chandra1297 2003 1b RCT: 20 patients, 40
sides
Floseal R© vs
thrombin-soaked
gelatin foam
Granulation and adhesions
at 6 weeks
Floseal R© had significantly more
adhesions
Miller1294 2003 1b RCT: 37 patients, 74
sides
Merogel R© vs
Merocel R©
Postoperative edema at 8
weeks
No significant difference
Kimmelman1291 2002 1b RCT: 10 patients, 20
sides
Sepragel R© vs nothing Synechiae, middle meatus
stenosis, mucosal status
All significantly better in
Sepragel R©-treated sides at
week 2
Baumann1275 2003 3b Individual
case-control: 50
patients, 100 sides
Floseal R© vs Merocel R© Middle meatal synechiae
and stenosis
No significant difference
Patient comfort
Kastl1285 2014 1b DBRCT: 47 patients,
94 sides
Nasopore R© vs nothing 1. Pain, breathing, sleep
disturbance, headache,
well-being; 2. Pressure;
3. Subjective assessment
of which side felt better
1. No significant difference in any
of these parameters. 2. Packing
showed slightly less on days 2
and 3. 3. No significant
difference
(Continued)
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TABLE X-12. Continued
Study Year LOE Study design Materials Outcome measure Findings
Verim1283 2014 1b Partly blinded RCT: 56
patients, 112 sides
Nasopore R© vs
Merocel R©
Pain, bleeding, facial
edema, nasal
obstruction
All significantly less with
Nasopore R©
Yu1278 2014 1b Nonblinded RCT: 41
patients, 82 sides
Aerosolized fibrin
sealant vs
Merocel R©
VAS score No significant difference while
pack in situ but greater pain
and nasal bleeding during
removal of pack
Cho1280 2013 1b RCT: 100 patients, 200
sides
Cutanplast R© vs
Merocel R©
Pain on pack removal Cutanaplast R© had significantly
less pain on removal
Mo1286 2013 1b DBRCT: 63 patients,
123 sides
Nasopore R© soaked in
lidocaine vs
Nasopore R©
Pain at 1, 4, 8, 16, 20,
and 24 hours
Significantly less pain at 1, 4, 8,
and 16 hours in
lidocaine-soaked group. Same
at 20 and 24 hours
Akbari1301 2012 1b DBRCT: 37 patients,
74 sides
Gloved Merocel R© vs
Merocel R©
Discomfort on removal Ungloved pack had more
discomfort on removal than
gloved pack
Antisdel1270 2009 1b Single-blinded RCT: 40
patients, 80 sides
Microporous
polysaccharide
hemospheres vs no
packing
Pain, obstruction, and
nasal discharge
No significant difference
Berlucchi1293 2009 1b RCT: 66 patients, 88
sides
Merogel R© vs
Merocel R©
Pain on packing removal Significantly decreased in
Merogel R© group
Shoman1284 2009 1b RCT: 30 patients, 60
sides
Nasopore R© vs
Merocel R©
1. Postoperative pain; 2.
Pain on packing
removal
1. Significantly decreased pain
with Nasopore R©; 2. No
significant difference
Bugten1287 2006 1b RCT: 59 patients; 31
packed with
Merocel; 28
unpacked
Merocel R© for 5 days
vs no packing
Pain, congestion,
headache, sleep
quality for 10–14
weeks after surgery
No significant difference in any
parameter scores between the
groups
Jameson1274 2006 1b DBRCT: 45 patients,
90 sides
Floseal R© with patties
vs patties alone
Pain in first week Significantly less in Floseal R©
group
Kimmelman1291 2002 1b RCT: 10 patients, 20
sides
Sepragel R© vs nothing Postoperative subjective
pain and congestion
Significantly less in packed group
Shinkwin1279 1996 1b RCT: 60 patients, 120
sides
Surgicel R© vs
Merocel R© or
petroleum ointment
gauze
Patient comfort Surgicel R© had less discomfort
on removal than Merocel R©
and ointment gauze
CD = chitosan-dextran; CMC = carboxymethylcellulose.
meta-analysis combined the results from the 2 RCTs to
demonstrate statistically significant reductions in the need
for postoperative intervention, oral corticosteroid usage,
polyposis, and adhesions.1319 An economic evaluation also
demonstrated that PropelTM is cost-effective in decreasing
postoperative intervention.1320
Concerns raised regarding the data to date have included
the lack of a nonstented arm in these studies, which might
show that the stenting material without the corticosteroid
is proinflammatory. Previous work in biomaterials in the
sinuses has shown the potential for some materials to
induce inflammation.1321,1322 Additional work is needed
to clarify this issue.
Corticosteroid eluting materials appear to have promise
in the postoperative period. Additional indications are
on the horizon.1323 Clinical experience with this device is
relatively narrow at this point and evidence, though at a
high level, is limited to short-term outcomes (Table X-13).
 Aggregate Grade of Evidence: A (Level 1b: 2 studies;
level 2b: 1 study).
 Benefit: Reduction in polyposis and adhesions forma-
tion, which translates to a reduction in postoperative
interventions.
 Harm: Potential for misplacement and local reaction.
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TABLE X-13. Evidence for use of drug-eluting stents with ESS in CRSsNP and CRSwNP
Study Year LOE Study design Study groups Clinical endpoint Conclusions
Han1319 2012 1a Meta-analysis 2 RCTs of outcomes at
postoperative day 30
1. MT lateralization; 2.
Adhesions; 3. Frank
polyposis; 4. Need for
postoperative
intervention; 5. Need
for postoperative
corticosteroids
Relative reduction of adhesions
and polyposis. 35% reduction
in postoperative intervention.
40% reduction in oral
corticosteroid usage
Marple1307 2012 1b Prospective, multicenter,
DBRCT using
intrapatient control
design (n = 105)
ESS for CRS 1. Postoperative
interventions at 30
days; 2. Endoscopy; 3.
Safety
Decrease in postoperative
intervention. Decreased
adhesions and polyposis. No
safety concerns
Murr1318 2011 1b Prospective multicenter
intrapatient DBRCT
(n = 43)
ESS for CRS 1. Endoscopic assessment
at day 21; 2. Safety
Decreased polyposis and
adhesions, no difference in
MT lateralization. No
device-related adverse
effects. No systemic
absorption
Forwith1317 2011 2b Prospective multicenter
single-cohort study (n
= 50)
Unilateral (n = 10) or
bilateral (n = 40) stent
placement
1. SNOT-22 and RSDI at 6
months; 2. Safety; 3.
Endoscopic follow-up to
60 days
Improvement in SNOT-22 and
RSDI. Safety with no ocular
risk. 1.1% adhesion rate.
4.4% MT lateralization
Lavigne1324
2014 4 Prospective, multicenter
nonrandomized cohort
study (n = 12)
Recurrent NP following
ESS treated with
non–FDA-approved
stent
1. Safety of device; 2.
Efficacy of device
1 case of ocular irritation and 1
nasal irritation. 21/24
successfully inserted. NP size
decreased. Need for revision
surgery eliminated in 64%
Matheny1325
2014 4 Prospective,
single-center,
nonrandomized cohort
study using PropelTM
20 patients post-ESS had
stent inserted within 7
days postoperatively
Feasibility of insertion and
safety of device
100% insertion rate. 90% of
patient very satisfied with
experience. Improvement in
SNOT-20 and endoscopic
scores
Ow1326 2014 4 Prospective single-center
nonrandomized cohort
study
5 patients with recurrent
NP treated with
non–FDA-approved
stent
Safety of device No systemic absorption or
adrenal suppression. 10/10
successful implant insertion
 Cost: Variable depending on stents and medication. The
PropelTM system is estimated at US$700 per implant.
 Benefits-Harm Assessment: Preponderance of benefit
over harm.
 Value Judgments: Corticosteroid-eluting stents have
been demonstrated to have beneficial impact on post-
operative healing and 1 study has shown them to
be cost-effective in preventing additional postopera-
tive interventions. Experience is early and the amount
of evidence is small, though high-level. Specific us-
age should be at the clinician’s discretion taking
into consideration various important patient-specific
factors.
 Policy Level: The authors could not come to a consensus
on the subject of corticosteroid-eluting stents. They were
divided between recommendation (due to the high LOE)
and option (due to the limited amount of evidence and
experience, as well as cost considerations).
 Intervention: Corticosteroid-eluting stents can be consid-
ered in the postoperative ethmoidectomy cavity.
X.E. Surgery for CRSwNP and CRSsNP:
Postoperative Management
In 2011, Rudmik et al.1020 published an EBRR on postop-
erative care after ESS and divided the types of postoperative
care into several distinct categories, which are followed in
this update. Additional evidence was identified for many
of these categories and also on the use of Mitomycin C, so
that category was added.
X.E.1. Saline Irrigation
One new study was identified that partially addressed this
intervention. Farag et al.791 reported a single-blinded RCT
comparing hypertonic saline irrigation with surfactant
(1% baby shampoo) irrigation after ESS, and the primary
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outcomes were olfaction and disease-specific QoL, with
secondary outcomes of patient-reported side effects. The
authors enrolled 40 patients, and found no differences
in QoL or olfaction between the 2 groups. The patients
prepared the irrigations themselves and were not blinded
to treatment, and they reported a higher proportion of side
effects with surfactant irrigation than hypertonic saline irri-
gation. The authors did not report a power analysis, so it is
possible that the lack of statistical significance in QoL or ol-
faction outcomes could be due to a Type 2 statistical error.
In the 2011 review,1020 the evidence supporting the use
of saline irrigations was grade B, and the group made a
recommendation for normal saline irrigations, beginning
24 to 48 hours after ESS.
X.E.2. Sinus Cavity Debridements
There were 2 new RCTs reported.1327,1328 One study1327
used a within-subject design with 1 side randomized to
receive outpatient debridement at 2, 4, and 6 weeks, and
the other side received no debridement. A surgeon blinded
to which side was debrided assessed the endoscopic ap-
pearance at 3 months after surgery and assigned a modified
endoscopic score. There were no significant differences in
overall endoscopic findings or score; however, a subgroup
analysis found that debridement significantly reduced ad-
hesions (p = 0.048). The sample was statistically adequate
to achieve the power desired based on a priori calculations;
however, it was still a small study (24 subjects). Examina-
tion of the raw data showed the modified Lund-Kennedy
mean endoscopic score was 1.50 on the debridement side
and 2.94 on the control side. This did not achieve statistical
significance, but it does not appear to be a trivial difference.
Furthermore, the within-subject study design restricted
the ability to obtain patient-reported outcomes such as
symptoms or QoL, which have been shown to be positively
affected by early postoperative debridement after surgery.
The other study1328 was a between-subject design in
which groups were randomized to no debridement for 4
weeks, or to outpatient endoscopic debridement at 2 and
4 weeks after surgery. Importantly, all patients received a
dissolvable spacer at surgery (no medication added) and
high-flow saline lavage and 3-week tapering dose of oral
prednisone after surgery. The authors found no significant
difference in endoscopic score or patient-based QoL at 6
months between the 2 groups. The authors also reported on
a new postoperative patient inconvenience questionnaire,
and found that the debridement group reported more
pain and more overall inconvenience. The authors noted
that their postoperative regimen was fairly aggressive,
with 3 weeks of corticosteroids and high-flow saline
irrigation, which might account for reduction in synechiae,
granulation, and other undesirable postoperative outcomes
in both groups.
The 2011 review1020 found grade B evidence on this
topic, which generally identified improved postoperative
appearance and reduced postoperative complications such
as synechiae if debridement was performed. The authors
made a recommendation for sinus cavity debridements
after ESS. In 2014, there was 1 new study showing limited
benefit, and 1 study showing no benefit of debridement.
Although both studies are RCTs, the methodology is still
different, with multiple variables differing between studies,
so that the evidence grade is still grade B, and compiling
all the evidence on this topic the recommendation for
postoperative outpatient debridement remains.
X.E.3. Topical Corticosteroids
There was a systematic review and meta-analysis of topical
corticosteroids reported in 2013.1009 The methodology
was excellent, and the authors found that, pooling the
results of several RCTs comparing topical corticosteroids
with placebo, there was significant improvement in the
corticosteroid group in the following outcomes: endoscopic
score at 6 and 12 months, symptoms score, and recurrence
rate of polyps.
The 2011 review1020 found grade A evidence supporting
the use of topical corticosteroids, and made a recommen-
dation for standard INCS. A subsequent review article
by some of the same authors1329 stated, “Topical steroid
therapy is integral for control of postoperative mucosal
inflammation and should be started following ESS.” A
strong recommendation is made for INCS following ESS.
X.E.4. Oral Antibiotics
No new studies were identified which addressed oral
antibiotics. However, there was a systematic review and
meta-analysis on this topic.1330 The review found a small
number of eligible trials, and concluded that the data
were unable to demonstrate clear evidence of complication
reduction or outcome improvement. The 2011 review had
concluded that the evidence supporting the use of antibi-
otics was level B, and the group made a recommendation
of option for use of antibiotics, citing both benefits and
potential side effects.1020
X.E.5. Topical Decongestants
No new studies were identified that addressed topical
decongestants. In the 2011 review,1020 there was insuffi-
cient evidence to support the use of topical decongestants,
and the group made a recommendation against topical
decongestants, because of potential side effects and no
clear benefit.
X.E.6. Packing/Spacers Without Medication
Impregnation
There was a systematic review and meta-analysis address-
ing the use of packing vs no packing after ESS.1331 The
review identified 8 studies with significant heterogeneity of
design, and materials used, and reported a nonsignificant
trend (risk ratio = 0.40; 95% CI, 0.14 to 1.12) toward
reduction in synechiae formation when packing was
used, and found that nonabsorbable spacers might have
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improved outcomes compared to absorbable spacers.
However, overall the data were too heterogeneous to
make definitive recommendations. Another systematic
review and meta-analysis1332 compared dissolvable vs
nondissolvable packing after ESS. They also found sig-
nificant heterogeneity between studies and calculated a
nonsignificant trend (risk ratio = 0.33; 95% CI, 0.04 to
2.78) toward better outcomes with dissolvable packing.
One new RCT was reported1283 comparing dissolvable
vs nondissolvable packing after ESS, and that trial found
no significant differences in postoperative endoscopy
scores at 6 months, but found increased pain while the
nondissolvable packing was in place.
This evidence on whether to pack is grade B, but
based on the lack of clear outcome difference and the
heterogeneity of studies, it appears packing is an option. If
packing is chosen, there appears to be grade A evidence of
its safety and efficacy (see Section X.D.5).
X.E.7. Drug-Eluting Spacers/Stents
There have been several new studies on this topic, which
are addressed in Section X.D.6.
X.E.8. Systemic Corticosteroids
There was 1 new RCT related to this topic, in which
every patient received a corticosteroid-eluting middle
meatus spacer, and then the groups were randomized to
receive either systemic corticosteroids (prednisone 30 mg
daily for 7 days) or placebo.1333 Eighteen subjects were
enrolled in each group, which satisfied the authors’ a priori
power analysis calculation. They found no significant
difference in endoscopic outcome or patient-based QoL
outcome between the 2 groups, and concluded there was
no additional benefit of systemic corticosteroids when a
corticosteroid-eluting stent was used.
The 2011 review1020 also found limited evidence on
this topic, but concluded that the use of systemic corticos-
teroids was an option. The current LOE also supports the
recommendation of option.
X.E.9. Mitomycin C
This drug, an antifibroblast chemotherapy agent, has
been used topically to prevent stenosis, scar formation,
and synechiae formation. In other areas of the head and
neck (airway, nasal choanae, lacrimal apparatus, etc.), the
evidence from controlled studies is generally lacking; either
studies have not been performed, or comparative studies
show no clear benefit of mitomycin C. However, many
clinicians believe their outcomes are improved with its use,
and they use it for revision or high-risk cases. The topical
use of mitomycin C is off-label.
There were 2 new studies on topical mitomycin
C,1334,1335 and a systematic review with meta-analysis.1336
The new studies were RCTs with similar design: within-
subject trials in which 1 side was randomly assigned to
medication application, and the opposite side was the
control. Mitomycin C was placed for 5 minutes after
surgery was complete. Objective endoscopic outcomes
were assessed, including synechia formation, granulation
tissue, and maxillary ostium narrowing; 1 study also
assessed subjective nasal obstruction.1335 Outcomes were
assessed about 1 week after surgery, and then at intervals
from 1 to 3 months. Both studies found no significant
long-term outcome differences, either in endoscopic
outcomes or symptomatic outcomes. One study1335 found
a statistically significant increase in adhesions at 1 week
in the control group, but there was no long-term outcome
difference. The studies enrolled 37 (Baradaranfar et al.1334)
and 50 (Venkatraman et al.1335) patients, but neither study
reported a power analysis. The lack of difference might
have been a type 2 statistical error, but in fact the raw data
indicated little difference between the groups, so even a
larger sample would likely not have made a difference.
The systematic review1336 found methodologic problems
with many of the individual studies, but when pooling
the data found some benefit (risk ratio = 0.34; 95% CI,
0.18 to 0.65) in short-term synechia formation, and in
maxillary sinus ostium stenosis (risk ratio = 0.26; 95% CI,
0.12 to 0.54). The authors did not pool long-term results,
however, which tended to show small or no difference in
outcome, and the authors cautioned that their pooled data
were potentially questionable.
These data lead to a recommendation against the use of
mitomycin C in following typical ESS, because there are po-
tential side effects and there are no clear long-term benefits.
X.E.10. Other Treatments
There was 1 study comparing Chinese herbal medicine
with oral antibiotics and with placebo.1337 because this is
nonstandard treatment, and because oral antibiotics (the
comparison) are only an option for treatment, this study
was not analyzed further.
X.E.11. Summary
Overall, the LOE and the study methodology on this topic
has improved significantly since the 2011 evidence-based
review. There were 12 RCTs on different topics, and there
were several systematic reviews/meta-analyses, whereas
when the literature was searched in 2010, there were
many more case series and only a handful of RCTs,
many with methodological issues. It is encouraging that
the methodologic quality of studies is improving. The
potential postoperative interventions and the treatment
recommendations are summarized in Table X-14.
X.F. Surgery for CRSwNP and CRSsNP:
Outcomes
Literature evaluating both clinician based (“objective”)
and patient-based (“subjective”) outcomes of surgery in
CRS, regardless of polyp status, broadly demonstrates that
ESS provides clinically significant QoL (overall and disease-
specific) as well as objective endoscopic improvements in
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TABLE X-14. Evidence for postoperative care after ESS in CRSsNP and CRSwNP
Benefit-harm
Intervention LOE Benefit Harm Cost assessment Policy level
Saline irrigations B Well-tolerated. Improved
symptoms and
endoscopic appearance
Local irritation, ear
symptoms
Minimal Preponderance of
benefit over harm
Recommendation for
use of nasal saline
irrigation
Sinus cavity
debridements
B Improved symptoms and
endoscopic
appearance. Reduced
risk of synechia and
turbinate lateralization
Inconvenience, pain,
epistaxis, syncope,
and mucosal injury
In-office procedure
with cost
Preponderance of
benefit over harm
Recommendation for
postoperative
debridement
Topical corticosteroids A Improved symptoms and
endoscopic
appearance. Reduced
recurrence rate of
polyps
Epistaxis, headache Moderate Preponderance of
benefit over harm
Recommendation for
standard INCS
Oral antibiotics B Improved symptoms and
endoscopic
appearance. Reduced
crusting.
GI upset, colitis,
anaphylaxis,
bacterial resistance
Moderate to high Balance of benefit and
harm
Option for oral
antibiotics
Topical decongestants N/A Potential reduced mucosal
swelling and bleeding.
Increased pain,
possible rhinitis
medicamentosa
Minimal Preponderance of
harm over benefit
Recommendation
against topical
decongestants
Packing/spacers
without medication
B Improved symptoms and
endoscopic
appearance. Reduced
risk of synechia and
turbinate lateralization
Pain, inconvenience,
potential for
creating synechia or
granulation
Moderate to high,
depending on
material
Balance of benefit and
harm. Potential
small benefit of
absorbable vs
nonabsorbable
packing.
Option for packing or
spacer
Drug-eluting
spacers/stents
A Reduction in inflammation,
polyps, adhesions.
Possible systemic
absorption, pain,
inconvenience
Moderate to high,
depending on
material and
medication
Balance of benefit and
cost.
Consensus regarding
recommendation
cannot be reached
at this point (see
Section X.D.6)
Systemic
corticosteroids
N/A Improvement in
endoscopic
appearance, reduction
in polyp recurrence.
Insomnia, mood
changes,
hyperglycemia,
gastritis, increased
intraocular
pressure, avascular
necrosis
Minimal Balance of benefit and
harm
Option for systemic
corticosteroids
Mitomycin C B Reduction in synechia
formation, improvement
in maxillary ostium
patency
Off-label use, systemic
absorption, local
toxicity
Moderate to high Balance of benefit and
harm
Recommendation
against mitomycin
C
N/A = not applicable.
patients that have failed AMT.75,77 In addition, cardinal
symptoms1338 and most symptoms classically ascribed to
CRS1339 substantially improve, and patient rating of health
utility increases to that of the normal population after
ESS.1340 Patients undergoing revision surgery, regardless
of polyp status, also experience significant improvement,
though the magnitude of improvement is slightly less than
primary surgery patients, likely because of a selection bias
of more severe inflammatory disease in those requiring
revision surgery.77,1341,1342
Health utility measurements (how patients value their
current state of health) of CRS with and without poly-
posis demonstrate substantial reduction in health utility
comparable to those with moderate asthma, end-stage
renal disease, or Parkinson’s disease.46,49 Significant health
utility improvements are seen with ESS and are comparable
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to those seen with joint replacement surgery and coronary
angioplasty.46,49,1340,1343
Comparative effectiveness studies of patients treated
medically vs surgically can be divided into RCTs and
real-world, nonrandomized observational comparison
studies. A Cochrane Review in 20061130 based on 3
RCTs suggested that ESS did not offer additional benefit
when compared to medical therapies.751,1344 However,
the included trials evaluated patients who had not failed
a trial of appropriate medical therapy prior to random-
ization. Smith et al.1131,1148,1342 published subsequent
nonrandomized, real-world, multicenter observational
studies and have demonstrated significant benefits of ESS
over continued medical therapy in patients who have
failed an initial trial of appropriate therapy. This AMT
typically included at least culture-directed or broad spec-
trum antibiotics, INCS, and in most cases, a trial of oral
corticosteroids.1131,1148,1342,1343,1345 These benefits were
reflected in substantially greater QoL improvements as
well as decreased used of antibiotics, oral corticosteroids,
and reduced absenteeism in the group treated surgically.
43,1131,1148,1342,1343,1345 Finally, a modeling based eco-
nomic evaluation demonstrates that an ESS strategy has
a higher probability of being the more cost-effective
intervention in patients with refractory CRS compared
to continuing with medical therapy alone.1346 The most
recent Cochrane review highlights the lack of high-quality
RCTs, which are insufficient to draw firm conclusions.1127
ESS Outcomes Differences Between CRSwNP
and CRSsNP
Clinicians have typically divided CRS into those with and
those without polyps in an effort to further subclassify the
disease and better understand outcome differences, recog-
nizing that this is a gross and insufficient categorization,
but one which has been traditionally applied in clinical
practice and clinical research.
Patients with CRSwNP have worse objective (endoscopic
and CT) disease severity both preoperatively and post-
operatively relative to their CRSsNP counterparts.75,1347
Despite this, clinicians see significant improvement in
objective findings regardless of polyp status, indicating
that ESS is important in bringing the objectively measured
inflammatory processes under control.69,75,1347 Patients
with CRSwNP tend to have better baseline QoL relative
to patients with CRSsNP; however, specific symptoms
such as nasal airway obstruction and olfactory disturbance
tend to dominate CRSwNP.75,77,868,1347,1348 Interestingly,
patients with CRSwNP have the greatest improvement in
QoL following ESS despite their relatively better baseline
QoL.75,77
Future Directions in ESS Outcomes Research
QoL instruments are currently considered critical to the
evaluation of ESS outcomes in both CRSwNP andCRSsNP.
In addition, the degree of baseline QoL impairment tends
to drive patient decision-making for ESS1349 and can help
predict postoperative outcomes.1350,1351 Future research
needs to evaluate how incorporating patient-reported
outcome measures into clinical decision-making can
improve the outcomes after ESS. In addition, further study
is needed in relation to 3 recent publications which have
suggested that early intervention with ESS for patients
with refractory CRS is associated with reduced long-term
healthcare utilization and improved long-term clinical
outcomes.1135–1137
X.G. Surgery for CRSwNP and CRSsNP:
Complications
There are several studies that evaluate the rate of com-
plications in ESS as well as give recommendations for
prevention and treatment. It is clear that complications
during ESS still occur; however, it is reassuring to note
that the most severe complications are very uncommon
and appear to be equivalent across studies. There are a
number of well-performed analyses of complications that
are of significant interest to those performing ESS.
May et al.1352 performed a systematic review of studies
covering complications in ESS. They found the overall rate
of complications to be 0.85%. The rate of CSF rhinorrhea
(most common complication) was 0.4%, the rate of orbital
hematoma was 0.15%, and the rate of severe bleeding
requiring transfusion was 0.2%. Other miscellaneous com-
plications (adhesions, orbital penetration, etc.) occurred in
6.9% of patients.
Stankiewicz et al.1353 reviewed their experience involving
ESS in 3402 patients and noted an overall complication
rate of 3.1%. These complications were subdivided into 14
different varieties of medical and surgical complications.
The most frequent complication was hemorrhage (41/3402
or 1.2%), which was primarily postoperative in nature.
Orbital hematoma was the second most common (20/3402
or 0.6%), and the third most common complication was
CSF rhinorrhea (19/3402 or 0.6%). Other less common
complications included meningitis, deep vein thrombosis,
toxic shock, permanent blindness (2/3402 or 0.06%),
temporary blindness (2/3402 or 0.06%), cardiac shock,
and diplopia. Factors felt to be associated with an increased
risk of these complications included age, revision surgery,
polyps, and anatomic variations. Hopkins et al.1354
reported a similar rate (0.4%) of major complications
in 3128 patients prospectively evaluated in 87 National
Health Service hospitals in England and Wales. Minor
complications were defined as any other untoward event,
and this occurred at an overall rate of 6.6% (207/3128).
As with the review by Stankiewicz et al.,1353 Hopkins
et al.1354 found the presence of polyps to be a risk factor
for complications; moreover, LM score, QoL scores, and
medical comorbidities were also found to be risk factors.
Interestingly, the extent of surgery, use of microdebrid-
ers, and surgeon experience were not identified to be
factors.
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Surgeon experience has been felt by several authors
to be a factor in complications. Both Stankiewicz1355
and Soyka and Holzmann1356 discuss whether risk is
commensurate with surgeon experience. After reporting
on an initial incidence of complications, Stankiewicz1355
demonstrated that after the experience of an additional 300
ethmoidectomies, the overall complication rate went from
29% down to 9.3%, suggesting that as experience with
the procedure increased, the likelihood of complications
decreased. Using the Rombout and de Vries1357 criteria,
Soyka and Holzmann1356 retrospectively evaluated 421
endoscopic procedures of varied complexity as performed
by surgeons of varied skill levels and found that there was
an overall complication rate of 39.7%, which included
both minor and major complications. However, there was
no significant correlation between the experience of the
surgeon and the incidence of complications. Extent of
surgery was not found to be correlated with complications
either. These latter 2 findings appear to support the
experience of Stankiewicz et al.1353 and Hopkins et al.,1354
and although conflicting, do remind the reader that
complications occur even with experienced surgeons.
In a broader review, Ramakrishnan et al.1358 reviewed
a nationwide database of 40,638 patients undergoing ESS
from 2003 to 2007. The overall rate of complications was
1.00%. The authors found that the rate of CSF leak was
0.17% and the rate of orbital injury was 0.07%. Most CSF
leaks were recognized the day of surgery, and 76% were
recognized within 30 days. CSF leaks were less common
in the pediatric population, but orbital complications were
more likely to occur in this group. The authors were unable
to make any definitive conclusions about the influence of
IGS on complication rates. This review is limited in its
collection of data, as it has been noted to be difficult to
assess how severe complications were and what possible
other surgical and/or medical or health-related QoL factors
may have contributed to the complications.
Similarly, Krings et al.1359 used a larger set of healthcare
data to determine the rates of complications in 78,944
patients undergoing primary ESS as well as 4151 patients
undergoing revision ESS during the years 2005 to 2008.
The overall complication rates in patients undergoing
primary ESS and revision ESS were 0.36% (288/78,944)
and 0.46% (19/4151), respectively. The rate of skull-base
complications in patients undergoing primary ESS and re-
vision ESS was 103 (0.13%) and 10 (0.25%), respectively.
The rate of orbital complications in patients undergoing
primary ESS and revision ESS was 178 (0.23%) and 12
(0.29%), respectively. The authors found that complica-
tions were significantly more common in patients aged 41
to 65 years, in patients age >65 years, in patients insured
with Medicaid, and in those undergoing frontal sinus
surgery. There were no differences in skull-base complica-
tions in surgeons who utilized IGS compared to those who
did not; however, the overall rate of complications was
higher in surgeries where IGS was utilized.
Asaka et al.1360 performed a prospective study on 706
patients undergoing ESS for CRS. The overall complication
rate in this group of patients was 5.8% (41/706). The rate
of CSF rhinorrhea in this group was 0.14% (1/706); orbital
complications occurred in 2.0% (14/706). Factors that
were significantly correlated with complications included
higher LM score, asthma and higher polyp score. Revision
surgery was not associated with a higher complication
rate in this series. The authors recommended evaluation
for lower airway disease as well as deploying preoperative
measures to reduce polyp scores in order to mitigate
complications. Because polyps widely appear to correlate
with an increased rate of complications, Devars du Mayne
et al.1361 compared polypectomy to ethmoidectomy in
patients with CRS. Although both groups enjoyed a similar
success rates (and recurrence rates), the group receiving
polypectomy alone did incur fewer complications. This
may be an expected result if the ethmoid is not completely
dissected, but it may serve as an alternative procedure
when indicated for the management of CRSwNP.
Armengot-Carcellar et al.1362 reported a 0.39% incidence
of intracranial complications in 763 patients; 3 patients
developed CSF rhinorrhea, 1 of which developed a brain
abscess requiring incision and drainage. Hou et al.1363 re-
viewed their series of ESS and found 19 cases of intracranial
complications. The intracranial complications included 14
CSF leaks, 3 direct frontal lobe injuries, 1 incident of sub-
arachnoid hemorrhage, 2 cases of meningitis, and 3 cases
of pneumocephalus. Pneumocephalus is a rare neurological
complication of ESS, and other than those reviews1362,1363
previously described, other case reports1364,1365 of pneu-
mocephalus after ESS seem to imply that this complication
is sufficiently managed with endoscopic closure.1366
Microdebriders or tissue shavers have revolutionized the
manner in which ESS is performed. Ironically, the speed
with which the microdebrider functions can be considered
1 of its largest shortcomings. The microdebrider does not
discriminate between orbital fat or muscle and polypoid
mucosa and will remove these tissues with equal efficiency.
Bhatti et al.1367 presented 2 unique cases of microdebrider-
associated ocular injury during ESS and reviewed the
literature concerning orbital injury during ESS, They
concluded that detailed preoperative review of imaging is
essential prior to surgery and that great care must be taken
when performing an ethmoidectomy. They also recommend
prompt intervention in the case of orbital injury. Despite
the seriousness of injury related to the microdebrider, it
continues to be a safe and effective instrument.1368
Balloon catheters are increasingly deployed during ESS.
Bolger et al.1369 reported the initial results of balloon
catheter dilation on patients with 24 weeks of follow-up
and no significant adverse events were noted. Vaughn1370
reviewed a number of uncontrolled studies pertaining to
the use of transnasal balloon catheters and determined that
the number of serious complications was low. Nonethe-
less, scattered reports1371,1372 indicate the possibility of
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catheter-related complications, including ethmoid CSF
leak,1373 which serves as a reminder that any tool used
during ESS may lead to complications. Transantral balloon
catheters that dilate the maxillary sinus ostium and
infundibulum have shown no significant adverse events
after initial use1374 and after 1 year of follow-up.1375
Fortunately, major complications in ESS are rare. These
reports nonetheless highlight that significant complications
can occur and that attention to details, meticulous dissec-
tion, and effective perioperative medical management of
the patient are essential to help avoid these complications.
XI. Pediatric Rhinosinusitis
XI.A. Pediatric ARS
XI.A.1. Pediatric ARS: Definition and Incidence
ARS is 1 of the most common problems encountered by
medical practitioners throughout the world.7,178,205,1376
There is a strong relation between viral URIs and ARS
and most agree that the clinical diagnosis of pediatric
ARS of bacterial etiology can be made clinically in 1 of
3 situations: URI symptoms (nasal discharge, congestion
and cough) persisting for more than 10 days; an abrupt
increase in severity of symptoms after initial improvement
(also known as double sickening); or a URI that seems
more severe than usual (high fever, copious purulent nasal
discharge, cough, and severe local pain).7,1376
EPOS defined pediatric ARS as the sudden onset
of 2 or more of the following symptoms: nasal block-
age/obstruction/congestion or discolored nasal discharge or
cough (daytime and nighttime) for <12 weeks.7 The 2012
EPOS further subdivides pediatric ARS into 3 categories:
acute viral RS; acute postviral RS; and ABRS. Acute postvi-
ral RS is defined as the increase of symptoms after 5 days or
persistent symptoms after 10 days with less than 12 weeks’
duration. ABRS is differentiated from the above conditions
by the presence of at least 3 symptoms/signs including:
discolored discharge (with unilateral predominance) and
purulent secretions; severe local pain (with unilateral pre-
dominance); fever (>38°C); elevated ESR/CRP; and double
sickening. In contrast, the AAP 2013 “Clinical Practice
Guidelines for the Diagnosis and Management of Acute
Bacterial Sinusitis in Children Aged 1 to 18 Years”1376
defines ABRS as persistent illness, ie, nasal discharge (of
any quality) or daytime cough or both lasting more than
10 days without improvement or worsening course, ie,
worsening or new onset of nasal discharge, daytime cough;
or fever after initial improvement; or severe onset, ie, con-
current fever (temperature 39°C/102.2°F) and purulent
nasal discharge for at least 3 consecutive days.1376 EPOS
defines pediatric ARS by symptoms lasting <12 weeks with
complete resolution whereas symptoms lasting >12 weeks
without complete resolution are consistent with CRS.7
Subacute rhinosinusitis is not included, as has been done
for adult RS in other consensus documents and guidelines,
because it is not clear that this is a distinct clinical entity.4
Most estimates of the incidence of pediatric ARS are
based on the above criteria. In a longitudinal study of 112
children age 6 to 35 months, 623 URIs were observed over
a 3-year period and episodes of RS as defined in the previ-
ous paragraph were documented by the investigators in 8%
of the cases. 1377 In an older study, 159 full-term infants
were followed prospectively for a 3-year period and the
frequency of URIs and complicating RS were evaluated.1378
The authors calculated the percentage of children expe-
riencing symptoms beyond 2 standard deviations from
the mean duration of respiratory symptoms (range, 16 to
22 days) and took that as an indicator of ARS. The
incidence based on these assumptions ranged between 4%
and 7.3% and was highest for children in their first year of
life and in daycare. Another study evaluating 2135 children
with respiratory complaints found that 139 fulfilled the cri-
teria for ARS (6.5%).1379 In 2 studies that queried children
presenting to pediatric practices for any reason and identi-
fied those who had symptoms consistent with ARS, the inci-
dence was 9.3% (121/1307)1380 and 8.3% (249/3001),1381
respectively. In a study of 2013 children, the addition of
a positive Water’s view to clinical symptoms decreased the
incidence estimate negligibly (7.2% to 6.7%).1382
XI.A.2. Pediatric ARS: Pathophysiology
Pediatric ARS, like adult ARS, is a disorder that involves
inflammation of the nasal and paranasal sinus mucosa.
Through various mechanisms—such as epithelial damage
and cytokine upregulation—viruses activate inflammatory
pathways and the parasympathetic nervous system to
generate the symptoms of ARS.1383 The inflammatory
process leads to edema, engorgement, fluid extravasation,
mucus production, and obstruction of the sinus ostium.
Similar to adults, the OMC is believed to be the critical
anatomic structure in ARS and is entirely present, though
not at full size, in newborns. The normal movement of
mucus by mucociliary transport toward the natural ostia
of the sinuses and eventually to the nasopharynx can be
disrupted by any ciliary dysfunction or edema related to
mucosal inflammation. Ostial obstruction impedes normal
ventilation and drainage of the sinuses, which can lead to
bacterial infection and ARS.
Nearly 30 years ago, cultures were obtained from
children with maxillary sinus opacification documented
by Water’s X-ray by means of maxillary sinus taps and
the most frequently isolated organisms were Streptococcus
pneumonia (in approximately 30%), nontypeable H.
influenzae, and M. catarrhalis (in approximately 20%
each).1384,1385 In these studies 25% to 30% of the aspirates
were sterile. Because of the difficulty in performing max-
illary sinus aspirates in healthy children, no recent data on
the bacteriology of ARS is available. Although in adults it
has been shown that middle meatal cultures mirror max-
illary contents, this has not been confirmed in the context
of pediatric ARS. Further, 1 study shows that the middle
meatus is colonized with S. pneumoniae, H. influenzae,
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and M. catarrhalis in healthy children.1386 Because of
these constraints, recent estimates of the microbiology of
ARS are extrapolated from those of acute otitis media, a
condition with traditionally similar microbiology.1376 The
routine use of pneumococcal conjugate vaccine has been
associated with a decrease in recovery of S. pneumoniae
from the middle ear fluid of children with acute otitis media
(AOM) and a relative increase in the incidence of recovery
of H. influenzae.1387 Assuming that approximately 25%
of the maxillary sinus aspirates would still be sterile, as
documented in earlier studies, one would extrapolate the
current bacteriology of ARS to consist ofH. influenzae and
S. pneumoniae (30% each) and M. catarrhalis (10%).1376
There is 1 limitation to extrapolating ARS conditions from
those of AOM. Although the AOM visit rate for children
younger than 18 years dropped after the introduction of
the heptavalent pneumococcal conjugate vaccine in the
United States, the visit rate for ARS remained stable at 11
to 14 visits per 1000 children between 1998 and 2007.14
XI.A.2.a. Pediatric ARS: Contributing Factors.
Conditions that can contribute to ARS include rhinitis (al-
lergic and nonallergic), coexisting medical conditions (CF,
immune deficiency, ciliary dyskinesia), and environmental
factors (smoking, daycare).1388 Chronic conditions such
as CF, immune deficiency, and ciliary dyskinesia are more
likely to be associated with CRS.
There are scant data on the correlation of AR and ARS in
children. In a retrospective study of 92 patients with RARS,
children with allergies sustained 1.09 more sinus infections
than nonallergic patients, a significant difference.1389 In
another study of children with ARS and CRS, there were
statistically significantly more patients with a clinical
history of AR in the CRS group (90.2%) vs the ARS group
(74.8%).1390 The percentage of positive skin-prick test re-
sults was similar in both groups (96.4% in ARS and 96.9%
in CRS). Most of the available studies suffer from referral
bias because they are conducted in allergy practices.
Adenoiditis can have a very similar clinical presentation
including anterior and posterior purulent drainage and
cough and is relevant in the differential diagnosis in the
pediatric age group. In a study of adenoid size evaluated
by MRI in a patient cohort with no symptoms related to
the adenoids or adenoid disease, adenoid size was larger
in the pediatric age group and declined with advancing
age.1391,1392 Peak size was between 7 and 10 years of age
and largest dimensions were in the group 4 to 15 years old.
In an attempt to differentiate between adenoiditis and ARS
based on endoscopic findings, Marseglia et al.1393 per-
formed a cross sectional study of 287 consecutive children
in whom ARS was suspected based on symptoms lasting
for more than 10 days. Nasal endoscopy was performed
and the diagnosis of ARS was made if purulent discharge
was identified in the OMC or sphenoethmoidal recess, and
the diagnosis of adenoiditis was made if there was purulent
drainage over the adenoids. Based on those criteria, ARS
was confirmed in 89.2% of the patients and was isolated in
80.8% and coupled with adenoiditis in 19.2%. Adenoiditis
alone was confirmed in 7% of the cohort. Combined in-
volvement of the sinuses and adenoids was more frequent
in younger patients (age 2 to 5 years) whereas isolated ARS
was more frequent in older children. Although this study
has limitations, such as the manner in which the diagnosis
was made, one would expect drainage from the sinuses
to involve the adenoids as it moves posteriorly within
the nasal cavity. This, combined with the lack of a more
objective measure to diagnose ARS, would suggest the
available data support the coexistence of infection of the
adenoids and the paranasal sinuses. It is also evident that
based on clinical presentation alone, the differentiation
between adenoiditis and ARS in children is difficult.
XI.A.3. Pediatric ARS: Diagnosis
The clinical diagnosis of ARS in children is challenging be-
cause symptoms are often subtle and the history is limited
to observation of the child and subjective evaluation by
the child’s parent. When evaluating a child with suspected
ARS there is a wide differential diagnosis including: acute
viral RS, acute postviral RS, ABRS, intranasal foreign
body, adenoiditis, CF, PCD, and unilateral choanal
atresia/stenosis. The initial diagnostic workup for such
patients should include a thorough history and physical
examination and nasal endoscopy, when appropriate.7
Because some younger children might not tolerate nasal
endoscopy, clinicians are sometimes hindered in their
physical examination and have to rely on history and/or
imaging studies for appropriate diagnosis. Symptom pro-
files of ARS in children include fever (50-60%), rhinorrhea
(71-80%), cough (50-80%), and pain (29-33%).20 In
a study of 69 children between the ages of 3 and 12
years, ARS was diagnosed by purulent nasal drainage for
more than 7 days and abnormal findings in the maxillary
sinuses on Water’s projection. In these children, the most
troublesome symptoms were PND, nasal obstruction,
and cough.1394 In a mail survey of American general
pediatricians, symptoms thought to be very important
in the diagnosis of ARS included prolonged symptom
duration, purulent rhinorrhea, and nasal congestion.1395
The physical exam in children includes anterior
rhinoscopy to examine the middle meatus, inferior
turbinates, mucosal character, and presence of purulent
drainage. This is often accomplished using the largest
speculum of an otoscope, or alternatively, a headlight
and nasal speculum. Topical decongestion may be used to
improve visualization. Nasal endoscopy allows superior
visualization of the middle meatus, adenoid bed, and
nasopharynx, and is strongly recommended in children
who are able to tolerate it. An oral cavity exam may
reveal purulent postnasal drainage, “cobblestoning” of the
posterior pharyngeal wall, or tonsillar hypertrophy.
As far as factors that could predict the presence of ARS
in the context of URIs, prospective studies using the above
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definitions (see Section XI.A.1) to identify ARS after URI
(prolonged duration or double-sickening) supplemented
the clinical diagnosis by obtaining plain X-rays of the
sinuses. In 1 of these studies, 54 of 258 (21%) children with
presumed ARS had normal sinus radiographs, suggesting
that they just had URI and not ARS.1396 The absence of
green nasal discharge and disturbed sleep, as well as milder
symptoms, was associated with the diagnosis of URI and
not ARS. No physical findings were particularly helpful in
distinguishing between children with normal vs abnormal
radiographs.
Obtaining a culture is usually not necessary in the con-
text of uncomplicated ARS. It might be useful in patients
who have not responded to conventional medical treatment
within 48 to 72 hours, in immunocompromised patients, in
the presence of complications, and if the child presents with
severe illness and appears toxic.20,1397 Although the gold
standard is a maxillary sinus tap, this is a relatively invasive
procedure and is difficult to perform in a child in the office.
The diagnosis of pediatric ARS is generally made on
clinical grounds and imaging is not routinely necessary.
Several studies have reported the presence of incidental
abnormalities of the sinuses on CT scan in asymptomatic
children1398,1399 and the occurrence of abnormal CT
or MRI sinus findings in a large proportion of children
with viral URIs.1400–1402 This reinforces the notion that,
like in adults, every URI is essentially an episode of RS
with common involvement of the paranasal sinuses by
the viral process. As a result, the AAP’s clinical practice
guidelines1376 state that imaging does not have a role in
distinguishing acute viral from acute bacterial RS and does
not have a role in uncomplicated ARS.
XI.A.4. Pediatric ARS: Management
Current guidelines recommend only symptomatic treat-
ment for children with uncomplicated ARS.7,1376 The 2012
EPOS further recommends antibiotic therapy for children
with complications or concomitant disease that could be
exacerbated by ARS. The initial antibiotic of choice remains
amoxicillin; additional first-line agents include amoxicillin-
clavulanate and cephalosporins.7 The 2013 AAP guidelines
recommend antibiotic treatment for patients with severe
onset of disease or worsening course. Patients with a per-
sistent illness defined as “nasal discharge of any quality or
cough or both for at least 10 days without evidence of im-
provement” can be offered antibiotic treatment or 3 days of
outpatient observation. The AAP recommends amoxicillin
with or without clavulanate for empiric treatment of ABRS.
The AAP cautions practitioners to monitor patients for
symptom improvement/resolution within 72 hours of the
initial treatment decision and to consider initiation of an-
tibiotic therapy for patients observed or adjustment of an-
tibiotic therapy for patients treated with amoxicillin with or
without clavulanate if there is not clinical improvement.1376
For patients allergic to amoxicillin, the AAP guideline
recommends a second-generation or third-generation
cephalosporin as monotherapy for ABRS because the
vast majority of patients with such sensitivity tolerate
cephalosporin therapy.1376 For patients under 2 years of age
with a documented type-1 hypersensitivity to penicillins
and moderate to severe ABRS a combination of clin-
damycin and cefixime is suggested.1376 A fluoroquinolone,
such a levofloxacin, can also be used to treat ABRS in
patients with a severe penicillin allergy.1376 It should be
noted that levofloxacin does not have an FDA-approved
indication for ABRS in children and has potentially serious
side effects, including tendonitis and tendon rupture, that
should be considered prior to the initiation of therapy.
In contrast, the 2012 Infectious Disease Society of Amer-
ica (ISDA) clinical guideline for the management of ABRS
recommends amoxicillin-clavulanate for empiric therapy
for ABRS in children.178 The ISDA guidelines also recom-
mended that high-dose amoxicillin-clavulanate, defined as
90 mg/kg/day orally twice daily, be used as a first-line ther-
apy in children who live in a geographic region with high
endemic rates of penicillin-nonsusceptible S. pneumoniae,
with a severe infection, who attend daycare, are less than 2
years old, who have had a recent hospitalization, who have
used an antibiotic within the past month, or who are in an
immunocompromised state.178 Macrolides, trimethoprim-
sulfamethoxazole, as well as second-generation and
third-generation cephalosporins were not recommended
for empiric monotherapy of ABRS. The recommendation
against the use of cephalosporins for empiric monotherapy
in penicillin-allergic patients is in contrast to that made
by the AAP.1376 The combination of a third-generation
cephalosporin with clindamycin was recommended as
second-line therapy for children with non–type I penicillin
allergy or from geographic regions with high endemic
rates of penicillin-nonsusceptible S. pneumoniae.178
Levofloxacin was the antibiotic of choice for children
with a history of type I hypersensitivity to penicillin, and
clindamycin plus a third-generation cephalosporin was
recommended for children with a history of non–type I
hypersensitivity to penicillin.178 The ISDA recommends
antibiotic treatment for a duration of 10 to 14 days.178
Regarding adjunctive treatments, the 2012 EPOS in-
dicates a role for INCS in the management of pediatric
ARS.7 A recent Cochrane review failed to detect any
evidence supporting the efficacy of nasal decongestants,
antihistamines, or nasal irrigations in the management of
pediatric ARS.205 There is no role for ESS in children with
uncomplicated ARS (Table XI-1).
 Aggregate Grade of Evidence: A (Level 1a: 4 studies).
 Benefit: Reduction in duration and severity of symptoms.
 Harm: Antibiotic resistance, gastrointestinal complica-
tions, risk of allergic reaction
 Cost: moderate for antibiotics other than amoxicillin.
 Benefits-Harm Assessment: Benefits likely outweigh
harms and costs.
 Value Judgements: Parental preference often plays a large
role in decision-making
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TABLE XI-1. Evidence for management of pediatric ARS
Study Clinical
Study Year LOE Study design groups endpoint Conclusions
Shaikh205 2014 1a Systematic review Multiple N/A No evidence supporting the use of nasal
decongestants, antihistamines, or nasal irrigations
Wald1376 2013 1a Systematic review Multiple N/A Definition, evaluation, and management
recommendations
Chow178 2012 1a Systematic review Multiple N/A Treatment recommendations
Fokkens7 2012 1a Systematic review Multiple N/A Definition, evaluation, and management
recommendations
N/A = not applicable.
 Policy Level: Recommendation.
 Intervention: Antibiotics should be given to pediatric pa-
tients with ARS although the specific antibiotic and ex-
actly when to intervene differ among clinical practice
guidelines.
XI.A.5. Pediatric ARS: Complications
Complications arising from pediatric ARS are uncom-
mon but require immediate medical attention. The main
complications from pediatric ARS are orbital (60-75%),
intracranial (15-20%), and osseous (5-10%).7,1376 Orbital
complications are the most common complications of
pediatric ARS and range from preseptal cellulitis to
orbital abscess, as described by Chandler.232 Additional
orbital complications can include blindness, optic neuritis,
corneal ulceration, and panophthalmitis. Intracranial
complications can include epidural abscess, subdural
abscesses, brain abscess, meningitis, and cerebritis, as well
as superior sagittal and/or cavernous sinus thrombosis.
Osseous complications include osteomyelitis of the frontal
and maxillary bones. Signs and symptoms of complications
arising from pediatric ARS include lethargy, headache, eye
pain, pain with eye movement, periorbital edema, high
fever, nausea/vomiting, diplopia, photophobia, papillary
edema, seizures, cranial neuropathies, and focal neurologic
deficits. The 2013 AAP guidelines on ABRS recommend
obtaining a contrast-enhanced CT scan of the paranasal
sinuses and/or an MRI with contrast whenever a child
is suspected of having orbital or central nervous system
complications of ABRS. The 2012 EPOS guidelines recom-
mend imaging for every complication other than preseptal
cellulitis.7,1376 Early orbital complications can sometimes
be managed with IV antibiotics alone, whereas the more
severe complications of pediatric ARS may require a
combination of IV antibiotics and surgical treatment.
XI.B. Pediatric CRS
XI.B.1. Pediatric CRS: Incidence/Prevalence
The incidence and prevalence of pediatric CRS (PCRS)
are unknown. Patients with chronic rhinorrhea, nasal
congestion, and cough may be commonly seen in primary
care and otolaryngology. In an attempt to understand how
many of these children actually have PCRS, 196 children
3 to 14 years of age presenting with these symptoms were
examined with CT scans. Maxillary sinus involvement was
noted in 63%, ethmoid in 58%, and sphenoid in 29%
of these children.1403 In a separate study, the incidence of
anatomical variations as a possible cause of PCRS has been
reported, with agger nasi cells present in 15.9%; concha
bullosa in 10% to 19%; NSD in 13%; and infraorbital
ethmoid cells in 5.3% to 7.5%. However, there was no
control group to determine whether those anatomical
variations were seen in a higher incidence in PCRS group
compared to children with no RS.1404
XI.B.2. Pediatric CRS: Pathophysiology
The pathophysiology of PCRS is not very well understood
and is thought to be multifactorial, possibly involving bac-
teria, biofilms, adenoiditis, and/or inflammatory cellular
changes.
Bacteriology has not changed over the last 2 to 3 decades,
except for a rise in S. aureus and anaerobic bacteria. In
a study by Muntz and Lusk in 1991,1405 the most com-
mon species were alpha hemolytic Streptococcus and S.
aureus, followed by S. pneumoniae, H. influenzae, and M.
catarrhalis. Anaerobes were seen in 6% of children. All
those were specimens obtained at time of sinus surgery.1405
In a more recent study, the most common species were
alpha hemolytic Streptococcus followed by H. influenzae,
S. pneumoniae, S. aureus, and anaerobes in 8% of surgical
specimens.1406 Several other studies between 1991 and
2010 were performed without much change from 2 decades
ago. When examining the susceptibility of organisms over
time, there was an increase rate of resistance for H.
influenzae as well as S. pneumoniae species. Resistance to
ampicillin amongH. influenzae rose from a little over 50%
in 2001 to more than 70% in 2006.1407
Adenoids are what distinguish PCRS from adult CRS.
The adenoids are thought to act as a reservoir of bacteria.
Bernstein et al.1408 in 2001 found that bacteria from
adenoids correlated with lateral nasal wall cultures in 89%
of cases with PCRS. Shin et al.1409 cultured the adenoids
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in patients with various degrees of abnormalities of their
maxillary sinuses on Waters views and found a significant
increase in bacterial isolation rate with increasing severity
of RS. Coticchia et al.1410 examined 16 adenoid samples
for biofilm. Seven were children with CRS and 9 were
children with OSA. All adenoid samples of children with
CRS had biofilm on their surface, covering an average of
95% of the surface area compared to only 2% coverage of
the surface area of the adenoids in children with OSA.1410
It is also believed that some children may have chronic
adenoiditis with no CRS because symptoms of the 2
entities cannot be distinguished without CT scan of the
sinuses.1411 There is controversy whether the size of the
adenoids matter in children with PCRS. Children with
symptoms of RS who had a CT scan of the sinuses and
underwent an adenoidectomy were investigated and results
showed no correlation between the size of the adenoids
and the severity of disease on CT scan.1412 This suggests
that symptoms can be due to adenoiditis and that the
bacterial reservoir of the adenoids, more than their size,
was the cause of symptoms in these children.1412 There
is also some evidence to suggest that the adenoids act
as an immunological organ. In 1 study comparing the Ig
expression of adenoid tissues of patients with adenoid
hypertrophy to those with CRS, there was a significantly
lower expression of IgA in the adenoids of children with
CRS. This suggests that the adenoids in CRS children can-
not mount a strong local immune response. Whether this
is a primary deficiency or a secondary response to chronic
nasal discharge cannot be determined from this study.1413
In order to examine inflammatory cellular changes, Chan
et al.1413 compared maxillary sinus biopsies of children
with CRS to adult archival maxillary sinus tissue. They
noticed more neutrophils and more lymphocytes in the
pediatric mucosa compared to adult mucosa. The adult mu-
cosa hadmore eosinophils andmajor basic protein–positive
cells. They also found less epithelial disruption and thick-
ening of the basement membrane in children compared to
adults.1413 In a similar study, sinus specimenswere obtained
from children with CRS and compared to samples that were
obtained from adults. Even though the children were older
in this study compared to the other study (mean 11.6 vs
3.9 years), the children’s samples had less eosinophils and
less epithelial damage than the adult samples.1414
XI.B.2.a. Pediatric CRS: Contributing Factors.
Asthma has been shown to be a factor in children with CRS.
At times asthma not responding to medical therapy can
be the only presenting symptom of PCRS. The relationship
between asthma exacerbations and PCRS has been shown
in several studies. In a series of 48 children with moderate
to severe asthma refractory to medical treatment with
daily wheezing for 7 months, 80% of children were able to
discontinue their asthma medications after their CRS was
treated medically or surgically. Eighty percent of these chil-
dren had normal findings on sinus X-rays after treatment.
Asthma symptoms returned when RS recurred.1415 In an-
other study of 18 children with poorly controlled asthma,
RS was treated with oral antibiotics and intranasal and
systemic corticosteroids. They were evaluated at baseline
and 1 month later. Their sinonasal symptoms resolved with
8 of 18 children having intermittent asthma and 10 of 18
children having mild asthma based on their symptoms and
spirometry compared to baseline. These and other studies
support the concept that controlling the CRS in these
children will contribute to controlling their asthma.1416
The association between AR and the development of
PCRS is controversial. Some studies have shown a possible
association, whereas others suggest that allergy is not a
significant factor. In a 2007 study of 2200 children who
were referred for chronic respiratory symptoms, 351 were
diagnosed with CRS. They underwent skin-prick testing:
29.9% were found positive, an incidence similar to that
noted in the general population (31.8%).1417 Similarly, in
a study of 4044 children with PCRS, AR was found to be
present in 26.9% of patients. Sedaghat et al.1418 in 2013
reviewed a cohort of children with AR and found that
patients who developed PCRS did not have any evidence
of more severe AR. The association between AR and PCRS
is thought to be multifactorial.1418
Immunodeficiency has been reported to be a factor in
several studies of PCRS. Abnormalities commonly seen
include IgG subclass deficiencies, IgA deficiency, and poor
response/deficiencies in pneumococcal titers.592,1419,1420
Management with IVIG for those children resulted in
decrease in antibiotic intake and reduced episodes of CRS.
Children with CRS may benefit from an Ig evaluation and
also titers for tetanus, diphtheria, and Pneumococcus.
CF is an autosomal recessive genetic disease associated
with a high incidence of PCRS and nasal polyposis. Any
child with NPs should be evaluated for the presence of
CF with a sweat test and, potentially, DNA testing.1421
Children who present with NPs as a component of PCRS
represent a distinct subgroup and should be dealt with
accordingly.1422
PCD is a rare cause of PCRS. Any disruption to the mu-
cociliary function can result in PCRS. PCD is the most com-
mon cause of ciliary dysfunction and should be suspected in
PCRS patients who are not responding to medical and even
surgical treatment. PCD is an autosomal recessive disorder
involving dysfunction of cilia with an incidence of 1 in
15,000 individuals. In 50% of the cases of PCD, situs inver-
sus and bronchiectasis are present; with the association of
CRS, PCD is known as Kartagener’s syndrome.1423 Screen-
ing tests include nasal NO and in vivo tests such as the sac-
charin transit test, which shows slower mucociliary transit
time. Those screening tests can be falsely negative in a good
percent of the children. A more definitive test is to obtain a
mucosal sample preferably from the carina (another option
is posterior tip of inferior turbinate) and examine the
specimen for cilia with light and electron microscopy. The
most common abnormality is lack of outer dynein arms or
a lack of both inner and outer dynein arms.1424,1425
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TABLE XI-2. Summary of selected evidence for PCRS management
Study Year Study design Conclusion
Brietzke1426 2014 Systematic review Evidence-based expert panel consensus in the diagnosis and
management of PCRS
Makary1433 2013 Systematic review ESS offers a surgical alternative in the treatment of CRS in children
with an excellent safety profile. Higher LOE is necessary
Fokkens7 2012 Systematic review Treatment evidence and recommended management algorithm
provided
Setzen1434 2012 Systematic review CT imaging in PCRS is recommended in the setting of treatment
failures and complications, either of the pathological process itself
or as a result of iatrogenic complications
Ozturk1429 2011 RCT The addition of oral corticosteroids to oral antibiotics reduced clinical
PCRS symptoms and CT findings
Wei787 2011 RCT High tolerance, compliance, and effectiveness of saline irrigation
support its use as a first-line treatment for PCRS
Brietzke1430 2008 Systematic review Adenoidectomy should be considered first line therapy for medically
refractory, uncomplicated pediatric RS, given its simplicity, low
risk profile, and effectiveness
Ramadan1432 2008 Retrospective series For pediatric patients with LM scores greater than 6, the addition of
maxillary sinus irrigation at the time of adenoidectomy was found
to improve clinical symptoms of PCRS 1 year postprocedure
Ramadan1431 1999 Cohort study Prospective, nonrandomized cohort evaluation revealing higher
success in PCRS patients failing medical therapy undergoing ESS
in comparison to adenoidectomy
Controversy and uncertainty exists about the role of
GERD in PCRS. An association has been suggested;
however, there is lack of evidence to support this asso-
ciation. In a recent consensus statement on PCRS, there
was agreement that empiric treatment for GERD in the
context of PCRS is not indicated. Similarly, consensus was
not reached regarding the contribution of GERD in the
pathogenesis of PCRS.1426
XI.B.3. Pediatric CRS: Diagnosis
PCRS is defined as signs and symptoms of nasal congestion,
colored nasal discharge, facial pressure or pain, or cough
that has been present for 12 or more weeks.1427 Two
or more symptoms are needed to diagnose PCRS. These
symptoms should be accompanied by findings of puru-
lent discharge, and mucosal edema/changes on anterior
rhinoscopy/nasal endoscopy. Nasal endoscopy when feasi-
ble will provide information that will aid in the diagnosis.
Also, this will allow examination of the adenoids and na-
sopharynx, as well as determine the presence of polyps.1426
Plain X-rays have no role in the diagnosis of PCRS. Find-
ings on plain radiographs have been shown not to correlate
well with those from CT scans in patients with PCRS. In a
prospective study, children with CRS symptoms were im-
aged using plain radiographs and CT. The findings on plain
radiographs did not correlate with those onCT scan in 75%
of the 70 patients studied. About 45% of the patients had
normal findings on plain radiographs but at least 1 sinus
with an abnormality of that sinus shown on CT scan, and in
35% of the patients with an abnormality of at least 1 sinus
on plain radiographs that sinus was normal on CT scan.1428
Once PCRS is suspected in young children these symptoms
can be a manifestation of chronic adenoiditis with or with-
out RS. At this point the only mechanism to distinguish
whether CRS is associated with chronic adenoiditis is by
the use of CT scan of the sinuses. In a study comparing
66 children with CRS symptoms to 192 control children
having CT imaging for nonsinus indications, it was noted
that children with a LM score of 5 or more had a sensitivity
and specificity of 86% and 85%, respectively, of having
CRS, whereas a CT score of 2 had an excellent negative
predictive value of CRS, making the diagnosis of chronic
adenoiditis more likely.1411 It should be noted that use of
CT should be reserved for when surgery is being considered
and not utilized routinely to make the diagnosis of PCRS.
XI.B.4. Pediatric CRS: Management
Management of PCRS can pose a challenge to the oto-
laryngologist and result in a difficult course for patients
and families. Certain treatment principles should assist in
guiding optimization of outcomes. Recent position papers
have summarized the current state of the literature and
clinical consensus on PCRS7,1426 (Table XI-2).
PCRS management should focus on long-term behaviors
and nasal hygiene to limit disease burden. The goal
of restoring sinonasal homeostasis may be achieved by
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quelling mucosal inflammation and initiating targeted
antibiotics.7
PCRS management therefore begins with medical ther-
apies. Consensus exists that nasal saline irrigations are
beneficial in the pediatric population with 1a LOE.7,1426
Adherence of the pediatric population with nasal saline
irrigations may be considered with skepticism, though with
parental assistance, compliance is greater than 90%.787
Reports on the efficacy of INCS such as fluticasone
and mometasone are conflicting.7 However, given the low
systemic absorption and low risk profile, use of INCS
is recommended as first-line therapy as a component
of conservative medical management and postoperative
treatment regimens, particularly in patients suspected to
have IgE-mediated pathophysiologic processes.7 Double-
blinded, randomized prospective data supports the use
of systemic corticosteroids in addition to antibiotics for
symptomatic and radiographic improvements in children
with CRS.1429 The potential for serious side effects with
systemic corticosteroid use should reserve consideration
of such therapy for disease recalcitrant to more conser-
vative measures and as a possible adjuvant to surgical
therapy. Randomized prospective studies supporting nasal
antihistamines or decongestants are lacking.
Both EPOS and clinical consensus support empiric
broad-spectrum treatment with transition to culture-
directed antibiotics for 3 to 12 weeks, though there is
need for high LOE studies.7,1426 Initial empiric treatment
should cover S. pneumoniae, M. catarrhalis, nontypeable
H. influenzae S. aureus, and possibly anaerobic bacteria.
Amoxicillin/clavulanate or second-generation (cefuroxime)
and third-generation (cefdinir and cefixime) cephalosporins
are first-line antibiotics. Patients with penicillin allergy may
be prescribed cephalosporins, and if allergies are demon-
strated to both, may alternatively be prescribed a macrolide
or clindamycin. Randomized prospective double-blinded
data did not find statistical differences in topical gen-
tamicin irrigations over saline alone in the pediatric
population.787
Contributing comorbid conditions may increase the
complexity of management and addressing underlying
factors that are worsening CRS should be attempted.
Examples include consideration of GERD, immunode-
ficiencies, PCD, and CF. Randomized prospective data
and clinical consensus supporting the role of anti-reflux
medication in PCRS treatment are lacking.1426
Consideration for surgical intervention is made after
failed conservative nasal hygiene and medical management.
An official definition for appropriate medical therapy and
failure of such therapy is lacking. It is suggested that
medical management prior to surgery should, however,
include a course of antibiotic therapy, topical nasal and/or
systemic corticosteroids, and nasal saline irrigation.7
Surgical options are age-dependent and anatomy-
dependent. In younger children, adenoid hypertrophy
may play a larger role in treatment than ESS of the
relatively underdeveloped sinuses. Clinical consensus that
adenoidectomy alone is an effective treatment for PCRS
is strong in children up to 6 years old and supported
through 12 years of age, though evidence is lacking
beyond this age group.1426 The role of adenoid tissue in
CRS may be obstructive and/or serve as a reservoir for
bacterial growth. A 2008 meta-analysis of 9 studies found
clinical improvement, as judged by caregivers, in 70% of
children with CRS after adenoidectomy. The quality of the
constituent studies was judged as moderate, with five level
2b evidence studies and four level 4 reports.1430 A 1999
prospective, nonrandomized cohort analysis analyzed
success of adenoidectomy and ESS, where failure was
defined as persistence of symptoms and need for additional
procedure at 6 months postoperatively. Adenoidectomy
had a 47% success rate, whereas ESS had a 77% success
rate.1431 For pediatric patients with LM scores greater than
6, the addition of maxillary sinus irrigation at the time of
adenoidectomy was found to improve clinical symptoms 1
year after the procedure. 1432
There are several potential roles of ESS in PCRS. One
use for pediatric ESS in CRS is opening anatomic corridors
for irrigation and topical therapy delivery. Most data
supporting ESS is retrospective, though a 2013 review
cites success rates over 82% with a complication rate of
1.4%.1433 Newer technologies such as balloon sinus dila-
tion do not yet have robust data supporting their efficacy
in children. Finally, consensus exists that CT imaging is
recommended prior to ESS, and IGS has a role in revision
ESS or if distorting polyposis is present.1426,1434 Though
a potential for therapeutic improvement is acknowledged,
consensus was lacking regarding turbinoplasty or exci-
sion of obstructive concha bullosa because of the lack of
pediatric-specific evidence in the literature. Unlike the adult
population, postoperative debridement is not felt to be
essential.1426
XI.B.5. Pediatric CRS: Complications
The etiologic role of PCRS in nasal and paranasal complica-
tions is likely an anatomic, bacteriologic, and inflammatory
vulnerability to an ARS exacerbation. Literature asso-
ciates orbital complications (91% of RS complications),
osteomyelitis of the frontal bone (Pott’s puffy tumor),
meningitis, subdural empyema, epidural abscess, and brain
abscess with ARS or AECRS.1435 As such, incidence of
these complications specifically secondary to PCRS is
lacking. Limited retrospective evidence suggests a potential
contribution of CRS on the development of paranasal sinus
frontal osteomyelitis. One of 5 cases in a series of pediatric
osteomyelitis of the frontal bone was felt to be secondary
to PCRS.1436 Postsurgical intracranial complications
have been reported in the CF population, prompting the
recommendation of systematic follow-up.1437
Orbital, periorbital, or neurologic symptoms should
prompt rapid multidisciplinary evaluation, imaging, IV
antibiotics, and potentially surgical intervention. Central
nervous system complications should be treated with
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IV cefotaxime or ceftriaxone and vancomycin pending
cultures and susceptibilities.7
Complications associated with surgical intervention for
PCRS include the spectrum of potential complications for
ESS. The rate of major and minor complications is cited at
0.5% to 1%and 5%, respectively.1438 Major complications
include orbital hematoma and CSF leak. More frequent
minor complications are bleeding and synechiae. A recent
review of ESS extensively details these complications.1438
XII. Special Considerations in
Rhinosinusitis
XII.A. RS Special Considerations: Chronic
Granulomatous Diseases
Chronic granulomatous diseases (CGD) include granu-
lomatosis with polyangiitis (GPA, formerly Wegener’s
granulomatosis), Churg-Strauss syndrome, and sarcoido-
sis. All CGD conditions produce hallmark perivascular
or perilymphatic noncaseating granulomas. GPA and
Churg-Strauss syndrome cause systemic, necrotizing,
antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis, whereas sarcoidosis produces a chronic inflam-
matory disease of uncertain etiology.
GPA can affect any organ system with classic manifes-
tations of systemic illness, otitis media, nodular infiltrates
on chest radiograph, renal disease, and subglottic stenosis.
From the rhinologic perspective, progressive ischemic
necrosis of the nasal epithelium and internal structures
can occur, resulting in epistaxis, nasal stenosis, septal
perforation, and saddle nose deformity.1439 Churg-Strauss
syndrome is associated with both ANCA-positive testing
and 4 of 6 of the following clinical findings: refractory
CRSwNP, peripheral eosinophilia, asthma, neuropathy,
pulmonary infiltrates; and systemic vasculitis.1440 For
these reasons, Churg-Strauss syndrome is also termed
eosinophilic granulomatosis with polyangiitis (EGPA).
Sarcoid is typified by nodular, infiltrative lesions in the
nasal mucosa, but patients may develop friable mucosa
with nasal crusting and structural deformities similar to
GPA.
Management of CGD in general includes systemic con-
trol of disease via immunosuppression, with individualized
medical and/or surgical rhinologic care. In GPA the nose
and sinuses are managed for the most part with nonsurgical
treatment, including INCS and saline irrigation therapy.
Some series suggest that surgery for CRS, mucocele forma-
tion, and nasolacrimal stenosis may be beneficial to control
sequelae of GPA for appropriately selected patients.1441
Systemic manifestations of both sarcoidosis and Churg-
Strauss syndrome are managed with chemotherapeutic
agents, oral corticosteroids ± immune modulators, but
like GPA, the literature supports use of medical manage-
ment while reserving surgical intervention for persistent
rhinologic symptoms in select patients.1442–1446 Given the
epithelial abnormalities present in CGD patients, patients
should be counseled regarding suboptimal and/or delayed
healing that can follow intranasal procedures.
XII.B. RS Special Considerations: PCD
PCD is a heterogeneous genetic disorder causing defects in
cilia structure or function, resulting in compromised MCC
from respiratory epithelial surfaces and recurrent airway
infections. The term Kartagener syndrome is reserved
for PCD cases presenting with the triad of CRS, solid
organ transposition (situs inversus), and bronchiectasis.
The estimated incidence of PCD is 1 in 15,000 to 30,000
births1447 and radiographic changes of PCD-associated
maxillary sinusitis may be observed as early as 6 months
of age.1448 The constellation of otolaryngology and
pulmonary findings associated with PCD include rhinitis,
congestion, RS, otitis media, chronic cough, bronchiec-
tasis, and recurrent pneumonia, all to varying degrees of
incidence and severity. Nasal polyposis in PCD patients
has a reported occurrence rate of 18% to 33% with onset
in adolescence.1447,1449,1450 Diagnosis relies on a combined
approach using ultrastructural analysis of respiratory
mucosal biopsies via electron microscopy and functional
assessment of CBF and pattern.1451–1453 Low NO pro-
duction is another measurement useful in the diagnosis
of PCD.1454,1455 PCD is most commonly an autosomal
recessive disease, yet testing for mutations in over 30 cilia
structural genes linked to PCD is not always feasible.1456
In both pediatric and adult PCD patients, aggressive
management of upper airway inflammation and infection
appears to be critical to maintenance of sinopulmonary
health and QoL. Medical management may include regular
nasal lavage, INCS, antibiotics, seasonal vaccinations, IV
gamma globulin, and prolonged macrolide therapy.1450
Although the literature regarding the role of ESS in PCD
is limited to case reports/series, the literature collectively
suggests that moderate improvements in rhinologic
symptoms following ESS procedures can be attained for
PCD patients. Following ESS, reduced rhinitis, purulent
discharge, and nasal congestion are documented, with
notable improvements in lower respiratory sequelae.1450
XII.C. RS Special Considerations: CF
CF occurs primarily in white populations in 1 in 2000
to 6000 births.1457 CF is caused by autosomal recessive
inheritance of mutations in the CFTR chloride transport
gene, and exocrine gland dysfunction. Secretions in
general, and the air-surface liquid in particular, become
viscous and stagnant in CF patients, impairing MCC, and
contributing to frequent bouts of CRS in the upper airway
and bronchopulmonary disease in the lower airway. CF
patients have an incidence of RS approaching 100%1458
and 44% to 58% have NPs.1459,1460
Medical management in adult and pediatric CF includes
nasal saline, INCS, topical antibiotics, dornase alfa, and
oral macrolides. Topical saline irrigations are extrapolated
for use in CF patients from literature noting improvement in
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symptoms and QoL scores in non-CF patients.696 In a sim-
ilar extrapolation, hypertonic solutions in nasal lavages are
often recommended by extension from positive pulmonary
outcomes with nebulized hypertonic solution.1461 Nasal
polyposis in CF is typically less responsive to corticos-
teroids, possibly due to an increased neutrophilic compo-
nent, but polyp volume reduction with symptom improve-
ment is reported.1462,1463 Topical antibiotic use has shown
reduced postoperative CF sinus exacerbations, endoscopic
score improvement, and reduced symptoms.782,785,1464
Dornase alfa reduces mucus viscosity and improves
objective CRS outcome measures.1465,1466 Oral macrolides
possess antibacterial and anti-inflammatory effects with
support for use in CF pulmonary manifestations and may
be utilized to treat CF-related CRS.1467,1468
ESS for CF-associated CRS improves both QoL and
endoscopic scores.1469 However, ESS in the CF pop-
ulation often has high rates of revision surgery and
persistent radiographic abnormalities. In addition, despite
radiographic evidence of RS by CT imaging, only a
small proportion (10-20%) will have self-reported CRS
symptoms/complaints.1470 There is evidence to support
ESS for asymptomatic patients given decreased hospital-
ization rates for CF lung transplant patients undergoing
ESS.1471 Outside of the transplant literature, pulmonary
outcomes for CF patients are mixed despite improved
QoL.1469,1472 Because of the pooling of maxillary sinus
secretions seen in CF patients and the frequent need for
revision ESS procedures, emerging literature suggests that
a widened/inferiorly-extended maxillary sinus antrostomy
surgery may permit improved drainage and larger volume
irrigant delivery.1473
XII.D. RS Special Considerations: Invasive
Fungal Rhinosinusitis
Fungal sinus disease is broadly divided as invasive or non-
invasive, with invasive fungal sinus (IFS) disease having
subcategories that differ based on the histology, clinical
presentation, and prognosis. These include acute invasive
fungal rhinosinusitis (AIFS), chronic invasive fungal
rhinosinusitis (CIFS), and granulomatous invasive fungal
rhinosinusitis (GIFS). Therapy for IFS should include
appropriate antifungal therapy, surgical debridement, and
reversal of the source of immunosuppression when present.
There is a paucity of high-level evidence in the literature
regarding treatment and survival of AIFS, CIFS, and GIFS.
In 2012 a systematic review of survival outcomes in AIFS
was performed on 52 studies that met entry criteria.1474
All of these were case studies or expert reviews (Level 4
and 5 evidence). A literature review of CIFS and GIFS
showed even fewer studies available and was restricted to
case reports and case series.
XII.D.1. Invasive Fungal Rhinosinusitis: AIFS
Based on a systematic review of AIFS, the disease is limited
to patients with impaired host defenses.1474 Almost any
fungus can cause AIFS, if the immunocompromise and
inoculation are great enough, but the most common species
in North America are Aspergillus fumigatus, Rhizopus,
or Mucor, and less commonly Fusarium, Scedosporium,
Pseudoallescherii boydi, and dematiaceous fungi. Usually
the fungal species cannot be differentiated histologically,
but require culture with sporulation to determine species
(this may take as long as 3 months). As with all fungi, prior
treatment with antifungal therapy may lead to no growth
on subsequent culture, so it is important that if AIFS is sus-
pected that fungal cultures be obtained prior to treatment.
Knowledge of the fungal species can direct appropriate
antifungal therapy. Aspergillus has been shown to be
more common in neutropenic patients (80% Aspergillus,
20% Mucor) whereas Mucor is more common in diabetic
ketoacidosis (80% Mucor and 20% Aspergillus).1475
In addition to antifungal agents, AIFS is treated with
attempts at reversing the cause of immunocompromise and
conservative surgical debridement. More than 90% of AIFS
originates in the nasal cavity with over 60% originating
on the MT. If this area is localized and can be surgically
excised, survival is improved.1476 In a systematic review
of all AIFS, survival for all patients was approximately
50%; however, certain subsets of patients were found to
have significantly improved prognosis, including diabetic
patients, those receiving liposomal amphotericin B, or
surgery. Mortality rate directly attributable to AIFS has
been reported as low as 11% in neutropenic patients, with
the vast majority of patients that reverse their neutropenia
resolving the AIFS.1475 Early detection of disease in at risk
populations can significantly reduce morbidity and number
of surgeries.1477 Symptoms common to patients with AIFS
include facial swelling (>60%), fever (>60%), and nasal
congestion (>50%). Negative prognostic factors include
advanced age and intracranial extension. Orbital and
intracranial symptoms occur in advanced disease and are
more common with mucormycosis than aspergillosis.1478
Sinus CT scans in early stages of AIFS are similar to viral
or bacterial RS, with the important difference of AIFS
patients having significant intranasal mucosal thickening
primarily involving the septum, nasal floor, and lateral
wall, and being commonly unilateral. Bony erosion is a
late and ominous finding.1479,1480
Aspergillus fumigatus is the most commonly cultured
fungus in AIFS in North America, afflicting patients
who are universally immunosuppressed (usually from
antirejection drugs, leukemia, or chemotherapy). Histo-
logically it appears as a septated fungus with 45-degree
branching hyphae. Mucormycosis is less common than
other fungal causes of AIFS in North America, but is the
main cause of AIFS in diabetics (especially in ketoacidosis)
and patients with excessive levels of serum iron (ie, from
deferoxamine therapy). With the increase in obesity in
India and associated untreated diabetes, mucormycosis has
become the most common cause of AIFS in India, with an
estimated 65,000 deaths/year and over one-half attributed
to the rhinocerebral form.1481 The term mucormycosis
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is used to designate invasive fungal infection from any
of the 6 fungal species in the order Mucorales, with
Rhizopus oryzea being the most commonly pathogenic.
Histologically, it is a broad, ribbon-like, rarely septate
hyphae that has a great affinity for vascular invasion and is
notable for rapid growth on media and rapidly progressive
disease. Common physical findings include facial and
nasal anesthesia, which may precede other findings by
several hours. The enhanced survival in diabetics reflects
the ability to reverse the diabetic ketoacidosis more readily
than other predisposing conditions.
The successful treatment of AIFS is dependent on
recovery of immune competence, whether this be recovery
of the neutrophil count in hematologic causes, reduction of
immune suppression in transplant patients, or resolution
of diabetic ketoacidosis and functional neutropenia. The
role of surgery is to remove the grossly involved tissue
and to reduce the fungal load until immune competence
is achieved and adequate antifungal therapy administered.
Regardless of the therapeutic measures employed, the
ultimate outcome is most dependent on recovery of the
immune system. With this in mind, decisions on the extent
of surgical resection should take into account the patient’s
prognosis for immune recovery.1475
XII.D.2. Invasive Fungal Rhinosinusitis: CIFS
CIFS is rare and usually occurs in immunocompetent
patients or those with very mild immunologic impairment.
Duration of symptoms prior to diagnosis can be months to
even years and requires long-term systemic antifungals and
multiple surgical debridements. The most common fungus
in this uncommon condition in North America is As-
pergillus fumigatus, although a wide variety of fungi have
been reported as causal. Orbital apex syndrome commonly
develops in association with the invasion of predominately
the ethmoid and sphenoid sinuses. The treatment is
systemic culture-directed antifungal therapy, usually via
an oral route and repeated surgical debridements.1482,1483
XII.D.3. Invasive Fungal Rhinosinusitis: GIFS
GIFS is uncommon in the United States, but is more com-
monly seen in areas such as the Sudan, Pakistan, Egypt,
and India. The initial largest series was reported from the
Sudan in the 1960s as an “aspergilloma of the paranasal
sinuses and orbit,” caused by Aspergillus flavus.1484 This
would now be classified as GIFS, and unlike CIFS these
patients have no detectible cause of immunocompromise
and histologically show a granulomatous reaction to the
fungal presence. Common clinical findings are a slow
development of unilateral proptosis, anesthesia over the
affected area, usually in a V2 distribution, unilateral
facial pressure, and nasal congestion.The prognosis and
treatment recommendations of CIFS and GIFS are the
same: systemic antifungals and conservative surgery. Prog-
nosis is dependent on accessibility to systemic appropriate
antifungals and conservative surgical debridement.1485,1486
XIII. Knowledge Gaps and Research
Opportunities
We have witnessed an explosion of research into RS over
the last decade. Although this has led to an improved un-
derstanding of the pathophysiology of the disease and the
impact of medical and surgical therapies, many knowledge
gaps remain. This ICAR:RS document outlines the evidence
surrounding RS and demonstrates numerous gaps in our
current understanding. Although practitioners are generally
successful treating ARS and RARS, treating CRSsNP and
CRSwNP remain a struggle. CRS is an inflammatory condi-
tion and work in other inflammatory diseases may overlap
and be relevant. Consequently, multidisciplinary research
and collaboration between disciplines, even if not appar-
ently related, should be encouraged to bring in new per-
spectives to an old problem. Additionally, there are likely
differences between adult and prediatric CRS with regard
to all of the knowledge gaps identified in the sections below.
XIII.A. Knowledge Gaps and Research
Opportunities: Etiology of CRS
Nearly all of our current research into CRS relies upon
patients who present with the disease or upon animal
models with genetic knockouts or experimental exposures
to mimic the inflammatory patterns present in CRS. In
adults, CRS occurs primarily in middle-aged patients. We
lack an understanding of what factors—genetic, environ-
mental, or both—lead to the development of CRS in a
previously healthy patient. Once CRS develops, there are
several disease modifying factors that have been discussed
in this ICAR:RS. Research opportunities include:
 Understanding development of CRS in previously
healthy patients;
 Impact of host vs environmental factors, causative vs
modifying factors; and
 Improved animal models.
XIII.B. Knowledge Gaps and Research
Opportunities: Clinical Assessment
Our current diagnosis of CRS requires cardinal nasal
symptoms and 1 objective sign of nasal inflammation.
These rudimentary diagnostic criteria result in a hetero-
geneous group of “CRS” patients, making it difficult to
investigate etiologies and outcomes. Further refinement has
been based upon polyp status and eosinophilia. Although
the CRSwNP phenotype can be readily determined using
endoscopy, it is impacted by surgical state and medical
therapies and has limited correlation to symptom severity.
Additionally, there is likely a spectrum of disease from
CRSsNP with mucosal edema to development of true nasal
polyposis that is not accounted for using crude phenotypic
classifications. Further refinements in clinical classification
would include biomarkers that correlate with symptoms
and better predict treatment response.
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Additional improvements in understanding how specific
symptoms are affected in various CRS patients are sorely
needed. Although nasal-specific symptoms are required
for the diagnosis of CRS, there is wide variability in the
severity of these symptoms. Similarly, CRS has a significant
impact upon cognitive function, depression, sleep, and
lower airway function, yet we do not understand how
certain host or environmental factors result in specific
constellations of rhinologic and nonrhinologic symptoms.
Optimal outcome instruments remain elusive. Many
studies use patient reported outcome measures. Although
these QoL instruments are valuable, they fail to take
into account important variables, such as overall disease
control, medication usage, and the economic costs of
CRS. A complete understanding of the impact of CRS will
require a compilation of these metrics. Areas for further
research include:
 Clinical classification that correlates with symptom
severity;
 Understanding the cause of specific CRS symptoms;
 Endotyping and biomarkers that correlate with clinical
presentation and outcomes; and
 Outcome instruments that account for symptom severity,
overall disease control, and economic impact.
XIII.C. Knowledge Gaps and Research
Opportunities: Medical Treatment of CRS
Current medical treatment of CRS revolves around anti-
inflammatory agents. Systemic steroids are effective, yet
side effects limit their prolonged use. This has prompted
widespread investigation into topical therapies. An im-
proved understanding of the need for delivery to the
paranasal sinuses, rather than simple nasal cavity treat-
ments, has resulted in the use of large-volume delivery
and steroid-eluting stents. Although these approaches have
achieved success, there are still many limitations, such as the
need for daily use of rinses or the cost and possible need for
periodic replacement of biodegradable stents. Improved de-
livery methods that permit targeted, sinus-specific delivery
of anti-inflammatory agents with minimal side effects and
prolonged duration of efficacy are greatly needed. As with
other chronic diseases, compliance with CRS therapy may
be an issue and needs to be addressed in future research.
In addition to steroids, a number of novel anti-
inflammatory agents show promise, such as monoclonal
antibodies against IL-5, IL-4R, or IgE.1487–1490 Currently
most of these are administered systemically with significant
cost and potential side effects. However, they might have
a place in patients with severe disease not controlled by
conventional drug therapy and/or surgical intervention, or
comorbid asthma.
Regardless of the anti-inflammatory agent or route of
administration, none of our currently available strategies
including surgery result in a cure for most patients,
especially those with CRSwNP. Long term correction of
immune dysfunction would offer the chance of a “cure”.
Research opportunities include:
 Improved delivery of topical therapies;
 Identifying predictors of response for various medical
therapies;
 Therapies that are an alternative or complementary to
surgery in recurrent disease; and
 Therapies that “normalize” the immune system, ie, a
“cure.”
XIII.D. Knowledge Gaps and Research
Opportunities: Surgical Treatment of CRS
With the exception of balloon dilation, there have been
few changes in sinus surgery instrumentation in the last
decade. Balloon dilation has stimulated discussion around
instrumentation; however, a more logical debate should
revolve around the final desired postoperative cavity, ie,
which sinuses to operate upon and how large surgical
ostia should be for each particular patient and underlying
disease process. Research opportunities include:
 Appropriate medical therapy prior to surgery;
 Predictors of response to surgery; and
 Individualized determination of optimal surgical cavity
including Draf/Lothrop procedures.
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